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Every day, we read about new scientific discoveries and technological advancements in 
the newspapers. The news has been very promising for medicine and health, in particular 
in reference to ‘genetics’ in the past 15-20 years: “Diabetes gene is found!”, “Heart attack 
gene is found!”, “Cancer gene is found”, “We’ll be able to prevent diabetes in 10 years!”… 
However, we don’t see these ‘genes’ actually at work in health services. Somehow, they 
don’t complete their journey from the laboratory to the society. 
This PhD research deals with the integration of personalized health care applications into 
health services. The setting, i.e. health services, into which genetic based innovations 
should be integrated, is a part of the broader context of health systems. Therefore, the 
first part of the dissertation explores health systems and its interrelations with ‘public 
health’. The second part introduces a preventive personalized health care model called 
Gentest, within the wider context of the field of personalized medicine and health care. 
This practice model is used as an example in this dissertation to explore the issues related 
to integration effectively. The third part investigates how this practice model can be inte-
grated into primary care services within European health systems. 
In this introductory chapter, first the conceptual background that signifies the societal 
need for prevention of chronic complex diseases and an approach towards prevention is 
explained. Then the practice model is briefly introduced. Finally, the aim and structure of 
the dissertation is summarized. 
1. Conceptual background 
1.1. Burden of chronic diseases and its impact on health systems 
As a result of the epidemiological and demographic transition, life expectancy has been 
rapidly increasing since the 20
th
 century. In the 21
st
 century, the main burden of disease is 
caused by chronic complex diseases, which stem from the complex interaction of human 
genome with lifestyle and environmental factors. Cardiovascular and cerebrovascular 
diseases, cancers and diabetes are among major chronic complex diseases, which account 
for approximately two third of all deaths in the world. Thus, 21
st
 century brings us to an 
aged population living with chronic conditions, creating a huge burden on health systems 
and society. 
Definition 
The terms used to refer to this group of diseases vary, depending on the perspective of 
the disciplines or type of stakeholders. Most common definition, used mostly in health 
care sector and among health professionals, is ‘chronic diseases’, referring to their long 
duration and slow progression. Another term mostly used by organizations and profes-
sionals that address the health problems on the population level, such as international 
and intergovernmental agencies, is ‘Noncommunicable diseases’ (NCDs). NCDs constitute 
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one of the three main clusters of diseases and conditions that lead to health loss in Global 
Burden of Disease Project [1]. NCDs largely overlap with chronic diseases and are often 
used synonymously. ‘Complex diseases’ is another term often used synonymous to ‘chron-
ic diseases’, but emphasizes the underlying cause of the conditions in question, i.e. com-
plex interaction of the genetic structure of the individuals with lifestyle and environmental 
factors. This term is more commonly seen in scientific and technological contexts. ‘Life-
style diseases’ is sometimes used in media when emphasizing the importance of lifestyle 
factors in development of chronic diseases. Throughout this dissertation, these terms are 
used to refer to chronic diseases, depending on the context and purpose. 
 
 
Figure 1: Total deaths by causes  
* Other conditions inc lude communicable,  maternal,  per inatal and nutri tional  condit ions.  
Data source:  WHO, 2014 [2]  
Extent of the problem globally and in Europe 
Chronic diseases are the leading cause of mortality globally, responsible for almost 70 % of 
the deaths in the world. 40% of them are premature deaths under the age of 70 years [3]. 
If not intervened effectively, deaths from chronic diseases will increase by 15% between 
2010 and 2020 [4].  
The burden of chronic diseases has been rapidly increasing in all parts of the world. In 
most countries, they cause 50% or more of all healthy life-years lost. In richer countries 
such as North America and most of Europe, this percentage is greater than 80% [1]. 
The situation regarding these conditions in Europe is serious due to two reasons. First, 
despite progress made in reducing mortality from ischemic heart disease and stroke in the 
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past 20 years, overall burden of chronic diseases continues to increase [5]. As of 2010, in 
European Union (EU) and European Free Trade Association (EFTA) countries, chronic dis-
eases are responsible for 90% of all deaths and 86% of the disease burden [6].  
Secondly, population in Europe is aging very rapidly. The population above the age of 65, 
as well as the proportion of aged people to working age (15-64) will double from 2010 to 
2060 [7, 8]. As the prevalence of chronic diseases increases with age, the problem of car-
ing for elderly with chronic diseases will lead to huge social and economic burden on the 
European countries. Nevertheless, one must note that chronic diseases are not only the 
problem of the elderly anymore. Rising numbers of young and middle-aged people have 
some sort of chronic health problem, leading to premature mortality, as well as morbidity 
in the working ages [9]. 
The economic impact of chronic diseases is serious. They constitute huge costs for individ-
uals, families, businesses, governments and health systems, cause billions of euros in loss-
es of the national incomes each year. And the problem is predicted to increase with time. 
The cost of chronic diseases will double from 2010 to 2030. The anticipated total econom-
ic toll of cardiovascular diseases, cancer, chronic lung diseases and diabetes in 2010-2030 
globally is more than 30 trillion United States Dollars (USD), representing 48% of global 
gross domestic product (GDP) in 2010 and pushing millions of people below the poverty 
line [10]. Moreover, chronic diseases have a negative effect on the labor market and for-
mation of the human capital [11]. Each 10% rise in prevalence of chronic diseases is asso-
ciated with 0,5% lowering of the rates of annual economic growth [4]. 
Currently, 70-80 % of all health care budgets, i.e. 700 billion Euro per year, are spent on 
chronic diseases in EU [12]. The health budgets (in health systems with national health 
services) and the social insurance funds (in health systems with social health insurance 
models), as well as the budgets related to chronic care of elderly, will face great difficulties 
in coping with the financial burden caused by aging populations living with chronic condi-
tions.  
Recognition of the problem and development of strategies 
The ever increasing burden of chronic diseases is recognized widely around the world, 
calling for development and adoption of effective intervention methods for their preven-
tion and control.  
A significant step has been the United Nations (UN) High Level Meeting on NCDs, held on 
19-20 September 2011. It focused on the four main chronic diseases: cardiovascular dis-
ease, cancer, chronic lung diseases and diabetes. This was only the second time in the 
history of UN General Assembly that a high-level meeting was dedicated to a health issue 
(the first time was on HIV/AIDS in 2001). As a result of the meeting, world leaders adopted 
a political declaration, stating that NCDs reached epidemic proportions globally and there 
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is an urgent need for greater measures to prevent and control them on global, regional 
and national levels [13]. Following this, World Health Organization (WHO) developed the 
Global NCD Action Plan for 2013-2020, which was endorsed by the World Health Assembly 
in May 2013, together with the global target to reduce deaths under 70 (premature 
deaths) from NCD’s by 25% by 2025 [14]. 
WHO Europe had already addressed the issue with ‘Gaining Health: the European Strategy 
for the Prevention and Control of Communicable Diseases’ in 2006 [15]. The significance 
of current and upcoming burden of chronic diseases has also been recognized on the EU 
level, leading to the first EU Summit on Chronic Diseases in Brussels on 3-4 April 2014 [12].  
The above mentioned international/ intergovernmental efforts and many others have 
been highlighting the importance of prevention as a key aspect of all strategies tackling 
with the burden of chronic diseases. In addition, management of the diseases and caring 
for the people living with chronic conditions is becoming a huge problem all around the 
world, in particular in Europe due to its rapidly aging population.  
The question is whether health systems are sufficiently adapted to deal with the burden of 
chronic diseases as they were designed for the previous century, when communicable 
diseases accounted for the biggest share of the disease burden. Unlike communicable 
diseases, chronic complex diseases have multiple causative factors and occur concurrently 
rather than in isolation (multi-morbidity). To respond to the increasing burden of chronic 
diseases effectively, the reductionist paradigm of the previous century, i.e. ’single cause -> 
single disease -> single treatment’, needs to be renewed with new visions and frame-
works, such as a system thinking paradigm [16] and application of ‘comprehensive’ ap-
proaches that address multiple determinants of health. The question therefore is whether 
current health systems can effectively address them and whether they are proactive, 
health oriented (not disease), and preventive enough to provide adequate chronic care, 
and whether they have the right focus on the whole spectrum of health care (not only 
medicine).  
Innovation is essential to equip health systems with new practices in order to respond to 
the growing burden of chronic diseases [17]. In an era where health systems are under 
serious pressure of the increasing costs and demands for increasing quality, they must 
innovate to keep functioning [18]. National Health Services (NHS) of United Kingdom (UK) 
has put it as: “… simply doing more of what we have always done is no longer an option. 
We need to do things differently. We need to radically transform the way we deliver ser-
vices. Innovation is the way – the only way - we can meet these challenges…” [19]. The 
urgent need for innovation has also been recognized on the EU level and addressed within 
the European Innovation Partnership on Active and Healthy Ageing [20]. This partnership 
developed strategies in three areas: prevention and health promotion, care and cure, and 
active and independent living of elderly people.  
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Scope of the dissertation in terms of chronic diseases 
UN High Level Meeting on NCDs and the Global NCD Action Plan 2013-2020 focused on 
four main chronic diseases: cardiovascular diseases, diabetes, cancer and chronic obstruc-
tive lung diseases [13, 14]. They are responsible for 80% of the deaths from chronic dis-
eases, and 55% of all deaths globally (Figure 1). These conditions mostly have an adult 
onset and share common behavioral risk factors: tobacco use, unhealthy diet, physical 
inactivity and harmful use of alcohol. Actually, chronic diseases as a group is very broad 
and also includes issues such as mental health disorders, renal diseases, neurodegenera-
tive conditions, musculoskeletal disorders and many others. They are associated with the 
risk factors of the above mentioned four major chronic diseases, but also have other spe-
cific risk factors. Since designing strategies to target them all would be unwieldy, the UN 
High Level Meeting on NCDs and the Global NCD Action Plan 2013-2020 have identified its 
focus as these four major ones. Due to similar concerns, it was decided to limit the scope 
of this dissertation to major chronic diseases of the adult onset, which share common 
underlying lifestyle factors. Examples of such conditions are: cardiovascular diseases, dia-
betes, cancer, chronic lung diseases and osteoporosis. It is of note that improved lifestyle 
will have a positive effect on not only these diseases, but also several other conditions, as 
well as slowing down the age related decline in physical and mental functions. 
1.2. A brief look at the underlying causes of complex diseases 
In order to develop strategies to tackle the problem of chronic diseases effectively and 
develop innovative solutions, we first need to understand how they are developing.  
Determinants of health and role of genetic structure in development of complex 
diseases  
There have been a number of models attempting to explain the factors that influence 
health and development of diseases [21-27]. What they all have in common is that health 
is influenced by multiple factors that surround individuals, although the specific clusters, 
layers and perspectives may vary.  
Based on the classical approach to ‘determinants of health’, health is affected by biological 
factors including genome, lifestyle and environmental factors, health systems in the 
broader and health services in the narrower context, and socioeconomic dimensions (Fig-
ure 2).  
Chronic diseases are caused by the interaction of genetic structure and lifestyle and envi-
ronmental factors. However, their genetic basis is different from, for example, the under-
lying abnormalities in genetic diseases. In order to understand the genetic basis of chronic 
diseases, we may visualize the diseases in a threshold model as shown in Figure 3. Here, 
diseases are grouped into four major areas, according to the causative factors. 
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Figure 2: Determinants of health  
 
 
Figure 3: Interaction of genes with lifestyle and environment from a disease threshold perspective 
* Estimates for burden of disease in EU and EFTA Countr ies based on data provided by the 
Global Burden of Disease  Study 2010 [6]  Source:  Modified from Cesuroglu et  a l. ,  2009 [28]   
The first group is genetic diseases, which are caused by abnormalities in the genetic struc-
ture of individuals. Down syndrome, cystic fibrosis, phenylketonuria are disorders caused 
by deleterious changes in genetic structure. They constitute a small fraction of burden of 
disease. External and lifestyle and environmental factors play little or no role in most of 
these diseases (first column in Figure 3).  
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The second group is caused by external factors and includes injuries, including traffic acci-
dents, violence, poisoning, etc. Genetic structure doesn’t have a prominent role in their 
development. They constitute around 10% of the burden of disease in EU and EFTA coun-
tries (second column in Figure 3).  
The third group includes infectious diseases that were believed to be only caused by path-
ogens. However, growing body of research indicates that host genomic factors also play 
an important role in manifestation of infectious diseases (third column in Figure 3). The 
burden of these conditions used to be very high over the course of the history of mankind; 
however it reduced drastically throughout the last century, in particular in high-income 
countries. Although infectious diseases still create a significant burden in certain parts of 
the world, such as Africa, globally their proportion is reducing.  
The fourth group consists of disorders where genetic structure creates a predisposition to 
the disease, but it is not enough to make one sick. They develop when other factors, main-
ly unfavorable lifestyle factors, as well as the environment, add on the genetic predisposi-
tion (fourth column in Figure 3). These are chronic (or complex) diseases that develop due 
to the interaction between these genetic and other components. The environment here 
refers to chronic exposure, whereas external factors in the previous group refer to short 
term events with substantial effect.  
Development of chronic complex diseases  
In order to develop intervention models to prevent chronic diseases, we need to under-
stand when and how to intervene. For this purpose, we take the column of chronic com-
plex diseases in Figure 3 (fourth column), and put it in a life course perspective in Figure 4. 
In this hypothetical model, the left end of the figure is conception of an individual and the 
right end is death. The genetic structure (yellow part in the bottom) doesn’t change in 
his/her life course. However, negative lifestyle and environmental conditions add on top 
of the genetic predisposition in time. For example, maternal smoking behavior, not being 
breastfed long enough, starting eating junk foods early in life, becoming physically inactive 
in school years, starting to smoke in teenage years, continuing unhealthy nutrition in early 
adulthood, living in polluted urban areas, continuing sedentary life, being exposed to work 
stress, financial problems and marital problems in later adulthood, etc. all add on (Phase I 
– Disease development).  
This continues until the individual reaches the ‘early signs’ threshold and enters ‘Phase II – 
Early signs of disease’. Here, for example, the blood pressure, fasting plasma glucose and 
LDL cholesterol become higher than normal. The individual is not aware of them; they can 
only be detected by body measurements, laboratory tests, etc. These are also regarded as 
‘risk factors’. 
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If the individual continues the negative lifestyle and keeps being exposed to negative envi-
ronmental factors, he crosses the disease threshold and develops, for example, a heart 
attack. This is ‘Phase III – Established disease’. 
 
Figure 4: Development of chronic diseases in a time perspective – Disease development curve 
Source:  This model was developed by Serdar Savas  at GENAR Inst i tute for Public  Health and 
Genomics  Research,  Ankara,  Turkey,  in 2008,  inspired by the disease progress ion curve of 
Snyderman [29]  to a certain extent.  
Until recent past, overwhelming focus of health services has been on diagnosing and cur-
ing the diseases after the disease develop, i.e. ‘late curative paradigm’. However, in the 
last decades, we have been witnessing a shift from ‘late curative paradigm’ towards ‘early 
diagnosis’. Importance of check-up and early diagnosis has being more and more recog-
nized because of possibilities to delay the onset of many diseases with preventive use of 
medications (such as aspirin, hypertension drugs and statins for cardiovascular disease 
prevention), as well as targeted diet and exercise. Thus, if the disease is caught and diag-
nosed in an early stage (Phase II) serious complications can be prevented or delayed. For 
example, many people with type 2 diabetes live with it undiagnosed, causing serious dam-
age on various organs in the body. Thus, in Phase II, the main preventive intervention is 
screening for the disease. 
The interventions on the earlier phases of disease development are more effective for its 
prevention, or minimization of the complications. Conversely, as the pathology develop-
ment progresses, the costs related to detection, management and treatment of the dis-
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ease and/or risk factors are increasing [29]. Thus, the effectiveness of the interventions 
increases and costs decreases as we shift our focus to the left in Figure 4. 
The shift from late curative paradigm to early diagnosis and medical management of the 
early signs of the disease has made significant contribution to reducing the mortality in 
industrialized countries for some diseases, such as cardiovascular diseases [30]. Neverthe-
less, this cannot slow down the increasing burden of many others, such as diabetes, 
chronic obstructive lung disease, and cancers. Thus, the current shift is not enough. There 
is still a large area, on the left side of the graphic: Phase I – Pathology development. This is 
the most crucial time period because the pathology actually develops in the long years 
before the early signs can be detected, starting from conception. However, this phase is 
currently not covered effectively by health interventions.  
Opportunities brought by personalized medicine and health care 
Currently, the best known prevention for chronic diseases is adopting a healthy lifestyle. 
However, this cannot be not achieved in many places of the world. Effective intervention 
models for lifestyle change to prevent these diseases are urgently needed. At this point, 
personalized medicine and health care can offer significant opportunities. 
Throughout the whole spectrum of health care, there has been a gradual shift from a ‘one 
size fits all’ strategy towards personalized interventions, which can be applicable for 
health promotion, disease prevention, diagnosis, treatment, and rehabilitation. This shift 
is driven by the general societal trend towards personalization, as well as the rapid scien-
tific and technological advancements in genome-based science/technologies and infor-
mation/communication technologies [31]. This future vision, in the broadest sense, can be 
called as personalized medicine and health care and offers great opportunities to tackle 
the burden of chronic diseases.   
2. A preventive practice model for personalized health care: 
Gentest 
As an endeavor to face the challenge of chronic diseases summarized in previous section, 
GENAR Institute for Public Health and Genomics Research in Turkey developed a health 
service model called Gentest.  
Gentest is a comprehensive and integrative model for prevention of common chronic 
diseases in primary care settings. It utilizes individuals’ personal health information (clini-
cal information), detailed lifestyle analysis, body composition, genotype, and other bi-
omarkers (such as LDL cholesterol, fasting plasma glucose, etc.) in order to prevent devel-
opment and progression of chronic diseases in a targeted way. Based on the results of the 
aforementioned components, risk assessments are made for the major chronic diseases 
including heart attack, stroke, type 2 diabetes, cancers (lung, breast, prostate, colon, and 
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gastric cancers), and osteoporosis. Using all of the assessments, an optimum lifestyle plan, 
including personal menu plans and food exchange lists, exercise plans, smoking cessation 
recommendations, and a medical follow-up plan are drawn. The model is developed to be 
provided via health care professionals. Its mission is changing the behavior and managing 
the health of individuals according to their health needs and priorities. The conceptual 
framework of the practice model is presented in Figure 5 [28, 32]. 
 
Figure 5: Conceptual framework of Gentest  
Source:  Cesuroglu,  et al. ,2009 [28]   
The purpose of Gentest model is prevention of the major chronic diseases and their com-
plications, through all stages of their development and progression, i.e. from the point 
where there is no disease to the point where there is fully established disease and further 
towards its complications. Having a look at the disease development curve (Figure 4), the 
practice model aims to catch the individuals during the stages on the left side, i.e. as early 
as possible, in order to slow down, delay, or if possible, reverse the progression towards 
the disease threshold. For this purpose, the model attempts to include as much as possi-
ble of all determinants of health to make a 360 degree assessment of health of the indi-
vidual. 
Gentest was developed by GENAR Institute for Public Health and Genomics Research, 
which was established in 2004, in Hacettepe University Science Park, Ankara Turkey. 
GENAR aimed to transform scientific developments in the area of biotechnology, especial-
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ly genetics and genomics, into products and services that improves human health, quality 
of life and performance, and extends life span. At the time of its establishment, it was the 
third public health genomics center in Europe. The author of this dissertation gained 
firsthand experience with the model while serving as the Research and Development Co-
ordinator of GENAR in 2005-2010.  
Gentest was identified as a best practice model for public health genomics in Europe by 
the Public Health Genomics European Network (PHGEN) in 2008. It was also successfully 
piloted by authorized practitioners (mainly physicians and some dieticians) as a service 
provided to more than 500 individuals in Turkey (as of 2010). These practitioners complied 
with a specific set of criteria and were authorized for application of this model after suc-
cessful completion of a training course on personalized medicine and nutrition by the 
Turkish Society of Public Health Genomics and Nutrigenetics/ Personalized Medicine 
(TOGEN) in collaboration with the GENAR Institute.  
Further information on Gentest and how it is implemented can be found in Chapter 6 and 
Appendix of this dissertation. 
Based on the current trends and developments in the world, feedback of scientific and 
industrial communities on the model, and past experiences with the practice model Gen-
test, it was identified that the main implementation area for such a preventive health care 
product would be primary care services in Europe. Within this setting, it can be provided 
by general practitioners/ family physicians. However, there has been no example of such a 
preventive personalized health care model that has been provided to large populations. 
Thus, there is a need for policy research in order to see how this model can be imple-
mented in health systems, in particular primary care settings, in Europe.   
3. The aim and structure of the dissertation 
This PhD research has been driven by the societal challenge of the burden of chronic dis-
eases, as well as the opportunities brought by personalized medicine and health care to 
tackle them. The example used in this dissertation, Gentest, was developed as a personal-
ized health care practice for prevention of chronic diseases. Now the question is how it 
can be integrated into in primary care services in Europe. Thus, the aim of this disserta-
tion is to explore how a personalized health care model, such as Gentest, can be inte-
grated in primary care services in European health systems, for prevention of chronic 
diseases.  
Under this broad question, ‘integration’ can be split into three elements: where to inte-
grate, what to integrate, and how to integrate? The dissertation is organized in three 
parts, each addressing one of these elements, as introduced below. 
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Where to integrate? – In order to effectively identify issues related to integration, we first 
need to understand the setting that the practice model will be integrated into. This set-
ting, in the broadest sense, is health systems. Therefore, Part I defines and introduces a 
framework for health systems, in its larger context of public health. This will provide the 
underlying basis needed when identifying integration issues. 
What to integrate? – Integration depends on the nature and properties of the interven-
tion. The future vision of personalization of medicine and health care is not addressed 
with standard terms, nor defined in a standard way. Moreover, there is no clear descrip-
tion of what kinds of practices constitute personalized medicine and health care. There-
fore, to have a good understanding of what will be integrated, Part I first looks at the 
broader context of personalized medicine and health care and, then, introduces the prac-
tice model that we aim to integrate into health systems. 
How to integrate? – Once we achieve a deeper understanding of ‘where to integrate’ and 
‘what to integrate’, we need to identify how to approach the integration problem. What 
are the issues we need to look at when investigating how such a practice model can be 
integrated into health systems? How can we identify them? Upon investigating existing 
approaches to answer these questions, Part III proposes a solution: a systematic approach 
that is built on the health system framework introduced in Part I; and takes the practice 
model Gentest introduced in Part II as its case example.  
After this introduction (Chapter 1), the dissertation presents 6 articles (Chapters 2-7), 
organized in three parts as laid above, and followed by a general discussion (Chapter 8). 
The appendix provides additional information on the practice model that is used as an 
example in this dissertation. The overall structure is presented in Figure 6 and each part is 
described below. 
Part I – Where to integrate? 
In scientific and grey literature, discussions on integration of personalized practices have 
mostly been focusing on the various separate parts of the health system in a piecemeal 
way. However, for their effective integration, it is important to see the big picture first. 
Therefore, in this chapter we took a step back and saw that the whole debate on ‘where 
to integrate’ needs to build on the concepts of ‘public health’ and ‘health systems’. How-
ever, there is confusion around these concepts and how they are interrelated. If we don’t 
have clarity about them, we cannot identify the issues related to integration of a personal-
ized practice into a health system effectively.  
As a solution, Chapter 2 took the endeavor to achieve a coherent terminology for policy 
makers in local, national and international levels. It does so by integrating the concepts of 
public health, including health system and its components, into a single coherent frame-
work called Health Globe. Among others, components of health system were described in 
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details. As it puts forward a comprehensive approach, this framework can be used to iden-
tify all issues relevant to integration in a health system. Thus, Health Globe provides the 
required framework for identification and assessment of issues related to integration in 
Part III, which will explore how the practice model can be integrated into health systems.  
Among various health systems around the globe, the one of the United States of America 
(USA) is positioned as the most progressive one in terms of medical technologies. USA also 
seems to be a leader in development of the concepts and practices of personalized medi-
cine and health care, as most of the existing examples and publications originate there. In 
order to understand the health system context of these ‘personalized’ practices, we inves-
tigated the status of U.S. health ‘system’ in Chapter 3. In the context of this dissertation, 
Chapter 3 serves to the purpose of taking lessons from USA when discussing how to and 
how not to integrate personalized practices in Europe. In the course of the editorial pro-
cess of the publication, the paper was abridged and the sections where we explained the 
shortcomings of the U.S. system in relation to broader policy values were taken out. To 
maintain coherence within this dissertation, these sections, which were omitted in the 
original publication, were put back into two boxes in Chapter 3 with an explanatory note. 
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Part II – What to integrate?  
The concepts of personalized medicine and health care are new and do not have standard 
and coherent definitions that are accepted across disciplines, sectors and settings.  With-
out knowing the broad picture of the field, it wouldn’t be possible to place Gentest, the 
practice model that is used as an example in this dissertation, in the right context. There-
fore, the broader context of personalized approaches is addressed in Part II, as well as the 
practice model. 
In our efforts to identify the broader context, we realized that there are a variety of terms 
and definitions for personalized approaches, used in ambiguous and inconsistent ways. 
They mostly have been made in a top-down manner by influential people or committees. 
Since the starting point of the PhD research is a practice model that was developed and 
piloted in real life, in Chapter 4, we chose to provide a different angle on the debate with 
a ‘practice-based perspective’, or in other terms a ‘bottom-up perspective’ by analyzing 
the content of ‘personalized’ practices published in the literature. These practices were 
identified with a systematic search, screening and eligibility strategy. After the content 
analysis, we reported the notions they imply for the definition of the personalized ap-
proaches and saw that ‘personalized’ practices are not a homogeneous group. Additional-
ly, using three country examples (USA, France and Taiwan) issues related to integration of 
practices into health services were discussed. While doing that, we used the earlier work 
on U.S. health system (Chapter 3). Eventually, Chapter 4 highlighted that health systems 
and policies of countries play a crucial role for successful integration.  
Chapter 4 showed the various facets of the personalized approaches but it was Chapter 5 
where a working definition of personalized health care was proposed. The article clarified 
what commonly used terms in the field, including personalized medicine, personalized 
health care and individualized medicine, meant to the authors. It also conveyed some of 
the underlying principles that were used in Gentest, including the need to cover all rele-
vant determinants of health, not just genes, when making health care personalized.  
Since ‘personalized’ practices are not a homogeneous group that can be covered in a ge-
neric way (as seen in Chapter 4), when developing a systematic approach to identifying 
issues related to integration of these practices, we needed to focus on a specific example. 
Chapter 6 provided us this example and introduced Gentest as a practice model for per-
sonalized health care. The article summarized the underlying societal need that led to 
development of the practice model, the approach of GENAR, the content of the practice 
model and how it was introduced and piloted in Turkey.  
Part III – How to integrate? 
After Part I that describes the setting, i.e. health systems, and Part II that focuses on the 
personalized preventive practice model in its wider context of personalized health care, 
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Part III explores how the practice model can be integrated into the setting, i.e. health 
system. 
If we want to integrate Gentest into primary care services in Europe, what are the issues 
that we should investigate? How can we approach this in a systematic and analytical way? 
What areas of the health system of the country should be investigated? Chapter 7 aimed 
to answer these by developing a systematic approach that was built on the health systems 
framework introduced as a part of Health Globe in Chapter 2. As we’ve seen in Chapter 4, 
‘personalized’ practices are diverse and cannot be covered with a generic approach. 
Therefore, Gentest, introduced in Chapter 6, was used to exercise and identify which is-
sues should be covered. Chapter 7 was enriched with examples provided from the Nether-
lands and the UK, as well as other European settings as necessary. All in all, this chapter 
provided a systematic approach to identification and assessment of the issues related to 
integration of the practice model into primary care services in Europe. This method can be 
applied to other practices and countries and, thus, provide a solution to the broader prob-
lem of the integration of personalized medicine and health care practices into health sys-
tems. 
General Discussion 
Chapter 8 takes a step back and explains why innovations in personalized medicine and 
health care must be coupled by innovations in the health system and vice-versa to effec-
tively prevent chronic diseases. Room for innovation is addressed for both fields, i.e. 
health system, as well as its broader context of public health, and personalized medicine 
and health care.  
The practice model Gentest is used as a vehicle in this dissertation in order to base the 
debate around integration issues on a concrete real life case. In the General Discussion, 
reflections are made on this choice and how the methodology of using a real life case may 
contribute to research in this field. 
Appendix 
The practice model is used as a practical case, a ‘vehicle’ in this dissertation, rather than 
being the central focus of the dissertation in terms of its technical and operational con-
tent. For readers who would like to get a better overview of the practice model with its 
strengths and weaknesses, some additional information is provided in the Appendix to 
complement Chapter 6, where Gentest was introduced. 
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Abstract 
There is confusion around concepts of public health, including health system and its com-
ponents, and how they are related to each other. In this paper we build on the existing 
literature and aim to integrate these concepts, which have been defined in separate con-
texts, into a single framework called ‘Health Globe’ and define them coherently.  
In Health Globe, the broad approach to health brought by World Health Organization’s 
‘Health for All’ vision is defined as public health and it is illustrated with a globe. Thus, all 
activities that directly or indirectly affect individuals’ health, including all medical and non-
medical interventions, governmental decisions and practices, and activities of the public 
sector, the private sector and NGOs, should fall within the scope of ‘public health’. Activi-
ties under the mandate of the ministry of health have been defined as ‘health system’, 
which is a part of the Health Globe. 
Within the Health Globe, there are other constituents that determine health, such as pre-
requisites for health and non-health systems’ health related activities. Governance for 
health is what keeps all the elements and activities together aligned towards the common 
goal: “the attainment by all peoples of the highest possible level of health”. 
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1. Introduction 
Environmental, political, economic, social and technological changes all have important 
implications for human health. In this context, in order to enable the countries to tackle 
current and newly-arising health challenges, guidance is required crucially from interna-
tional/ intergovernmental bodies on health matters, including World Health Organization 
(WHO) as the leading one. However, a consensus is lacking on the meaning of concepts of 
public health, including health system and its components, and the ways public health 
and health systems relate to each other. It is not possible to provide proper guidance 
globally if the interrelations of these basic concepts that are used so frequently in the 
international fora are not clear to all involved parties.   
The scientific and grey literature is rich in definitions and descriptions of concepts that are 
related to public health, health system and its components, and some major areas such as 
governance for health. Certain groups might consider that there is a fair consensus on one 
or more of these for different contexts or purposes. However, when it comes to bringing 
them together to use in practice, various areas of confusion within the terminology ap-
pear. There is no conceptual framework that brings all these together in a coherent way 
and explains how they are interrelated.  
The overall aim of this paper is to contribute to the goal of achieving a coherent terminol-
ogy, mainly from the perspective international/ intergovernmental bodies on health mat-
ters, in particular the WHO. For that, we take the endeavor to integrate the concepts of 
public health, including health system and its components, into a single conceptual 
framework, explaining how they are interrelated, and provide a visual depiction. We will 
first make a brief review of the key concepts we will use and highlight the problems with 
this terminology and causes of confusion. We will then propose our conceptual framework 
and some further clarifications as possible solutions. Then, we will discuss and conclude 
with the possible added values of Health Globe in the field. 
2. Main concepts and confusion within the terminology 
In this section, we provide the conceptual basis of the components that will be used in the 
framework we’ll introduce in the following section.  
2.1. Overview of the main terms and definitions 
A brief historical context and the list of concepts that will be used are provided below. We 
summarize some of the prominent and/or conflicting definitions that we’ve identified for 
each.  
Context and purpose of ‘Public Health’ 
The Global Strategy for Health for All by the Year 2000 [1], encapsulates the paradigm 
shift that took WHO from a ‘combating disease’ approach to one that considered health 
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policy in the broadest sense. WHO’s ‘Health for All’ (HFA) defined health not as the sole 
domain of national ministries of health, but as a phenomenon that is shaped by the entire-
ty of a nation’s activities. As a result, numerous different areas came within the scope of 
HFA strategies: peace as a prerequisite for health, agricultural policy, income distribution, 
housing policies, national education, urbanization, etc. 
The implementation of HFA strategies necessitates that all societal decisions' implications 
on health should be considered. Legislation and regulation, governmental implementa-
tions of policies, juridical decisions, and the actions of the public and private sector and 
non-governmental organizations (NGOs), all need to comply with the objective of “the 
attainment by all peoples of the highest possible level of health” [2]. This approach to 
decision making refers to ‘governance for health’ (see later).  
Health is not only the product of activities with the primary intention for health. Ottawa 
Charter introduced that there are pre-requisites for health, which consist of peace, shel-
ter, education, food, income, a stable eco-system, sustainable resources, social justice, 
and equity [3]. Non-health systems’ health related activities are those that don’t have 
health as their primary mandate, but have the potential to influence health, such as traffic 
control, the taxation of tobacco products, the regulation of agricultural products, etc.  
The importance of non-health sectors’ activities on the health status of the population is 
emphasized once more with the introduction of Health in All Policy (HiAP) by the Finnish 
EU Presidency in 2006 [4]. It emphasizes the fact that all policies such as transport, hous-
ing, the environment, education, fiscal policies, tax policies and economic policies have an 
impact on health. Health is determined by not only health related activities, but also the 
social and economic context of individuals, emphasizing the social determinants of health 
as an epidemiological concept [5]. 
Public Health 
One of the earliest and most prominent public health definitions is made by Winslow. This 
is the largest possible definition within the context of his time (1920): “the science and art 
of preventing disease, prolonging life, and promoting physical health and efficiency 
through organized community efforts for the sanitation of the environment, the control of 
community infections, the education of the individual in principles of personal hygiene, 
the organization of medical and nursing services for the early diagnosis and preventive 
treatment of disease, and the development of the social machinery which will ensure to 
every individual in the community a standard of living adequate for the maintenance of 
health”. 
Until the 1970s, WHO’s activities focused primarily on combating disease. Beginning in 
that decade, HFA policies were adopted in order to attain WHO’s constitutional objective 
of “the attainment by all peoples of the highest possible level of health” [2]. This approach 
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brought health’s political, economic and social dimensions to the fore, with a particular 
emphasis on equity. This visionary paradigm shift led to the broadening of the scope of 
public health. In 1988, Acheson defined public health as “the science and art of preventing 
disease, prolonging life and promoting health through the organised efforts of society”. 
This definition captures also the HFA approach, and remains complete to this day. That 
said, attempts have been made to elaborate this definition further and emphasize certain 
key terms [6, 7]. It is also of note that, public health encompasses the ‘health services’, 
including more narrow concept of ‘medical care’ [8, 9], as a part of the ‘organised efforts 
of society’ in Acheson’s definition. 
Terms similar to ‘public health’ are used in different contexts with different meanings, and 
can lead to confusion: The ‘public’s health’ or the ‘health of the public’ [10] refers to 
society’s health level. ‘Public health services’ (emphasis on ‘public’) refers to health ser-
vices that are offered by the governmental sector or other public bodies [8], as opposed to 
the private sector. This is analogous to the use of ‘private hospitals’ versus ‘public hospi-
tals’, or ‘private health insurance’ versus ‘public health insurance’. ‘Public health services’ 
(emphasis on ‘public health’) refers to special types of health services. For example, the 
sanitary-epidemiologic services offered under the former Soviet Union’s Semashko 
scheme are an example of public health services. 
Within the context of the Region of Americas (Pan American Health Organization - PAHO), 
and especially in the USA, the debate has focused on the assignment of a mandate for 
public health. While early discussions emphasized the responsibilities of public authorities 
[11, 12], the current understanding has settled on a scope that defines society as a whole 
as actors (i.e., including the private sector) and, therefore, bearing certain responsibilities 
in the area of public health [13, 14]. As a part of this discussion, the 10 essential public 
health services was defined by the Public Health Functions Steering Committee in US [15]. 
These outline the minimum responsibilities that must be borne by public authorities. 
The scope of public health is often narrowed as a part of public health education. This is 
primarily because such education is provided by medical schools / faculties, and is misla-
beled as ‘public health’, when the content is actually ‘community/social medicine’ [9]. 
Similarly, in instances where public health education is provided outside of medical facul-
ties, health services have been moved out of public health’s scope, and the term has been 
limited to the study of environmental and social influences on health and disease, focusing 
on disease prevention and health promotion [16].  
The new European health policy framework developed by the World Health Organization 
Regional Office for Europe (WHO Europe), Health 2020, initially introduces public health as 
“…a dynamic network of stakeholders at all levels of society and aims to support action 
with unity of purpose across the Region.” in its Foreword by the Regional Director, Z. 
Jakab [17]. This approach takes public health at a higher level encompassing all relevant 
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actors involved in health. Nevertheless, the rest of the document, as well as other related 
initiatives of WHO Europe [18], uses ‘public health’ in the context of a (core) set of ser-
vices/ operations that are provided in population level, which are apart from health care 
services. 
Health System and its Components 
Various definitions and frameworks on health system have been developed, in particular 
to provide a basis for assessment of its performance within various countries. A highly 
coherent and influential one was developed by Murray and Frenk in 2000 [19]. They drew 
the borders of the health system with ‘health actions’, which is any set of activities 
whose primary intent is to improve or maintain health. “And a health system includes the 
resources, actors and institutions related to the financing, regulation and provision of 
health actions.” [19] This concept was reflected to the framework of WHO on health sys-
tems performance [20] and was further elaborated in 2007 to mean “… all organizations, 
people and actions whose primary intent is to promote, restore or maintain health” [21].  
In 2002, PAHO had stated that “Public health is an integral part of the health system which 
is understood to be the interventions carried out in society with health as the primary 
goal” [13]. This definition is problematic in terms of both its scope and purpose. By putting 
it under the health system, it reduces ‘public health’ into a set of services/ functions/ 
tasks, and narrows down its meaning.  
In 2008, the Tallinn Charter defined a health system as follows: “Within the political and 
institutional framework of each country, a health system is the ensemble of all public and 
private organizations, institutions and resources mandated to improve, maintain or re-
store health. Health systems encompass both personal and population services, as well as 
activities to influence policies and actions of other sectors to address social, environmen-
tal and economic determinants of health.” [22] Thus, by going beyond ‘the activities 
whose primary purpose is health’, Tallinn definition crossed the demarcation line made in 
2000 and entered the non-health sectors’ territories when defining health system.   
In their conceptual framework, Murray and Frenk defined goals and functions of health 
systems. Three main goals are health, responsiveness and fairness in financial contribu-
tion. Four basic functions that need to be performed by every health system are financing, 
provision, stewardship and resource generation. This framework provided the basis of 
WHO’s health system performance assessment framework, which was used in World 
Health Report 2000 [20].  
In the context of WHO’s guidance development for health systems strengthening, in 2007, 
WHO simplified this into six building blocks, which are prioritized areas of health systems 
that commonly needs strengthening: Health services; health workforce; health infor-
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mation system; medical products, vaccines and technologies; health financing; and leader-
ship and governance [21].  
A more recent work by Atun and Menabde emphasized that health systems are complex 
dynamic systems and effective interventions can be developed only when they are ana-
lyzed together with their demographic, economic, political, legal and regulatory, epidemi-
ological, social and technological contexts which they interact with [23].  
There are also various other frameworks or tool sets that are, for example, developed to 
measure, assess or compare health systems’ performance [24], to guide health reforms 
[25], to analyze the investments for health systems strengthening [26], or for the context 
of specific countries [27]. 
Governance for Health 
The use of the concept of (good) governance [28] became widespread at the end of the 
1980s, making its way into WHO terminology in the 1990s, where it was used in the con-
text of public health [20, 29, 30]. Despite the growing interest in this concept globally, a 
consensus on a clear and actionable description of this function has been lacking [31]. In a 
recent report commissioned by WHO Europe in the context of Health 2020, Kickbusch and 
Gleicher define governance for health as “the attempts of governments or other actors to 
steer communities, countries or groups of countries in the pursuit of health as integral to 
wellbeing through both a ‘whole-of-government’ and a ‘whole-of-society’ approach” [32]. 
In the broader context of HiAP, governance can be considered as the verb for acting on 
social determinants of health to achieve HiAP [5]. The whole-of-government and whole-
of-society approaches have been embraced in various recent policy documents and re-
ports [17, 33, 34]. 
Governance is a term that is distinct from ‘government’ [35]. It should further be noted 
that ‘government’ does not refer solely to the executive branch, but also encapsulates the 
state’s legislative and judiciary functions. 
Stewardship (health system function) 
Stewardship defines strategic directions for the health system. It also sets, implements, 
and monitors the rules of the health system [19]. Stewardship assures a level playing field 
for all actors in the system [19]. Stewardship can be divided into six subfunctions: overall 
system design, performance assessment, priority setting, inter-sectoral advocacy, regula-
tion, and consumer protection [19, 36].  
Health Services (health system function) 
Provision of health services has been described as “combination of inputs into a produc-
tion process that takes place in a particular organizational setting and that leads to the 
delivery of a series of interventions” [19]. Murray and Frenk clarify the conventional dif-
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ference between personal and non-personal health services: “The former refer to services 
that are consumed directly by an individual, whether they are preventive, diagnostic, 
therapeutic or rehabilitative, and whether they generate externalities or not. The latter 
refer to actions that are applied either to collectivities (e.g., mass health education) or to 
the non-human components of the environment (e.g., basic sanitation).” 
Health System Financing (health system function) 
“Health system financing is the process by which revenues are collected from primary and 
secondary sources, accumulated in fund pools and allocated to provider activities” [19].  
Resource Generation (health system function) 
Resources in a health system cover human resources, physical resources such as facilities 
and equipment, and knowledge [19].  
Health Gain 
Health gain is an increase in the measured health of an individual or population, including 
length and quality of life [37]. 
Equity 
“Equity in health implies that ideally everyone should have a fair opportunity to attain 
their full health potential and, more pragmatically, that no one should be disadvantaged 
from achieving this potential, if it can be avoided. The term inequity ... refers to differ-
ences in health which are not only unnecessary and avoidable but, in addition, are consid-
ered unfair and unjust.” [38]  
Environmental Health Services 
In the HFA context, environmental health was defined in the broadest sense as “… those 
aspects of human health, including quality of life, that are determined by physical, chemi-
cal, biological, social and psychosocial factors in the environment.” and the environmental 
health services as implementation of the environmental health policies, without re-
striction to any sector [39].  
Primary Care Services 
Primary care services are the first level of contact that individuals and the family have 
with health care services, bringing health care as close as possible to where people live 
and work. These form the first element of a continuing health care process [40, 41]. It 
should be noted, however, that the scope of the ‘primary care services’ is narrower than 
the scope adopted for ‘primary health care’ in the Alma-Ata declaration [41, 42]. 
2.2. Main confusion areas within the terminology 
The terminology around the concepts of public health, including health system and its 
components, is confusing in various points, such as listed below:  
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 Public health concept is used inconsistently, even within WHO, in a way that it 
means different things in different contexts and time frames, in particularly ow-
ing to the use and meaning of ‘public’ in the noun phrase.  
 The relationship of public health with health systems is not clear. This leads to 
confusions in communication in the field. Some consider that ‘public health’ or 
‘health system’ contains the other and some consider them equally separate 
(public health services vs. health (care) services). 
 Clarity on the levels of health services is lacking, in particular in relation to what is 
considered as ‘public health services/functions/operations’. 
 The place and content of primary care services within the health services is not 
always clear. 
 Governance and stewardship concepts are (still) used inter-changeably, leading 
to confusion on the responsibilities of ministries of health.  
 The growing interest in making health a whole-of-government and whole-of-
society agenda item is further complicating the clarity of the above-mentioned 
definitions and creating confusion on who is responsible for which services. 
Overall, various concepts are defined for specific purposes, which might be coherent and 
well valid for their own context. However, they don’t make a whole picture when they are 
brought together in a piecemeal way. There is a need for coherent overarching conceptual 
framework that integrates them and clarifies their meanings. 
3. Proposed solution 
3.1. Health Globe 
In this section, we build on the definitions made in the previous section and propose 
‘Health Globe’ as a coherent framework that integrates different elements of public 
health, including health system and its components, into a single framework. The HFA 
paradigm of WHO is used as an overarching approach to health, which integrates all com-
ponents in the Health Globe in Figure 1. It defines the approach adopted by HFA as ‘public 
health’ in its entirety. Since Acheson definition is also in line with HFA, it is compatible 
with Health Globe’s approach. Everything that relates to a society’s health is thus catego-
rized as a part of public health, in the sense that it aims to attain the highest possible level 
of health by all peoples. 
The involvement of whole-of-society and whole-of-government in health is labeled as 
governance for health on the Health Globe (the fluid filling the globe in Figure 1), adopting 
the term in the broadest sense as defined by Kickbusch and Gleicher [32]. Pre-requisites 
for health and non-health systems’ health related activities are depicted with two types of 
particles as seen in the Health Globe (Figure 1). 
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Figure 1: Health Globe 
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Figure 2: Health System Pyramid and its Three Facades 
 
Chapter 2 
44 
The pyramid inside the Health Globe represents the ‘health system’. The framework de-
veloped by Murray and Frenk provide the coherent basis to structure its components. We 
adopt this framework to a large extend, while elaborating it at some functions as de-
scribed below. 
As Murray and Frenk described, health system has four key functions: stewardship, financ-
ing, service provision and resource generation [19, 20]. In Health Globe, the term ‘health 
services’ has been preferred over ‘service provision’ since it will be covered in more details 
as lines of services (see later). Here, we adopt the ‘health actions’ concept [19] and, thus, 
this pyramid covers activities that fall within the mandates of ministries of health. 
For visual clarity, health services function has been depicted in the first facade of the pyr-
amid (Figure 2, Facade 1). The services listed on this surface move up vertically from the 
bottom: societal to individual; and general to specialized.  
As the services go up, they become more specifically a health sector issue and as they go 
down, they become more multi-sectoral in nature, falling into the domains of non-health 
sectors as well. For the latter, we cover the tasks of the health system, in particular the 
contribution of the ministries of health in this pyramid.  
Health Globe adopts the clarification made between personal and non-personal health 
services by Murray and Frenk, and denotes latter as ‘population based’, in the first facade. 
Each service type is covered below. 
For environmental health services, we adopt a modified version of the definition made by 
Fitzpatrick and Bonnefoy [39]. They defined the term to cover all activities related to im-
plementation of environmental health policies, by all sectors. For the sake of coherence, in 
the context of this pyramid, the tasks of the health system, in particular ministries of 
health, within the environmental health services are covered. 
Population based health protection initiatives refer to the regulation of activities that 
have the potential to damage people’s health. These include, among others, the regula-
tion of food additives, safety standards for tools, including toys, and rules such as manda-
tory seat-belt use in motor vehicles. The health system may not be the one that operates 
or executes these functions, but play an important role in their realization by creating 
awareness, generating and disseminating knowledge, developing guidelines and providing 
advisory and consultancy functions. 
Population based health promotion includes initiatives that target the whole society to 
combat unhealthy behaviors, as well as the promotion of healthy nutrition and physical 
activity. Depending on the context of the countries, the role of non-health sectors might 
be more prominent in some of these activities and health system may carry out the tasks 
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that support the non-health sectors, as listed above for population based health protec-
tion. 
The most common examples for population based disease prevention include the vac-
cination of school children, mass screening campaigns targeting certain types of diseases, 
disease awareness initiatives and prevention of epidemics. 
We adopt the primary care services definition and clarification that was made in the pre-
vious section. Additionally, primary care services include home care, which is also given by 
a primary care services team. Primary care services cover the following four groups:  
A) Services provided to the individual for the promotion of a healthy lifestyle, covering 
aspects such as nutrition, physical activity, smoking cessation, and psychosocial well-
being, fall under personal health promotion services. 
B) Personal disease prevention services refer to interventions that protect against disease 
at the individual level. They include personal preventive services conducted by a family 
physician or general practitioner. Influenza shots for seniors, smear tests for women, the 
prescription of aspirin for those with high cardiometabolic risk, and travel vaccinations 
(can be provided in different settings) are some examples of such services. 
C) Primary diagnostic and curative services are activities that aim to diagnose and treat 
diseases within the scope of primary care services. 
D) Primary care rehabilitative services are composed mostly of follow-ups to specialized 
care. These include services such as the rehabilitation of patients after cardiac or orthope-
dic surgeries. These are coordinated through a primary care service provider.  
Specialized care covers services provided by specialized health professionals, usually in 
hospitals, outpatient or inpatient settings. Such activities were formerly classified as sec-
ondary or tertiary care services and referred solely to inpatient care. Since this distinction 
no longer exists, we group all of these activities under specialized care. 
Crisis management involves the health services component of emergencies, natural disas-
ters and other health crises. This includes preparedness for and response to all such situa-
tions. All levels of health services have their mandates within this vertical responsibility. 
However, one should keep in mind that crisis management has a wider scope under the 
governance for health, including risk reduction measures such as flood mitigation works 
and appropriate land-use planning. 
The second facade of the pyramid shows the functions of the health system (Figure 2, 
Facade 2): stewardship, resource generation and financing. These enable the provision of 
health services, which was depicted in Facade 1. They are represented vertically, since 
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they involve all levels of the health services covered in the first facade of the pyramid. We 
adopt the stewardship definition made by Murray and Frenk, summarized in the previous 
section. However, we modify its subfunctions to include priority setting, legislation and 
regulation, steering, administration and management. In general, stewardship can be 
considered as the primary function of a country’s ministry of health. In line with Murray 
and Frenk, resource generation refers to human resources, physical resources and 
knowledge. Universities, pharmaceutical and medical technology companies and many 
other public and private organizations and initiatives can fall under this heading. Murray 
and Frenk’s health system financing definition can be shortly sub-grouped as revenue 
collection, fund pooling and purchasing.  
The third facade of the pyramid depicts the objectives of the health system (Figure 2, 
Facade 3). Modifying Murray and Frenk’s slightly, we set the objectives as health gain, 
equity, responsiveness, and effectiveness and efficiency. We adopt the health gain and 
equity definitions quoted in the previous section. Health gain is an increase in the meas-
ured health of an individual or population, including length and quality of life [37]. Within 
the context of health services, equity refers to the idea that everyone should have access 
to health services in accordance with their needs, and should contribute to the financing 
of these services in accordance with their means. The third objective is enhancing the 
responsiveness of the health system to the legitimate expectations of the population, as 
described by Murray and Frenk [19]. Patient satisfaction and satisfaction of the health 
workforce also fall under this category. 
Effectiveness and efficiency are a health system’s economic objectives. Effectiveness is 
about allocating resources to the right interventions to ensure the maximum level of 
health gain, whereas efficiency is to use resources in the most convenient way to reduce 
the costs. Effectiveness is doing the right thing; efficiency is doing the thing right. 
3.2. Further clarifications 
A few areas remit further emphases and/or clarifications.  
As for the discussion on whether health system is a part of public health or the other way 
around, as we have proposed in Figure 1 and in line with the scope adopted by HFA, we 
are in opinion that the health system is a part of public health. As summarized in Section 
2, confusions are mainly caused by the use of noun phrase and the meaning of ‘public’ in 
it. In order to avoid such confusions: 
 The term ‘public health services’ used to cover services not targeting individuals, 
but populations, could be replaced with the term ‘non-personal health services’ 
or ‘population based services’ [8, 19]; 
 The term ‘publicly provided health services’ could be used to refer to health ser-
vices provided by public entities;  
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 Reference to the concept of the ‘health of the public’ could be made using the 
term the ‘public’s health’. 
The term ‘essential public health services/ functions’ [13, 15] used in the Americas is com-
patible with the ‘health systems’, and encompasses various elements from the three fa-
cades of the health pyramid. Similar efforts to define ‘public health’ as tasks, services, 
operations or functions across countries are highly likely to yield problematic results be-
cause these are eventually (sub)functions of health systems and each country have differ-
ent structures to fulfil them. Furthermore, it creates confusion on the side of policy mak-
ers on what public health is. Is it a set of tasks, or is it the broad approach to population 
health?  
To be more explicit; we criticize use of ‘public health’ in any way that narrows down its 
meaning to tasks, functions, operations or services. If the purpose is to list a set of specific 
services that should be provided by (certain) public agencies, it should be done so with the 
use of the technical name of the services; for example ‘sanitation’, ‘environmental health’ 
or ‘training of health workforce’. The tendency to call a set of ‘services’ as ‘public health’ 
seems to be (historically) rooted in the institutions that provide education on these, as 
conveyed in section 2.1.  
The terms governance and stewardship has often been used inter-changeably depending 
on the purpose and perspective of the document in question. However, as clarified in the 
previous section, stewardship refers to a ministry of health’s function within a country’s 
health system. The initiatives conducted by a ministry of health in coordination with other 
ministries and sectors, which aim to influence health through areas outside of the health 
system, form the ministry’s ‘governance for health’ activities. Therefore, these terms 
should not be used inter-changeably. As such, the part of the Tallinn Charter on health and 
stewardship (“activities to influence policies and actions of other sectors to address social, 
environmental and economic determinants of health” [22]) should be handled at a higher 
level, under the definition of governance. 
4. Discussion and conclusions 
In this paper, we proposed Health Globe as an endeavor to integrate concepts of public 
health into a single framework, in order to achieve a coherent terminology for policy mak-
ers and those who guide them internationally. In Health Globe, we provided an under-
standing of the term ‘public health’ in line with the HFA vision, where all activities that 
directly or indirectly affect individuals’ health, including all medical and non-medical inter-
ventions, governmental decisions and practices, and the activities of the public sector, the 
private sector and NGOs, falls within the scope of ‘public health’.  
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A point to note here is the distinction between ‘individuals’ and the ‘public’. Any approach 
that does not include the health services provided to individuals under public health will 
both prove inadequate in light of the medical advances of the 21
st
 century, and will be 
problematic from a policy making perspective. 
We paid particular attention to design the framework to be applicable to different parts of 
the globe and different health systems, and conceptually and practically be relevant to 
real life contexts. It can in particular be useful for WHO, which serves to member states all 
around the globe. 
We believe that Health Globe might provide an added value to the existing literature and 
practices in three areas: 
First of all, Health Globe invites health policy makers to think on crucial points and revisit 
the HFA strategy in determining a course for public health policy in the 21
st
 century. The 
discussions that took place after HFA have not been able to make a significant leap over 
what HFA described in the broad sense. HFA still provides a robust, technically correct, 
visionary and up-to-date approach. When new approaches beyond HFA are explored in 
WHO, its member states or academia, this should be kept in mind. 
Second point is that Health Globe serves to the efforts to reach a coherent terminology. 
When we look at the debates in the last decades, we see that a common language hasn’t 
been established in terms of the terminology and concepts. We believe that Health Globe 
can be instrumental to solve this problem since it aims to integrate the definitions that 
have been made in different contexts. There will surely be ones who do not agree with 
this framework. We invite them to propose alternative frameworks that aim to describe 
the interrelations of these concepts. In such endeavors, it is crucially important to attain 
coherence and consistency within these frameworks and relevance with the real life in the 
field. Professional and institutional conservatism must be avoided, as well.  
Finally, Health Globe describes the interrelations of these concepts in a simple visual 
frame. Visual depictions enable concepts and their interrelations to be understood and 
communicated more easily. This eventually can facilitate the debate on the terminology. 
References 
1. Global Strategy for Health for All by the Year 2000. Geneva: World Health Organization 
1981. 
2. Constitution of the World Health Organization: World Health Organization 2006. Available 
from: http://www.who.int/governance/eb/who_constitution_en.pdf. 
3. Ottawa Charter for Health Promotion, First International Conference on Health Promotion, 
Ottawa, 21 November 1986: World Health Organization; 1986 November 17-21, 1986. 
    
A framework for public health and health systems interrelations: Health Globe 
49 
4. Ståhl T, Wismar M, Ollila E, Lahtinen E, Leppo K. Health in All Policies: Prospects and 
potentials. Finnish Ministry of Social Affairs and Health, European Observatory on Health Systems 
and Policies, 2006. 
5. McQueen DV, Wismar M, Lin V, Jones CM. Introduction: Health in All Policies, the social 
determinants of health and governance. In: McQueen DV, Wismar M, Lin V, Jones CM, Davies M, 
editors. Intersectoral Governance for Health in All Policies. Observatory Studies Series. 26. 
Copenhagen: World Health Organization on behalf of the European Observatory on Health Systems 
and Policies; 2012. p. 3-23. 
6. World Health Report 1998: Life in the 21st century – A vision for all. Geneva: World Health 
Organization; 1998. 
7. Pencheon D, Guest C, Melzer D, Gray M. Introduction. In: Pencheon D, Guest C, Melzer D, 
Gray M, editors. Oxford Handbook of Public Health Practice: Oxford University Press; 2006. 
8. Frenk J. The new public health. Annu Rev Public Health. 1993;14:469-90. PubMed PMID: 
8323599. 
9. Terris M. Editorial: The distinction between public health and 
community/social/preventive medicine. Journal of public health policy. 1985 Dec;6(4):435-9. 
PubMed PMID: 4093498. 
10. Verweij M, Dowson A. The Meaning of ‘Public’ in ‘Public Health'. In: Dawson A, Verweij M, 
editors. Ethics, Prevention, and Public Health: Oxford University Press; 2009. 
11. The Future of Public Health. Washington, D.C.: The National Academies Press; 1988. 
12. Essential Public Health Functions. 42nd Directing Council & 52nd Session of the Regional 
Committe, Washington, D.C., 25-29 September 2000. (CD42/15): Pan American Health Organization, 
World Health Organization; 2000 [cited 27 August 2012. Available from: 
http://www.paho.org/english/gov/cd/cd42_15-e.pdf. 
13. Public Health in the Americas: Conceptual Renewal, Performance Assessment, and Bases 
for Action. Washington, D.C.: Pan American Health Organization - Pan American Sanitary Bureau, 
Regional Office of the World Health Organization; 2002. 
14. The Future of the Public's Health in the 21st Century: The National Academies Press; 2003. 
15. Public Health Functions Steering Committee. Public health in America 1994 [11 April 
2013]. Available from: http://health.gov/phfunctions/public.htm. 
16. "L. White. Healing the schism: epidemiology, medicine, and the public’s health. New York: 
Springer-Verlag; 1991.” In: Khoury MJ, Gwinn M, Burke W, Bowen S, Zimmern R. Will genomics 
widen or help heal the schism between medicine and public health? Am J Prev Med. 2007 
Oct;33(4):310-7. PubMed PMID: 17888858. Epub 2007/09/25. 
17. Health 2020. A European policy framework and strategy for the 21st century. Copenhagen: 
World Health Organization Regional Office for Europe; 2013. 
18. European Action Plan for Strengthening Public Health Capacities and Services: World 
Health Organization Regional Office for Europe; 2012. Available from: 
http://www.euro.who.int/en/what-we-do/event/first-meeting-of-the-european-health-policy-
forum/documentation/working-papers/strengthening-public-health-capacities-and-services-in-
europe-a-framework-for-action. 
19. Murray CJ, Frenk J. A framework for assessing the performance of health systems. B World 
Health Organ. 2000;78(6):717-31. PubMed PMID: 10916909. Pubmed Central PMCID: 2560787. 
20. World Health Report 2000: Health Systems: Improving Performance. Geneva: World 
Health Organization; 2000. 206 p. 
 
Chapter 2 
50 
21. Everybody’s business: Strengthening health systems to improve health outcomes: WHO’s 
framework for action. Geneva: World Health Organization; 2007. 44 p. 
22. The Tallinn Charter: Health Systems for Health and Wealth. Adopted at WHO European 
Ministerial Conference on Health Systems: “Health Systems. Health and Wealth” Tallinn, Estonia, 27 
June 2008.: World Health Organization Europe. Available from: 
http://www.euro.who.int/__data/assets/pdf_file/0008/88613/E91438.pdf. 
23. Atun R, Menabde N. Health systems and systems thinking. In: Coker R, Atun R, McKee M, 
editors. Health Systems and the Challenge of Communicable Disease: Experiences from Europe and 
Latin America. European Observatory on Health Systems and Policies Series. Berkshire, England: 
Open University Press; 2008. p. 121-40. 
24. Kelley E, Hurst J. Health Care Quality Indicators Project Conceptual Framework Paper. 
Paris: Organisation for Economic Co-operation and Development; 2006. Available from: 
http://www.oecd.org/els/health-systems/36262363.pdf. 
25. Roberts M, Hsiao W, Berman P, Reich M. Getting Health Reform Right: A Guide to 
Improving Performance and Equity: Oxford University Press; 2004. 332 p. 
26. Shakarishvili G, Lansang MA, Mitta V, Bornemisza O, Blakley M, Kley N, et al. Health 
systems strengthening: a common classification and framework for investment analysis. Health 
policy and planning. 2011 Jul;26(4):316-26. PubMed PMID: 20952397. Pubmed Central PMCID: 
3118911. 
27. The Commonwealth Fund Commission on a High Performance Health System. Framework 
for a High Performance Health System for the United States: The Commonwealth Fund; 2006. 
Available from: http://www.commonwealthfund.org/~/media/files/publications/fund-
report/2006/aug/framework-for-a-high-performance-health-system-for-the-united-
states/commission_framework_high_performance_943-pdf.pdf. 
28. Sub-Saharan Africa: From Crisis to Sustainable Growth. Washington, D.C.: World Bank; 
1989. 
29. Health for all in the twenty-first century. Revista Panamericana de Salud Pública. 
1998;4:132-41 (condensed from WHO Document A51/5, Health for all in the twenty-first century. 
Geneva, World Health Organization, 1998). 
30. Health21: the health for all policy framework for the WHO European Region. Copenhagen: 
World Health Organization Regional Office for Europe; 1999. 
31. Barbazza E, Tello JE. A review of health governance: Definitions, dimensions and tools to 
govern. Health Policy. 2014 5//;116(1):1-11. 
32. Kickbusch I, Gleicher D. Governance for health in the 21st century Copenhagen: World 
Health Organization Regional Office for Europe; 2012. 128 p. 
33. Adelaide Statement on Health in All Policies: moving towards a shared governance for 
health and well-being - Adelaide: World Health Organization, Government of South Australia; 2010. 
Available from: http://www.who.int/social_determinants/hiap_statement_who_sa_final.pdf. 
34. UCL Institute of Health Equity. Review of social determinants and the health divide in the 
WHO European Region: final report. Copenhagen: World Health Organization Regional Office for 
Europe; 2013. Available from: http://www.instituteofhealthequity.org/projects/who-european-
review. 
35. Dodgson R, Lee K, Drager N. Global Health Governance - A Conceptual Review: Centre on 
Global Change & Health, London School of Hygiene & Tropical Medicine; Dept of Health & 
Development, World Health Organization; 2002. Available from: 
http://whqlibdoc.who.int/publications/2002/a85727_eng.pdf. 
    
A framework for public health and health systems interrelations: Health Globe 
51 
36. Londoño J-L, Frenk J. Structured pluralism: towards an innovative model for health system 
reform in Latin America1. Health Policy. 1997 7//;41(1):1-36. 
37. "Roberts, J.L. Terminology for the WHO Conference on European Health Care Reform. 
Copenhagen, WHO Regional Office for Europe, 1996." In: Health21: the health for all policy 
framework for the WHO European Region. Copenhagen: World Health Organization Regional Office 
for Europe; 1999. 
38. Whitehead M. The concepts and principles of equity and health (EUR/ICP/RPD 414, 7734r). 
Copenhagen: World Health Organization Regional Office for Europe; 1990. 
39. Fitzpatrick M, Bonnefoy X. Environmental Health Services in Europe 4: Guidance on the 
Development of Educational and Training Curricula. Copenhagen: WHO Regional Office for Europe; 
1999. 
40. Declaration of Alma-Ata - International Conference on Primary Health Care, Alma-Ata, 
USSR, 6-12 September 1978: World Health Organization. Available from: 
http://www.who.int/publications/almaata_declaration_en.pdf. 
41. Western Pacific regional strategy for health systems based on the values of primary health 
care: World Health Organization, Western Pacific Region; 2010. 
42. Primary health care – Main terms used: WHO Europe web site;  [cited 2012 27.08.2012]. 
Available from: http://www.euro.who.int/en/what-we-do/health-topics/Health-systems/primary-
health-care/main-terms-used. 
 52 
Life is difficult. This is a great truth, one of the greatest truth... Once we truly know that life 
is difficult-once we truly understand and accept it-then life is no longer difficult. Because 
once it is accepted, the fact that life is difficult no longer matters. 
M. Scott Peck 
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Health for America: European Arguments for a Paradigm Shift. 
Abridged version of the chapter is published in Shah A, 
Colombano J, editors. Learning from the World: New Ideas to 
Redevelop America Palgrave Macmillan; 2013. p. 167-84. 
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Abridged version of this chapter was published as Savas BS, Cesuroglu D. Health for America: Euro-
pean Arguments for a Paradigm Shift. In Shah A, Colombano J, editors. Learning from the World: 
New Ideas to Redevelop America, Palgrave Macmillan; 2013. p. 169-86. 
In the course of the editorial process of the above mentioned book, this chapter was abridged by 
taking out the two sections that explained the shortcomings of the US system in depth, in particular 
in relation to broader policy values. In this dissertation, these sections are added in the form of two 
boxes, as noted also in the text.  
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1. Introduction 
The United States is faced with a major ethical responsibility in health. While it is the 
world’s largest economy, with by far the most powerful army. the level of health of its 
citizenry is relatively low, out of line with its income and development level. 
The health status of the US populace is one of the worst among countries in the Organisa-
tion for Economic Co-operation and Development (OECD), as shown by life expectancy, 
mortality, and morbidity indicators. The US ranks 27 within its peer group of 34 OECD 
countries for life expectancy at birth (78,2 years for the total population in 2009) (see 
Figure 1). The infant mortality rate was 6,5 deaths per 1.000 live births in 2008, well above 
the OECD average of 4,4 in 2009. Obesity is at an alarming rate for adults and children, 
with 34 % of the adult population classified as obese and 32 % of children classified as 
obese or overweight in 2008. These levels are the highest among OECD countries. 
Given these health indicators, it is interesting to note that the US is by far the highest 
spender on healthcare among OECD countries (see Figure 2), both in terms of the per-
centage of gross domestic product (17 %) and per capita expenditure ($7.960) devoted to 
health. This per capita number is 2,5 times more than the OECD average of $3.223. 
Unlike most OECD countries, where health spending is mainly financed by the government 
out of taxes or social security contributions, government spending in the US accounts only 
for half of total health expenditure. That said, the total level of health spending in the US 
is so high that per capita public (i.e., government) spending on health is greater than in all 
other OECD countries, except for Norway and the Netherlands. Despite this high level of 
expenditure, the US government provides coverage only for a limited group of people, 
which includes the elderly and disabled (through Medicare) and a portion of the poor 
(through Medicaid and the State Children’s Health Insurance Program). This per capita 
amount would be enough for most OECD country governments to provide universal health 
insurance coverage. 
The high expenditure and low health outcomes show that the US health system is ineffec-
tive. The country’s wealth is not translated into gains in health. 
The US system establishes a strong basis for an inequitable distribution of health. There 
are more than 50 million uninsured people in the U.S. (17 % of the population in 2011) 
who are not provided health insurance by an employer and are unable to afford, cannot 
qualify for, or choose not to purchase health insurance. When healthcare services through 
charity are not available, they simply do not get the medical care and treatment they 
need. Furthermore, healthcare costs create a significant burden even for insured families. 
It is estimated that around one-fifth of the insured population is actually ‘underinsured’.   
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Such people have some form of health insurance, but face significant cost-sharing provi-
sions or limits on benefits. These factors render their insurance useless in paying for need-
ed health services. This is evidenced by the fact that, in 2007, nearly 80 % of bankruptcies 
linked to medical expenses (which formed 62 % of all bankruptcies) were filed by people 
who had health insurance. 
The system also hosts disparities in access to health and health status. Even more striking 
than the percentage of uninsured people is the fact that 10 % of children under 18 are 
without any coverage, neither public nor private. For children in poverty, this rate increas-
es to 15 %. Indicators also show important disparities in health for disadvantaged popula-
tions, such as minorities, women, children, and the elderly. For example, Hispanic/Latino 
Americans and African Americans, and especially their children, are much more affected 
by the obesity epidemic. 
The system causes great inefficiencies owing to various factors, including payment sys-
tems that reward inputs, processes, and outputs, rather than actual health outcomes; high 
administrative costs; and an inadequate focus on disease prevention. 
The US healthcare industry’s administrative costs are strikingly high. Health administration 
costs in 1999 were $1.000 per capita in the US as compared with $300 in Canada. Such 
costs flow through the system to affect the entire range of actors, including insurance 
companies, healthcare providers, and pharmaceutical, diagnostic, and medical supplies 
industries. Additional administrative costs accrue from several factors, including the bu-
reaucracy surrounding the filing of insurance claims, the bureaucracy necessary to ensure 
compliance with state and federal regulations, lobbying and marketing, and the malprac-
tice insurance system for healthcare professionals—mainly doctors and healthcare facili-
ties. The direct costs of malpractice litigation represent a small fraction of total healthcare 
costs (0,46 %). ‘Defensive medicine’ practices, however, which are characterized by the 
increased utilization of tests and procedures by physicians to protect against future law-
suits, create the real financial burden on the system. These are estimated by some critics 
to represent 5–9 % of total health expenditure. 
This chapter proposes solutions to problems of the US health system. The solutions we 
propose draw heavily on the experiences of European countries. We emphasize practical 
policy choices over academic concerns. While there are also positive properties of the 
current state of the healthcare sector in the US, some of which are superior to other in-
dustrialized countries, for the sake of brevity these will not be covered here. 
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Box 1: The main problems of the American Health System1 
It is possible to group the problems of America’s health system under three major head-
ings: 
America does not have a health policy 
For many years, health literature emphasized models that viewed the determinants of 
disease through a biological framework. During this period, health was supposed to be 
derived through medical care. This approach was transformed in the 1970s, as a result of 
studies that demonstrated the importance of socio-economic, environmental and behav-
ioral factors on health outcomes. 
The resulting enlarged set of the determinants of health are shown in Figure 3: 
 
Figure 3: Determinants of health and disease 
As seen above, there are four main factors, each with several sub-components that inter-
act to determine an individual’s health. A country’s health policies must be formulated to 
address all of these factors. 
Yet, discussions around ‘health policy’ or the formation of a ‘health system’ in the U.S. are 
centered solely on the provision of ‘health care’, just one of the four determinants of 
health. While it is an important determinant, it cannot be the sole component of a com-
prehensive system. As such, the U.S. does not have a health policy that leads the nations 
                                                                
1
 The section where we explained the shortcomings of the U.S. system in relation to broader policy 
values was taken out in the course of the editorial process of the publication. To maintain coherence 
within this dissertation, this material is put back in the form of a box in this chapter. 
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towards defined health outcomes, based on a thorough engagement of all determinants 
of health. 
America does not have a ‘health system’ 
Every sub-component of what could be called ‘health care’ in America developed individ-
ually and independently, in an organic manner that responded to certain historical reali-
ties. Various health care stakeholders have shaped policy and practice through the years, 
in accordance with their own desired outcomes and expectations, through lobbying and 
the targeted shaping of public opinion. Rather than aiming for a healthier nation, the re-
sulting structure is one that serves the interests of a diverse group of stakeholders. In 
short, there is no health care structure that aims to improve the nation’s health. 
Debates around ‘health problems in USA’ are centered on financial issues such as the 
rising costs of health care and shortfalls in insurance coverage. Barack Obama’s ‘health 
reform’ is the latest attempt to address these issues. This package falls far short of com-
prising a ‘reform’; it is only another incrementalist effort towards improving health care 
financing, access, coverage and costs. 
However, health care has parts other than financing, such as service delivery and steward-
ship. America does not have a values-based health system that addresses the population’s 
needs, unites all of these parts, and defines the functions of and relations between the 
various sub-parts in a consistent manner. 
In its simplest form, a ‘health system’ is composed of four main parts (Figure 4). 
‘Users’ in USA are divided between several sub-groups. Among the insured, there are 
those insured through their employers or service sectors, those that receive insurance as a 
result of their age or gender, those that pay for insurance out of pocket, and others that 
fall into insurance categories as a result of their retirement status or other reasons. Each 
policy has its idiosyncrasies, with different premium payment features and benefits. There 
are also people who are not insured. Individuals’ benefit packages are not shaped by their 
needs, but are rather formed by their initial level of health and the amount of their premi-
um payments. This is one reason why the American health system creates inequity. 
There is also a wide range of institutions on the ‘payer’ side. There are those that are not 
for profit (government schemes such as Medicare and Medicaid) as well as for-profit pri-
vate insurance companies. Each payer institution has its own internal mechanisms. In 
general, payers tend to avoid cost-effective interventions that incur costs in the present, 
but prevent disease and subsequent complications in the future, increase quality of life 
and prolong life-span. Rather, they choose to pay for the interventions that will save mon-
ey today and in the short run, but that have continued to result in ever-increasing long 
term costs. Recent legislative changes made under the presidency of Barack Obama man-
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date ceilings on administrative costs. Yet, instead of actually lowering these costs, these 
legislative changes are bound to lead to their re-classification, showing up as increased 
costs elsewhere. Such administrative costs, combined with the profit motive of many 
payers, result in upward pressure on insurance premiums. 
 
Figure 4: Main parts that constitute a health system  
The service provider landscape is similar. It spans public and private, for-profit and non-
profit institutions, without a standardization of functions. Access to primary health care 
provision is limited, and it can be said that U.S. medical staff are not trained in line with 
any overarching policy goal. Complex governance systems, profit motives, malpractice 
insurance and the subsequent tendency for defensive medicine are factors that keep costs 
high on the health service provider side. 
The three parts (Citizens – Payers – Providers) are steered and governed by a complex 
web of legislation and regulations, the organizational and management perspectives of 
which are disjoint and irregular. The stewardship and governance of the U.S. health care 
sector is not premised on common goals and objectives. 
The absence of a unified and purposeful health system in USA stems from a belief that 
health is a commodity that can be allocated efficiently and effectively through a free-
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market mechanism. This view is advocated primarily by stakeholders who benefit from the 
current system, and discussions relating to the sector consistently feature a misuse of 
concepts, which is often deliberate. 
As a result, the U.S. health system does not aim to achieve a higher, more equally distrib-
uted level of health for its citizens. It does not possess a body of values that would direct 
health initiatives towards areas that would lead to the largest improvements in health. 
Furthermore, instead of working in harmony in a synergistic manner, the various parts of 
the health system display tension and dissonance. 
The health care debate in America is conducted on ideological grounds, 
not based on sound economic theory 
An overview of the health care debate in America reveals an ideological approach, as op-
posed to an economic one. It is continuously claimed that the most appropriate method 
for the provision of health services is through the rules of a free market economy, that a 
different approach would constitute socialized medicine, that this would be the imple-
mentation of a socialist / communist system, and that this would therefore lead to lower 
efficiency and quality. 
Yet, if one were to leave ideological prejudice aside, one would see, from a scientific per-
spective, that health economics has much to say on these issues. Our intention within the 
limited scope of this paper is not to present facts that could be found in any health eco-
nomics textbook. It is important, nonetheless, to underscore a few points of importance in 
order to provide a background for our approach. 
There is a significant information imbalance between the producers (especially physicians) 
and the consumers (citizen / patient) of health care. A patient approaches a physician with 
a complaint. The patient has a need, but this need has not yet been translated into de-
mand in the economic sense. Following an examination and further diagnostic procedures, 
the physician makes a decision on what should be done with the patient. There is an agen-
cy relationship between the patient and the physician. The physician’s decision forms the 
patient’s demand. This is called supplier induced demand. Research shows that the de-
mand for treatment induced by the physician is not always for the benefit of the patient. A 
consideration by the physician of his or her own interests can be a factor that plays into 
the recommended course of action. This informational asymmetry means that there is 
limited transparency in a patient - physician relationship. Since transparency is a precondi-
tion for the efficient functioning of a free market, supply and demand cannot interact 
freely under such conditions. 
Health care also results in certain externalities, especially in the case of infectious diseas-
es. The vaccination of a child to protect her from an infectious disease reduces the chanc-
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es of her friends catching that disease. 
In addition to this, the non-excludable nature of certain health services means that health 
care is a public good: it is not always possible to prevent people who have not paid for it 
from benefiting from it. For example, in the fight against malaria, once a drainage, sanita-
tion or spraying effort has been undertaken, it is not possible to tell the remaining mos-
quitoes to only bite those people that have not paid for these services. 
The provision of health services features significant barriers to market entry, especially for 
physicians. Anyone can sell a car, a television or a vacation, but not anyone can sell diag-
nostic and treatment services. A country can import rice and textiles, but not health ser-
vices. Medical associations, not only in America but throughout the world, endeavor to 
erect barriers to entry for others in an effort to protect the interests of their professional 
membership. There are also many instances of barriers to entry in the market for insur-
ance, leading to certain regional insurance monopolies.   
Monopolies also exist in the pharmaceutical sector, where pharmaceutical companies are 
granted immunity from competition through legal arrangements such as patents and data 
protection, so that they can profit from their significant investments in research and de-
velopment.  
Most of the factors listed above lead to price increases and the implementation of treat-
ments that are harmful or the health benefits of which are limited. Furthermore, in a free 
market system where health care is purchased through out-of-pocket expenditure, citi-
zens without the ability to pay cannot afford health care, leading to serious health inequi-
ties.  
The above is not an exhaustive list of arguments for why health care cannot be treated as 
a free market commodity. A survey of health economics literature will yield other argu-
ments, in addition to further detail on those listed above. 
For years, the main beneficiaries of the status quo of the American health system have 
been groups that have benefited from the market failures outlined above. As such, these 
groups deliberately refrain from using scientific or economic arguments, and employ ideo-
logical terminology that prevents the formation of a healthy, facts-based debate.  
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Box 2: Values and principles that should guide establishment of 
American Health System2 
America needs a comprehensive, holistic, rational change in its understanding of ‘health 
policies’ and ‘health systems’. This requires a fundamental paradigm shift in the political, 
social and economic dimensions of health, challenging certain prevailing presumptions in 
American politics. Such a transformation cannot be implemented through one, two or 
three presidential terms. It requires a state policy that will manage change for several 
decades. This paradigm shift can be affected by developing an American Health Policy and 
establishing an American Health System based on certain values and principles. 
There are several values and principles inherent in many European health policies, which 
would be required for such a paradigm shift in America: 
1. Health is a basic human right 
2. Health is the complex result of many biological, social, economic, environmental, 
behavioral and health care related factors, and cannot be reduced to ‘health 
care’ alone. 
3. Health can be improved through a concerted effort undertaken by society as a 
whole 
4. Health policies must be long term and supra-political 
5. A health system should be based on the following combination of values: 
a. Health gain 
b. Solidarity 
c. Equity 
d. Effectiveness 
e. Efficiency 
6. Factors such as externalities and the vast information asymmetries between us-
ers and providers / payers mean that a free market approach to health care will 
result in significant shortcomings 
7. Health is a public good 
There is a discourse in USA that embraces these values and principles and incorporates 
suggestions that would take America towards such a values-based approach. ‘The Future 
of Public’s Health in the 21st Century’ report of the Institute of Medicine (2002) can be 
                                                                
2
 The section where we summarized the recommended policy values and principles was taken out in 
the course of the editorial process of the publication. To maintain coherence within this dissertation, 
this material is put back in the form of another box in this chapter. 
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cited as one such example. Despite thorough and thoughtful studies and recommenda-
tions put forward by these commissions, this fundamental approach and its accompanying 
system of values have not been able to penetrate into the health sector. As a result of the 
absence of a unified health system, discussions relating to public health take place in a 
vacuum that remains separated from the health services sector.  
2. Developing an ‘American Health Policy’ 
An American Health Policy must address all the determinants of health. It should not be 
legally binding. It should aim to be a guiding document that draws a framework for future 
governments, decision makers, managers, health professionals, and other related industry 
participants. Such a document should aim to declare a ‘national commitment’ to improv-
ing the health of the American nation. As a result, such a policy must incorporate rational 
and measurable long-term goals for mortality and morbidity. 
For example, the policy could set a target for “reducing deaths from coronary heart dis-
ease in the US by 20 % by 2040”. Such a target would necessitate changes in socioeconom-
ic policies, individuals’ behaviors, and environmental factors, in addition to changes in the 
provision of healthcare. These changes would include a range of efforts, such as the pre-
vention of obesity, the promotion of healthy eating habits and exercise, campaigns against 
tobacco use, the taxation of certain ‘public bads’, the identification of risks for coronary 
heart disease in the population and its sub-groups, the establishment of risk control sys-
tems, an analysis of the most cost-effective treatment methods, and the development of 
early diagnostics and timely intervention methods. Only a small proportion of these activi-
ties relate to the healthcare sector. The majority involves areas ranging from education to 
agriculture to labor policies, from taxation to inner-city traffic controls and athletics. The 
American Health Policy must establish a platform for all of these activities. It must further 
ensure that the health impacts of non-health policies (e.g., construction, transportation, 
energy policies) are considered and evaluated at all times using health impact assessment 
tools. 
Targets must be established in a similar fashion for all matters that lead to loss of health 
and life, from diabetes to osteoporosis, from asthma to traffic accidents. The necessary 
activities relating to each such field must be identified through a participatory, multi-
sectoral process, as in the example of coronary heart disease above. 
In general, the American Health System must aim for the maximum possible level of 
health for its citizens. As explained above, this will require explicit commitments to reach 
predefined targets within a certain timeframe. Ideally, targets should be ‘SMART’: Specific, 
Measurable, Accurate, Realistic, and Time-bound. 
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Successful target setting requires a thorough understanding of health and disease and the 
ability to measure the effectiveness of health interventions, as well as epidemiological, 
demographics, and modeling expertise. The US is not short on such skills. 
We argue that a policy for health extends far beyond ‘healthcare’. As such, the responsibil-
ity for developing such policies should not rest with healthcare professionals, but should 
be the task of an inter-sectoral body formed under the auspices of the federal govern-
ment. This body should include members of the government, the private sector, and soci-
ety at large. As it conducts its works at the federal level, similar state commissions should 
be formed to perform the same task at the state level. Inconsistencies between federal 
and state policies must then be resolved in order to create nationwide harmony in policy 
goals and targets. 
Our coronary heart disease example set 2040 for its targeted completion date. Yet it is 
important to establish interim targets and milestones while pursuing long-term policies. 
Monitoring bodies at the federal and state levels must follow and evaluate developments. 
Furthermore, the development of an American Health Policy must be accompanied by an 
effective communication strategy. 
The development of a national health policy in Finland is a good example for such a com-
prehensive effort, and can serve as a useful case study. The Health 2020 document that 
has recently been developed by the World Health Organization’s Regional Office for Eu-
rope can also provide an inspiring framework. 
3. Developing an American Healthcare System 
For an American Health Policy to reach its goals, and for healthcare in America to develop 
into a congruent system, the structure and function of its parts must be defined, with the 
aim that these parts are made to work together as a whole. 
Healthcare must become preventive, predictive, personalized, and participatory. A ‘one 
size fits all’ approach is no longer viable. Developments in genomics and system biology 
further mandate the need for older practices to give way to new ones. While designing the 
American Healthcare System, this vision of the future, its possibilities, and its prerequisites 
must be taken into consideration. 
The system’s users 
In its simplest form, a ‘health system’ is composed of four main parts: the system’s users 
(citizen), payer (financing institution), service providers, and governance. It is the basic 
human right of every American citizen to access health services in accordance with his or 
her needs. This is the model for almost all European countries. Financial, physical, social, 
and economic barriers in the way of access must be removed. While all barriers must be 
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tackled, the most pressing obstacles are financial. Those who are most in need of 
healthcare are also individuals of lower socioeconomic standing. However, since risks are 
individually determined in the American insurance model, these individuals have to pay 
higher premiums for healthcare. Insurance companies have also been allowed to keep 
high-cost individuals out of the system. Bans and regulations cannot prevent these prac-
tices entirely as long as the system is profit-oriented; different methods of exclusion will 
continue to develop. 
The payers’ perspective 
Healthcare financing must be organized such that it fosters social cooperation and solidar-
ity. Within this model the healthy will support the sick, the young will support the elderly, 
and the rich will support the poor. 
A comprehensive financing system must begin with the establishment of an insurance 
pool that covers every citizen. In general, bigger insurance pools are better able to provide 
coverage for catastrophic expenses. Universal coverage is a standard characteristic of 
European healthcare systems. These can be grouped into two main categories. 
The first is the Beveridge model, which originated in the United Kingdom. It is used by a 
number of European countries, including the United Kingdom (through the National 
Health Service) and the Scandinavian countries. Under this system, all health expenses are 
paid by the government through the public budget. Taxpayers do not pay a supplemental 
premium for healthcare. 
The second is the Bismarck model, which originated in Germany and whose variants de-
veloped in countries in continental Europe. This is a health insurance system of a public 
nature. Individuals, with the help of employees, transfer a portion of their salaries to in-
surance funds as a type of earmarked tax. As such, citizens pay a health premium along-
side their taxes. 
On both models, the premium or tax that an individual pays correlates to the individual’s 
income level. A poor, sick individual, who would have paid a higher premium for health 
insurance in America, would, under both systems, pay less than a healthy individual with 
high income. This is where the social solidarity of the European models becomes appar-
ent. 
The health system that has been developed in Turkey over recent years is an example 
worth analyzing. The Turkish Healthcare Reform was developed in the 1990s and imple-
mented in the 2000s. At the time of its development, a key topic of debate was the choice 
of financing through general taxes or through a separate health insurance contribution. 
 
Chapter 3 
68 
Tax revenues in Turkey are primarily composed of taxes deducted from the incomes of 
salaried workers, and indirect value added taxes (VATs), which are paid at the same level 
regardless of income. Income taxes and corporate taxes contribute much less to the tax 
pool than in other European countries or in the US, as a result of an ineffective tax collec-
tions mechanism. Financing health expenses through taxes would therefore result in the 
financing of the system by lower income groups. Turkey has chosen a general health in-
surance model and tries to ensure equity through premiums linked to an individual’s level 
of income. In this system, premiums of individuals below a certain income level are paid 
by the state. The inequality that would result from financing healthcare through taxes was 
compared with the extra costs that would result from the need to collect additional pre-
miums, and a choice was made in favor of the latter. 
Conditions in the US are significantly different from those in Turkey. America has an effec-
tive tax collection system. Tax receipts are composed primarily of income and corporate 
taxes, and the level of taxation is, for the most part, directly correlated with income, lead-
ing to a relatively just tax structure. As such, leveraging the pre-existing tax system to 
cover health expenditure would be a more equitable approach to financing healthcare. A 
co-payment requirement might be considered, once again in line with an individual’s abil-
ity to pay. Those without an ability to pay would be exempt from such a requirement. The 
collection of additional health premiums would also create an additional expense item in 
the US. Therefore, paying for healthcare through general tax receipts would not only be 
more equitable but would also keep costs lower by avoiding expenses associated with the 
collecting of premiums. 
Every state should allocate resources from its tax pool for healthcare. Additionally, some 
funds may be transferred to states from the federal budget to provide nationwide equity. 
Regarding the use of resources by individual states, we suggest the creation of ‘Geograph-
ic Purchasing Units’ (GPUs) for every million citizens. These units would purchase health 
services from providers based on the health indicators, primary health problems, age and 
gender distributions, and ethnicities prevailing in their areas. These purchasing units must 
also be skilled in public health, epidemiology, statistics, economic evaluations of 
healthcare, health services planning, health service quality, contracting, and contract 
management. 
The reorganization of healthcare providers 
Owing to the introduction of new technologies, the distinction between primary, second-
ary, and tertiary care levels is not as strong as it was 30 years ago. However, these con-
cepts are of particular importance for the US. All individuals should be analyzed for risks. 
Precautions should be taken for high-risk individuals, especially those with chronic or 
complex risks, such as heart attack, stroke, diabetes, cancers, or depression (risk man-
agement). For individuals with developed diseases, complications, and other co-
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morbidities, they should be prevented through secondary prevention (disease manage-
ment). In severe cases where co-morbidity has developed, tertiary prevention (case man-
agement) should be applied. 
We recommend a three-level structure that consists of first-level healthcare, outpatient 
specialist care, and inpatient specialist care (hospital care). First- level healthcare should 
be positioned at the center of the decision-making mechanism, taking the driver’s seat. It 
would consist of family physicians or general practitioners, supported by nurses, midwives 
(in Holland, for example, around 30 % of deliveries are midwife-led home deliveries), 
technicians, and administrative staff, and would be the first stop for all individuals, with 
the exception of emergencies. First-level healthcare providers (also referred to as primary 
care services) should assume a gatekeeper role. Pediatricians and gynecologists should be 
no exception. 
Based on the experiences of countries such as the UK, Denmark, Iceland, Finland, Norway, 
and Sweden, it is expected that an efficiently organized first-level healthcare unit will be 
able to treat at least 80 % of all cases. First-level healthcare units should be responsible for 
meeting outcome-based performance goals set with regard to the population they serve. 
These units should have responsibilities in primary, secondary, and tertiary prevention 
areas, and they should be responsible for ensuring continuation of care. First- level 
healthcare units must employ emerging information, genetics, diagnostic, and treatment 
technologies through a ‘point of care’ approach. These units can bring together public and 
private elements. Such decisions should be taken based not on ideological factors but on a 
case-by-case basis for each unit. 
A careful forecast of the needs of physicians and nurses must be modeled when transi-
tioning to such a system. This model must account for population and workload distribu-
tion, and should feed into further plans regarding the formation of training processes that 
will develop the required skills and knowledge base. 
Outpatient and inpatient specialist care could be purchased from public or private 
sources. What is important is that these providers can fulfill the services at the prices 
determined by the GPUs in their areas. Competition will play a role for reducing prices and 
increasing health outcomes, and will be critical in ensuring that the American Healthcare 
System meets its targets. 
In the new system, health outcomes must feature into providers’ compensation schemes. 
Current payment models (fee for service, diagnosis-related groups, cost and volume, and 
others) are based on inputs, processes, and outputs. The quality evaluation of providers is 
also based on an inputs–processes– outputs triangle. There is a false perception that out-
puts from high-quality inputs and processes will produce good outcomes. For this reason, 
quality and certification services in the US are limited in their abilities to increase health. 
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As in the Danish example, the indicators of providers with regard to health outcomes 
should be compared to determine the providers with the best health results. By creating 
databases, every clinic and doctor will be able to compare their results with others. These 
databases should be anonymous, since the goal is not to create a system of rewards and 
penalties but, rather, to generate better health outcomes. 
Current malpractice regulations should also be addressed. These regulations create a 
financial burden on the system and on patients because of excessive insurance expenses 
that add to costs. Malpractice compensation is also seen as a source of income for some 
patients, and is a profitable field for lawyers and insurance companies. In short, financial 
compensation leads, ultimately, to behavior that increases the system’s costs. Therefore, 
rather than wealth-producing compensation for patients, malpractice regulations should 
be directed toward professional development. These regulations should, therefore, be set 
by professional bodies within an ethical and scientific framework, and should not employ 
tools that create a financial burden. 
4. Managing Change 
The organizational and systems changes recommended above are complicated and diffi-
cult to undertake. This chapter proposes a paradigm shift that is hard for many stakehold-
ers to accept. Heading the list of these stakeholders are medical professionals, private for-
profit insurers, private for-profit providers, pharmaceutical companies, and medical device 
manufacturers. As in the past, these groups will advance the following arguments: 
1. The American health system is the best in the world and does not need big struc-
tural changes. 
2. The US is a world leader in medical practices. 
3. The free market is a magic bullet for every problem. 
4. The professional freedom of physicians is indispensable. 
5. Citizens should make their own decisions. 
6. Citizens should have the right to choose. 
7. Proposed structural changes will cause job losses in the health sector. 
The first six arguments are ideologically driven and are crafted to serve the interests of the 
groups listed above. In the past, such initiatives to change the system have been called 
‘socialized medicine’ in an effort to press the American public’s ‘hot buttons’. As for the 
last argument, while job loss will be encountered within unnecessary structures and func-
tions, these losses will be countered with employment gains necessitated by new struc-
tures and functions. 
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It is not adequate to simply make the right arguments; the manner in which they are 
communicated is also important. The development of the American Health Policy must 
begin with the formation of an eight-digit annual PR budget and a well-executed cam-
paign. Those who profit from the status quo spend hundreds of millions of dollars on 
campaigns and lobbying. To counter this force, non-governmental organizations (NGOs) 
and other civil society groups must be strengthened and supported under an umbrella 
‘Health for America’ campaign.  
Transition to the new system should be progressive and tiered. The old system’s infra-
structure and capacities should be recycled and incorporated to the extent that this is 
possible. This would also ease some of the resistance toward a new system. For example, 
Health Maintenance Organizations (HMOs) and private health insurers may be used when 
creating the GPUs. Providers in the new system will mostly comprise current providers 
with different, disciplined work methods. 
5. Conclusion 
Chronic and complex diseases are rising at a steady pace around the world, and especially 
in the US. One need not consult a psychic to see that the American public’s health is wors-
ening, that healthcare spending will continue to spiral upward, and that the system will 
eventually come to a gridlock. It is not a technically difficult task to affect the paradigm 
shift proposed in this chapter, to create a national health policy and develop a better 
healthcare system. There is considerable experience and know-how in these fields, espe-
cially originating in Europe. 
As a result of concerted lobbying efforts by the beneficiaries of the status quo, the US has 
so far not been able to take radical action for reform and has wasted time with incremen-
talist, palliative initiatives. The efforts of politicians cannot arrest this trajectory and usher 
in the change required for a healthier American nation with a functional health system. In 
addition to political power, this paradigm shift requires people with effective leadership. 
There are several instances of such transformative change in American history. The task at 
hand is to demonstrate the leadership not to pursue short-term political gains but to state 
bravely the actions that need to be taken in order to improve the health of a nation that is 
so important to the rest of the world. Success will come gradually through the focused and 
persistent efforts of the leaders of this movement. 
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The worst form of inequality is to try to make unequal things equal. 
Aristotle 
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Abstract 
Background 
Various terms and definitions are used to describe personalized approaches to medicine 
and health care, but in ambiguous and inconsistent ways. They mostly have been defined 
in a top-down manner. However, actual practices might take different paths. Here, we 
aimed to provide a ‘practice-based’ perspective on the debate by analyzing the content of 
‘personalized’ practices published in the literature. 
Methods 
The search in PubMed and EMBASE (April 2014) using the terms frequently utilized for 
personalized approaches resulted in 5.333 records. Two independent researchers used 
different strategies for screening, resulting in 157 articles describing 88 'personalized' 
practices that were implemented or presented on at least one individual/patient case. The 
content analysis was grounded on this data and didn't have a priori analytical frameworks.  
Results 
‘Personalized medicine and health care’ can be a commodity in health care market, a way 
how health services are provided, or a keyword for emerging applications. It can help 
individuals/patients to gain control of their health, health professionals to provide better 
services, health care organizations to increase effectiveness and efficiency, or national 
health systems to increase performance. Country examples indicated that for integration 
of practices into health services, attitude towards innovations and health system and 
policy context is important. Categorization based on the terms or the technologies used, if 
any, wasn’t possible. 
Conclusions  
This study is the first to provide a comprehensive content analysis of the 'personalized' 
practices in the literature. Unlike the top-down definitions, our findings highlighted not 
the technologies but real life issues faced by the practices. 'Personalized medicine' and 
‘personalized health care’ can be differentiated by using former for specific tools available 
and latter for health services with a holistic approach, implemented in certain contexts. To 
realize integration of personalized medicine and health care into real life, science, tech-
nology, health policy and practice, and society domains must work together.  
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1. Introduction 
A trend towards ‘personalization’ in medicine and health care has become increasingly 
prominent in the past 10-15 years. It has been perceived and described from different 
angles by various opinion leaders, institutions and stakeholder organizations. The terms 
used include ‘personalized medicine’, ‘personalized health care (healthcare)’, ‘P4 Medicine 
- Predictive, Personalized, Preventive/ Preventive, and Participatory Medicine’, ‘individual-
ized medicine’, ‘precision medicine’ and ‘systems (bio)medicine’.  
These terms are heavily used in both scientific and grey literature. However, until now, 
there has been no consensus on their precise meaning and how they are distinguished. 
The situation is complicated by ambiguous and inconsistent use of terminology.  For ex-
ample, in some cases two terms are used interchangeably (e.g. individualized medicine 
and personalized medicine at Medical Subject Headings of PubMed [1]) whereas in anoth-
er, each are used to describe different concepts [2]. Each individual, research group or 
manuscript seems to have a preferred term and working definition for it. Moreover, many 
publications seem to use ‘personalized medicine’ as a buzz word and/or a ‘catch-all’ term, 
resulting in a steep increase in its appearance in the literature [3, 4]. These create chaos 
within terminology in the literature. Within the present article, the abbreviation PM/PHC 
will be used to address the wide scope of the personalized medicine, personalized health 
care and others. 
Problems with the terminology have been a subject to several publications [2-10], the 
most recent of them being a comprehensive overview by Pokorska-Bocci [3]. So far, influ-
ential definitions and descriptions of the field have mainly been launched by institutions 
[11-14], organizations representing major stakeholder groups such as industry and aca-
demia [15-17], and respected opinion leaders [18-23]. The body of literature that ad-
dressed or discussed the terminology has mostly referred to these influential ‘top-down’ 
definitions. There is an implicit assumption that there is such thing as a best definition or 
classification of PM/PHC and that the practices in this field will intend to develop accord-
ingly. However, as the studies in other advanced technological domains have shown [24], 
in reality, actual practices in health care might take their own path, thus ‘enacting’ in their 
practices implicit definitions of what is at stake in their field. These definitions then de-
termine what direction the field is heading towards.  
The problem with the definitions and terminology is not just a linguistic one. In the broad-
er context, it is very likely to be connected with the bigger problem of unexpectedly slow 
integration of personalized practices in real life. PM/PHC has been on the agenda of scien-
tific fora for over a decade. Personalized approaches were proposed to be a solution to 
the main problems of today’s health systems, including prevention and treatment of 
chronic complex diseases, which are responsible for the main burden of disease globally 
[19, 23, 25, 26]. However, PM/PHC hasn’t fulfilled the expectations so far. Diffusion of 
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practices in regular health services hasn’t taken place with the exception of cancer related 
programs in some countries. Can the underlying assumptions and origins of the top-down 
definitions be contributing to this problem? If so, can the practice side of the coin give us 
clues on what matters for integration of personalized approaches in health care? 
Inspired by these ideas, we decided to look at the PM/PHC practices that are emerging in 
the literature, which use various terms listed above. We assumed that these practices 
actually reflect their implicit views on PM/PHC and their analysis may provide better in-
sight in what is happening on the practice side of the field. Thus, this study aims to start 
developing an understanding of how the field can be defined from a ‘practice-based’ per-
spective. This can make a valuable contribution to the debate on the terms and defini-
tions, and help seeing how the field is actually evolving. We will then look at what the 
findings mean for integration of PM/PHC into real life. In the discussion, we will compare 
the implicit notions on PM/PHC as enacted in actual practices with notions underlying the 
‘top-down’ definitions, and propose a ‘practice-based’ look at the health care integration 
problem in the field and possible solutions. 
2. Methods 
2.1. Approach 
In order to approach the field from a ‘bottom-up’ or ‘practice-based’ perspective and 
avoid the influence of the top-down definitions, we needed to be careful about common 
assumptions seen in ‘top-down’ definitions. We identified two of them as important. 
First one is linked to the drivers of the personalized vision. Two drivers seem to have a 
prominent place in the background of top-down definitions: 1) the general societal trend 
towards personalization and 2) the scientific discoveries and technological developments 
in various fields, mainly genome-based and information/communication technologies (ICT) 
[2]. The top-down definitions seem to be influenced in particular by the second driver. 
Most of them tend to define the field from the perspective of a certain sector or discipline, 
such as by the use of certain interventions (drugs, etc.) or technologies (genomics, ICT, 
etc.) [1, 11, 12, 15, 18, 19]. In this work, we took a sector, discipline- and technology- in-
dependent stand, which can help us identify new innovative approaches that are emerg-
ing using tools and disciplines that are not traditionally covered in descriptions of the 
personalized approaches. 
Second assumption we avoided was thinking in silos of the ‘pipeline’ approach to innova-
tions in health care. In the top-down approaches, innovative practices or interventions are 
often perceived to be an end result of the research and (technological) development pro-
cess. The whole process is seen as stages, such as basic research, applied research, devel-
opment, pilot and implementation, which are assumed to follow one another in a linear 
way. However, in real life, neither scientific advancements nor technologies get into 
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health practice in a predictable pattern or ‘pipeline’ [27]. Innovations stemming from 
actual practices might not necessarily follow those in a structured way and the borders 
between these stages are not always clear [24].  
2.2. Systematic search and selection strategy 
In order to identify the practices, we used a systematic search and selection strategy 
summarized in Figure 1. It is based on the PRISMA flow diagram [28], modified according 
to the purpose of our study. For full details of the process, refer to Supplementary materi-
al 1. 
Information sources and search strategy  
PubMed (via PubMed.gov on 1 April 2014) and EMBASE (via OVID on 14 April 2014) were 
chosen for the search as they cover the highest number of journals related to ‘personal-
ized medicine’.  
The following terms were searched in the title or abstract of the manuscripts: personal-
ized health care (healthcare), personalized medicine, P4 medicine, precision medicine, 
stratified medicine, systems (bio)medicine, individualized medicine and their UK English 
versions (personalised and individualised). The search was limited to English articles, with 
no time limitations. 
The search within PubMed resulted in 4.317 records and 6.328 in EMBASE, all of which 
were imported to EndNote. Duplicates and meeting/conference abstracts were removed. 
This resulted in 5.333 records. 
The search was restricted to scientific publications only and did not include websites, 
reports and other grey literature sources, since it not always possible to assess the validity 
of claims made about the practices in those mediums. 
Screening and selection process 
The focus of this study is practices presented in relation to PM/PHC. Since ‘health practice’ 
or ‘medical practice’ doesn’t have a formal and/or operational definition, we used the 
concept of ‘health intervention’, as “…an activity performed for, with or on behalf of a 
person or a population whose purpose is to improve, assess or modify health, functioning 
or health conditions.” [29]. Thus, our inclusion criteria focused on articles that describe a 
health intervention that is developed (designed) and/or implemented and presented in 
association with one of the terms used to describe PM/PHC (see the search terms).  
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Figure 1: Flow diagram of data collection process  
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More precisely, we searched for health intervention/ practices that 1) were implemented 
on at least one real-life case or had contacted with the patient/ individual or his data (i.e. 
a case, series of cases, feasibility studies, pilots, trials, reports on products/ services on the 
market; etc.) and 2) had enough description details provided in the article(s). The stage of 
research, development and implementation, how well the implementation is established, 
or the technological components were not included in the analysis.  
The selection was done independently by two researchers (TC and ES) on two occasions. 
First, during the initial screening, resulting in 277 articles and second, during the eligibility 
screening. Within the screening phase, independent researchers used two different strat-
egies for triangulation. The results of both researchers were compared and differences 
were discussed until consensus was reached. At this stage 179 articles were included. 
Upon inclusion some of the articles identified from the references and exclusion of those 
not providing enough information, the end list of 157 articles was formed. The reasons for 
exclusion are summarized in Figure 1.  
2.3 Identification of practices from the articles 
Practices were extracted from the articles, different articles describing the same practice 
were identified, and list of the practices was formed. From this stage onwards, practices 
(not the articles) became the unit of analysis in this study. Some practices could be clus-
tered under certain groups, based on their similarities. For example, various drug-genetic 
test pairs could be grouped under ‘pharmacogenetics’, since no apparent differences were 
expected during the analysis and the available data in the articles was also presented to 
support grouping. Eventually, 9 groups of practices were formed (treated as one practice 
in the rest of this article) in addition to 79 individual ones, summing up to 88 practices (see 
Table S1 in Supplementary material 2). The “P- numbers” in Table S1 are used as the iden-
tifier of each practice in the rest of the article and referred with a “P-“ in front of it in 
brackets. For example, (P-1) refers to “Group: Pharmacogenetics (drug - gene)”. Details of 
the group of practices are presented in Table S2 in Supplementary material 2. 
2.4 Content analysis 
The author (TC) read the articles, investigated the practices from different perspectives, 
identified their distinctive properties and discussed various categorization possibilities 
with the co-authors (ES, AK, FF). We decided to start with the axis of ‘application form and 
context’, since many articles provided ample information on that topic (Axis-1). While 
comparing similarities and contrasting differences among the practices within and across 
categories, the categorization was refined and re-defined. This resulted in reorganization 
of the practices under the categories. This took several rounds, until the description of the 
categories matched with the content of the practices included and the categories became 
mutually exclusive.  
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The second area we decided to investigate focused on “who is served by this practice?”. 
This involves ‘users’ or ‘clients’ (Axis-2). Using a method similar to Axis-1, we identified 
various groups who are eventually served by this practice and clustered them in 4 groups. 
Many of the practices served to more than one group, some of which were minor or op-
tional clients, or implied to be served in the articles. We preferred to note these in the 
tables as well (with notes such as ‘minor’, ‘optional’, ‘indirect’) because many of the prac-
tices are in the conception or infancy phases now and in the future may evolve to direc-
tions that seem minor now. Eventually, the groups that emerged in this axis were not 
mutually exclusive. Therefore, we called them ‘groups’ rather than ‘categories’.  
During several discussions we identified that issues such as who the practice is available 
for, who controls access to it and who benefits from it are important topics for integration 
of practices into (health) services. However, these topics are tightly related to the health 
system, including the health financing, of the country where the practice is implemented. 
However, as we collected our data from the scientific literature, where information on 
revenue models, benefits, availability, access etc. are not reported regularly, we chose to 
present three country examples to compare how the practices are integrated. 
The analysis was made by the author, and co-authors challenged it providing critical feed-
back in several rounds. The discussions among the team continued until an agreement on 
the axes and their components was reached. MS Excel was used for the analysis. 
Before and after the analysis process summarized above, we also explored if there is an 
identifiable pattern in the use of different terms referring to the personalized approaches. 
However, we didn’t observe a consistent pattern in their use in terms of technologies 
and/or disciplines involved, the purpose (prevention, therapy, disease management, etc.), 
target groups, etc. We didn’t observe a pattern in terminology according to the categories 
we identified either. 
After the analysis, the results were summarized into tables, where short descriptions 
based on the articles were added. Since we based the analysis on only the articles, chang-
es that happened afterwards the publications, such as stopping service or changing its 
form, were not taken into account. For practices that were reported to have a web site, 
the web sites were checked to see if the provider has apparently changed or stopped 
services after the publication and this was put as a brief note in the relevant tables as 
necessary.  
3. Results 
The basic properties of the 88 practices identified from the articles are presented in Table 
S1 in Supplementary material 2. Figure 2 presents the general view of the axes and their 
components, which are summarized in below text with examples from the practices.  
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Figure 2: The axes and their components that emerged from the analyzed practices 
3.1. Axis-1: Application form and context 
Data analysis revealed three main categories in terms of the application form and context: 
1) Practices available to be used in health services, implying that PM/PHC is a commodity 
that is provided on the health care market; 2) Implementation models where the product 
or service is developed and/or implemented in a wider context (i.e. in an institution), im-
plying that PM/PHC is a way how health services are organized and provided; and 3) 
Emerging practices which haven’t evolved to one of the first two groups yet, implying 
PM/PHC as keyword which indicate a ‘future’ or ‘novel’ potential.  
All practices were categorized in only one of the three categories, except for Gentest (P-
20) [26] and GeneInsight (P-32) [30] as these two practices had two service facets. Practic-
es are summarized in separate tables for each category in Supplementary material 2 (Ta-
bles S3, S4 and S5 for Category-1, 2 and 3, respectively).  
3.1.1. Category-1: Practices available in health care market 
This category includes products/services that are available in the health care sec-
tor/market. Their uptake and use depends on the decision of the health professional 
and/or individuals/patients. Tests, test-drug pairs, drugs, (bio)informatics services, devic-
es, online tools, and web sites fall into this group. Most of these are commodities available 
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on health care market, which have a cost for the payer (whomever the payer is, i.e. third 
party payer, the patient or others) just as other services and products in health care. An 
example is pharmacogenetic tests and related drugs (P-1), which are ordered by the physi-
cian. (see Box 1) 
A few interventions are available publicly, not commercially, e.g. the tools available freely 
in the literature and internet for predicting the risk or prognosis of a disease, such as cor-
onary risk scores (P-12). (see Box 1) 
Box 1: Examples to practices available in health care market (category-1) 
Pharmacogenetic tests and related drugs (P-1) 
In pharmacogenetic testing, the sample of the patient is tested for a certain (genetic or 
genomic) biomarker in the laboratory to predict the response of the individual to a certain 
drug. The physician can use this information to choose the most appropriate drug or de-
cide its dose. For example, individuals respond differently to warfarin, an anticoagulant 
drug used for prevention and treatment of thrombosis and thromboembolism. Therefore 
the warfarin dose must be titrated according to the response of the individuals, as meas-
ured by the INR (International Normalized Ratio) value in the blood. Therapeutic index for 
INR is rather narrow, and higher and lower than desired levels increase risk of serious 
complications (hemorrhage) and lack of desired effect (thrombosis). Genetic polymor-
phisms in CYP2C9 and VKORC1 genes are responsible for the 40-60% of the variability in 
the therapeutic warfarin dose. Testing individuals for these polymorphisms before the 
initiation of warfarin therapy can help to optimize the starting dose of the warfarin and 
might reduce the risk of hemorrhagic complications [31-36]. 
Coronary risk scores (P-12) 
The risk of cardiovascular diseases can be calculated using classical scoring systems such 
as Framingham risk score (USA) [37]. The scoring is available in the literature or can be 
calculated automatically in the internet when the personal clinical variables of the individ-
uals, such as age, gender, total and HDL cholesterol levels, smoking status and hyperten-
sion/ blood pressure information are entered (http://cvdrisk.nhlbi.nih.gov/). 
3.1.2. Category-2: Implementation models 
This category includes products or services that are developed for and/or implemented in 
a certain context; i.e. a health care institution, a country and worldwide. Practices can be 
run under a project, a program or a service framework that aims to implement, pilot, or 
assess feasibility of the implementation of products or services, as well as related tools in 
a certain setting. The implemented products or services can already be available on the 
market (category-1) or developed specifically for that setting. These PM/PHC practices 
imply that PM/PHC is not just a tool, product or service available (category-1), but also the 
way how health services are organized and delivered. 
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We labeled the practices in this category broadly as ‘implementation models’ because 
they not only focus on the product/ service or its technical use, but also take into account 
its implementation within an organization or setting. By definition, they all are expected to 
involve a health professional for their administration, except Athlete Biological Passport 
(explained below). Examples to three implementation contexts are presented below. (see 
Box 2) 
1. Institutional context: Projects, programs or service frameworks developed for and/or 
implemented at a specific health care institution are included under the ‘institutional 
context’. They can be as small as a physician practice, or as large as a chain or group of 
major academic medical centers, including home health services. 
A variety of practices are implemented in an institutional context. For example, a number 
of programs explore, develop and pilot the ways of implementing pharmacogenomics in 
clinical practice in major medical centers (P-25, P-57, P-62, P-66, P-68, P-82). Some of the 
practices are service frameworks that are developed at specific institutions, focusing on 
other aspects of personalizing the health services, such as psychosocial needs (P-86). 
2. National context: The only example of implementation in national scale is the French 
National Cancer Institute's (French NCI) nationwide program for tumor genomics (P-44).  
3. International context: Currently, the only practice in this subcategory is Athlete Biologi-
cal Passport (P-42), a program offered by World Anti-Doping Agency and implemented by 
anti-doping agencies around the globe. 
Box 2: Examples to implementation models (category-2) 
Pharmacogenetics related programs (P-25, P-57, P-62, P-66, P-68, P-82) 
A number of programs involve genotyping a group of patients for identified genotypes 
before the relevant drug and testing is indicated (preemption), and aim to investigate the 
results of this practice in various aspects, such as, outputs, patient outcomes and costs, 
and others: CLIPMERGE PGx Program at Mount Sinai Medical Center (P-25) [38], PREDICT 
project at Vanderbilt (P-57) [39], Personalized Medicine Program at University of Florida 
Health (P-62) [40], Clinical Pharmacogenomics Implementation Program at University of 
Chicago (P-66) [41, 42], Coriell Personalized Medicine Collaborative (Pharmacogenomics) 
(P-68) [43, 44], and Preemptive PGx protocol at Mayo Clinic (P-82) [45], all in USA. 
Youth Area for adolescent and young adult cancer patients (P-86) 
‘Youth Area’ at CRO National Cancer Institute, Italy is a special unit for adolescents and 
young adults at a cancer research hospital to provide assistance to them, in particular for 
their psychosocial needs [46]. 
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French National Cancer Institute's (NCI) nationwide program for tumor genomics 
(P-44) 
The program aims to provide available genomic tests to all relevant cancer patients in 
France. French NCI runs it with a network of 28 laboratories in France. Each laboratory is 
located in a specific geographic area to provide tumor genomics services to all cancer 
(public and private), thus covering whole France. Funded by the French NCI and Ministry 
of Health, all patients have free access to the identified biomarkers that predict response 
to certain cancer treatments [47]. 
Athlete Biological Passport (P-42)  
Athletes’ are monitored longitudinally with tests on hematologic and steroidal profiles. 
Recent changes and disparities in the parameters can be a result of performance-
enhancing drugs or a medical condition that needs to be investigated. The program is 
developed by the World Anti-Doping Agency. Anti-doping agencies around the globe can 
implement it using the relevant guidelines [48]. 
3.1.3. Category-3: Emerging practices 
Practices in this category include remaining ones. They have made a ‘contact with the 
patient (data)’, however information on its current use is not (yet) available in the litera-
ture. These, unlike practices in category-1, are not yet available on the market (at the time 
of the data collection) and are not developed for a specific (institutional) context like the 
ones in category-2. They may evolve into these two, or to other directions. (For examples, 
see Box 3) 
We didn’t observe a pattern by which the practices per se can be grouped, but the ways 
they are reported in the articles seem to have three prominent ways:  
1. Demonstration of applicability or proof of concept: These practices were applied or 
presented on cases (one or more) or datasets, such as the ‘IT-based Diagnostic Instrument 
System’ (P-13), a personal wearable device and home tele-health system for measurement 
of a variety of parameters and bio-signals of the individuals. The applicability of algorithms 
or bioinformatics tools are demonstrated by applying them on datasets, such as the algo-
rithm that predict the outcome of gliomas based on their transcriptomic profile, Glio-
maPredict (P-28).  
2. Trial implementation: These practices are implemented specifically for research pur-
poses in one or more settings. This can be a pilot to assess feasibility, usability, clinical 
validity and utility (efficacy and effectiveness). Unlike the pilots reported in category-2 of 
Axis-1, which were programs developed for specific institutions, here, the product or ser-
vice is not developed for the setting where it is tested. 
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An example is the Computer-Assisted Brief Intervention for Tobacco (CABIT) Program (P-
47), which is a web-based, multimedia tobacco intervention for use in opportunistic set-
tings. It was piloted in a number of health care settings for its initial evaluation including 
aspects of patient and provider satisfaction and treatment initiation. It is unknown at this 
point if it became a long-term program for those settings or if it became available for dif-
ferent settings. Another example explored physicians’ reactions to the prototype of an 
algorithm and reporting system for a pharmacogenetic test (CYP3A5 - tacrolimus dose) (P-
85). 
3. Exploratory/investigational cases: These cases initially had an investigational or explora-
tory purpose, without knowing if it would have specific health practice implications. A 
specific health practice wasn’t (fully) designed prior to the start of the case, but eventually 
led to a health practice. ‘integrative Personal Omics Profile (iPOP)’ project (P-50) carried 
out longitudinal extensive omics profiling on blood components from a generally healthy 
individual. Another individual followed various parameters related to his body longitudi-
nally using digital biomedical measurement devices and blood and stool biomarkers (P-
59). In both examples, the follow-up led to clinical diagnosis of diseases. 
Box 3: Examples to emerging practices (category-3) 
IT-based Diagnostic Instrument System (P-13) 
It is a set of diagnostic medical instruments which have been integrated into a personal 
wearable device (wrist-worn health monitoring device), which measure a variety of pa-
rameters in the body, a blood glucometer integrated to a cell phone and a home tele-
health system including bio-signal measurement systems that can measure, for example, 
ECG, body temperature, body-fat ratio on a toilet seat. It is developed at Seul National 
University (Korea) [49]. 
GliomaPredict (P-28)  
GliomaPredict is an algorithm for prediction of the outcome of gliomas (a brain tumor) 
based on their transcriptomic profile. It is validated on datasets and available for use in 
one institution, National Cancer Institute, USA [50]. 
Computer-Assisted Brief Intervention for Tobacco (CABIT) Program (P-47) 
CABIT is an opportunistic computer based tool to assist quitting smoking in clinical settings 
(Cooper University Hospital & Polaris Health Directions, Inc., USA). It is a self-administered 
computerized assessment to produce reports for health care provider and patient. Based 
on the assessment, the tool provides a video intervention to the individual (based on the 
stage-of-change for the individuals smoking habit) and provides referral for smoking ces-
sation [51]. 
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A prototype for automated interpretation of a pharmacogenetic (CYP3A5 - tacro-
limus dose) (P-85) 
Tacrolimus is a drug used to prevent rejection in organ transplantation. The needed dose 
for this drug may change according to the CYP3A5 genotype. An algorithm and reporting 
system was developed for CYP3A5 test and recommending tacrolimus dose at Oslo Uni-
versity Hospital, Norway [52]. 
integrative Personal Omics Profile (iPOP’ project) (P-50) 
Extensive omics profiling of blood components from a generally healthy individual was 
performed over a 14 month period at Stanford University, USA. The whole genome se-
quencing data was analyzed with RiskOGram algorithm, which integrates information from 
multiple alleles associated with disease risk. It indicated an increased risk of type 2 diabe-
tes, which actually developed during the follow-up period and was diagnosed by a physi-
cian [53]. The primary aim of the project was not to provide a ‘health practice’. However, 
the analysis made on the whole genome data, i.e. risk assessment of various diseases, had 
implications as a health practice. 
Quantified-self (P-59) 
An individual followed various parameters related to his body longitudinally using digital 
biomedical measurement devices and blood and stool biomarkers (USA). He observed that 
episodically elevated stool protein markers were accompanied by increased blood CRP 
levels, indicting inflammation. He got colon imaging studies and biopsies, which diagnosed 
that he had a late-onset Crohn’s disease, which is an inflammatory bowel disease [54]. 
3.2. Axis-2: The group served by the practice, i.e. the ‘user/client’ 
This axis involves with the question “who is the main group or entity served by this prac-
tice?” In other words, “who turns out to be the main ‘user’ or ‘client’ of this practice, and 
what definition of PM/PHC does this imply”?  
Data analysis revealed 4 main groups: 1) Individual (including the patient), implying that 
(PM/PHC) means tools that involve and/or empower the individuals to gain control over 
matters related to their health; 2) Health professionals, implying that PM/PHC tools help 
them provide better tailored and therefor better quality health services; 3) Health care 
organizations, implying that PM/PHC means ways to increase effectiveness and efficiency 
of health care delivery; 4) Other organizations, such as a payer organization, a national 
health system and international system.  
Axis-2 is summarized in Tables S3, S4 and S5 as a separate column in Supplementary mate-
rial 2. 
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3.2.1. Group-1: Individuals 
If the articles indicate that the practice is used by the individual for management of their 
health or disease (risk), it is considered to serve the individual. The term individual covers 
both ‘patients’, i.e. people with disease, and healthy individuals. (For examples, see Box 4) 
A prominent example here is direct-to-consumer genetic tests that identify predisposition 
to or predict risk of certain diseases (P-6). The individual can order the test and receive the 
results without the involvement of a health professional. Another example includes vari-
ous smartphone based personal, pervasive health informatics services that support indi-
viduals’ self-care to stay healthy and prevent diseases (P-9). 
The practices serving primarily to the individual place him/her in the center of the service 
and help them be more involved with their health. Here, personalization implies empow-
ering persons to take care of themselves or to gain control of their own health. 
This group also includes practices that serve the people surrounding the individuals, such 
as families of the adolescents and young adults in cancer wards (P-86) (see Box 2). This is 
considered as a continuum of the ‘individual centered’ approach; taking the individual 
with people who can support or help them. 
Box 4: Examples to practices serving to individuals (group-1) 
Direct-to-consumer genomic tests ('personal’ or ‘consumer’ genomics) (P-6) 
These tests are also called ‘consumer genomics’ or ‘personal genomics’ services, common-
ly exemplified by 23andMe [55-59]. 23andMe, a U.S. company, provides genome wide 
DNA test (“Personal Genome Scan”) over the internet directly to consumers. A saliva sam-
ple of the individual is used to detect variations in the DNA, with the purpose to provide 
information on two areas: ancestry/genealogy and health. Under the ‘health’ section, 
disease risks based on common polymorphisms as well as highly penetrant variations, 
carrier status of monogenic disorders, some physical traits and response to drugs are 
provided online as results of the test. Individuals are free to take these to their doctors for 
discussion or medical follow-up. (This description is based on the articles included, with 
the latest from 2012. It is of note that the content of 23andMe changed in December 2013 
due to the warning of Food and Drug Administration of USA [60] and the company no 
longer offers the ‘health’ section to new customers [61]). 
Smartphone-Based Personal, Pervasive Health Informatics Services (P-9) 
Smartphone-based personal health informatics, including sensor, signal and imaging in-
formatics are applications for provision and improvement of diagnosis, acute and chronic 
treatment, and rehabilitative health services as well as supporting self-care to stay 
healthy/prevention of diseases [62]. Many of these services are available for the individu-
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als, for example, for fitness monitoring using GPS and accelerometers, sensors for heart 
rate monitors, and devices that combine these to a wrist-worn device such as FitBit. 
3.2.2. Group-2: Health professionals 
If the health professionals use the practice for medical management of the disease (risk) 
or the patient, it is considered to serve this group. Laboratory tests ordered by the physi-
cian and the drugs prescribed are included here because they mainly assist the medical 
management of the disease, carried out by the physician and other health professionals A 
prominent example here is tumor genetics/genomics tests and related drugs (P-2). (For 
examples, see Box 5) 
An electronic questionnaire that identifies the psycho-cognitive status of the patients 
before the physician meets them (ALGA-C, P-84) provides feedback to the physician to 
optimize his/her communication style and interaction with the patient. Thus, the ques-
tionnaire is filled in by the patient but it eventually is a tool that serves the physician.  
A few practices serve primarily both the individuals and the health professionals. One of 
them is Gentest, which is a preventive practice model provided to individuals via author-
ized physicians (P-20). The output of the service is a report, which includes, among others, 
the summary of assessments made for the individual, an optimum lifestyle program and a 
medical follow-up program, thus serving to both the individual and the physician. 
The practices that primarily serve the health professional are PM/PHC tools that help the 
health professional (mostly a physician) deliver even better or more accurate health ser-
vices to the individuals, potentially leading to more successful prevention, diagnosis and 
treatment. They can be perceived as ‘high-profile’ or elaborate products or services used 
by professionals. 
Box 5: Examples to practices serving to health professionals (group-2) 
Tumor genetics/ genomics tests and related drugs (P-2) 
Here, the laboratory test is carried out on the tumor tissue, to predict its response to a 
given cancer drug [63-68]. The technology used for the test varies: genetic tests (specific 
mutation or sequencing), gene expression analysis, or immunohistochemistry, in situ hy-
bridization, etc. In the recent years, there have been increasing number of cases of pairs 
of cancer drugs and accompanying laboratory tests (companion diagnostics), which are 
developed, received regulatory approval and presented to the health care market togeth-
er [33, 66, 67, 69-73]. 
ALGA-C (questionnaire that measures and collects psycho-cognitive information 
about patients) (P-84) 
ALGA-C is an electronic questionnaire focusing on cognitive, physical-related and psycho-
logical aspects of the patients. It is filled by the patients before meeting with the doctor. 
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The results provide a psycho-cognitive picture of the patient with whom the physician is 
about to meet. The physician can use this information to optimize the communication 
style and interaction with the patient. It is developed by the P-medicine project (Greece, 
Italy, UK) [74]. 
Gentest (P-20) 
Gentlest is an integrative preventive model that utilizes an individual's personal health 
information, family history, detailed lifestyle analysis (nutritional habits, food consump-
tion using a food portion size atlas, physical activity and exercise, and smoking), anthro-
pometric and bioimpedance measurements, genotype, and other biomarkers to stratify 
individuals into risk groups to prevent complex diseases in a targeted way. It is provided to 
individuals via authorized physicians. Based on the results of the aforementioned compo-
nents, risk assessments are made for the major complex diseases including heart attack, 
stroke, type 2 diabetes, cancers (lung, breast, prostate, colon, and gastric cancers), and 
osteoporosis and an optimum lifestyle plan, including personal menu plans and food ex-
change lists, exercise plans, smoking cessation recommendations, and a medical follow-up 
plan are drawn. It is developed by GENAR Institute for Public Health and Genomics Re-
search in Turkey [26]. 
3.2.3. Group-3: Health care organizations 
Practices which have a major organizational component within the health services, such as 
involvement of different stakeholders (disciplines/departments) within an organization or 
across organizations for development and implementation of it, clinical and/or laboratory 
workflows, and targeting to increase effectiveness and efficiency in a health care institu-
tion, are included here. These are actually issues that are related to the goals of a health 
care provider institution, i.e. effectiveness, efficiency (costs) and patient and employee 
satisfaction. Thus, PM/PHC becomes tools or ways for health care organizations to per-
form better in their services, which may help to improve their businesses in the competi-
tive environment. (For examples, see Box 6) 
The Mayo Clinic’s Individualized Medicine Clinic (P-71) is an example of an initiative that 
opened a new service line within an organization. This initiative involved several issues 
such as setting up and/organizing the infrastructure (laboratory, coordination, systems to 
handle samples and report results, education materials, etc.), putting the clinical work-
flow, and putting the administrative workflow which includes, among others, coverage of 
test costs by the insurance, involving relevant disciplines within the organization, etc.  
Geisinger Medical Center introduced algorithms and warning systems in their service lines 
with the aim to reduce unnecessary blood component utilization for patients undergoing 
surgery (P-33). This involved several stakeholders at the hospital and served to increase 
effectiveness and efficiency of the patient care.  
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This group is strongly related to the second category in Axis-1, i.e. Implementation Mod-
els. All the practices in category-2 had a direct or indirect component of health care organ-
izations, as summarized above. 
Box 6: Examples to practices serving to health professionals (group-3) 
Mayo Clinic’s Individualized Medicine Clinic (P-71) 
Two lines of services are introduced in this clinic: 1) tumor genomics services for patients 
with advanced cancer who fail standard therapy; 2) Whole Exome Sequencing and inter-
pretation services for patients with a suspected genetic condition for whom previous ge-
netic testing did not reveal an etiology. A common infrastructure for these was built and 
processes were designed with involvement of several disciplines and functions. These 
included IT, bioinformatics, bioethics, patient access management, education, revenue 
cycle, operations and the research sequencing facilities under the Individualized Medicine 
Clinic Working Group (USA) [75].  
Geisinger blood component utilization program (P-33) 
Geisinger Medical Center (USA) initiated a program with the overall goal to reduce unnec-
essary blood component utilization for patients undergoing surgery. Within this program, 
algorithms were developed to clarify when and which blood components to use and a 
system was set for communication between the pathologist and the patients' clinical team 
7/24, involving clinical pathologist when too much blood components were used for a 
given patient in the given time frame. The program was developed by the Transfusion 
Committee of the hospital [76]. 
3.2.4. Group-4: Other organizations 
Three practices go beyond the borders of health care organizations. The first one eventu-
ally serves a national health system: the French NCI’s nationwide program for tumor ge-
nomics (P-44) (see Box 2). The program aims not only increasing effectiveness and effi-
ciency of cancer treatment, but also providing equitable services to the population. These 
correspond to the main goals of a health system (effectiveness, efficiency, patient and 
employee satisfaction and equity). Thus, PM/PHC becomes linked to tools/ways for health 
systems to perform better.  
Second example is a health care payer organization: a social health insurance fund, Tech-
niker Krankenkasse, in Germany, which implies that PM/PHC is not only for health care 
providers but also for payers. Within the ‘Telemedicine for the Heart’ program, telemedi-
cine services for heart failure patients within their insured population were provided (P-
60) (see Box 7). In the case of the payer organization, PM/PHC becomes a tool in the ser-
vice package of the payer organization to provide more efficient and effective services. 
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Third practice is an international system of national and local antidoping agencies, as well 
as the World Anti-doping agency (P-42) (see Box 2). 
Box 7: Examples to practices serving to other organizations (group-4) 
Telemedicine for the Heart (P-60) 
A telemedicine program which consists of nurse-calls to motivate patients to perform 
regular self-measurements (blood pressure, pulse, weight) and their recording was offered 
to the members of Techniker Krankenkasse, which is a sickness fund (social health insur-
ance fund) in Germany. In the case the measured values are outside of set limits, calls to 
physicians were placed for therapy adjustments [77]. 
3.3. Integration of practices into real life  
The two axes summarized above can give new perspectives on PM/PHC. However, they 
are not enough to provide a wider picture of issues around integration of these practices 
into real life (health) services. Are these practices available to everyone in their respective 
countries as commodities in the health care market (category-1)? Are the implementation 
models (category-2) available in all health institutions in a given country? Even if they are 
available, can the individuals access them without geographical, financial or other barri-
ers? What about the situation globally? 
It was not possible to get the answers to these questions for most of the practices because 
issues around availability and accessibility are not regularly reported in articles describing 
practices in the scientific literature. Moreover, many of these are inherent in the health 
system where the provider is placed in. Considering these, we chose three country exam-
ples among the practices in category-2: USA, France and Taiwan, which included some 
information on these dimensions.  
3.3.1. Cases: USA, France and Taiwan 
In category-2, (implementation models) we see that several medical centers (centers that 
combine health care service provision, research and medical education) and other major 
health care providers in USA have initiated some sort of a program or project on ‘person-
alized’, ‘individualized’, or ‘precision’ medicine in the last five years. These programs often 
involve a genetic component, such as tumor and cancer genomics and pharmacogenomics 
(P-25, P-30 [78], P-32, P-38 [79], P-41 [80], P-56 [81], P-57, P-61 [82], P-62, P-71, P-75 [83], 
P-77 [84], P-80 [85], P-82) (see Box 2 and Box 6). Many of the institutions initializing these 
projects are world-renowned major medical centers, which often pioneer introduction of 
innovations in mainstream medicine in the world. Many of their ‘personalized’ programs 
in category-2 are probably one of the first of their kind in USA or worldwide.  
However, from ‘availability’ point of view, these ‘personalized’ programs are actually 
‘prestigious’ services that are available to a very limited number of people who have geo-
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graphical and financial access to these major medical centers. For the rest of the U.S. pop-
ulation, the availability is unknown. 
Moreover, the U.S. health system has serious problems with accessibility to health ser-
vices. Uninsured and underinsured population and ineffectiveness of the insurance based 
health finance are major ones that leads to disparities in the system [86]. 
In France, the NCI’s nationwide initiative provides tumor genetics/ genomics services to 
all cancer patients and is funded by the NCI and Ministry of Health (P-44, see Box 2). Thus, 
tumor genomics services are not limited to certain hospitals, or geographical regions and 
are available and accessible (geographically and financially) for all cancer patients who 
need it. This indicates “equity”. 
Third example is from Taiwan. A program called Ubiquitous Healthcare was developed 
and introduced at the National Taiwan University Hospital (P-24). It is a set of tele-
health/tele-care solutions which aim to provide services to patients living in remote areas. 
In a sense, it is an attempt to overcome geographic accessibility problems, in the context 
of a country that embraced mobile technologies widely. However, the fact that this service 
is being promoted among the target group of patients by a marketing team suggests that 
it is to be paid out-of-pocket. The costs seem not to be extremely high (e.g. monthly cost 
of a cardiovascular patient is around 150 EUR). Nevertheless, for people from lower in-
come groups, it can still be unaffordable. Thus, at this stage where it is not yet covered by 
the National Health Insurance of Taiwan, it is available only to people who has access to 
the university hospital at least once, and can afford it.  
Box 8: Example to a practice provided with out-of-pocket payment 
Ubiquitous Healthcare (P-24) 
National Taiwan University Hospital (Taipei, Taiwan), combined the home healthcare ser-
vice network and sensors network into a new service known as the Ubiquitous Healthcare 
(U-Health) service system in order to continually provide personalized healthcare services 
to patients who live in remote areas. The system included six service components that are 
introduced in an integrated manner: tele-education, tele-diagnosis, tele-monitoring, tele-
consultation, tele-therapy and lifetime health. The services were targeted towards the 
following patient segments: post-discharge patients, patients suffering from cardiovascu-
lar diseases, patients suffering from chronic diseases and patients in hospice care. It re-
duced re-hospitalization rate and emergency room visits during the post-discharge period. 
[87]  
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3.3.2. Contextual factors: attitude towards innovations and health systems 
and policies 
These cases indicate that two factors, among others, may be important for integration of 
personalized practices in services: attitude of health care providers and society towards 
innovations and the health system and policy context. 
USA has long been regarded as a global leader in medical technology innovation [88] and, 
as a matter of fact, PM/PHC have been closely linked to technological advancements. 
Apart from the publication tradition of these high profile centers in scientific journals in 
English; high number of publications from USA may give the impression that uptake of 
innovation is higher in USA. However, we don’t know if these services are limited to these 
high profile centers, or widely available. There is a strikingly different example from the 
other side of the Atlantic: French NCI’s initiative, making tumor genomics services availa-
ble and accessible for everyone who needs it. 
These contrasting cases illustrate that not only the attitude of the country towards health 
innovations, but also the health system and policy values play an important role in the 
uptake and implementation of personalized practices. French health system has ‘equity’ as 
a central policy value, reflected with universal health coverage for all citizens. In line with 
this, they provide this service in an equitable way to all citizens with a special program. On 
the other hand, a prominent policy value in U.S. health system is ‘liberty’, supporting the 
free market economy largely even in the health system, at cost of the equity [86, 89] (see 
also Chapter 3). Thus, prestigious high profile medical centers compete for newer and 
more innovative applications. Lack of equity as a policy value also results in a huge propor-
tion of uninsured and underinsured population who cannot access health services. This 
means that, even if the individuals can geographically access the high-profile medical cen-
ters, they may not be able to access the ‘prestigious’ ‘personalized’ services due to their 
inability to pay for it.  
We also see the effect of components of health systems on these examples. Such contex-
tual issues are not explicitly addressed, but implied in a few of the articles. For example, 
some of the health care institutions from USA refer to ‘insurance coverage’ for the prac-
tices they offer [75, 82, 90, 91]. In the country context, this implies all the issues behind it 
within the U.S. health system, which create a barrier to operationalization of these ser-
vices such as the difficulty of dealing with multiple payers (insurances) which decide inde-
pendently on coverage of these new, not yet standardized, ‘personalized’ services. On the 
other hand, in a single payer health system, i.e. France, it was possible to cover the whole 
population for tumor genomics services with a special program and dedicated funds for it.  
In the case of Taiwan, where out-of-pocket services account for almost 40% of the health 
care expenditure [92], we see that a tele-care practice enters the market as an out-of-
pocket service. For some countries, it is customary for new technologies to enter the 
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health care market as an out-of-pocket service and gradually become covered by third 
party payers. This means that the availability and accessibility of a practice in a given 
country can evolve with time.  
4. Discussion 
4.1. Summary of the main findings 
In this study, a systematic search and inclusion strategy was used to identify ‘personalized’ 
practices within the scientific literature. Neither the terminology used to describe the 
practices (personalized, individualized, systems, medicine, health care, etc.) nor the tech-
nologies used showed a consistent pattern among the included practices. Thus a different 
angle grounded on the practices was taken to analyze them to reveal notions of PM/PHC. 
The analysis of ‘the application form and context’ indicated that PM/PHC can be a com-
modity for the health market, a way in which health services are organized/provided, or 
‘future’ or ‘novel’ emerging applications. When reviewing whom these practices were 
aiming to serve, we identified that PM/PHC can serve individuals (or patients) to empow-
er them to gain control of their health, health professionals to help them provide ‘even’ 
better health services, health care organizations to help increasing the effective-
ness/efficiency of health care delivery in the competitive environment, or national health 
systems to help increasing their performance in terms of effectiveness/efficiency and 
equity. During the analysis it was noted that for successful integration of the practices into 
health services, not only the attitude of the country towards innovations, but also the 
health system and policies context is crucially important.  
4.2. Strengths and limitations 
This article aimed to investigate the field of “personalized” care from a practice-based 
perspective, not restricted by current (top-down) theoretical frameworks. Due to unique-
ness of the research aim and heterogeneity of the included practices, a combination of 
methods was used at every step of analysis. Among these were: triangulation with differ-
ent strategies applied by two independent researchers during the screening phase, utiliza-
tion of the ‘health intervention’ definition of ‘International Classification of Health Inter-
ventions (ICHI)’ to assist the selection process, content analysis grounded on the data 
(practices/articles) for identification of relevant patterns. This combination of methods 
and tools allowed us to include a broad range of sectors/technologies and research/ de-
velopment stages, which enabled us to demonstrate the spectrum of ‘personalized’ prac-
tices reported in the literature. To our best knowledge, this makes the paper unique in the 
field.  
The main limitation of our study is that the search was carried out using the scientific 
literature alone without inclusion of information from web sites. As a consequence, some 
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well-established existing practices may not have been included in the analysis. This re-
striction was deliberately made in order to ensure the quality and credibility of the prac-
tices analyzed.   
Data on integration of practices into health services was very limited. Therefore, three 
prominent and contrasting country examples were identified to discuss some of the im-
portant factors that affect availability and accessibility. Since only the identified articles 
were analyzed, we weren’t able to cross-check or elaborate on all aspects. Further re-
search with a targeted approach using various other data sources can yield a more com-
prehensive analysis of the issues raised. 
4.3. Implications of the findings for the integration of personalized 
approaches  
Since early 2000s, there has been a growing expectation that ‘personalized medicine’ 
would enter the health services within a decade and gradually become common practice. 
In the early stages, it was mostly genomics that fueled these expectations, but later ‘per-
sonalization’ became a broader theme. However, as years proceeded, the genome-based 
applications did not enter routine practices as anticipated. This led to questioning whether 
personalization of medicine is a ‘myth’ rather than reality [93-95]. It is now expected that 
clear examples of application of genome-based information in medicine and health care 
may start to flourish in this decade, but will probably become more prominent in the peri-
od beyond the year 2020 [96]. The below discussion on the implications of our ‘practice-
based’ findings for integration of PM/PHC may provide insights on some of the possible 
factors contributing to these unfulfilled claims. Among them are: excessive technological 
focus, issues with definitions, issues with the transformation of practices, and discrepancy 
between initial vision and practice. 
4.3.1. Excessive technological focus 
There is a striking contrast in terms of the technological orientation, in particular ge-
nomics, between the top-down descriptions and the findings of this study. The axes that 
emerged in our study didn’t point technologies or methods to define PM/PHC. Instead, 
they reflected on some of the real life issues that practices face. 
Many of the ‘top-down’ descriptions build the definition of the personalized approaches 
on the use genome-based technologies and molecular markers [12, 14, 15, 18]. However, 
many of the practices identified in this study didn’t have a genomic or molecular compo-
nent. This is illustrated in the Results section by giving at least two examples to each cate-
gory and group: one that includes and one that doesn’t include genomic/molecular tech-
nologies. Besides, there are some practices that have no technological component at all 
(e.g., P-12, P-81 [97], P-86, P-18 [98]). Thus, our findings indicate that it is not the use of 
certain technologies or methods, including genomic or molecular markers what makes 
PM/PHC ‘personalized’.  
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The problems around equating PM/PHC to genomics have already been raised. First of all, 
this causes attribution of currently unfulfilled expectations of genomic medicine to the 
broader application of PM/PHC [5]. Furthermore, genomic markers can be one of the 
components but is not the only factor that makes individuals unique or medicine personal-
ized [2]. 
4.3.2. The definitions 
The axes that emerged in this study were very different from the dimensions highlighted 
by the more common top-down definitions. However, the practices still did not yield a 
single common theme shared among them, which was also the case for top-down defini-
tions as addressed in the Introduction. Our findings indicated that PM/PHC practices are 
present in several forms and contexts, serving a variety of groups, having different conno-
tations in terms of availability and accessibility around the world. It is not a realistic expec-
tation to have one definition to cover all of these. Is PM/PHC a commodity that can be 
bought or sold? Is it a tool to empower individuals to gain more control of their health? Is 
it a tool for health professionals to provide even better health care? Is it the way how 
health services are organized and provided? Is it something or anything novel (with or 
without genomics) that is emerging? Is it ‘prestigious’ applications in ‘high-profile’ clinics? 
All or none of these?  
Thus, similar to the case of top-down definitions, a consistent and unified definition of the 
personalized approaches cannot be made from the practice-based perspective either. This 
means that people may presume that they talk about same concepts when they are using 
the same terms, while they actually have very different perceptions and ideas. This scene 
can be recognized by many people who try to follow the field via the literature or by par-
ticipating in related meetings, in particular the multidisciplinary ones. Lack coherence in 
the use of concepts and terminology can be a significant factor contributing to the unful-
filled claims. 
Looking at some specific aspects of existing definitions, the distinction made earlier be-
tween ‘personalized medicine’ and ‘personalized health care’ [5] seems to apply to the 
practices as well. The findings of the axis-1 indicated that having a product or service 
available for use in the market is one thing (category-1), and actually implementing it in 
a certain context is another (category-2).  
The ‘personalized health care’ description [5, 23, 99, 100] seems to match with the cate-
gory-2, which includes practices that are implemented in a certain context, mostly a 
health care provider setting. Typical examples of ‘personalized health care’ are My 
PREVENT Plan (P-49)[101] and Gentest (P-20), which use personal health profiles and 
‘personalized medicine tools’ in a broader context to prepare personalized health plans 
(the former focus more on chronic disease management whereas the latter on their pre-
vention). 
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In the framework of Simmons et al., personalized health care is differentiated from the 
personalized medicine [5]. While the former is focused on a strategic approach to patient 
care, i.e. health services, the latter deals with the use of specific ‘tools’ in medicine. Fur-
ther, ‘personalized medicine’ definition by Personalized Medicine Coalition, USA [15], has 
some sort of a match with category-1 in the sense that the Coalition also position person-
alized medicine as a commodity in health care market, but with particular focus on diag-
nostic tests and related drugs which involve genomic and molecular markers [102]. Most 
practices in category-1 are some sort of tests or drugs that are, however, not restricted to 
genomics or molecular markers. 
On a map of the various concepts defining the personalized approaches, Pokorska-Bocci et 
al. depicted personalized health care as a superset of all of them [3]. This gives the impres-
sion that the difference is in their scope, but it is probably beyond that. There are two 
dimensions that distinguish them. First one is the application form and context, as sup-
ported with our findings and explained above (commodities/tools in the market vs. im-
plementation model in a health care context). Second dimension is that personalized med-
icine is used to refer to specific tools, whereas personalized health care is used for a 
broader, holistic approach to health. 
In brief, our findings support the strategy to use ‘personalized medicine’ for specific tools 
that are available for practice in medicine (such as tests, test-drug pairs, predictive algo-
rithms, etc.), as in category-1, whereas refer to personalized health care for health ser-
vices that have a holistic approach to the individual to be implemented in certain con-
texts.  
4.3.3. Transformation of practices 
PM/PHC is a new and dynamic field, thus it is possible that the available approaches 
transform or converge from one category to another. For example, an implementation 
model designed by one institution (category-2) may become a solution available to other 
stakeholders (category-1), i.e. GeneInsight Suite (P-32), or a generic practice available 
within the health care market (category-1), i.e. Gentest (P-20). Practices in category-3 
(emerging practices) might converge to those available on the market (category-1) or 
institutional models (category-2). It is possible that some will evolve in different ways that 
hasn’t been identified in this study. A targeted research using different data sources can 
explore how the practices evolve and transform through time.  
For example, integrative Personal Omics Profile (iPOP) (P-50) and an example of ‘quanti-
fied self’ movement by Smarr (P-59) are categorized as emerging practices (category-3) in 
axis-1. They are single cases that use longitudinal health data, in line with the P4 medicine 
vision of Leroy Hood [25]. A new initiative called 100K Wellness Project takes the P4 medi-
cine vision to a larger scale longitudinal research project with a practice component, 
where health coaches are trained to guide the participating individuals to change their 
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lifestyle based on available ‘actionable’ data [25]. If we apply the distinction between 
personalized medicine (tools/commodities) vs. personalized health care (implementation 
models) to this case, 100K Wellness Project is essentially an example to personalized 
health care, indicating transition from P4 medicine towards P4 health care.  
Such transformations indicate the highly dynamic nature of the field, which is making the 
definitions more difficult. Moreover, by the time one definition framework is agreed on, it 
runs a risk to become outdated as new advances have emerged.  
4.3.4. Discrepancy between initial descriptions and practice 
One of the factors that contribute to why the field of PM/PHC hasn’t fulfilled the expecta-
tions might be how PM/PHC was envisaged and defined in the first place. The top-down 
descriptions focus on the theoretical promises of available and forthcoming technologies 
and try to guide the field in that direction. They were designed mostly by highly influential 
individuals and committees on the science and technology side and assume that if the 
technology alone is good enough, it can solve the problems of today’s health care. For 
example, P4 medicine was proposed to eventually lead to a universal democratization of 
health care by increasing effectiveness of preventive and curative interventions, and re-
ducing the costs, thus lessening the social and financial burden of diseases [19, 25]. 
There is clearly a difference between how the field is depicted in these theoretical models 
and real life as reflected in the practices we identified and analyzed. In real life, innova-
tions do not diffuse and enter services just because they are technically possible [103]. 
Policy makers, practitioners and/or individuals do not (decide to) use tools just because 
they exist. In line with the authors such as Bijker et al. [104] and Berg and Mol [105], de-
velopment and integration of new practices are much more complex than the science and 
technology alone. It involves people, functions and bodies in health services in the whole 
context of health system, in interaction with the society.  
Health practice side of the coin has been widely neglected. Practitioners are not ‘empty 
vessels’, who only absorb all the literature, guidance and visions set forth by the commis-
sions and opinion leaders. As Green states, they are “… full of prior knowledge, attitudes, 
beliefs, values and, above all, contextual constraints at any given point in practice time” 
[27]. Practitioners adjust methods and technologies they use in order to successfully adapt 
them to the context, which inevitably changes and transforms them [105]. At the end of 
the day, it will be those health care practices, which will actually construct the field and 
shape how personalized approaches will actually take place in medicine and health care.  
Health systems and policies context has also been underrepresented. For example, can 
inequity in a health system be solved by personalized practices alone? As seen in the case 
examples of USA, France and Taiwan, strengths and weaknesses of health systems have 
direct implications on the personalized practices. The practice cannot be isolated from the 
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context. Moreover, issues related to health systems cannot be solved in isolation either. 
Various publications have discussed and reported the barriers, challenges or agendas 
for/of personalized medicine. They list a number of items that need to be solved, such as 
reimbursement, data issues, physician education, and others, and try to tackle each indi-
vidually, one at a time, independent from each other and the general context. This isolat-
ed and piecemeal approach is unlikely to solve the real life problems efficiently because 
they are all interlinked with each other and the context. Health system must be addressed 
in its entirety. 
4.4. Proposed solution: towards a true multi-disciplinary ap-
proach in the field 
Realization of the PM/PHC depends on science, technology, health care and society do-
mains [106]. Health care domain includes not only the health professionals who are in the 
front line of health services, but also other professionals, functions and bodies that make 
health care services available within local, regional and national context, thus covering 
both health policy and practice. When defining and working towards PM/PHC, predomi-
nance of specific domains hinders the progress by creating unrealistic expectations. In-
stead, the field must be created with a collaborative effort of all domains.  
These efforts should not be limited to higher-level meetings, where academicians assem-
ble and discuss the topics. To bring PM/PHC into practice, these domains must come to-
gether effectively in teams working on concrete projects. An inspiring example relevant to 
this field is the Institute for Systems Biology (ISB) in USA. Established in 2000, co-founded 
by Hood, ISB has been pioneering the field of systems biology. To study complex biological 
systems in a holistic way, a cross-disciplinary culture of research which uses technology to 
solve biological questions was required. For that, ISB created a special and unusual institu-
tional platform, where scientists from different disciplines learn one another’s languages 
and work effectively in teams, instead of disciplinary departments [107]. 
To bring PM/PHC to life, we also need an integrative ‘systems’ approach. The system here 
is much broader than the organism. It includes science, technology, health and society 
domains. Just like the interaction of genes, lifestyle and environmental factors, socioeco-
nomic factors and health services, which determine health and disease, individuals from 
different disciplines and sectors need to come together, interact with each other and form 
real collaborations to realize PM/PHC. Various mechanisms can be used to facilitate this, 
such as double appointments in science, policy and practice, financial incentives to make 
different parties work together, and events across domains to trigger cross-fertilization. In 
terms of facilitating structures, ISB can be an inspiring example. In addition, education of 
health professionals (under and postgraduate), in particular physicians, is crucially im-
portant for them to be able to adopt innovations in practice. 
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PM/PHC can fulfill its promises only if it is tackled in a collective way. If the field focuses 
only on science and technology, it can make significant discoveries and perhaps bring out 
tools for the health care market, but their real life use will be questionable.  
4. Conclusion 
This work presents an important endeavor of looking at the practice side of the coin of 
PM/PHC. For the first time, such analysis was based on empirical data in such an extensive 
way. The perspective presented in this article, methods used and the findings may trigger 
discussions on new ways to describe the personalized approaches. The practices identified 
and earlier publications show that personalized medicine and personalized health care are 
different entities, one involving commodities and tools available in health care market and 
the other involving holistic approaches to individuals and their implementation in actual 
settings. Science or technology alone is not enough to have an impact on the health of 
individuals. Health policy and practice side of the coin must also be taken into account to 
address innovation for health in its entirety. For that, science, technology, health care 
(including policy and practice) and society domains should work collectively towards reali-
zation of PM/PHC. 
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Supplementary Material 1 
Detailed description of the search and selection process 
Choice of databases 
We searched for journals that include ‘personalized’ or ‘personalised’ in their title or de-
scription in National Library of Medicine Catalog as well as Google.  
- NLM Catalog search (18.03.2014) with the terms “personalized medicine journal” 
and “personalised medicine journal” 
- Google search (18.03.2014) with the term “journal personalized medicine” 
We identified 9 scientific journals with these terms in their name or description. By check-
ing the journal web sites and, when necessary, databases, we listed where each journal is 
indexed. We identified that among the database combinations, PubMed and EMBASE 
together would give the maximum number of journals covered for the search (8), and 
therefore decided to choose them. The journals included in either of those databases are:  
- Current Pharmacogenomics and Personalized Medicine (Bentham Science, Dubai) 
- EPMA Journal (BioMed Central) 
- Journal of Personalized Medicine (MDPI, Basel) 
- Journal of Translational Medicine (BioMed Central) 
- Personalized Medicine (Future Medicine, London) 
- Personalized Medicine Universe (Elsevier)  
- Pharmacogenomics and Personalized Medicine (Dove Press, New Zealand) 
- Mount Sinai Journal of Medicine: A Journal of Translational and Personalized 
Medicine (Wiley) 
Only one journal, International Journal of Functional Informatics and Personalised Medi-
cine (InderScience, UK) is indexed in neither PubMed, nor EMBASE.  
Identification 
PubMed was searched on 1 April 2014 via PubMed.gov and EMBASE on 14 April 2014 via 
OVID. The following search string was used in both:  
“personalized health care” OR “personalized healthcare” OR “personalized medi-
cine” OR “P4 medicine” OR “precision medicine” OR “stratified medicine” OR 
“systems biomedicine” OR “systems medicine” OR “individualized medicine” OR 
“personalised health care” OR “personalised healthcare” OR “personalised medi-
cine” OR “individualised medicine” 
In both databases the title or abstract was searched, limited to English articles, without 
time limits. 
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The search at PubMed gave 4.317 records and EMBASE 6.328, all of which were imported 
to EndNote. By using different strategies in EndNote (automated, half automated and 
manual) 4.063 duplicates were removed. It is of note that in this very large set of records, 
duplicates were present not only between databases, but also within databases. Records 
of meeting abstracts were also removed since there is no full-text available for them and 
5.333 records remained. 
Inclusion criteria: Our inclusion criteria was “health intervention that is developed (de-
signed) and/or implemented and presented in association with one of the terms used to 
describe the personalized vision in medicine and health care (see the search terms)”. To 
be more clear in our inclusion criteria, we looked for health intervention/ practices which 
were implemented/demonstrated on at least one case (it can be as an example or a pilot; 
a drug and test on the market; a short test to assess feasibility, etc.) and had enough de-
tails provided in the relevant article(s). These criteria applied to both Screening and Eligi-
bility stages.  
Screening 
Screening was carried out by two independent researchers, with two different strategies. 
First researcher (TC) screened all of the 5.333 titles and, as necessary, abstracts.  
For triangulation, second researcher (ES) applied a different strategy: she made a second 
search within the database of 5.333 records using a large list of terms that are potentially 
relevant for identifying the practices and screened titles and abstracts of the records re-
vealed by this search. The second search terms included the following:  
“analytical model”, “application”, “case study”, “clinic”, “clinical”, “clinical prac-
tice”, “clinical AND evaluate”, “clinical AND translation”, “education”, “evaluate”, 
“evaluation”, “implement”, “implementation”, “innovat”, “innovation”, “intro-
duce”, “introduction”, “introduction AND clinic”, “model”, “patient”, “patient da-
ta”, “pilot”, “practical”, “practice”, “real-life”, “testing”, “tool”, “transition”, 
“translate”, “translation”, “valorization” 
The two researchers compared and discussed their results and reached a consensus for 
inclusion of 277 records in the screening phase. Full text manuscripts were obtained for 
262 records (95% of the included ones).  
Eligibility (1st stage) 
Articles were reviewed using the inclusion criteria as set above by two researchers (TC and 
ES) independently. They compared their results, had a discussion and reached a consensus 
to include full text of 179 articles in the analysis. The reasons for exclusion (83 records) are 
presented below: 
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- not implemented/presented on a case: 44 
- not ‘health intervention’: 14 
- not associated with ‘personalized medicine’ (or other keywords searched): 2 
- research and development tool or strategy: 14 
- review of gene-disease or gene-drug associations: 2 
- not enough details: 7 
Some articles could have been excluded for more than one reason from the above list, but 
it was counted only for the most apparent reason. 
Additional references 
While the full texts were investigated, additional records were identified from the refer-
ences. They were included only if they were present in the first set of 5.333 records and 
complied with the inclusion criteria. This brought 5 additional references, leading to 184 
included items. 
Eligibility (2nd stage) 
While specific practices were determined from the articles (see below) it was identified 
that 27 articles didn’t actually meet the inclusion criteria and therefore excluded (see 
Figure 1). The reasons for exclusion (27 records) are presented below: 
- - not implemented/presented on a case: 16 
- - not ‘health intervention’: 1 
- - not enough details: 10 
 Eventually, 157 articles were included.  
For the flow diagram, please refer to Figure 1 of the article. 
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Supplementary Material 2 
Lists of practices identified 
This material contains the tables that list, summarize and present the properties of the 
practices identified as a result of the systematic literature search. The articles referred in 
the tables are listed at the end under ‘references’. Table S1 to S5 summarizes the practices 
identified as a result of the systematic literature search. 
List of tables: 
Table S1: Basic properties of included practices    122 
Table S2: Details of grouped practices and their references   131 
Table S3: Practices available in health care market (Category-1)  134 
Table S4: Implementation models (Category-2)    137 
Table S5: Emerging practices (Category-3)     144 
References        149 
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 C
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 c
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b
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 d
ev
el
o
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at
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 r
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 d
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n
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 c
o
o
rd
in
a-
ti
o
n
 o
f 
ca
re
, u
si
n
g 
th
e 
h
ea
lt
h
 p
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 c
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p
at
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at
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 p
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 c
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at
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ra
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 c
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 D
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 C
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l o
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 p
at
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 f
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 p
re
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 b
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 C
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at
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 b
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 c
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 d
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 t
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 r
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at
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 t
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 c
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 p
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 p
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, p
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 o
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b
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 o
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 t
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 c
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l c
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 m
u
ta
ti
o
n
s 
re
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 f
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 o
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 c
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 p
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 p
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th
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re
sp
o
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d
ru
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w
h
ic
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ke
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 b
e 
p
re
sc
ri
b
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ft
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 t
h
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p
ro
ce
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h
ar
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ac
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ge
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ar
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p
o
ra
te
d
 t
o
 e
le
ct
ro
n
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 c
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 c
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at
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 p
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 b
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 p
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. b
ef
o
re
 t
h
e 
re
le
va
n
t 
d
ru
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ed
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b
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 p
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b
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 p
o
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h
ic
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 b
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l o
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 f
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n
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 C
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ci
n
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U
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A
n
 in
te
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p
lin
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m
o
d
el
 o
f 
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re
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 p
ro
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d
ed
 f
o
r 
fa
m
ili
es
 w
it
h
 a
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is
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ry
 o
f 
su
d
d
e
n
 c
ar
d
ia
c 
d
ea
th
 o
r 
ev
en
t,
 a
d
d
re
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in
g 
ge
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 m
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 C
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 d
ev
el
o
p
ed
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g 
an
d
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n
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u
b
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 d
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p
h
ar
m
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o
ge
n
et
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 d
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fo
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p
h
ar
m
ac
o
ge
n
et
ic
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is
k 
re
p
o
rt
in
g.
 T
h
es
e 
re
p
o
rt
s 
ar
e
 d
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iv
er
e
d
 t
h
ro
u
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re
 w
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 p
o
rt
al
, a
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es
si
b
le
 b
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th
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in
d
iv
id
u
al
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an
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s.
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 C
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 d
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 c
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 d
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 d
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 d
ia
b
e
te
s 
ge
t 
a 
m
ed
ic
al
 v
is
it
. 
H
ea
lt
h
 p
ro
fe
ss
io
n
al
; 
H
ea
lt
h
 c
ar
e 
o
rg
an
iz
at
io
n
 
 
 
Chapter 4 
142 
 
P
-N
o
.  
† 
P
ra
ct
ic
e
s 
S
e
tt
in
g
: 
In
st
it
u
ti
o
n
 
im
p
le
m
e
n
te
d
 
C
o
u
n
tr
y
 
S
h
o
rt
 d
e
sc
ri
p
ti
o
n
 
A
x
is
-2
: G
ro
u
p
  
se
rv
e
d
 t
o
 
7
1
 
In
d
iv
id
u
al
iz
e
d
 M
ed
ic
in
e
 C
lin
ic
 a
t 
M
ay
o
 
C
lin
ic
 
M
ay
o
 C
lin
ic
 
U
SA
 
Tw
o
 li
n
es
 o
f 
se
rv
ic
es
 a
re
 in
tr
o
d
u
ce
d
 in
 t
h
is
 c
lin
ic
: 
1
) 
tu
m
o
r 
ge
n
o
m
ic
s 
se
rv
ic
es
 f
o
r 
p
at
ie
n
ts
 w
it
h
 
ad
va
n
ce
d
 c
an
ce
r 
w
h
o
 f
ai
l s
ta
n
d
ar
d
 t
h
er
ap
y;
 2
) 
W
h
o
le
 E
xo
m
e 
Se
q
u
en
ci
n
g 
an
d
 in
te
rp
re
ta
ti
o
n
 
se
rv
ic
es
 f
o
r 
p
at
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 p
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 t
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at
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 t
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 t
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 p
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 m
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 f
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 t
h
e
 E
n
vi
ro
n
m
en
t 
G
eo
rg
ia
 In
st
it
u
te
 o
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 d
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b
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at
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A gradual shift from a ‘one-size-fits-all’ strategy towards personalized interventions is 
observed in the whole spectrum of healthcare, including personalized prevention, diagno-
sis and therapy, and the concept of personal health. This shift is caused by two major 
drivers. The first one is a general societal trend towards ‘personalization’, where individu-
als demand services or products that are customized to their needs, possibilities and 
choices. The second driver is rapid scientific and technological advancements in genome-
based science and technologies (which is a term that covers the full breadth of knowledge 
that is being amassed in all ’omics fields [1, 2]), information, and information and commu-
nication technologies (ICT). 
The future paradigm in health and healthcare has become increasingly visible in the past 
10–15 years and has been commonly defined as ‘personalized medicine’ although the 
exact definition varies among different stakeholders and opinion leaders. In the ongoing 
communications, the term personalized medicine comprises two separate and independ-
ent approaches. The first approach is based on biomarkers and statistical methods subdi-
viding a heterogeneous group into smaller less heterogeneous groups leading to stratified 
medicine. The stratification into smaller and smaller subgroups is limited by the statistical 
power, and may therefore, not incrementally lead to individualization. The other approach 
is based on ’omics and other data obtained from the individual in conjunction with com-
puter modeling approaches leading to ‘individualized medicine’. 
‘Personalized’ mostly refers to the use of genome-based information and technologies for 
providing more stratified (and possibly personalized) interventions. Some authors put the 
emphasis not only on medicine but on healthcare as a whole and prefer the term ‘person-
alized healthcare’, which is mostly used interchangeably with personalized medicine. 
However, personalized healthcare is much broader in its scope and covers all interven-
tions in a healthcare system including interventions in the medical, as well as, public 
health setting [3]. 
The publication of the initial draft and final version of the Human Genome Project in the 
early 2000s created high expectations for ‘genome-based’ medicine and personalized 
medicine. But only with the intervention of the new sequencing technologies termed next-
generation sequencing, it was possible to analyze the genomes of individuals in larger 
numbers. Although it is now evident that genomic information has revolutionized our 
understanding of (human) biology, its translation in drug discovery and medical practice 
has not been straightforward. So far ‘genome-based’ personalized medicine has provided 
limited output that can be translated into practice. This led to questioning whether per-
sonalization of medicine with genome-based information is a ‘myth’ or reality [4, 5]. We 
now recognize that the last decade was more about understanding the biology of ge-
nomes, whereas the coming decade will bring more information for understanding the 
biology of diseases [6]. Clear examples of advancing the science of medicine and improv-
ing the effectiveness of healthcare using genome-based information can be expected to 
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start to flourish in this decade, but will probably become more prominent in the period 
beyond the year 2020 [6]. 
In addition to genome-based personalization, there are other drivers that will mark the 
future trends and opportunities in medicine and healthcare, such as prediction by using 
early markers of progression from a healthy state to disease, prevention by personalized 
early diagnosis and targeting the specific mechanisms that are determining the disease 
progression in each individual, and participation of the individual in decision-making and 
management of the disease. Together, these aspects shape predictive, preventive, per-
sonalized and participatory (P4) Medicine [7]. It is of note that developments in imaging 
and sensor technologies will also play an important role in the near future to individualize 
medicine and healthcare. 
There are several issues and challenges in the journey towards this future paradigm of 
medicine and healthcare. In this commentary, we are addressing some of them that might 
be critical on the way from genome-based discoveries to real-life implementation with a 
public health perspective. 
Interaction among factors that surround the individual 
In the initial comments on personalized medicine, genomic information of individuals was 
the main focus. This was interpreted commonly by media and some scientists in a way 
that the genome, which is unique for every individual, would be the ultimate means for 
individualization. The truth here is both shocking and simple: our genome is not the only 
factor that makes us unique. As genome science evolves, the old truth that the phenotype 
is shaped by interaction of our genotype with our environment re-emerges and straight-
forward interpretation of genotypic variation into personalized medicine is ‘confounded’ 
by multiple environmental interactions. Often genotypic variations turn out to be only 
minor contributors to disease etiology. The environmental factors surrounding individuals, 
such as exposure to pathogens or toxins, socioeconomic factors, physical activity, nutrition 
and other lifestyle factors are constantly interacting with each other, as well as with the 
genomes. As science progresses, the importance of understanding these genome–
environment interactions is getting more and more important. We are moving towards a 
new understanding of health and disease, showing that these genome–environment in-
teractions change from day-to-day within an individual. Neither genomics nor the envi-
ronment is stable. Biological pathways or networks are permanently interacting with envi-
ronmental networks such as social networks. Thus, a comprehensive model of future 
healthcare taking into account integrative genomics alongside environmental, social and 
lifestyle factors will become essential to realize the P4 Medicine as the future paradigm of 
healthcare systems. 
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Specific examples of environmental factors are the ‘exposome’ of individuals, representing 
the combined exposures from all sources that reach the internal chemical environment, 
and can be measured as metals in toenails [8, 9]. Pathogens are also strong external fac-
tors that lead to disease. A prominent example of interaction of pathogens and the host 
genome is human papilloma virus and cervical cancer, whereby a pathogen may cause 
cervical cancer although ‘cancer’ is a disease traditionally classified as ‘noncommunicable’. 
Moreover, one of the factors that determines if and when progression to the disease will 
take place is the host’s genomic background [10]. The future is likely to show us more and 
more of such examples. 
The interaction of genome and lifestyle, as well as other environmental factors, may be-
come more visible by studying epigenomics. Epigenomics may also provide insights to 
interactions with socioeconomical factors and play a crucial role for public health by bridg-
ing social and biomedical sciences [11]. For example, nightshift work, which can be cate-
gorized as a ‘lifestyle’ or ‘socioeconomical’ factor, increases the risk of breast cancer [12]. 
This effect may be mediated by an epigenomic change in circadian rhythm genes and 
‘night shift’ may also turn into an inherited risk factor for breast cancer with potential 
effect for future generations [13]. 
From genomic to systems approaches in personalized health 
The path to evolve from genome-based personalized medicine to personalized medicine 
that takes all the relevant factors into account is the transition from genomic to systems 
approaches in personalized health. Systems biology is defined as an integrative, interdisci-
plinary approach to biological science that is built around the concept of close integration 
of computational methods, technology development and global measurement and analy-
sis of biological systems [14]. The integrative approach of systems biology has so far fo-
cused on the biological determinants of health and integrates various levels of information 
for discovery of disease causing biological networks. For example, nutritional systems 
biology [15] integrates ‘nutrition’, which is classified as a ‘lifestyle factor’, into systems 
biology studies by taking into account all biological mechanisms and processes that are 
affected by dietary components on all relevant levels of complexity. Integration of other 
determinants of health into systems biology approaches may provide further insight to 
understanding the biology of health and diseases. This approach is supported by the Public 
Health Genomics European Network (PHGEN), which is currently producing the first edi-
tion of “European Best Practice Guidelines for Quality Assurance, Provision and Use of 
Genome-based Information and Technologies” assisting all EU Member States [European 
Commission. European best practice guidelines for quality assurance, provision and use of 
genome-based information and technologies (2012), Policy report in preparation] [16, 17]. 
The integrative approach should not only be a concept for scientific discoveries, but also a 
main constituent of personalized medicine approaches in practice. In order to manage an 
 
Chapter 5 
166 
individual’s health, disease risks and diseases, we need to involve all available information 
related to the individual; make a 360-degree assessment of the individual’s health, includ-
ing personal, health, socioeconomic and lifestyle information, biomarkers and ’omics in-
formation; develop a personalized plan; and follow-up the progress made by the individual 
[18]. There are published and unpublished models indicating similar integrative approach-
es, which are conceptually developed [3, 19], prepared for implementation or developed 
as a practice model and implemented as a pilot study [18]. It is likely that more integrative 
approaches will soon emerge around the globe. 
Role of the individual 
While various attempts are made to understand and manage health, disease risk and dis-
eases, the perspective and expectations of the individual, who is in the center of all, 
should also be taken into account. Individuals are taking more and more control of their 
health because they have better access to health-related information and a higher desire 
to control their own life and health. It is not uncommon anymore to hear about patients 
who challenge their healthcare professionals with information they have found on the 
internet or obtained from their ‘peers’ with the same condition and/or symptoms. Social 
networking platforms such as PatientsLikeMe [20] enable its members to share condition, 
treatment and symptom information in order to monitor their health over time and learn 
from real-world outcomes. Furthermore, recently Sage Bionetworks launched a project 
called ‘Portable Legal Consent’ being a tool for patients to tell doctors, researchers, com-
panies and other stakeholders in the healthcare system, that they, the patients, own the 
rights to the data generated from their bodies. Portable Legal Consent states that “what 
the patient desires is for the data to be shared broadly in the public domain, to serve sci-
entific progress as a whole, regardless of the particular individual or institution that makes 
the breakthrough” [21]. 
Individuals should have the lifelong skills to find and assess the relevant and reliable in-
formation on the internet, which is also related to the concept of health literacy. In Europe 
the consortium of the European Health Literacy Project (HLS-EU) [22] defined four dimen-
sions of health literacy. Using this definition health literacy can be used as a catalyst to 
accelerate the accessibility, understandability, appraisal and application of genome-based 
information matching the needs within different population groups. In this context, exam-
ples such as Google [23] provide a powerful health literacy friendly electronic environ-
ment facilitating self-management, simplicity and user-centered applications. Thus, the 
future patient may turn from a passive consumer of health interventions into a proactive 
consumer or ‘prosumer’ [24, 25]. 
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ICT as facilitating factors 
ICT plays a central role in the implementation of personalized medicine in real life at sev-
eral points. The development of a new, data-rich, individualized medicine is likely to sur-
pass the demands of all other ICT development fields. As data-intensive analysis and com-
puter-intensive modeling technologies become common clinical practice, ICT capacity and 
organization will become key limiting factors in medicine, resulting in shifts of resources 
from personnel intensive to ICT intensive application. Data-rich, individualized medicine 
poses unprecedented challenges for ICT, in hardware, storage and communication. 
The combined genomic and phenotypic analysis may become very complex and needs 
algorithms and mathematical models to provide a clear diagnosis and therapy. A doctor’s 
computational brainpower is not enough to process all of the different factors surround-
ing the individual where there are hundreds or maybe even thousands of data to be con-
sidered, make current status and risk assessments, and based on these, draw personal 
plans for management of the individual’s health, risks and diseases. ICT is also essential in 
optimal coaching and patient empowering, both in complicated therapies (compliance) 
and in lifestyle coaching for prevention and health optimization. In order to facilitate a 
healthcare professional’s adoption of personalized medicine, we need strong information 
and communication platforms integrated into healthcare services to collect and analyze 
data, assess and interpret it, develop personal plans, follow-up the implementation and 
provide updates and revisions to the plan. At the same time, this should be a closed circuit 
that feeds science in identifying new hazards, both environmental and genomics, for dis-
ease risk and progression [26]. 
The IT Future of Medicine (ITFoM) provides such a platform for Europe being one of six 
pilot projects in the European Future and Emerging Technologies Flagship scheme [27]. It 
produces computational models of individual persons (‘the virtual twin’), which will follow 
the person during the whole life course through the healthcare systems enabling 
healthcare professionals to virtually simulate and optimize treatments. In the end, medical 
decision-making may turn into in silico decision-making. 
Conclusion 
There are several opportunities and challenges on the way to the future vision of medicine 
and healthcare. One of the key factors for its realization is aiming for an integrative ap-
proach towards an individual’s health, risks and diseases, considering all relevant factors 
surrounding them, such as genome, stages of life (from preconception to old age), expo-
sure to pathogens, nutrition, toxins, physical activity and other lifestyle factors, social 
interactions, stress and other socioeconomic factors, and healthcare systems. ICT will be 
critically important at all phases of this journey, including scientific discovery and transla-
tion and application to healthcare practices.  
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Future perspective  
Personal health drives a fundamental change not just in what is known, but also in how we 
think of ourselves and the way we are living, thus redefining our society. The political will 
is there, but we have to prepare for all the various organizational changes. The real para-
digm shift depends on the willingness to restructure policies. For realization of P4 Medi-
cine, there is a clear urgency to prepare healthcare systems and policy makers in time.  
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If we could give every individual the right amount of nourishment and exercise, not too 
little and not too much, we would have found the safest way to health. 
Hippocrates 
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Abstract 
Epidemiological and demographic transition has brought populations to an extended life 
expectancy in the 21
st
 century. The diseases of this century are complex, which stem main-
ly from the complex interactions of the human genome with lifestyle and environmental 
factors. These diseases are common, chronic and costly. Currently, the best-known pre-
vention for complex diseases is adopting a healthy lifestyle. However, this is not achieved 
in many places in the world. Effective intervention models, including lifestyle changes for 
the prevention of these diseases, are urgently needed. In this report, we introduce a pre-
ventive healthcare model based on personalized healthcare. It is based on the application 
of public health genomics tools and concepts on an individual level, in order to stratify 
individuals according to risk groups, prevent diseases and detect them early.  
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Life expectancy has been steadily increasing in almost all regions of the world since the 
beginning of the 20th Century. This happened as a result of epidemiologic and demo-
graphic transition in the world [1]. In the beginning of the 20th Century, life expectancy 
was below 50 years in western countries, whereas today it is above 75 years. Populations 
are rapidly aging. 
The diseases of the 21
st
 century are chronic and complex, which stem mainly from the 
complex interaction of the human genome with lifestyle factors. Cardiovascular and cere-
brovascular diseases, cancers, diabetes, obesity, osteoporosis, neurodegenerative diseas-
es and psychiatric diseases are among major chronic and complex diseases, which account 
for approximately 84% of deaths and 76% of the burden of disease in high- and upper-
middle-income countries [2]. The prevalence of chronic diseases increases significantly 
with age. Thus, the 21
st
 century brings us to an aged population living with chronic condi-
tions, creating a huge burden on healthcare systems and society. Complex diseases are 
not only the problem of high-income/industrialized countries, but also low-income coun-
tries in the process of industrialization. 
One of the biggest challenges of the health and social systems of the 21
st
 century is to add 
productivity and life quality to prolonged life years, while keeping the healthcare costs 
under control by reducing the burden of complex diseases. The solution lies in preventive 
interventions that start in earlier ages, much earlier than the onset of the complex diseas-
es. As the most important preventive measure, individuals must follow an appropriate and 
personal lifestyle plan. Giving general information and recommendations on health issues 
to the public has limited effectiveness to change the lifestyle of individuals. Therefore, an 
effective intervention model including lifestyle changes for prevention of these diseases is 
urgently needed. 
1. Complex diseases, genetics & personalized healthcare 
1.1. Complex diseases & genetics 
Complex diseases are caused by the interaction of genetics with the lifestyle of an individ-
ual. In order to understand the genetic basis of diseases, we can visualize the diseases in a 
threshold model, as shown in Figure 1. Here, diseases are grouped into three major areas, 
according to the disease-causing factors. 
The first group of diseases is caused by alterations in the genetic structure of human be-
ings. Down’s syndrome and cystic fibrosis are disorders caused by deleterious changes in 
the genes associated with the diseases. They constitute a small fraction of the burden of 
disease. External factors play little or no role in most of these diseases. With today’s con-
ditions, there is limited space for measures to prevent the disease occurrence in individu-
als carrying a genetic abnormality (see first column in Figure 1). 
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The second group of diseases is caused directly by external factors such as infectious dis-
eases, injuries, poisonings and so on (see second column in Figure 1). Genetics has a very 
limited role in these conditions. This group, especially infectious diseases within it, was the 
major burden of disease before the industrial revolution. The burden of disease caused by 
this group has reduced relatively, parallel to the developments in science and technology 
such as sanitation, antibiotics and vaccines. 
 
Figure 1: Diseases, genes, environment and lifestyle interaction from a disease threshold perspec-
tive 
The third group consists of disorders where common variations in genetic structure (pol-
ymorphisms) create a predisposition to the disease, but cannot cause the disease without 
other factors, mainly unfavorable lifestyle factors of individuals (see third column in Figure 
1). Because of this complex nature of gene–lifestyle interaction, they are called complex 
diseases. Main examples include cardiovascular and cerebrovascular diseases, diabetes, 
osteoporosis, cancers, neurological conditions and psychiatric disorders, which are mostly 
late-onset chronic diseases. They arise from an individual’s lifestyle and environmental 
factors imposed on their genetic predisposition. They consist of a large proportion of bur-
den of disease all over the world. The burden of chronic complex diseases will continue to 
expand steadily as a result of demographic and epidemiological transition in the next 20 
years [2]. 
1.2. Opportunities for the use of genetics in complex diseases 
Since the successful completion of the Human Genome Project, we have an exponentially 
increasing understanding of genetic factors and complex diseases. The identification of 
new genes and polymorphisms that have influence in diseases is helping to understand 
the underlying biology of the diseases, and leading to new therapeutic approaches, as well 
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as understanding of how genetic variations are of influence in predisposition of different 
individuals to different diseases. The knowledge regarding associations of polymorphisms 
with complex diseases is constantly growing. 
One of the success factors of nutritional interventions is prediction of the response of the 
individual to specific interventions. At this point, nutrigenetics is expected to play a major 
role. Nutrigenetics, which studies an individual’s specific response to diet owing to genetic 
variants (polymorphisms) [3], is positioned as the emerging face of nutrition that, when 
considered with more classical approaches, will provide the necessary stepping stones to 
achieve the ambitious goal of optimizing an individual’s health. Similarly, pharmacogenet-
ics will allow us to tailor the pharmacological interventions according to the specific needs 
of individuals, and minimize side effects while maximizing efficacy. 
The strong interaction of biological and genetic factors with lifestyle factors in the devel-
opment of chronic and complex diseases has brought us to a new understanding of ‘genet-
ics’, where genetics is not only related to the study of rare hereditary disorders, as under-
stood in ‘conventional’ medical genetics. In the late 1990s and early 2000s, it was foreseen 
that genetics/genomics would revolutionize medicine [4-6], and that genetics would be-
come a tool widely used for prediction, diagnosis and the optimization of treatment in 
most common diseases within the current decade [4, 5]. 
New issues and problems arise related to various aspects of this new potential practice; 
such as practice models of complex genetics, nutrigenetics and pharmacogenetics; clinical 
utility and validity of genetic tests; and ethical, legal and social aspects. They fall under the 
area of public health genomics, which is defined as a multidisciplinary field concerned with 
the effective and responsible translation of genome-based knowledge and technologies to 
improve population health [7]. Public health genomics uses population-based data on 
genetic variation and gene–environment interactions to develop evidence-based tools for 
improving health and preventing disease [8]. 
One of the most promising implication areas of genomics lies in preventive healthcare, 
especially for complex diseases. Applications of personalized medicine combined with the 
advent of health information technology in clinical practice will bring a new kind of medi-
cal care: personalized healthcare [9]. It is healthcare that works better for each patient, 
based partly on scientific information that is new, and partly on technology to make com-
plex information useful [9]. 
1.3. Facts & challenges for the use of genetics in complex diseases 
As we are approaching the end of the decade, science has made important progress in the 
discovery of genes and polymorphisms. However, their integration into medical practice 
has been limited. Current examples of the usage of common polymorphisms in clinical 
practice are polymorphisms in F5 (Factor V), F2 (Factor II) and MTHFR for thrombophilia 
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and perinatology; APOE for cardiovascular risks and Alzheimer’s disease risk; 
and CYP2C9, CYP2C19 and CYP2D6 for pharmacogenetics. Limited use of polymorphisms in 
medical practice has been the result of the fact that evidence demonstrating the effec-
tiveness in clinical use is not fully established yet. On the other hand, the current 
knowledge about the above-mentioned areas already has the potential to be used for the 
benefit of the individual and society. 
There are limitations and room for improvement for the current scientific information. 
Although the knowledge about associations of polymorphisms with complex diseases is 
constantly growing, evidence is not fully established. Current linkage analysis and genome-
wide association studies are focused merely on the genotype–disease relationship. Geno-
type information can be investigated together with other contributing factors for assess-
ment of disease risks (lifestyle including smoking, nutrition, and exercise; personal health 
history; family history; environmental exposures, and so on). On the other hand, current 
studies investigating the interactions between genotype and lifestyle factors are bringing 
limited evidence owing to small sample sizes. The limited number of prospective studies 
demonstrates the benefit of selected nutrition or nutritional supplement use based on 
selected genetic structures [10]. This type of prospective intervention study is needed for 
various other claims regarding nutrient–genotype interactions. 
Limited information suggests that personal risk assessments and personalized recommen-
dations can be a more effective means compared with classical approaches to change the 
lifestyle of the individuals [11]. In addition, the current level of technology allows us to 
make personalized risk assessments and develop personalized recommendations based on 
health information of individuals, including genetic information. There are several initia-
tives to benefit from genetic data to make personalized risk assessments and recommen-
dations [12-15]. However, the effectiveness of such applications has not been thoroughly 
evaluated (i.e., controlled prospective studies). 
2. Approach of GENAR Institute 
As the GENAR Institute for Public Health and Genomics Research (Ankara, Turkey), we 
have been working on the development of a practice model called Gentest
®
, which is an 
endeavor to face the above-mentioned challenges as an integrative preventive model that 
utilizes an individual’s health information, lifestyle factors, biomarkers and genotype in 
order to prevent and detect chronic and complex diseases early in a targeted way [16] (for 
information on GENAR Institute, see Box 1). 
The mission of this practice model is changing the behavior and managing the health of 
individuals according to their health priorities.  
The conceptual framework of Gentest is presented in Figure 2. Its components are de-
scribed in the implementation stages below.  
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Box 1: GENAR Institute for Public Health and Genomics Research. 
The GENAR Institute for Public Health and Genomics Research was established in 2004, in 
Hacettepe University Science Park, Ankara, Turkey. It is the third public health genomics 
center in Europe and a cooperating institute of Public Health Genomics European Network 
(PHGEN) [17]. The GENAR Institute aims to transform scientific developments in the area 
of biotechnology, especially those in genetics and genomics, into products and services 
that improve human health, quality of life and performance, and extend lifespan. The 
GENAR Institute has a broad range of working area, mainly on chronic complex diseases. 
The R&D activities focus on understanding the underlying genetic and genomic basis of 
these conditions and developing products based on targeted prevention, early detection 
and treatment strategies. 
The GENAR Institute is comprised of three centers: GENAR Biotechnology and Molecular 
Genetics Research and Diagnostic Laboratories, which is a high-throughput molecular 
genetic analysis laboratory; GENAR Center for Nutrigenetics and Lifestyle Research, which 
focuses on quantifying the nutrition and other lifestyle factors of individuals and develop-
ing models for personalized nutrition and lifestyle advice for optimization of individual 
needs; and the GENAR Center for Personalized Medicine and Pharmacogenetics, which 
aims to catalyze transfer of developments in genetics to the health of individuals with a 
public health vision. There has also been an implementation center in Istanbul, Turkey, to 
pilot the developed models. 
Gentest is designed to be implemented in primary-care settings where the health profes-
sional(s) (physicians and/or dieticians) can focus on preventive healthcare interventions. 
For the piloting phase of the model, it is mainly practiced in the Gentest Implementation 
Center, which is run by GENAR. In addition, health professionals are authorized to be prac-
titioners of Gentest after participating in training of the Turkish Society of Public Health 
Genomics and Nutrigenetics and the GENAR Institute. 
The diseases/health areas that are undertaken in Gentest are selected based on their 
prevalence, the burden they create and the ability to recommend lifestyle and medical 
interventions to reduce the risks or delay the onset of these diseases. Currently, the fol-
lowing diseases and health areas are undertaken in Gentest: 
 Cardiovascular and cerebrovascular diseases; 
 Insulin resistance, Type 2 diabetes and obesity; 
 Inflammation; 
 Osteoporosis; 
 Antioxidation and detoxification mechanisms; 
 Cancers in general, and the five most prevalent cancers in particular, which are 
lung, breast, prostate, colon and stomach. 
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Figure 2: Conceptual framework for the Gentest practice model 
2.1. Implementation stages of the practice model 
2.1.1. Data & information collection stage 
An individual who applies to the Gentest Implementation Center is first explained what 
Gentest is, and what it is not (see Table 1). The most suitable Gentest package for that 
individual’s personal characteristics and requirements is chosen with the help of the phy-
sician. 
Special attention is paid to create proper consumer expectations, as defined in Table 1. 
For this purpose, a sample Gentest, which is an anonym report of a real case, is presented 
to the individual. After oral and written acknowledgments explaining the issues summa-
rized in Table 1, the individual signs the consent form for DNA analysis. An appointment is 
given to come with overnight fasting. 
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Table 1: What is Gentest and what is not? 
What is Gentest? What is not Gentest? 
Gentest is developed to assist health pro-
fessional and the individual in their efforts 
to prevent diseases and promote health. 
 
Gentest recommendations are subject to 
the evaluation of and can be changed by 
the health professional. 
 
Gentest can only be implemented through 
authorized health professionals (physician 
and/or dieticians, according to the con-
tent of the packages). 
Gentest is not a direct to consumer ser-
vice. 
Gentest provides information on disease 
predispositions and risks. 
Gentest does not diagnose diseases or 
give treatment advice.  
Gentest does not provide deterministic 
information if a person will develop a dis-
ease or not. 
The main purpose of the risk calculations 
is to provide the lifestyle and medical 
follow-up interventions in a targeted way. 
 
Gentest gives personal recommendations 
to decrease one’s health risks and lead a 
healthier life within their own genetic 
make-up. 
Being predisposed to a disease does not 
mean that the person will definitely de-
velop it. 
Risk calculations are based on population 
studies and refer to the risk of subgroups 
of individuals carrying the characteristics 
of the individual subject to the test. The 
characteristics used for the calculations 
are age, gender, health information, bi-
omarkers, lifestyle factors and genetic 
make-up.  
Carrying the risk of the disease does not 
mean that the person will definitely de-
velop it.  
Following the medical follow up and life-
style recommendations given in Gentest 
report scientifically reduces one’s disease 
risks. 
Following the medical follow up and life-
style recommendations given in Gentest 
report does not completely eliminate 
one’s risks. 
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Box 2: Inputs of Gentest 
 
When the person comes to the appointment, blood and urine samples are taken. Anthro-
pometric measurements are made using scales and a tape measure, and bioelectrical 
impedance is used for body composition analysis. Blood pressure and pulse is measured. 
The individual fills in a detailed questionnaire collecting the necessary inputs listed in Box 
2 with the assistance of a health professional. Gentest Food Portion Atlas (Figure 3), which 
is developed by GENAR, is used during collection of food consumption data. It takes ap-
proximately 2 h for measurements and filling in the information form. 
Blood and urine biomarker analysis are carried out by an external biochemical laboratory 
and the results are forwarded to the GENAR Institute. One tube of blood sample is trans-
ported to GENAR Laboratories for genetic analysis. 
1.1.1. Assessments 
The questionnaire is analyzed by the GENAR Center for Nutrigenetics and Lifestyle Re-
search, to quantify the nutrient intake, physical activity status and causes of smoking. The 
current consumption status of macro- and micro-nutrients are assessed with the analysis 
of both food consumption records and food frequency questionnaires. 
 Personal information 
– Age 
– Gender 
 Health information 
– Personal history (current and past diseases and medications) 
– Family history 
 Living and working conditions 
– Occupation 
– Past and present occupational and environmental exposures 
 Lifestyle information 
– Physical activity and exercise 
– Smoking and drinking habits 
– Supplement consumption 
– Nutritional habits 
– Food consumption (24 h recall and food frequency) 
 Anthropometric and bioimpedance measurements 
– Height, body weight and composition 
– Waist circumference 
 Biomarkers 
 Genotype information 
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For each macro- and micro-nutrient, a minimum and maximum level of intake recommen-
dation is determined. These nutrients include: macronutrients such as protein, carbohy-
drate and fat, including different saturated/unsaturated fats and omega 6/omega 3 fatty 
acids; vitamins; minerals; and key functional foods. Recommended levels are based on 
age, gender, current diseases, genetic information and lifestyle information of the individ-
uals. Recommendation algorithms are based on international and national guidelines on 
macro- and micro-nutrients and literature on nutrition and nutrigenetics research. The 
recommendations are presented both in tables and figures (for an example of figures, 
see Figure 4). 
 
Figure 3: An excerpt from the ‘Food Portion Atlas’ 
 
 
Figure 4: An excerpt from the ‘Assessment of Nutrition and Nutritional Supplements’ section of a 
Gentest report 
Assessment on body composition is made using anthropometric measurements and bi-
oimpedance analysis (Figure 5). 
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Figure 5: An excerpt from the ‘Assessment of Body Composition’ section of a Gentest report 
 
 
Figure 6: An excerpt from the ‘Assessment of Physical Activity and Exercise Status’ section of a 
Gentest report 
Current exercise status related to eight different areas of physical fitness is assessed. 
These areas are cardiorespiratory fitness, muscle strength, bone strength, muscle endur-
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ance, flexibility, balance, insulin sensitivity and body composition. Currently, this assess-
ment is based on the type, intensity, duration and frequency of the exercises carried out 
by the individual. More objective methods to assess the physical fitness levels of the indi-
vidual are under development. The recommended level of exercise for each physical fit-
ness area is determined according to disease risks, genetic predispositions and personal 
preferences (Figure 6). 
If the individual is smoking, causes of smoking are also assessed using questionnaires. The 
types of smoking assessed are nicotine craving/physiological addiction, stimulation, relax-
ation/pleasure, crutch/tension reduction, habit and handling (hand contact with the ciga-
rette). 
In parallel to assessment of the lifestyle information, genetic analysis is carried out by 
GENAR Biotechnology and Molecular Genetics Research and Diagnostic Laboratories. 
Genetic analysis covers common polymorphisms related to common complex diseases and 
conditions listed above (see Approach of GENAR Institute section). For each health area, 
the results are presented in a table that presents information on the gene, function/role in 
health-related area, polymorphism and the genotype result of the individual, as well as 
what the result indicates for that disease/health area (for a sample page, see Figure 7). 
The number of polymorphisms studied varies from 35 to 65 in the different packages. 
 
Figure 7: An excerpt from the ‘DNA Analysis Results and Genotype Assessment Table’ section of a 
Gentest report 
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Polymorphisms in the health area of interest are selected qualitatively based on consider-
ing a number of aspects. The studies that show a positive association and no association 
are evaluated in their design, statistical power, presented odds ratios and p-values, as well 
as the credibility of the published journal. Frequency of the polymorphism in white Cauca-
sians are also taken into account. Studies on gene–lifestyle interactions are also evaluated 
with this perspective in mind. 
Biochemical markers such as blood lipids, fasting plasma glucose, liver and kidney function 
tests, homocysteine, high-sensitivity C-reactive protein and fibrinogen are analyzed by 
external clinical laboratories. The biomarkers are selected and assessment methods are 
developed in light of the current medical guidelines and literature. 
The results of lifestyle assessment, genetic analysis and biomarker tests are gathered in 
the GENAR Center for Personalized Medicine and Pharmacogenetics, in order to produce 
the report of the individuals. 
In the GENAR Center for Personalized Medicine and Pharmacogenetics, risk assessments 
for the most common chronic complex diseases are made. These include myocardial in-
farction, stroke, Type 2 diabetes, osteoporosis and the five most common cancers (lung, 
breast, prostate, colon and stomach). Risk assessment algorithms are based on risk factors 
conveyed by various epidemiological studies and risk assessment models. The genetic 
analysis results are also used as a factor in risk assessment, but with very small effect sizes 
given the limited demonstrated effect of discovered polymorphisms on overall risks of 
diseases. The inputs of the risk assessment algorithms are listed in Box 2. 
Risks are presented for two cases: the estimated risk using the current data and the esti-
mated risk for the case that the recommended optimum lifestyle and medical follow-up 
plan is followed (for examples of risk graphics, see Figures 8, 9 & 10). 
Risk graphics (both the current and estimated reduced risk with the optimum lifestyle and 
medical follow-up plan) are presented in the report for two main purposes. The first one is 
to provide the lifestyle and medical follow-up interventions in a targeted way. The second 
one is to promote lifestyle changes through creating personal vulnerability perception and 
individual risk perception [18]. 
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Figure 8: An excerpt from the ‘Disease Risks’ section of a Gentest report: ‘Heart Attack Risk with 
Current Lifestyle in the Following 30 Years’ 
 
Figure 9: An excerpt from the ‘Disease Risks’ section of a Gentest report: ‘Reduction of Heart 
Attack Risk in the Following 30 Years After Implementation of Optimum Lifestyle and Medical 
Follow-up Plan’ 
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Figure 10: An excerpt from ‘Disease Risks’ section of a Gentest report: ‘Colon Cancer Risk’ 
The report of an individual includes the results of the above-mentioned assessments and 
an ‘Optimum Lifestyle Plan’ developed for the individual. It includes a plan for reaching 
and/or maintaining optimum body composition, personal nutrition plans and food ex-
change lists, supplement plans and exercise plans. Smoking cessation recommendations 
are personalized according to the causes of smoking. Recommendations are given for 
medical follow-up with personalized screening plans. For all medical follow-up recom-
mendations, it is highlighted that they are subject to evaluation of the physician and can 
be changed if necessary. If any medical problem that needs further investigation or cura-
tive interventions is detected, it is presented in the ‘physician note’, which is provided for 
the physician separately. 
When developing methodologies for all components of Gentest, the most important deci-
sion criterion is this: for all the information and recommendations we give, there has to be 
good probability of benefit with no possibility of harm. This is ensured by always comply-
ing with the nutritional and medical guidelines. For example, recommendations on the 
upper and lower limits of the intake of a nutrient are always within the upper and lower 
limits that are recommended in the nutrition guidelines. Properties that can be used to 
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further personalize the recommendations, but not referred in the guidelines yet, such as 
genetic information, are used to narrow down the general recommendation range. 
1.1.2. Counseling & follow up 
Gentest reports are ready approximately 4–8 weeks after sample taking and filling out the 
questionnaire. The report is sent out to the physician who explains the report results to 
the individual during an hour long appointment. The nutrition program is explained by a 
dietician trained in nutrigenetics. 
If the individual would like to have assistance in making the lifestyle changes, the follow-
up program is started. This option is usually chosen by the overweight or obese individuals 
who are recommended to reach their optimum body composition. 
1.2. Experiences of GENAR 
The practice model has been in service for piloting purposes for approximately 2 years in 
Turkey. Approximately 500 individuals have used this pilot service. The results of this pilot 
implementation phase are being assessed and will be published in another manuscript. A 
noteworthy observation is that Gentest might have a better outcome for behavior change 
than providing general information on healthy behaviors. In particular, initiation of exer-
cise, smoking cessation and weight loss has been observed. This observation surely needs 
to be confirmed with publication of related data. 
We think that Gentest may have an important effect in creating awareness by informing 
individuals about their current lifestyle and genetic predispositions. Furthermore, it causes 
an attitude change by creating a vulnerability perception. Finally, it is observed that be-
havior change is achieved with the follow-up program and the trainings (Figure 11). 
 
Figure 11: Model of attitude and behavior change with Gentest 
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2. Criticisms to the approach of the GENAR Institute 
Our practice model has been presented to the scientific community at a number of occa-
sions. These are the 1st Congress of the International Society of Nutrigenet-
ics/Nutrigenomics (Athens, Greece, 13 November, 2007) [16], 16th European Conference 
on Public Health, European Public Health Association (Lisbon, Portugal, 7 November, 
2008), Conference on Public Health Genomics in Europe, Public Health Genomics Europe-
an Network (Istanbul, Turkey, 26 November, 2008). The practice model being comprehen-
sive (containing several factors such as personal, medical and lifestyle information, and 
genetic information), multidisciplinary, prevention-orientated and implemented through 
health professionals have been the appraised characteristics. 
On the other hand, the main criticism to this practice model has been that its effective-
ness has not been demonstrated yet. Since 2004, GENAR has developed the model, pi-
loted its components and the whole model, and further developed it with feedback. This 
gave GENAR the chance to see if such a model is applicable in a preventive healthcare 
setting, and if there is a potential benefit for the consumers. Currently, we are working on 
the design and implementation of research for the evaluation of the effectiveness of the 
proposed practice model. The effectiveness will be assessed from outcome perspective 
(prevention of diseases and disease complications), bioprocesses perspective (lipid profile, 
inflammation, glycemic control and so on), lifestyle changes and applicability. Collabora-
tion with cohorts are also planned to further develop the algorithms. 
3. Conclusion 
Public health genomics and personalized healthcare will play major role in combating the 
chronic complex disease burden of the aging populations of the 21
st
 century. In parallel to 
exponentially increasing knowledge gained through research, healthcare systems need to 
foresee these upcoming developments and prepare for the transition. The approach of 
GENAR is an example of the translation of genome-based knowledge into preventive 
healthcare. The definition of public health genomics suggests that this translation should 
be effective and responsible [8]. By assuring that the information and the recommenda-
tions has good probability of benefit but has no possibility of harm, the Gentest practice 
model can be considered as a responsible one. However, the effectiveness has not yet 
been demonstrated. 
4. Future perspective 
As the populations continue to age, the burden created by complex diseases will increase. 
The future healthcare systems will not be able to cope with the societal and economic 
burden of complex diseases. An effective intervention model including lifestyle changes 
for prevention of these diseases is urgently needed. Like we did a century ago with the 
vaccines against infectious diseases, the world needs a cost-effective health intervention 
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to prevent complex diseases, as well as decrease the disability and increase the life quality 
of aging populations. 
In order to achieve this goal, the medicine of the future needs to target the individual, 
rather than general public or population subgroups. Thus, healthcare practice models 
need to be individualized, assessing different characteristics of the individuals, such as 
personal health data, lifestyle information and genetic information, to provide individual-
ized interventions and recommendations. This vision is defined as ‘personalized 
healthcare’. 
Personalized healthcare holds great potential to combat the burden of complex diseases. 
In 5–10 years’ time, personalized healthcare interventions are expected to be widely uti-
lized in primary care settings for primary and secondary prevention of complex diseases 
and their complications. 
Executive summary 
The need for effective intervention models to combat complex diseases 
 Complex diseases, which stem mainly from the complex interaction of the human 
genome with lifestyle and environmental factors, cause the main burden of dis-
ease in the 21
st
 century. Currently, the best-known prevention for complex dis-
eases is adopting a healthy lifestyle. However, this is not achieved in many places 
of the world. Effective intervention models including lifestyle changes for preven-
tion of these diseases is urgently needed. 
Facts & challenges for the use of genetics in complex diseases 
 In the late 1990s and early 2000s, it was foreseen that genetics/genomics would 
revolutionize medicine, and genetics would become a tool widely used for predic-
tion, diagnosis and to optimize treatment in most common diseases within the 
current decade. As we are approaching the end of the decade, science has made 
important progress to discover genes and polymorphisms. However, their inte-
gration to medical practice has been limited, owing to the fact that evidence 
demonstrating the effectiveness of the genomic markers in clinical use is not fully 
established yet. On the other hand, the current knowledge about the above-
mentioned areas already has the potential to be used for the benefit of the indi-
vidual and society. 
Approach of the GENAR Institute 
 The GENAR Institute for Public Health and Genomics Research has developed a 
practice model called Gentest® as an integrative preventive model which utilizes 
individual’s health information, lifestyle factors, biomarkers and genotype in or-
der to prevent and early detect chronic and complex diseases in a targeted way. 
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Based on the results of the aforementioned components, an optimum lifestyle 
plan is developed, including personal menu plans and exchange lists, exercise 
plans, smoking cessation recommendations based on the individual causes of 
smoking, and a medical follow-up plan. 
 The mission of this practice model is changing the behavior and managing the 
health of individuals according to their health priorities. It is thought that the 
model creates awareness by informing individuals about their current lifestyle 
and genetic predispositions. Furthermore, it causes an attitude change by creat-
ing a vulnerability perception. Finally, it is observed that behavior change is 
achieved with the follow-up program and the trainings. 
Criticisms to the approach of GENAR Institute 
 The practice model being comprehensive (containing several factors of the indi-
vidual), multidisciplinary, prevention orientated and implemented through health 
professionals have been the appraised characteristics. On the other hand, a criti-
cal point is raised, which is that the effectiveness of the intervention is not yet 
demonstrated. 
 The efforts of GENAR so far has been on the development of the model and pilot-
ing its components and the whole model. The crucial future step is to conduct a 
research for evaluation of the effectiveness of the proposed practice model. 
Conclusion 
 Personalized healthcare holds a great potential to combat the burden of complex 
diseases, provided that the safety is ensured and the effectiveness of the utilized 
tests and practice models are demonstrated scientifically. 
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A camel is a horse designed by a committee. 
Attributed to Sir Alec Issigonis  
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Abstract 
It is a serious bottleneck to integrate ‘personalized medicine/personalized health care’ 
into health systems. To solve this, we propose applying a systematic approach to identify 
and assess issues related to integration. The presented case was developed on a preven-
tive personalized health care model, but it can be applied to other practice models in 
different countries. 
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Recent developments in science and technology will allow us to shift from general rec-
ommendations and “one size fits all” strategies towards more personalized interventions 
throughout the whole spectrum of health care, from prevention to therapy. This shift is 
driven by advances in ‘genome-based knowledge and technologies’ and ‘information and 
communication technologies’ (ICT), as well as by the general societal trend towards ‘per-
sonalization’. Although this vision is shared by various opinion leaders and institutions, the 
terms they use for it and their definitions of what it entails differ considerably. Neverthe-
less, most definitions seem to agree on the attributes of it being Predictive, Personalized, 
Preemptive/ Preventive, and Participatory, previously coined as the term ‘P4 Medicine’ by 
Leroy Hood [1, 2]. 
Among the variety of terms, personalized health care seems to be the most comprehen-
sive [3] in terms of scope and depth [4] (see also Chapter 4). The term ‘health care’ covers 
not only medicine, i.e. diagnosis and therapy, but the whole spectrum of health related 
interventions [4]. Personalized health care utilizes, but is not restricted to genomic medi-
cine and other technology driven personalized medicine tools [5]. Any advancement that 
serves to better prevention, prediction and personalization can be part of personalized 
health care. Most importantly, personalized health care provides a holistic approach to 
the individual, covering his/her different characteristics such as personal health history, 
family health history, lifestyle, genomics, other biomarkers, and socioeconomic factors, 
rather than focusing on a single determinant of health [4]. Thus, personalized health care 
offers a valuable opportunity to develop and deploy personalized interventions for pre-
vention of chronic complex diseases, which create a serious burden on health systems and 
societies in the 21
st
 century [6, 7]. 
Regardless the struggle for common terminology, one problem is common across the 
fields: integration of ‘personalized’ practices into different health systems. Personalization 
of medicine and health care has been on the agenda of the scientific community for over a 
decade. Nevertheless, integration of related technologies into the health system for the 
benefit of the population has been slower than initially expected. To tackle this problem 
effectively, we need to have a holistic view of the issues to be thought of and covered. As 
all the topics within health systems are interrelated, this approach can be more effective 
than listing items individually and trying to solve them one by one, independent from each 
other and the general context. We must first see the broader picture. 
This paper describes our attempts to obtain an overview of all issues (and their intercon-
nections) involved to when integrating a preventive personalized health care model into 
health systems, developed particularly for the European context. First, we will briefly in-
troduce the practice model for prevention of chronic diseases we used as an example and 
justify the need for a systematic approach for its integration. Upon introducing the over-
arching framework that guided our efforts, we’ll explain how the systematic approach was 
developed and applied to identify issues around integration of the practice model in Euro-
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pean context. Then, possible uses and potential benefits of such a systematic approach 
will be summarized. Concluding remarks will call to focus on health rather than disease, 
and to establish a dialog between the fields of ‘personalized medicine/personalized health 
care’ and health systems and policies. 
Integration of a preventive personalized health care model 
A personalized health care model called Gentest was developed in Turkey for prevention 
of chronic complex diseases in primary care services [6](for more information, see Box 1). 
After its pilot, it was decided to look for possibilities for further expansion of the practice, 
targeting other European countries. 
Box 1: A practice model in personalized health care 
The practice model we used, Gentest, was developed by GENAR Institute for Public Health 
and Genomics Research in Turkey as an endeavor to face the challenge of chronic complex 
diseases [6]. It utilizes individuals’ personal health information (clinical information includ-
ing family history), detailed lifestyle analysis (nutrition, exercise and smoking), body com-
position, genotype, and conventional biomarkers (such as LDL cholesterol, fasting plasma 
glucose, etc.) in order to prevent development and progression of chronic diseases in a 
targeted way. Based on the analysis of the aforementioned components, risk assessments 
for the major chronic diseases are compiled. The range of conditions includes heart attack, 
stroke, type 2 diabetes, common cancers (lung, breast, prostate, colon, and gastric can-
cers), and osteoporosis. Diseases selected for the model represent the highest burden of 
diseases in Turkey. Using all assessments, an optimum lifestyle plan, including personal 
menu plans and food exchange lists, exercise plans, smoking cessation recommendations, 
and a medical follow-up plan are drawn. The model is implemented via health care profes-
sionals, in particular physicians. Its mission is to change the behavior and manage the 
health of individuals according to their health needs and priorities. 
The purpose of Gentest model is prevention of the major chronic diseases and their com-
plications, within the whole continuum of their development and progression, i.e. from 
the point where there is no disease to the point where there is fully established disease 
and further towards its complications. The results of the analysis and recommendations 
change depending on where a specific individual is on the disease development and pro-
gression line for different conditions. The general aim is to catch the individuals on as 
early as possible stages of disease development to slow down, delay, or if possible, re-
verse the progression towards the disease and its complications. For this purpose, the 
model aims to include as much as possible of all determinants of health to make a 360 
degree assessment of health of the individual. 
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Gentest was developed by GENAR Institute for Public Health and Genomics Research, 
which was established in 2004, in Hacettepe University Science Park, Ankara Turkey. It was 
identified as a best practice model for public health genomics in Europe by the Public 
Health Genomics European Network (PHGEN). It was piloted on more than 500 individuals 
in Turkey via authorized practitioners (mainly physicians) and now offered as a privately 
paid health service via authorized practitioners (physicians) in major cities in Turkey. 
Based on the experiences with Gentest, feedback from scientific and industrial communi-
ties, and current trends and developments in the world, it was agreed that the main im-
plementation area for such a preventive intervention would be primary care services in 
Europe, where it can be provided via ‘general practitioners/family physicians’ (will be 
collectively abbreviated as ‘GP’). However, there has been no example of such a preven-
tive personalized health care model provided to large populations. Thus we were faced 
with questions like “What are the issues we need to look at when investigating the poten-
tial integration of Gentest into primary care services? And how can we identify them?”  
To answer them, we first looked at the scientific and grey literature on ‘personalized med-
icine/personalized health care’. We identified that the main focus in this field is on scien-
tific and technological developments, in particular on diagnosis and therapy. Issues related 
to integration into health systems are mainly tackled in a piecemeal approach with bullet-
point lists on ‘challenges’ or ‘barriers’. The topics raised usually concentrate around licens-
ing/approval by authorities, reimbursement/finance, data use and protection, physician 
and patient acceptance/education, and ethical, legal and social implications [2, 8-14]. (See 
also Chapter 4) These indeed are important issues that need to be tackled; however it is 
arguable if they make a whole picture when they come together and whether their cover-
age will automatically improve the integration process. Moreover, these points are mostly 
identified for diagnostics and therapeutics scenarios, and have limited relevance to pre-
ventive models to be integrated into primary care services. In order to avoid this frag-
mented vision, there is a need for a systematic approach to assess how a ‘personalized’ 
practice can be integrated into a country’s health system. 
How to analyze integration into health systems 
In search for a systematic approach, we turned to the field of health systems and policies 
to see what analytical approaches to health systems exist. Among the various conceptual 
frameworks of health systems [15-19], the one developed for World Health Organization’s 
health system performance assessment efforts in 2000 [16] provides a comprehensive 
way of looking at the a health system. We used an adapted and elaborated version of this 
model (see Chapter 2), where a health system has four key functions: stewardship, financ-
ing, health services and resource generation (the elaboration was done in particular under 
‘health services’). These functions provided the overarching framework of our systematic 
approach (Table 1).  
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Table 1: Functions of a health system  
A. Stewardship 
o Priority setting    
o Legislation and regulation 
o Steering    
o Administration and management 
B. Financing 
o Revenue collection   
o Fund pooling  
o Purchasing 
C. Health services (listed in order from societal to individual and general to special-
ized) 
o Environmental health services 
o Population based health protection 
o Population based health promotion 
o Population based disease prevention 
o Personal health promotion services  
o Personal disease prevention services 
o Primary diagnostic and curative services   
o Primary care rehabilitative services 
o Specialized care 
D. Resource generation 
o Human resources  
o Physical resources  
o Knowledge 
Source:  Adapted and elaborated version of Murray and Frenk [ 1 6]  by Savas and Cesuroglu 
(Chapter 2)   
By using this framework (Table 1) and our preventive personalized health care model (Box 
1), we carried out an exercise to identify which areas need to be assessed when investigat-
ing how this practice model could be integrated into health systems in Europe. We identi-
fied 24 areas that need to be assessed under the functions and sub-functions of health 
systems (the first column in Table 2).  
Not all of the 24 areas and numerous criteria and issues have the same importance when 
a practice model is integrated into a health system. Therefore, we organized the areas in 
three levels of importance: crucial, priority and secondary (the second column in Table 2). 
Crucial areas are a ‘must’ and should be the first areas to be investigated in a given coun-
try. If they don’t yield favorable results, it is virtually impossible for the practice model to 
be integrated in that country and therefore, investigation of other areas would not be 
necessary. For example, due to the economic crisis, some countries in Europe are facing 
Primary care services 
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drastic budget cuts in public sector (Area 13 in Table 2 and Table S1 in supplementary 
material). In those countries where austerity policies are implemented, it is practically 
impossible to make a new investment such as the practice model. 
Another crucial area we identified is ‘15. Strength and place of primary care services in the 
health system and its relationship with other levels of care’. The beneficial effects of the 
practice model would be most prominent in systems where the primary care physician 
(GP) has the function to manage the health and risks of individuals registered to his/her 
practice. If the primary care services are strong and the GPs have a ‘gate keeper’ position 
regulating access to specialized care, implementation of the practice model would yield 
the best results. If it doesn’t have the gate-keeper function, it will be very difficult for 
primary care settings to assume the function of managing the health and risks of individu-
als and, therefore, application of the practice model wouldn’t yield expected benefits. 
Therefore, we identified that a strong primary care service structure is one of the prereq-
uisites for implementation of this model. 
Priority areas are the ones that should be ‘favorable’ in a given country. If assessment of a 
priority area doesn’t yield a favorable profile, it will be difficult to integrate the practice 
model as envisaged in that country, even if it fits in the other areas perfectly. For example, 
if ‘the general environment and culture of the health system’ (Area 9) is not favorable for 
innovations, it would be very difficult to integrate the practice model.  
Secondary areas are the ‘complementary’ ones that need to be addressed to prepare and 
plan for the investigation of the practice model. 
In order to complete the exercise, we used examples from the Netherlands and the UK to 
check if and how our areas were applicable in real systems, as well as to identify new is-
sues as necessary. We chose these two countries since we had access to information on 
them. In order to enrich the exercise, we used relevant examples from other European 
contexts as we came across with them. An example of an issue identified on a country 
level is a specific Dutch regulation covering ‘screening’ programs, which has implications 
for preventive health interventions. Although Gentest is not intended to be a ‘screening’ 
tool, due to various laboratory tests used, it may fall under this law (Area 3. Regulation of 
non-diagnostic services which aim prevention, Table S1). Thus this systemic approach 
helped us to identify that if this practice is integrated into primary care services in the 
Netherlands, it should be made clear if and what parts of it fall under this regulation. 
Moreover, similar regulations should be screened for in other candidate countries as well. 
Another prominent example is the UK’s recent initiatives on using whole genome se-
quencing (WGS) for ‘research’ purposes for large number of patients (100.000), which may 
be considered as a pilot for the possible future services of WGS [20]. This can be a signal of 
a ‘pro-genomics’ environment in this country and facilitate the integration (Area 9. Gen-
eral environment and culture of the health system for innovation, Table S1). 
 
Chapter 7 
204 
Table 2: Areas identified for assessment of a country’s health system for integration of the prac-
tice model 
AREAS IMPORTANCE1  
A. STEWARDSHIP  
Priority setting  
1. Health policies, strategies and programs Secondary  
2. Strategies on relevant applications and technologies Priority  
Legislation and regulations  
3. Regulation of non-diagnostic services which aim prevention Secondary 
4. Regulation of genetic testing, including predictive testing for im-
plementation in primary care services 
Priority  
5. Regulations on ethical issues in terms of implementation Secondary 
6. Regulations on liability of the practice model Secondary 
7. Regulations on data protection, privacy and confidentiality Secondary 
8. Regulations on cross-border health care Secondary  
Steering  
9. General environment and culture of the health system for innova-
tion 
Priority 
10. Stakeholders, processes and mechanisms involved in implementa-
tion of new applications in health care 
Secondary 
Administration and management  
11. Mechanisms related to evaluation of new applications and deci-
sion making in health care services 
Priority 
B. FINANCING 
2
  
12. Health financing system of the country  Priority 
13. General health expenditure structure of the country Crucial 
3
 
14. Payment mechanisms for primary care services, i.e. GPs Priority 
C. HEALTH SERVICES (Primary care services) 
4 
  
15. Strength and place of primary care services in the health system 
and its relationship with other levels of care 
Crucial 
16. Scope of primary care in terms of (primary) prevention Crucial  
17. Performance assessment in primary care services Secondary 
18. Service delivery in primary care services Secondary 
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AREAS IMPORTANCE1  
D. RESOURCE GENERATION  
Health workforce  
19. Health workforce in primary care services Secondary 
20. General environment and culture of the primary care services for 
implementation of a new practice model 
Secondary 
Knowledge  
21. Education and training of the health workforce Secondary 
22. Information flow and information systems Secondary 
Physical resources  
23. Logistical aspects Secondary 
24. Laboratory services Secondary 
Notes of the  table:  
1 Importance in terms of the decision for integration of the practice model in the given country 
2 Within the general framework of functions of health systems (Table 1), financing has three sub-functions: 
revenue collection, fund pooling, purchasing. However, for the purpose of assessment of integration a practice 
model, those subdivisions were not necessary. Therefore, areas are identified for financing function in general. 
3 Under ‘normal’ circumstances, this area wouldn’t be labeled as ‘crucial’. However, due to ‘extraordinary’ eco-
nomic situation in Europe, i.e. the economic crises, some countries in Europe are implementing very strict 
monetary policies and are having budget cuts for even regular health services. For those countries, it might be 
almost impossible to consider making a new investment in health care, such as the practice model. Therefore, 
this area needs to be investigated before moving to the other areas. See further explanation under ‘13. Gen-
eral health expenditure structure of the country’ in Table S1 in Supplementary material. 
4 Within the general framework of functions of health systems, health services cover a range of services (see 
Table 1). Since this practice model is envisaged to be implemented in primary care services, health services 
heading practically cover primary care services. 
Supplementary material provide the detailed results of this exercise in Table S1, including 
explanations for each area and examples to illustrate in what ways these are relevant for 
real-life settings.   
Not all of the 24 areas and numerous criteria and issues have the same importance when 
a practice model is integrated into a health system. Therefore, we organized the areas in 
two levels: priority and secondary (see the second column in Table 2). If assessment of a 
priority area doesn’t yield a favorable profile in a given country, it will be difficult to inte-
grate the practice model as envisaged, even if it fits in the other areas perfectly. For ex-
ample, if ‘the general environment and culture of the health system’ is not favorable for 
innovations, it would be very difficult to integrated the practice model.  
Three of the ‘priority’ areas are further marked as ‘crucial’, being a ‘must’. These should 
be the first areas to be investigated in a given country. If they don’t yield favorable results, 
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investigation of other areas would not be necessary. For example, due to the economic 
crisis, some countries in Europe are facing drastic budget cuts in public sector (Area 13 in 
Table 2 and Table S1). In those countries where austerity policies are implemented, it is 
practically impossible to make a new investment such as the practice model. 
Another crucial area we identified is ‘15. Strength and place of primary care services in the 
health system and its relationship with other levels of care’. The beneficial effects of the 
practice model would be most prominent in systems where the primary care physician 
(GP) has the function to manage the health and risks of individuals registered to his/her 
practice. If the primary care services are strong and the GPs have a ‘gate keeper’ position 
regulating access to specialized care, implementation of the practice model would yield 
the best results. If it doesn’t have the gate-keeper function, it will be very difficult for 
primary care settings to assume the function of managing the health and risks of individu-
als and, therefore, application of the practice model wouldn’t yield expected benefits. 
Therefore, we identified that a strong primary care service structure is one of the prereq-
uisites for implementation of this model. 
Possible uses and potential benefits of this systematic approach 
The presented systematic approach proposed the use of health system functions as a 
framework to identify areas to be assessed for integration of an innovative model into a 
country. It was developed using a preventive personalized health care model as a case-
study. Nevertheless it can be applied to other ‘personalized’ practices, such as diagnostics, 
prognostic tools and pharmaceuticals, to be integrated into different health systems.  
A comprehensive set of functions of health systems ([16] and Chapter 2) provided the 
overarching framework to our approach. A previous initiative used another health system 
framework to analyze integration of health programs in different countries [21, 22]. Alt-
hough the nature of interventions they took, as well as their purpose of analysis were 
different, and therefore, not applicable to our case, it indicates that using health systems 
frameworks to assess integration issues is a credible approach. 
When the presented systematic approach is applied to other ‘personalized’ practices, the 
functions and, possibly, the sub-functions that should be investigated (Table 1) will stay 
the same for all cases. However, as it is applied to new cases, each case will identify dif-
ferent set of areas, as well as the specific issues under them. The purpose (e.g. retrospec-
tive or prospective analysis), the nature of the practice (intervention), the level of progress 
towards its integration, and the country settings will also influence the decision on the 
relevance of different areas.  
It might be disappointing for some to see that there is no fixed list of areas related to 
integration of all ‘personalized’ practices, which would apply to all countries. An important 
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point is to realize that ‘one size doesn’t fit all’ here, either. First of all, ‘personalized’ prac-
tices are not a homogeneous group. When we analyzed the content of 88 ‘personalized’ 
practices, which were identified by a systematic search in the literature, we found that 
there are different practices (commodities in health care market or implementation mod-
els on how health services are provided), with various purposes (prevention, early detec-
tion, diagnosis, treatment, prediction of prognosis, etc.) and serving different groups (indi-
viduals/patients, health professionals, health care organizations, etc.) (see Chapter 4). 
Moreover, countries have diverse health systems. It is not a realistic attempt to develop a 
single solution that applies to all these diverse cases, purposes and settings in a uniform 
way. Therefore, instead of a prescriptive approach with a fixed list of issues, we are pro-
posing a systematic approach, where areas and issues related to integration can be identi-
fied in a dynamic way, individually for each case.  
If this systematic approach is picked up by others and applied on different cases, we en-
courage them to publish it for two purposes. First of all, exercises carried out on different 
cases will possibly inspire new ones while identifying areas and issues under them. Sec-
ondly, when these different exercises are analyzed in the future, patterns might emerge 
and enable us to see which areas are important for which cluster of ‘personalized’ practic-
es. This may lead to developing a number of issues and areas that are highly relevant for 
certain groups of practices, which can serve as a ‘starter set’ for the ones to come.  
An advantage of approaching the integration issues in a systematic way is that it helps to 
make sure that no relevant area is missed. It can also help to avoid over-representation of 
certain perspectives during the efforts to identify the issues and provide a more realistic, 
and thus possibly more useful, picture of the integration of a practice into health systems. 
Concluding remarks 
Enlarge the focus to cover ‘health’, not only ‘disease’ 
The main focus of the ‘personalized medicine/ personalized health care’ field has so far 
been on diagnosing and treating diseases in a more precise way, with success stories 
mostly in cancer-related areas. Prevention has been a neglected area in this field. Howev-
er, ‘health’ is a broader concept than medicine (diagnosis and therapy) alone. The focus 
should be enlarged to cover health in a more holistic way, including prevention.  
It is of note that prevention is not only early detection of the disease [23] or progression 
towards disease. Diseases develop gradually in the long years before the onset, where no 
signs of the disease can be detected, not even molecular ones. Traditionally, the interven-
tions targeting this phase are called ‘primary prevention’ and usually target the population 
collectively. However, as we are moving towards a more individualized health care, our 
focus for this phase should be ‘personalized health management’. Innovative tools and 
implementation models can be used to manage the health of individuals before the onset 
 
Chapter 7 
208 
of diseases. For people who have developed risk factors, same strategy can be applied as 
‘personalized risk management’. In the latter phases, for people who have developed the 
disease, we can target ‘personalized disease management’ to prevent complications [24]. 
These present a huge opportunity to tackle the burden of chronic diseases that is increas-
ing every day.  
Establish a dialog between personalized health care and health policy 
fields 
The field of ‘personalized medicine/personalized health care’ is very strong in identifica-
tion of scientific and technological agenda that is needed to discover and develop ‘person-
alized’ practices. However, its capacity to approach integration issues in a comprehensive 
and systematic way is limited. As a solution, the field of health systems and policies has 
much to offer in provision of the necessary theoretical frameworks and guidance in identi-
fication and addressing the issues effectively. In this paper we presented such an attempt 
to look at the integration issues from the perspective of the field of health systems and 
policies and this yielded very useful results.  
To start working on integration, it is important to establish an effective dialog among the 
fields of ‘personalized medicine/ personalized health care’ and health systems and policies 
so that they can understand each other’s worlds and provide effective solutions to the 
problem of integration into health systems. One way to start this dialog is by using the 
systematic approach presented in this paper. It may provide the common ground for these 
fields to be able to convene and work together. As this collaboration identifies issues re-
lated to integration of ‘personalized’ practices correctly in their entirety, the ‘barriers’ in 
front them can be overcome effectively. 
Supplementary Material  
Table S1. Details of the areas identified for assessment of a country’s health system for 
integration of the practice model. Areas and criteria and issues under them that are iden-
tified for assessment of a country’s health system for integration of the practice model, as 
well as comments, examples and preliminary recommendations to countries and the prac-
tice model.  
References 
1. Hood L, Heath JR, Phelps ME, Lin B. Systems Biology and New Technologies Enable 
Predictive and Preventative Medicine. Science. 2004 October 22, 2004;306(5696):640-3. 
2. Green ED, Guyer MS. Charting a course for genomic medicine from base pairs to bedside. 
Nature. 2011 Feb 10;470(7333):204-13.  
3. Pokorska-Bocci A, Stewart A, Sagoo GS, Hall A, Kroese M, Burton H. 'Personalized 
medicine': what’s in a name? Personalized Medicine. 2014 2014/03/01;11(2):197-210. 
A systematic approach to assess integration of a preventive personalized health care model  
into health systems 
209 
4. Cesuroglu T, van Ommen B, Malats N, Sudbrak R, Lehrach H, Brand A. Public health 
perspective: from personalized medicine to personal health. Personalized Medicine. 2012 
2012/03/01;9(2):115-9. 
5. Simmons LA, Dinan MA, Robinson TJ, Snyderman R. Personalized medicine is more than 
genomic medicine: confusion over terminology impedes progress towards personalized healthcare. 
Personalized Medicine. 2011 2012/01/01;9(1):85-91. 
6. Cesuroglu T, Karaca S, Erge S. A practice model for personalized healthcare with a public 
health genomics perspective. Personalized Medicine. 2009 2009/09/01;6(5):567-77. 
7. Snyderman R. Personalized medicine 2014: has healthcare been transformed? 
Personalized Medicine. 2014 2014/06/01;11(4):365-8. 
8. Teng K, Eng C, Hess CA, Holt MA, Moran RT, Sharp RR, et al. Building an innovative model 
for personalized healthcare. Cleveland Clinic Journal of Medicine. 2012 Apr;79 Suppl 1:S1-9.  
9. Overby CL, Tarczy-Hornoch P. Personalized medicine: challenges and opportunities for 
translational bioinformatics. Personalized Medicine. 2013 Jul 1;10(5):453-62.  
10. Jakka S, Rossbach M. An economic perspective on personalized medicine. Hugo J. 
2013;7(1). 
11. European Alliance for Personalized Medicine. Innovation and Patient Access to 
Personalised Medicine - Report from Irish Presidency Conference March 20th/21st 2013. Brussels: 
EAPM; 2013 25.06.2015]. Available from: http://euapm.eu/wp-content/uploads/2012/07/EAPM-
REPORT-on-Innovation-and-Patient-Access-to-Personalised-Medicine.pdf. 
12. Staff NP, Runge BK, Windebank AJ. Breaking Down Translation Barriers: Investigator’s 
Perspective. Sci Transl Med. 2014 September 3, 2014;6(252):252cm7. 
13. Personalized Medicine Coalition. The case for personalized medicine (4th Edition). 
Washington D.C. (US): PMC; 2014 25.06.2015]. Available from: 
http://www.personalizedmedicinecoalition.org/Resources/The_Case_for_Personalized_Medicine. 
14. Horgan D, Jansen M, Leyens L, Lal JA, Sudbrak R, Hackenitz E, et al. An index of barriers for 
the implementation of personalised medicine and pharmacogenomics in Europe. Public Health 
Genomics. 2014;17(5-6):287-98.  
15. World Health Report 2000: Health Systems: Improving Performance. Geneva: World 
Health Organization; 2000. 206 p. 
16. Murray CJ, Frenk J. A framework for assessing the performance of health systems. B World 
Health Organ. 2000;78(6):717-31.  
17. Roberts MJ, Hsiao W, Berman P, Reich MR. Getting Health Reform Right: A Guide to 
Improving Performance and Equity. Oxford: Oxford University Press; 2003. 
18. Everybody’s business: Strengthening health systems to improve health outcomes: WHO’s 
framework for action. Geneva: World Health Organization; 2007. 44 p. 
19. Atun R, Menabde N. Health systems and systems thinking. In: Coker R, Atun R, McKee M, 
editors. Health Systems and the Challenge of Communicable Disease: Experiences from Europe and 
Latin America. European Observatory on Health Systems and Policies Series. Berkshire, England: 
Open University Press; 2008. p. 121-40. 
20. Couzin-Frankel J. U.K. Unveils Plan to Sequence Whole Genomes of 100,000 Patients 
[News]. 2012. 10 December 2012: [Available from: 
http://news.sciencemag.org/scienceinsider/2012/12/uk-unveils-plan-to-sequence-whol.html]. 
 
Chapter 7 
210 
21. Atun R, de Jongh T, Secci F, Ohiri K, Adeyi O. Integration of targeted health interventions 
into health systems: a conceptual framework for analysis. Health policy and planning. 2010 
Mar;25(2):104-11.  
22. Atun R, de Jongh T, Secci F, Ohiri K, Adeyi O. A systematic review of the evidence on 
integration of targeted health interventions into health systems. Health policy and planning. 2010 
Jan;25(1):1-14.  
23. Ilbawi AM, Anderson BO. Cancer in global health: How do prevention and early detection 
strategies relate? Sci Transl Med. 2015 2015-03-11;7(278):278cm1. 
24. The use of health management, risk management, disease management and case 
management concepts as an alternative to primary, secondary and tertiary prevention classification 
was developed by Serdar Savas for Diyabet 2020: Vizyon ve Hedefler - Türkiye [Diabetes 2020: Vision 
and Targets - Turkey]. Istanbul: Turkish Diabetes Foundation, under the auspices of the Turkish 
Ministry of Health, in collaboration with World Health Organization Regional Office for Europe and 
International Diabetes Foundation Europe; 2010. 
 
 
A systematic approach to assess integration of a preventive personalized health care model  
into health systems 
211 
Supplementary Material 
Background 
A personalized health care model that aims to prevent common chronic diseases was 
developed by GENAR Institute for Public Health and Genomics Research in Ankara, Turkey 
[1]. It was identified as a best practice model by the Public Health Genomics European 
Network in 2008 and piloted in Turkey. It was seen that the main implementation area for 
such a preventive health care intervention would be wide spread approaches where it is 
provided within the primary care services in Europe.  
However, there has been no example of such a preventive personalized health care model 
that has been provided to large populations. There was a need for a systematic approach 
to answer these questions: What are the issues we need to look at when investigating 
how such a practice model can be integrated to primary care services within health sys-
tems? How can we identify them? 
In our efforts to answer this question in a systematic way, we used the ‘health system 
framework’ that was published earlier [2] as the underpinning of our approach. An 
adapted version of this framework was presented in Chapter 2. The framework included 
functions of a health system, which provided the overarching framework to our systematic 
approach. By using this framework, and our preventive personalized health care model, 
we carried out an exercise to identify which areas to assess when investigating (if) and 
how this practice model could be integrated into health systems in Europe. While doing 
this exercise examples from countries were needed to see what kind of issues can be cov-
ered under each area. These were mostly derived from the Netherlands and the UK, since 
we had access to information on these countries. We used prominent examples from 
other European contexts as necessary. 
Content 
Table S1 presents the results of this exercise. Here, we identified 24 areas that need to be 
assessed to see how a preventive personalized health care model called Gentest can be 
integrated into primary care services of health systems in Europe. They are organized 
under the functions (and sub-functions, as necessary) of health systems, since this had 
provided the overarching framework to this analysis. 
In the table, for each area, first the content and/or the relevance of the area to the topic 
and/or the case of the practice model is briefly stated.  
“Criteria and issues to be considered” list the criteria and issues identified so far by inves-
tigation of the practice model, general health system frameworks, relevant literature on 
related areas, as well as the country examples. This is not ‘the’ exhaustive list of criteria 
and issues, but ‘a’ list that has been derived so far. As the analysis expands to other coun-
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tries, or goes deeper for given a country/ countries, the list will be likely to be enriched 
with new items.  
“Comments and examples” indicate a general view to the analysis and/or give examples 
from European settings, in particular from the United Kingdom (UK) and the Netherlands. 
These also exemplify the relevance of the criteria and issues that have been identified.  
Preliminary recommendations are made based on the comments and examples taken and 
presented mostly in two levels. One is to improve the countries’ readiness to integration 
of such a model, which mostly involve the health system in the macro-level. The second 
one is the preliminary recommendations made for planning of integration of the practice 
model. The depth of the recommendations varies, as does the comments and examples.  
This systematic approach proposed that the health system functions can be used as a 
framework to identify areas that need to be assessed for integration of a practice model 
into a country. Thus, overall approach can be used for a given personalized practice, for its 
integration to a given country or set of countries. The specific areas will change from case 
to case and the issues and criteria identified will also change and may grow as it is applied 
to different country cases. The added value of this paper is not the exhaustive list, but the 
systematic approach used to identify the broad picture of integration issues under health 
domain. 
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Table S1: Details of the areas identified for assessment of a country’s health system for integration 
of the practice model: Areas and criteria and issues under them that are identified for assessment of 
a country’s health system for integration of the practice model, as well as comments, examples and 
preliminary recommendations to countries and the practice model. 
A. STEWARDSHIP 
Priority setting 
1. Health policies, strategies and programs 
Health policies as a whole and in its components in forms of strategies must be considered when 
assessing a country’s health system. 
Criteria and 
issues to be 
considered 
 Existence of coherent written health policy or strategy 
 The presence and importance of combating noncommunicable/ chronic 
complex diseases in the health policy and strategies 
 Orientation of the health system and policies towards prevention in individual 
and population level 
 Within the health policy, strategies and programs, presence and role of  
o Personalized medicine and health care as a whole or with its compo-
nents 
o Technologies that are used in the practice model, such as genomics and 
information and communication technologies  
Comments 
and examples  
 The European Union (EU) doesn’t have a unified single health policy that 
covers all EU countries in all aspects. Each member state is individually re-
sponsible for organization and delivery of health services and medical care 
(Lisbon Treaty, 2007 [3]).  
 On the other hand, the EU Health Strategy document (2007) [4] highlights 
some strategies for ‘cooperative action at Community level’. “Supporting Dy-
namic Health Systems and New Technologies” is one of the objectives of the 
Commission within this strategy. This highlights new technologies such as e-
health, genomics and biotechnologies, and addresses evaluation including 
cost effectiveness and equity, health professionals' training and capacity im-
plications and possible ethical concerns. 
 The European Strategy for the Prevention and Control of Noncommunicable 
Diseases by World Health Organization Europe (2006) [5] has indicated that 
“The personal risk of developing disease can be dependent on the interaction 
between the individual, his or her personal susceptibility and the wider envi-
ronment”. The report highlights that increasing number of tests will be de-
veloped for genetic predisposition to common diseases and introduction of 
these tests into health care “…is likely to have significant consequences for 
the organization, staffing and delivery of health services, as well as to raise is-
sues of ethics and equity of access.” 
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 Country level applications are heterogeneous. Target countries’ health policy 
should be considered individually, using various documents that indicate the 
policy directions in the country, such as policy documents, strategies and 
programs.  
 For example, in England, in the public health policy paper (Healthy Lives, 
Healthy People: our strategy for public health in England, 2010) [6] there is no 
reference to personalized health care, other personalized approaches or pub-
lic health genomics. In this document, references to modern biology are also 
very rare [7]. 
 Another recent example is from the Netherlands. Dutch Government has 
identified more personal, customized services and better prevention among 
the six tasks of the planned transformation of the social domain  [8]. Other 
tasks include, among others, ‘less escalation to primary and secondary care 
and support’ and ‘more integration’. These indicate the increasing emphasis 
on prevention and personalization in the health related strategies in the 
Netherlands. 
Preliminary 
recommen-
dations  
To improve countries’ readiness: 
 In order to address the major transformation in health care that we may face 
with personalized health care applications, countries need to take into ac-
count this issue proactively in their overall health strategies [9]. 
 It is important that the country for integration is a ‘breeding ground’ for 
development and implementation of personalized health care models. This 
can be achieved by including personalized health care and its critical success 
factors within health policies.  
2. Strategies on relevant applications and technologies 
Some countries may have separate strategies, programs or initiatives for relevant applications 
(such as practice models in personalized health care, e-health, etc.) and/or technology fields (hu-
man genomics, information and communication technologies in health care, biotechnology for 
health, etc.).  
Criteria and 
issues to be 
considered 
 Presence and content of a strategy or program on one or more of the applica-
tion areas and/or technology fields (as described above) 
 Stakeholder involvement in development of the strategy 
 Endorsement and/or implementation of the strategy in actual life 
Comments 
and examples  
 The report of “Human Genomics Strategy Group” on “Building on our inher-
itance - Genomic technology in healthcare” in the UK [10] is an example to 
such policies. 
 The ‘Health initiative’ of the Luxembourg government which aims to trans-
form Luxembourg into a center of excellence in the area of personalized med-
icine [11] and in its continuum, the country’s vision to become “the first na-
tion in the world in which every person has an opportunity to avoid prevent-
able diseases, to access effective diagnostic and therapeutic care for curable 
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diseases, and to adapt and self-manage when faced with unavoidable sources 
of suffering.” [12] are examples to comprehensive strategies in this area. 
Preliminary 
recommen-
dations  
To improve countries’ readiness: 
 If and when possible, creating strategic and cross-cutting programs with the 
involvement of relevant stakeholders can enable turning research and devel-
opment into implementation in the fragmented environment of science, 
technology and health care. 
Legislation and regulations 
3. Regulation of non-diagnostic services which aim prevention 
The practice model is not a diagnostic tool since it aims to prevent diseases. Therefore, it may not 
fall into a clear area of regulation. For this purpose, the regulations should be investigated from 
different angles. One of them is to investigate if there are any regulations that cover services that 
aim prevention but not diagnosis. 
Criteria and 
issues to be 
considered 
 Presence of specific regulations that regulate services or tests that aim pre-
diction and prevention but not diagnosis 
 If there are any restrictions in other legislative documents 
 Any related guidelines 
Comments 
and examples  
 In the Netherlands, “Wet op het bevolkingsonderzoek”, “Act on population 
screening” [13] regulate use of tests for screening of diseases, not diagnosis. 
The main aim of this regulation is to prevent burden that might be brought by 
unnecessary screening programs.  
 The primary aim of Gentest is identification of risk factors and risks, not early 
diagnosis of diseases. However, various components of Gentest may lead to 
early diagnosis of diseases. For example, blood glucose levels higher than 121 
mg/dL will lead to, if replicated, diagnosis of diseases. Therefore, this regula-
tion may have various implications of how the practice model is positioned 
and organized within health services in the Netherlands. 
 The Royal Dutch Medical Association (KNMG) has already issued a multidisci-
plinary guideline on ‘preventive medical examinations’ in 2013, to guide doc-
tors on the principles of ‘check-up’ programs they will provide [14].  
 Fueled by the introduction of  ‘total body scans’ in the Netherlands, Health 
Council of the Netherlands published an advisory report on population 
screening, which included the criteria that must be met by the ‘health 
checks’, in 2015 [15]. 
 All these have important implications on how Gentest can be offered in the 
Netherlands.  
Preliminary 
recommen-
dations  
For integration of the practice model:  
 With the help of public authorities and health lawyers, it should be made 
clear if and what parts of Gentest falls into the scope of the “Act on popula-
tion screening” in the Netherlands. In addition, the criteria brought by the 
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Health Council on heath checks must be investigated. Strategies should be 
developed to make the implementation compliant with the law and the crite-
ria of the Health Council. If there are fundamental principles that explain why 
some parts are not compliant, it should be made clear and well-articulated. 
 Implementation of Gentest should be carried out in compliance with guide-
line on ‘preventive medical examinations’ in the Netherlands. 
To improve countries’ readiness: 
 Our practice model, Gentest, is not a conventional approach among health 
interventions. When regulations are made, an umbrella regulation might 
have been developed to prevent harm from specific practices; which may 
create a barrier towards implementation of Gentest. This illustrates that 
regulations should be made to protect the individuals, while giving the room 
for innovations that may benefit them to be implemented. 
4. Regulation of genetic testing, including predictive testing for imple-
mentation in primary care services 
Genetics is one of the inputs of the practice model. In many countries, genetic testing has a specific 
legislation, which mainly targets genetic diagnosis. However, the practice model in question 
doesn’t involve diagnosis. Nevertheless, relevant regulations should be investigated to see if there 
are any restrictions for implementing a model which contains genetic factors as one of its compo-
nents. 
Criteria & 
issues to be 
considered 
 Any restriction on use of genetic data for a practice model implemented in 
primary care 
Comments 
and examples  
 The genetic testing for prevention of common complex diseases is mostly 
considered to be predictive genetic testing, and due to direct-to-consumer 
(DTC) tests in Europe and mainly in the United States of America (USA) avail-
able via internet, there is an increasing sensitivity in Europe on genetic tests 
outside medical genetics. There are several reports on views on regulation of 
DTC tests (such as European Society of Human Genetics’ statement in 2010 
[16] and European Academies Science Advisory Council and Federation of Eu-
ropean Academies of Medicine’s report in 2012 [17]). It should be noted that 
the practice model in question is not a direct-to-consumer test since it will be 
implemented by a medical doctor, i.e. a general practitioner.  
 Due to the concerns over DTC tests, it seems that more stringent regulations 
have been entering into force in Europe in the past years. For example, in 
Germany, diagnostic and predictive genetic tests can be conducted only by 
medical doctors who are certified specialists in human genetics as set forth by 
the law [18, 19]. Several aspects needs to be explored to identify if a practice 
model which aims to prevent complex diseases and utilizes genetic factors in 
combination with other markers in primary care services would fit in that 
regulatory framework.  An important discussion would be how the genetic in-
formation obtained in the context of practice model would be classified ac-
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cording to the laws. 
 Target countries’ legislation on genetic testing should be considered individu-
ally. 
Preliminary 
recommen-
dations  
To improve countries’ readiness: 
 One of the foundation principles of primary care services is to provide a 
holistic care to individuals based on the principles set forth in Declaration of 
Alma-Ata in 1978. It is the first level of contact of individuals, the family and 
community with the national health system bringing health care as close as 
possible to where people live and work, and constitutes the first element of a 
continuing health care [20, 21]. Prevention is one of the core functions of 
primary care services. Therefore, prevention of complex diseases would defi-
nitely fall under the scope of primary care services. In the practice model, ge-
netic factors function as one of the inputs, but not the main purpose. Thus, as 
in many practices of primary care services, several different types of inputs 
are considered. 
 If the regulatory framework that restricts ordering and interpretation of 
genetic tests would be a barrier for implementation of this practice model, 
which includes genetic factors among the several parameters, in primary 
care, this would be contradictory to the underlying philosophy of primary 
care services. 
 In addition, the next question would be: Why is the genetic part of the prac-
tice model special? As a doctor, why can the primary care physician process 
all the relevant information of the individual to prevent the complex diseases, 
but not the genetic factors? This also would match with the criticisms on 
German law for practicing ‘genetic exceptionalism’ [22, 23]. 
 If all the aspects of the practice model would be interpreted by relevant 
specialty fields, such as genetic aspects by medical geneticist, cardiologists in 
charge of assessment and recommendations on cardiovascular diseases, dia-
betologist in charge of diabetes, etc., it would not only create fragmentation, 
but also lead to huge inefficiency.  
 As a conclusion, regulatory frameworks must be shaped considering this role 
of primary care services in the overall health system.  
5. Regulations on ethical issues in terms of implementation 
The practice model involves risk assessments for common chronic diseases. Currently, the genetic 
information is not included in the risk assessment algorithms within the practice model. It is used 
only for prioritization and tailoring of the lifestyle factors. However, as the scientific developments 
progresses, it is expected that various types of genome-based information can be incorporated to 
risk assessment algorithms.  
With or without use of genomic markers, assessment of risk of complex diseases may require 
ethical issues to be considered. In addition, the use of genetic information in the model requires 
compliance to ethical principles on genetic testing for human health. As the main principle, the 
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needs and rights of the individuals, their families and the society must be balanced. 
Criteria and 
issues to be 
considered 
 Any ethical restrictions on this kind of service 
 The need for informed consent  
 Any possible effects of family involvement 
Comments 
and examples  
 The informed consent must be obtained as set forth in the national regula-
tions of each country. For example, if the consent form must be signed in 
presence of a doctor and/or co-signed by a doctor, this needs to be taken into 
account. 
 Primary care services not only provide a holistic approach to the individual, 
but also the family as a whole. The family members not only share their DNA, 
but also most lifestyle factors and living conditions. In addition, in terms of 
implementation of the practice model, family involvement can play an im-
portant role to increase the success rate of implementing the lifestyle rec-
ommendations. On the other hand, the family involvement may also lead to 
pressure on the individuals. These ethical issues must be considered when 
outlining the service delivery models.  
Preliminary 
recommen-
dations  
For integration of the practice model: 
 Since implementation of the practice model will involve large numbers of 
people, other types of informed consent (waiver of documentation of in-
formed consent and implied consent) can be considered for practices that are 
not related to diagnosis of (monogenic) diseases. 
To improve countries’ readiness:  
 Ethical frameworks on genetic testing should consider use of genetic infor-
mation not only for diagnostic tests, but also models which utilize genetic in-
formation as one of its several components. 
6. Regulations on liability of the practice model 
As a report which involves health related advice, the liability of the assessments and recommenda-
tions made in the report must be ensured.  
Criteria and 
issues to be 
considered 
 Any legislative framework available on liability of  
 How liability issues are handled in examples of other applications, such as 
cardiovascular (CV) risk assessment programs and tele-health applications 
Comments 
and examples  
 If there is a legislative framework available in the country on the liability of 
such practice models, assessment tools or health recommendations, that as-
sist medical doctors, nurses, dieticians and other health professionals, these 
must be considered. 
 However, it is very likely that there is no ready clear legal framework for this 
issue in many countries. In that case, the legal framework will need to be es-
tablished by the health authorities and decision makers. 
 If there is no legislative framework, examples of applications of CV risk as-
sessment and tele-health can also be investigated to see how liability issues 
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are handled. 
Preliminary 
recommen-
dations  
For integration of the practice model: 
 It is important to make early contact with health authorities to start discus-
sion on such matters, including liability.  
 An option can be assigning the liability to the Chief Medical Officer and/or the 
Medical Advisory Board that needs to be established within the enterprise 
that will implement the practice model in Europe.  
 In the consent form, it should be made sure that it writes that on one hand, 
applying the lifestyle advice doesn’t eliminate the risk of diseases and on the 
other hand, the risk assessments doesn’t indicate any certainty if the person 
will get the disease or not. 
7. Regulations on data protection, privacy and confidentiality 
As in all health related applications, the issues on data protection, privacy and confidentiality must 
be considered and safeguarded.  
Criteria and 
issues to be 
considered 
 The general framework of data protection, privacy and confidentiality in 
Europe and of the target country. Some specific aspects that need attention, 
among others: 
o Informed consent 
o Data collection and use; including purpose, data storage duration 
o Rights of the data subjects 
 Measures required for security and confidentiality of data processing 
 Need for data protection impact assessment and assignment of a data pro-
tection officer 
 Other national issues that are related to data protection, privacy and confi-
dentiality in health services 
Comments 
and examples  
 EU Directive on Data Protection [24] provides an important framework for 
this area. On the other hand, the regulations and practices of each country 
differ in the current situation, making it necessary to investigate each country 
individually.  
 The proposed regulation on Data Protection [25] may be expected to lead to 
harmonization of data protection issues in Europe and a level playing field in 
all member states but the issues that will come up in the actual practice after 
the adoption of the regulation is difficult to be foreseen for each country. 
Therefore, each country must be investigated individually. 
Preliminary 
recommen-
dations  
For integration of the practice model: 
 The principles and obligations in relation to data protection legislation should 
be identified for each country for provision of the practice model in primary 
care services. 
 The proposed regulation on Data Protection has been heavily criticized by 
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researchers in Europe with the argument that it may seriously impede use of 
health care data for research, due to the restrictions proposed on the use of 
health data, even for research purposes. For the case of Gentest, it is im-
portant to set up a system where data collected during its implementation 
feeds back to research. Developments in the EU level in terms of the pro-
posed regulation for Data Protection will have a profound effect on how this 
system will be set up. 
8. Regulations on cross-border health care 
Directive on cross-border healthcare was adopted by the Council of the European Union in 2011. 
Member states must transpose the directive’s provision into national health legislation. The di-
rective meets the needs on patients' rights in cross-border healthcare while preserving member 
states' rights to organize their own health systems [26].  
Criteria and 
issues to be 
considered 
 Possible consequences of the cross-border regulation for implementation of 
this practice model in primary care services 
Comments 
and examples  
 The implementation of the practice model will be embedded in primary care 
services. The practice model is envisaged to be an integral part of the health 
record of the individual in primary care services. 
 As a definition, primary care services is the first level of contact of individuals, 
the family and community with the national health system bringing health 
care as close as possible to where people live and work, and constitutes the 
first element of a continuing health care process [20]. Unlike some other are-
as of health care, primary care services is not a one-off type of service to be 
used. In many countries, a person must enroll to a primary care service pro-
vider, usually a general practitioner or family physician (GP). In line with the 
definition of primary care services, geographical proximity and logistics plays 
a very important role in choosing a primary care provider [27]. Although the-
oretically possible, it would be very questionable for individuals to enroll to a 
GP in a cross border setting.  
 Primary care services are organized in the level of countries and, to a certain 
extent, regions within countries (federal states or governments). It would be 
fairly unlikely for the resident of one country to enroll to a GP in another 
country because individuals want to be treated as close to home as possible 
in a system they feel familiar with [28]. 
Preliminary 
recommen-
dations  
For integration of the practice model: 
 As different cases arise in terms of implementation of this directive in Euro-
pean countries, their implications on the case of Gentest should be consid-
ered. 
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Steering 
9. General environment and culture of the health system for innovation 
The main added value of the practice model in question is not the technologies utilized (genetic 
technologies, information and communication technologies, tools and techniques on measure-
ment of lifestyle factors, etc.), but how the information is analyzed and synthesized in an integra-
tive and holistic way for the purpose of prevention of complex diseases in individual level. Thus, it 
should be regarded as an ‘innovation’, rather than a ‘technology’ per se. 
The practice model conflicts with the current mindset in the health sector in some aspects, includ-
ing the following: 
 The classical paradigm stipulates that “Prevention can be done either in population level, 
targeting primary prevention (population strategy), or individual level, targeting secondary 
prevention (high-risk strategy).” (this paradigm dates back to Rose, 1985 [29]). However, the 
practice model brings a new approach: population wide (inclusive) prevention in individual 
level. This doesn’t comply with the ‘either-or’ paradigm stated in the first sentence.  
 Moreover, in the classical paradigm, primary prevention interventions almost always target 
the population level. The practice model also challenges this classical paradigm by providing 
individual level services for primary prevention. Thus, to understand and integrate the mod-
el, the stakeholders and health authorities need to ‘think out of the box’.  
These new aspects not only require putting a new application in practice, but also some change in 
the perspective and mind-set of the stakeholders. In addition, reorganization or redesign of pre-
ventive services in primary care will highly likely be required for successful implementation of the 
model. It also requires change management and, to some extent, social engineering focusing on 
health sector. 
Criteria and 
issues to be 
considered 
 The attitude of the health policies and strategies on the need for innovation 
 The openness of health sector in general and health authorities to innovation 
(recent new applications in health sector might be taken as a case or if there 
are  
 The actual implementation of innovations in health sector  
 Barriers against implementation of innovations 
Comments 
and examples  
 In European level, there are programs addressing the need for innovation for 
specific contexts, such as European Innovation Partnership on Active and 
Healthy Ageing (established in 2011, targeting 2020 [30]).  
 An example to country level programs is the UK’s program on ‘Innovation, 
Health and Wealth, Accelerating Adoption and Diffusion in the National 
Health Service (NHS)’. It sets out an integrated set of measures that together 
will support the adoption and diffusion of innovation across the NHS and sets 
a delivery agenda that will significantly ramp up the pace and scape of change 
and innovation [31]. 
 In terms of willingness to implement new technologies, the UK’s plan to make 
whole genome sequencing on 100.000 patients with cancer and rare diseases 
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can be taken as an example [32]. The aim is “to make UK world genetic re-
search leader”, as announced by the Prime Minister David Cameron [33]. 
Among the main aims of the project is to kickstart the development of a UK 
genomics industry. These signal a ‘pro-genomics’ environment for integration 
of genome-based technologies into health services. 
 There is no available ‘scale’ that determines willingness to accept innovation 
in health care sector for each country. The surveys on innovation and health 
sector innovation can be used as data sources to some extent. 
 The countries’ response to ‘tele-health’ applications can be considered as 
examples that can be studied because it also requires changing the mind sets 
and redesigning services for prevention (tertiary prevention). 
Preliminary 
recommen-
dations  
To improve countries’ readiness: 
 Understanding the need for innovation in health systems is a key for reducing 
the costs of health care while increasing the life expectancy and quality of 
life. 
10. Stakeholders, processes and mechanisms involved in implementation 
of new applications in health care 
Countries’ health systems have different approaches to implementation of new technologies in 
health care with involvement of different stakeholders and processes. There is also variability in 
stakeholders and processes among different types of applications (prevention, diagnosis, screen-
ing, etc.) in different settings (primary care, hospitals, etc.).  
As stated under ‘9. General environment and culture of the health system for innovation’, the 
practice model utilizes several different types of information which interact each other and anal-
yses and synthesizes them in several layers, making it a ‘complex intervention’[34]. The complexity 
of the intervention also leads to involvement of various disciplines and stakeholders, making the 
process of putting the model into practice also complex. It is important to understand the stake-
holders, processes and mechanisms involved in implementation a new application such as the 
practice model.  
It is important to note that there is no such application that has been developed and implemented 
in a health system in Europe, i.e. a personalized health care model utilizing several types of infor-
mation on the individual in an integrative way with the purpose of prevention of complex diseases 
and implemented in primary care services. Therefore, cases which have some common properties 
can be investigated as examples. These include e-health and tele-health applications, application of 
services which involve genetic/genomic testing (such as pharmacogenomics), and cardiovascular 
(CV) risk assessment and management programs. 
Criteria and 
issues to be 
considered 
 Stakeholder analysis 
 If known, positions of stakeholders about various aspects of the model, 
including service redesign in primary care services, use of individual level in-
terventions for primary prevention, use of genomic technologies and infor-
mation and communication technologies in health care 
 Study of cases that have similarities in some aspects to the practice model (as 
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stated above) 
 Study of cases on how a recently new technology with complex interventions 
has been implemented or prepared in the health system, preferably in prima-
ry care services  
Comments 
and examples  
 Each target country should be considered individually. Focus should be on 
examples of preventive applications (not preferably tests) in primary care 
services. Data would not be readily available on various aspects of the crite-
ria. Therefore, one or more studies will need to be carried out. 
 For example, in the UK, the case of implementation of tele-health in primary 
care can be taken as a case example [35-39]. For the Netherlands, CV risk as-
sessment and management programs that have been introduced in GP prem-
ises can be investigated as a case example. 
Preliminary 
recommen-
dations  
For integration of the practice model: 
 It is important to know the stakeholders, processes and mechanisms in each 
country in general and specifically for primary care services and prevention. 
Administration and management 
11. Mechanisms related to evaluation of new applications and decision 
making in health care services 
While supporting innovation, it requires a balancing act on the side of the decision makers to pro-
tect the citizens, maintain the health care budgets (of all kinds of third party payers), and allow and 
promote innovation in health systems. Mechanisms related to evaluation of new applications and 
decision making can indicate how well this balance can be achieved in the given health system. 
Criteria and 
issues to be 
considered 
 Presence and functions of a body or mechanism for proactive horizon screen-
ing for scientific and technological developments in health care “Early aware-
ness and alert systems” (for examples, see EuroScan [40]) 
 The process for authorization of an application for market entry 
 The process for an application to be covered by a third party payer (If national 
health system type finance, it is national health budget. If social health insur-
ance type finance, it is the budget of the each social health insurance fund 
and/or the national reimbursement lists) 
 Utilization of Health Technology Assessment (HTA)  
 Existing HTA reports on applications which have some common properties, 
such as complex interventions that require service redesign in primary care 
services, use of individual level interventions for primary prevention, use of 
genomic technologies and information and communication technologies in 
health care 
 The country’s general level of ‘strictness’ in decision making 
 Recent decisions on implementation of new applications (as much as possible 
which have similarities to the practice model, as pointed out in 
10.Stakeholders, processes and mechanisms involved in implementation of 
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new applications in health care) and how those decisions were made 
 Evaluative framework implemented in that country  
 Economic evaluation methods utilized  
 Decision making when there is an evidence gap for promising applications 
which are evaluated as ‘safe’ 
 Decision makers early involvement in development of new technologies [41] 
Comments 
and examples  
 There is an International Information Network on New and Emerging Health 
Technologies (EuroScan International Network [40]).  
 Some countries have horizon screening bodies, such as NIHR HSC (The Na-
tional Institute for Health Research Horizon Scanning Centre [42]), and others 
have this function covered by other agencies such as HTA agencies. Functions 
can be investigated for each target country. 
 The process experienced in the UK on guidance development for gene ex-
pression profiling and expanded immunohistochemistry tests to guide the use 
of adjuvant chemotherapy in early breast cancer management (MammaPrint, 
Oncotype DX, IHC4 and Mammostrat) can be used for comparison, for exam-
ple. It seems that, for example, the UK may have a more strict approach on 
evaluation of (cost-) effectiveness compared to other countries [43]. 
 Some countries have a specific evaluative framework and a specific perspec-
tive and method in terms of economic evaluation. For example, the UK (NICE 
- The National Institute for Health and Care Excellence) has a clear perspec-
tive, which is ‘health budget perspective’ and doesn’t consider any benefits 
other than health at the economic analysis and decision making. In relation to 
this, the preferred method for economic evaluation is cost-effectiveness 
analysis. [44] 
 On the other hand, Sweden (Swiss HTA) have a prior normative commitment 
and consider also ‘social preferences’ perspective such as non-discrimination, 
protection of autonomy, equal access to appropriate health care, effectively 
maintaining or restoring health-related quality of life, functioning and capa-
bilities. In relation to this, they support methodological pluralism and decide 
the most appropriate evaluation method based on the specific research ques-
tion [45]. (If benefits other than health are to be included in the analysis, 
cost-benefit is the most likely analysis method to be used) 
 Some countries have the option of ‘coverage with evidence development’ 
when there is an evidence gap for promising applications which are evaluated 
as ‘safe’ [46]. (Also, among Khoury’s Tier 1-3, tier 2 corresponds here. See 
Khoury et al, 2012 [47]). The presence of this option is very important since 
the practice model is highly likely to fall into this category, if such a category 
exists. 
Preliminary 
recommen-
dations  
For integration of the practice model: 
 Communication with decision makers (decision makers including public 
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authorities and third party payers) and their involvement should be initiated 
in the early stages of the preparations for evaluation of the practice model 
for specific countries. 
B. FINANCING 1  
12. Health financing system of the country 
The general picture about the financial system and expenditures of the country needs to be 
known. 
Criteria and 
issues to be 
considered 
 General resource generation and financing system (national health system, 
social health insurance, others) 
 The financing system specific to primary care services, particularly GP premis-
es 
 The financing system from the perspective of prevention of complex diseases, 
in particular, the payer and the benefiter of investments in health care ser-
vices 
Comments 
and examples  
 In terms of health systems and policies, Europe has a diverse profile. There-
fore, each target country must be investigated individually. In a very broad 
sense, there are national health service (NHS) based systems which are fund-
ed from general taxation (such as the UK), and social health insurance (SHI) 
based systems which are mainly funded from wage related contribution (such 
as Germany). It is of note that, in general, there is a trend of convergence be-
tween NHS and SHI [48, 49]. 
 The type of the financing of the health system can have an impact on how 
new applications are evaluated and the decision making processes (see also 
11. Mechanisms related to evaluation of new applications and decision mak-
ing in health care services). 
 From technology perspective, in principle, there should be two thresholds for 
a technology in a health system. The first threshold is for entering the health 
care market, indicating that a technology is safe enough to enter the market. 
Second one is the threshold for financial coverage (reimbursement) indicating 
that the technology is cost-effective enough for the costs to be covered by a 
third party payer. 
 In the UK, NHS, for example, these two thresholds practically merged because 
there is a national single payer, who also decides on cost effectiveness. If sin-
gle payer doesn’t cover this technology due to lack of cost effectiveness, 
practically, the technology doesn’t have a place in the market. 
                                                                
1
 Within the general framework of functions of health systems (Table 1 in the main article), financing 
has three subfunctions: revenue collection, fund pooling, purchasing. However, for the purpose of 
assessment of integration a practice model, those subdivisions were not necessary. Therefore, areas 
are identified for financing function in general. 
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 Different phases of the implementation can match with different financing 
systems better. For example, countries with social health insurance can be a 
better place for pilot and implementation while generating evidence (11. 
Mechanisms related to evaluation of new applications and decision making in 
health care services), because different social health insurance schemes can 
have different ideas for implementation, increasing the chances of implemen-
tation. On the other hand, once evidence is generated on health gains and 
costs and cost effectiveness is demonstrated, single payer national systems 
can be a better environment for wide scale implementation. 
 Another question is from prevention perspective. An important incentive for 
preventive interventions is that the investment today can save significant 
costs in the future. However, preventive measures usually have their effect 
(in terms of both health outcomes and cost savings) in long time spans. So, it 
is important to know who the (third party) payer is and who will benefit from 
the long term cost savings gained from prevention of diseases and/or compli-
cations. What is the time span, horizon of the payer? For example, health in-
surance companies in the Netherlands seem to have a short span (possibly 3-
5 years), because they don’t know if the person who is in their policy scheme 
will be there after 3 years. They might be reluctant to invest in services such 
as this practice model considering that the cost savings from the prevention 
would happen in the longer term which is not in their horizon.  
Preliminary 
recommen-
dations  
For integration of the practice model  
 It can be considered that different phases of evidence generation and imple-
mentation can be carried out in different countries, based on their ad-
vantages and disadvantages. 
 Countries where third party payer for primary care services would be the 
benefiter in the time span of the return of the investment should be pre-
ferred. 
To improve countries’ readiness: 
 Preventive interventions provide a ‘return on investment’ in the long term. 
This may lead to inertia in countries with a SHI system for introduction of per-
sonal health promotion and disease prevention services, because the finan-
cial benefits of these interventions might take place later than the desired pe-
riod by SHI funders. 
13. General health expenditure structure of the country 
The general picture of health expenditures of the country is required. 
Criteria and 
issues to be 
considered 
 Size and distribution of health expenditure, such as per capita health expendi-
ture, proportion of public expenditure in overall expenditures, if data availa-
ble, expenditure on preventive measures in health care, in particular on com-
plex diseases 
Comments  This should be investigated per target country. 
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and examples   In general in the whole Europe, health care costs are rising and systems are 
looking for ways to reduce health care costs. The financial crisis has made it 
even worse; “Health systems require predictable sources of revenue with 
which to plan investment, determine budgets and purchase goods and ser-
vices. Sudden interruptions to public revenue streams can make it difficult to 
maintain necessary levels of health care.” [50] 
 In particular, austerity policies in response to financial crises can be a hinder-
ing factor for new investments. Countries implementing strict monetary poli-
cies, especially ones that are subject to loans of the Troika, are having budget 
cuts for even regular health services. It might be almost impossible to make a 
new investment such as the practice model. 
 Countries with higher public expenditure can be a better option because, in 
principle, public funders can have a longer time span for expecting the return 
of the investments than private funders (see also 12. Health financing system 
of the country) 
 In addition, the non-health benefits of implementation of new preventive 
measures can be more appreciated within the publicly funded health systems 
(increased productivity, etc.). 
Preliminary 
recommen-
dations  
For integration of the practice model: 
 Countries with short and medium term budget cuts due to the financial crises 
would have difficulty for making new investments in health care. Therefore, 
those countries are not good candidates for integration of this practice mod-
el.  
 Countries with dominant public health expenditure might be preferred. 
14. Payment mechanisms for primary care services, i.e. GPs 
Payment systems have an important impact on the behavior of primary care doctors [51]. The 
payment mechanisms can have an important effect on acceptance and/or applicability new appli-
cations which target prevention in primary care services. 
Criteria and 
issues to be 
considered 
 The payment mechanism for primary care services, i.e. GPs 
 Underlying principles for payment, i.e. fee-for-service, capitation, fee-for-
performance 
Comments 
and examples  
 Each target country should be investigated individually.  
 If the system is process and output oriented, the payment for prevention is 
difficult, because what is most important in prevention is not the activity it-
self, but its outcome. Therefore, outcome oriented health systems, especially 
in primary care services, would invest more in preventive applications. (see 
also 17. Performance assessment in primary care services) 
 If the payment principle is mainly ‘fee-for-service’, the practice model is less 
likely to be accepted by the GPs. If it is a ‘fee-for-performance’ system, espe-
cially where the performance is indicated by outcome measures, instead of 
outputs and processes, it is more likely for GPs to accept and adopt the prac-
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tice model.  
 As an example, the UK has a payment system where performance related 
payment play an important role and GPs are incentivized to maintain the 
health of the individuals and a number of performance criteria are used. On 
the other hand, in the Netherlands, there is a mixture of capitation fee per 
registered patient and fee-for-service [52]. It can be speculated that the GPs 
would be more willing to adopt a practice model on prevention when the 
model is linked with their performance criteria, such as the example of the 
UK. On the other hand, this wouldn’t be the case for GPs in the Netherlands 
who are already overloaded with patient care in their practices. (see also 17. 
Performance assessment in primary care services) 
Preliminary 
recommen-
dations  
For integration of the practice model: 
 Countries where GPs are paid (also) for performance, rather than only ser-
vices should be preferred. 
C. HEALTH SERVICES (Primary care services) 2 
15. Strength and place of primary care services in the health system and its 
relationship with other levels of care 
The beneficial effects of the practice model would be most prominent in systems where the prima-
ry care physician has the function to manage the health and risks of individuals registered to 
his/her practice. The GP can assume this function only if he/she has a ‘gate keeper’ role. If the 
primary care services are strong and the GPs actually have a ‘gate keeper’ position which regulates 
access to specialized care, then implementation of the practice model would yield best results. If 
there is no gate keeping role of the GP, this means that the primary care cannot have the function 
to manage the health and risks of individuals and, therefore, application of the practice model 
wouldn’t yield expected benefits. Therefore, there is a need for strong primary care system for the 
follow-up program to be successfully implemented. 
Criteria and 
issues to be 
considered 
 The position and strength of primary care services within the health system 
 Health care budget spent on primary care services 
 The gate keeping role of the GP 
 Relationship of primary care services with the whole spectrum of health 
services 
Comments 
and examples  
 Each target country should be considered individually.  
 In countries such as the UK, where the primary care has the actual gate 
keeping role, the practice model could play a central role on management of 
the health, risks, and diseases of the individuals. The report generated and 
                                                                
2
 In the general framework of functions of health systems, health services cover a range of services 
(see Table 1 of the main article). Since this practice model is envisaged to be implemented in prima-
ry care services, health services heading practically cover primary care services. 
A systematic approach to assess integration of a preventive personalized health care model  
into health systems 
229 
updated by the practice model can be a crucial part of the health records of 
the individual, which may allow the GP to manage the health of the individual 
effectively and efficiently.  
 If a country has a weak primary care, such as Spain, the benefits of the prac-
tice model would be minimal, because the follow-up would not be effective, 
leading to diminished success in terms of the outcomes (health gains) of the 
model. 
 On the other hand, if there are plans for strengthening or restructuring the 
primary care services within a health reform program, it can be considered as 
a good opportunity to structure the GP’s services in a way that includes the 
practice model. 
 If the primary care system has good links with other levels of care, i.e. special-
ized care, the effectiveness of the system would be enhanced. In the ideal 
system, the reports of the practice model should follow the patient from pri-
mary care to other settings. Therefore, it is also important if the patient rec-
ords already have a continuum from primary care to specialized services and 
other settings of health system. (see also 22. Information flow and infor-
mation systems) 
Preliminary 
recommen-
dations  
For integration of the practice model and improving countries’ readiness: 
 The success of this application model lies in being implemented in a strong 
primary care service system. Therefore, a strong primary care service struc-
ture is one of the prerequisites for implementation of this model. 
 Countries with weak primary care services wouldn’t be a suitable place for 
implementation, unless it is considered to be embedded within a program on 
restructuring and strengthening of primary care services.  
16. Scope of primary care in terms of (primary) prevention 
Although traditionally primary care services have prevention, including primary prevention, within 
their scope, the practice might be different due to several factors (see also 14. Payment mecha-
nisms for primary care services, i.e. GPs, 15. Strength and place of primary care services in the 
health system and its relationship with other levels of care, 17. Performance assessment in primary 
care services) 
In many countries, primary prevention is in the scope of both population based services (also re-
ferred as ‘public health’ in the sense of health services provided to the public in general, disambig-
uation addressed in Chapter 2) and primary care services. However, in different countries, these 
two layers have different roles and different weights in terms of prevention of complex diseases. 
Criteria and 
issues to be 
considered 
 The primary care service provider‘s focus and attitudes towards prevention, 
in particular, primary prevention 
 Strength of the relationship between primary care services and population 
based services 
 If primary care have a mandate to improve the health of the people in their 
areas or if their tasks are limited to diagnostic and curative services (scope of 
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the doctor) 
 Presence of examples of risk assessment and disease prevention practices in 
primary care, such as CV risk assessment and prevention programs (see also 
18. Service delivery in primary care services) 
Comments 
and examples  
 In the Netherlands, the scope of GP premises start from secondary preven-
tion and get more intense on diagnostic and curative services and tertiary 
prevention. However, activities related to primary prevention are not gener-
ally in the scope of GPs. This perception likely has its roots at the perfor-
mance assessment and payment system of the GPs (see also 14. Payment 
mechanisms for primary care services, i.e. GPs, 15. Strength and place of pri-
mary care services in the health system and its relationship with other levels 
of care, 17. Performance assessment in primary care services). On the other 
hand, in the UK, the role of GP for primary prevention is more clear and visi-
ble. 
 In parallel to this perception, primary care service providers’ attitude towards 
prevention of complex diseases might be different. For example, it seems that 
the GPs in the UK have a proactive attitude towards prevention, inviting peo-
ple in their area for CV risk assessment and smoking cessation advice proac-
tively.  
 In the Netherlands, CV risk screening program was introduced within GP 
premises in the last decade. These settings employ a practice nurse for man-
agement of chronic diseases and they also carry out the CV risk screening 
program under supervision of the GP. The majority (82%) of the Dutch popu-
lation as well as 94% of GPs consider general practice to be the preferred lo-
cation for cardiovascular risk detection [53, 54]. However, this acceptance 
level might not hold true for primary prevention that involve lifestyle inter-
ventions. 
 In addition, the relationship of the primary care with population based ser-
vices seems to be weak in the Netherlands, whereas stronger in the UK.  
 Each target country should be considered individually. Data may not be 
readily available on this issue for the target countries. It would be preferable 
to conduct a separate study, but a literature review may also give some indi-
cation. 
Preliminary 
recommen-
dations  
For integration of the practice model and to improve countries’ readiness:  
 The practice model can more easily be implemented in countries where the 
primary care practitioners consider prevention, in particular primary preven-
tion in the scope of their practice. 
 The role of primary care services in prevention of complex diseases must be 
strengthened, in particular in terms of personal health promotion and per-
sonal disease prevention services.  
 If primary care services don’t have a strong focus on (primary) prevention, 
integration of this practice model can be used as an opportunity to expand 
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the scope of primary care services towards primary prevention. 
17. Performance assessment in primary care services  
Health systems and, as a part of it, primary care services can be oriented towards processes and 
outputs, which means ‘doing more procedures’ is rewarded, or outcomes, which means ‘delivering 
better outcomes’ is rewarded. This orientation can be visible in (presence of) the performance 
assessment system (if there is any). 
Criteria and 
issues to be 
considered 
 Presence of a functioning performance assessment system in primary care 
services 
 The link of this performance system with payments 
 The performance criteria’s orientation: process and output or outcome 
 Place of prevention and chronic diseases among the performance criteria 
Comments 
and examples  
 If there is a well-functioning performance assessment system in primary care, 
there is a need and potential for the practice model to be integrated and/or 
harmonized with that performance assessment system. 
 For example, in the UK, there is QOF – Quality Outcomes Framework, which is 
a voluntary incentive scheme for GP’s in the UK, rewarding them for how well 
they care for patients [55]. “The QOF contains groups of indicators, against 
which practices score points according to their level of achievement… and 
gives an indication of the overall achievement of a practice through a points 
system. Practices aim to deliver high quality care across a range of areas, for 
which they score points. Put simply, the higher the score, the higher the fi-
nancial reward for the practice.”  
 If the practice model is to be implemented in the UK’s primary care, there are 
several issues that need to be harmonized between these two, as well as op-
portunities for enhancing each other’s functions: 
a. Within QOF, there should be one or more indicators on implementation 
of the practice model on the targeted populations. 
b. Since it cannot be possible to call-in all individuals enrolled to a GP at 
once, there needs to be a prioritization. It is envisaged that the practice 
model can be implemented gradually, starting from high-risk groups 
(determined by age and risk factor) to lower risk groups (see also 18. 
Service delivery in primary care services). The QOF has already criteria 
that focus on high risk groups and this is integrated to the information 
system and electronic health records of the GPs. (see also 20. General 
environment and culture of the primary care services for implementa-
tion of a new practice model) So, the doctor can call in patients auto-
matically who fall into certain criteria, which are also linked to the per-
formance criteria. Such an existing system would provide an important 
opportunity to call in the patients to the GP premise for the practice 
model. 
c. In addition, the follow-up targets of the individuals determined after 
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the implementation of the practice model can be integrated in the per-
formance assessment system, which will incentivize reaching the tar-
gets. 
Preliminary 
recommen-
dations  
For integration of the practice model: 
 Presence of a performance assessment system that is linked with the patient 
records provides an important opportunity for implementation of the prac-
tice model. 
 The practice model and the performance assessment system should be har-
monized with each other for optimum functioning and creating incentives to 
reach results. 
18. Service delivery in primary care services 
The practice model is a personal health promotion and disease prevention intervention that is 
planned to be applied in wide populations. There is no early example of this yet: a comprehensive 
model covering primary, secondary and tertiary prevention in several health areas, which is an 
individual level intervention but can target the whole population. (See also 9.  General environ-
ment and culture of the health system for innovation)  
CV risk assessment programs that are being implemented recently, and which mainly focus on the 
people who might be in risk groups or have certain conditions (e.g. hypertension or hypercholes-
terolemia) is an example of a high risk approach. Although it doesn’t exactly match the practice 
model, since there are no examples, the service delivery model can be considered somewhat simi-
lar to CV risk assessment programs, but more comprehensive.   
Criteria and 
issues to be 
considered 
 Presence of active CV risk assessment and management programs in place in 
primary care services 
 The level of implementation of these programs 
 If that is a proactive program where individuals are called in (based on identi-
fied criteria), or a reactive one that runs based on the demands of the indi-
vidual or by the GP as an opportunistic screening 
 Opinions and attitudes of primary care workforce on current screening and 
risk assessment programs 
 Other programs (if there is any) that run at primary care settings for preven-
tion of complex diseases 
 Presence of trained workforce in place for lifestyle recommendations (such as 
nurse practitioner, dietician, etc.) and how widespread they are 
 If the primary care can be organized to implement the follow-up program 
Comments 
and examples  
 Each target country must be investigated individually. 
 As an example, the CV risk assessment program in the UK is a part of the GP 
services, where people are called in proactively by the GP’s team based on 
their risk profile (identified from the electronic health records) for risk as-
sessments by the nurse practitioner. The CV risk assessment is a part of the 
performance assessment program (17. Performance assessment in primary 
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care services) and brings a financial reward. The lifestyle advice is given by 
the nurse practitioner and in some GP premises, dieticians are also employed. 
 On the other hand, some GPs have a critical approach to screening programs 
that run in GP level [56]. 
 In the Netherlands, the CV risk assessment program is newly introduced. It is 
not a proactive one yet, only individuals who demand it can receive it, and al-
so, possibly the individuals referred by the GP. The risk assessment program 
is remunerated as a ‘fee-for-service’.  
Preliminary 
recommen-
dations  
For integration of the practice model: 
 The practice model can be introduced to the primary care services as a new 
program and in time, it must become an integral part of the primary care 
practice to help the GP and other professionals manage the health, risk fac-
tors and diseases in the context of main chronic complex diseases of the indi-
viduals enrolled to their practices. If there are existing CV assessment practic-
es, it can facilitate implementation of the practice model.  
 There should be a system to invite people in to the program on implementa-
tion of the practice model. To be able to manage the resource requirements, 
target population must gradually be expanded starting from high-risk groups 
(determined by age and risk factor) to lower risk groups 
D. RESOURCE GENERATION 
Health workforce 
19. Health workforce in primary care services 
The human interaction is crucial in order to effectively deliver the health care and make it 'person-
alized' to the individual.  However, human workforce is expensive. Therefore, a balance needs to 
be sought.  
The health workforce related functions of the practice model is as follows: 
a. Explain the individuals the scope, process, result and the limitations to create realistic expec-
tations and avoid undue anxiety  
b. Assistance in signing of the informed consent (the type of health professional can change 
based on the informed consent requirements of the country, see also 5. Regulations on ethi-
cal issues in terms of implementation) 
c. Assistance in filling in the (online) questionnaire and answer possible questions 
d. Answer questions on current situation findings to the individual 
e. Explain the risk assessment graphics to the individual 
f. Explain the lifestyle program to the individual, make revisions if and when necessary and set 
targets with him/her for the follow-up period 
g. Explain the medical follow-up program with the individual and make revisions if and when 
necessary 
h. Carry out the follow-up program on lifestyle factors, using different methods such as coach-
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ing, goal setting, motivational interviewing, etc. 
i. Carry out the medical follow-up program (integration to the usual practice of GP premise) 
These functions can be covered by various professionals in primary care services, depending on the 
country setting. 
Criteria and 
issues to be 
considered 
 The existing composition of health professionals that are present or can be 
hired at GP premises 
 Presence of culture of multidisciplinary teams in primary care services, in 
particular, role of nurse practitioners. 
 Opportunities to incorporate dieticians and other personnel on lifestyle 
modification 
 Baseline knowledge and skills of the primary care team on the issues listed 
above 
 How the above listed tasks can be distributed to the present workforce in GP 
premises  
 If there are any functions that are not met with the present system or can be 
met with a cheaper workforce type that is not currently present in the health 
system 
 The presence of in-service training platforms for GPs, practice nurses and 
other professionals in primary care services 
Comments 
and examples  
 In most primary care systems, GPs function together with practice nurses. 
However, the rest of the composition can change in different target coun-
tries.  
 For example, nurse practitioners run the CV risk assessment programs in the 
UK and the Netherlands. GP premises can employ dieticians in both countries, 
but it would be questionable, and must be investigated, what percentage of 
GP premises employ a dietician. 
 It must be investigated how the listed tasks can be distributed to the present 
workforce in GP premises and the required human resources in terms of 
numbers (assumptions can be made). It can be estimated that the practice 
model will create a serious workload in GP premises and the overall health 
system in the early years. On the other hand, if the practice model becomes 
successful in prevention of complex diseases and help reduce their burden, in 
the medium and longer term it will have a favorable impact on the need for 
health workforce. 
 There is a shortage of health workforce in Europe, especially nurses, and as 
the population is getting older, the shortage will increase because the num-
ber of new graduates to be employed in health sector is reducing, whereas 
the number of old people to be cared for are increasing. Therefore, creative 
solutions need to be found for meeting the health workforce requirements of 
the practice model. 
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Preliminary 
recommen-
dations  
For integration of the practice model: 
 With additional training, present primary care teams can probably meet the 
functions required for implementation of the practice model. However, the 
quantity of the workforce required can be difficult to be met. 
 As a solution, human interaction should be kept at crucial points where the 
presence of the health professional would make a real difference for further 
personalization of the model, rather than repeating all what is written in the 
report.  
 Individuals who will be enrolled to the program can attend group trainings to 
get general information on the process, results and limitations. 
20. General environment and culture of the primary care services for im-
plementation of a new practice model 
Various factors may play a role on GPs attitude towards new practices in the health system. 
Criteria and 
issues to be 
considered 
 Job satisfaction levels of the primary care team members, in particular GPs 
and nurse practitioners 
 Current workload of GPs 
 Opinions and attitudes of GPs to new applications, in particular their attitudes 
towards health authorities and decision makers 
 Professional liability insurances and possible effects of the practice model on 
them 
Comments 
and examples  
 In the Netherlands, there is a general perception among GPs that after the 
introduction of the Dutch Health Insurance Reform, their workload became 
very high [57, 58]. Any additional task in their job description might cause re-
actions since they already feel overloaded and overwhelmed. 
 GPs in the UK who might be reactive towards the screening programs that 
run in primary care [56]. (see also 18. Service delivery in primary care ser-
vices) 
 If the country has professional liability insurance schemes, the practice of the 
model in primary care services may have an impact on the scope and premi-
ums of the insurance scheme. Such effects may influence the willingness of 
the GPs to adopt the model in their practices. 
Preliminary 
recommen-
dations  
For integration of the practice model: 
 The practice model should be implemented in a way that doesn’t increase the 
work load of the GP (and also the other primary care team members) and/or 
remunerate the additional labor required. 
To improve countries’ readiness: 
 Job satisfaction of primary care workforce is important for every country 
since it might affect the openness of the workforce to innovations and devel-
opments in the health system, as well as their specific practices. 
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Knowledge 
21. Education and training of the health workforce 
Information contained in the report of the practice model should follow the individual in all rele-
vant layers and settings of the health services. Therefore, all health professionals, including health 
service managers will need some sort of training on the practice model so that they can under-
stand the consequences of the report. This training must be tailored to the baseline level of the 
health workforce. Therefore, current knowledge of the workforce is important. 
Education of the new cohorts of physicians, nurses and other personnel is crucial. The implementa-
tion of the practice model should be gradually introduced to the population, starting from high risk 
and older groups going to younger age groups gradually, which will probably take 10-15 years’ 
time. The education of new cohorts of health professionals will help meeting the need for more 
trained workforce in the future years. 
As new technologies such as next generation sequencing enters into health services, such technol-
ogies can also be incorporated to the practice model. The human workforce requirement for that 
future should also be considered.  
Criteria and 
issues to be 
considered 
 The profile of the current primary care team and their level of knowledge on 
the role of genetics in complex diseases, risk assessment approaches, lifestyle 
factors, skills that are required for assisting individuals in lifestyle changes, 
such as coaching, motivational interviewing, etc. 
 The place of the above mentioned areas in the curricula of the health profes-
sionals  
 The training needs for primary care team, specialists and health managers 
and other support personnel 
 Human workforce requirement for the future of genome-based technologies 
Comments 
and examples  
 In the UK, a report by PHG Foundation lays out the importance and responsi-
bilities of bioinformaticians for services related to next generation sequencing 
[59]. 
 Education and training curricula will depend on the planned roles for differ-
ent professionals. For example, GPs might be in charge of medical aspects, 
whereas nurse practitioners may focus on lifestyle aspects. 
Preliminary 
recommen-
dations  
For integration of the practice model and to improve countries’ readiness: 
 Different health systems may have different roles for the primary care team. 
Considering an average primary care team in Europe, the following options 
can be explored: 
 The program manager of this practice model within the primary care setting 
must be the practice nurse for the following reasons: The model doesn’t only 
involve people with risk factors or existing diseases. It involves individuals 
without health problems. Therefore, the role of the doctor should be limited, 
because involvement of the doctor ‘medicalizes’ the process and creates ‘pa-
tients’. This holds a threat of turning every individual into potential ‘patients’. 
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Therefore, the nurse should be in central position, rather than the doctor, 
during the implementation. 
 Management of lifestyle factors is crucial for the success of the practice 
model. Coaching is one of the methods for this purpose. The best person to 
do the follow-ups for lifestyle change in the current system seems to be the 
practice nurse. Therefore, she needs to be educated and trained for that in 
nursing schools. Or perhaps, an additional training can be given to the nurses 
who want to do this type of work. Coaching lifestyle change is the key. 
 Considering the shortage of dieticians and their specific training for providing 
nutritional plans for ‘patients’, role of dietician can be focused on people who 
need certain dietary advice due to a disease – i.e. practicing dietetics. In this 
case, nurse can focus on ‘coaching’ for lifestyle change. 
 If nurses are too expensive or not available, a new type of health care worker 
can be identified: ‘lifestyle coaches’.  The education for this type of health 
workforce can cover a technical education in higher education system. Unlike 
dieticians, their focus should not only be nutrition, but also exercise and 
smoking cessation. Alternatively, ‘lifestyle coaching' can be a certificate pro-
gram for people with basic training in health related fields (such as certifica-
tion of ‘lactation consultants’). 
 Until ‘lifestyle coaches’ are trained as new cohort of professionals, nurses and 
dieticians would be the best type of professionals to run the follow-up pro-
gram for management of lifestyle factors. 
 Bioinformaticians are a new and important type of professionals for two 
reasons: 1) For analysis of data collected for research and development pur-
poses, bioinformaticians are needed. 2) For new technologies such as next 
gen sequencing, we need to understand the meaning and value of muta-
tions/polymorphisms that is not defined before, also for service provision. 
Therefore, bioinformaticians are important workforce need. (see ‘Next steps 
in the sequence’ by PHG Foundation, the UK [59]) 
22. Information flow and information systems 
Established information systems in primary care, in particular effective use of electronic health 
records would provide opportunities as well as challenges. 
Criteria and 
issues to be 
considered 
 Established information systems in primary care, in particular effective use of 
electronic patient/health records in primary care services 
 Integration of information systems between different layers and settings of 
health care services, including the link between primary care services to hos-
pitals (is the data following patient?) 
 Interoperability between the electronic patient/health records and the prac-
tice model 
 Possibilities on data to be securely stored and processed (also linked to 7. 
Regulations on data protection, privacy and confidentiality) 
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Comments 
and examples  
 Presence of electronic patient records in primary care would be an important 
asset since the primary care team would be used to implementing such sys-
tems. On the other hand, the interoperability issues between the electronic 
health record and the practice model can be a challenge.  
Preliminary 
recommen-
dations  
For integration of the practice model and improve countries’ readiness 
 Interoperability with electronic health records must be considered when the 
software for the practice model is being developed. 
 If there is no widespread use of electronic patient records in primary care, 
implementation of the practice model can be used as an opportunity for in-
troducing it as well. 
Physical resources 
23. Logistical aspects 
Application of the practice model requires a system for collection of samples from primary care 
practices to be delivered to relevant medical laboratories. Physical infrastructure is needed for 
space and information and communication technologies in the GP premises. 
Criteria and 
issues to be 
considered 
 Present systems for collecting samples from primary care practices and 
sending them to laboratories 
 Space and infrastructure (computers, online connection, etc.) available at 
primary care settings 
Comments 
and examples 
 If there is an established logistics system for collection of samples from GP 
premises and delivery to the relevant laboratories, it creates an advantage. 
 The GP premise must be equipped with relevant infrastructure for ICT, as well 
as an active electronic patient record system. 
Preliminary 
recommen-
dations 
For integration of the practice model and improve countries’ readiness 
 If there is an established logistics system for collection of samples from GP 
premises and delivery to the relevant laboratories, it creates an advantage. 
 The GP premise must be equipped with relevant infrastructure for ICT, as well 
as an active electronic patient record system. 
 If the GP premises don’t have the required ICT infrastructure, implementation 
of the practice model can be used as an opportunity to establish this infra-
structure which is required also for several other purposes in contemporary 
practice of medicine. 
24. Laboratory services 
Countries have different arrangements for laboratory services in general and specific to genotyp-
ing. 
In the near future, whole genome / exome sequencing can become a part of health services. 
Therefore, this future possibility also needs to be investigated. 
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Criteria and 
issues to be 
considered 
 Facilities for high-throughput genotyping at local, regional or national levels, 
which are licensed (or can be licensed) for carrying out genetic tests for medi-
cal purposes 
 Possibilities on infrastructure and expertise for the future scenarios, including 
use of other levels of genome-based information (such as whole genome se-
quencing)  
Comments 
and examples  
 Each target country must be investigated for the arrangement of laboratories 
in general and specific to genotyping facilities. Especially, the capacity of the 
available local, regional and national laboratories that can provide the re-
quired high-throughput services must be investigated. These laboratories 
must be licensed for carrying out genetic tests for medical purposes. (also 
linked to 4. Regulation of genetic testing, including predictive testing for im-
plementation in primary care services). 
 In the UK, there are preparations for using whole genome sequencing for 
‘research’ purposes for a very large number of patients (100.000), which may 
be considered as a pilot for the possible future services [32]. The relevant re-
ports highlight the requirements and possibilities for implementation of next 
generation sequencing in the UK [59]. 
Preliminary 
recommen-
dations  
For integration of the practice model 
 Presence of functioning high throughput genotyping laboratories and possi-
bilities to use upcoming genome-based technologies are advantages for the 
implementation phase. 
 In many countries, current framework and regulations for genetic testing 
laboratories is based on the ‘diagnosis of monogenic diseases’ paradigm. This 
can create some problems in the practice of this model. If the genotyping 
service providing laboratory is licensed for providing genetic testing services 
for medical purposes and complying the relevant legislation, in principle no 
legislative problem is expected.  
Abbreviations: 
CV: Cardiovascular 
DTC: Direct-to-consumer 
EU: European Union 
GP: General practitioner / Family physician (main physicians who provide primary care services) 
QOF: Quality Outcomes Framework 
ICT: Information and communication technologies 
NHS: National Health Services 
SHI: Social health insurance 
UK: United Kingdom 
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The starting point of this PhD research was a serious societal problem that creates a huge 
burden and economic toll on health systems and societies: chronic complex diseases. 
Driven by scientific and technological developments, personalized medicine and health 
care have the potential to provide solutions for effective prevention of chronic diseases. 
However, integration of ‘personalized’ practices into health services has been a challeng-
ing process [1, 2]. This dissertation addressed this challenge and took a journey through 
the fields of personalized medicine and health care, and health systems and policies. Gen-
test, a preventive personalized health care model, has been my ‘vehicle’ in this journey.  
The aim of this dissertation was to investigate how a personalized health care model, 
such as Gentest, can be integrated in primary care services in European health systems, 
for prevention of chronic diseases. To answer that, I asked three sub-questions. 1. Where 
will the practice model be integrated?; 2. What will be integrated?; and 3. How can the 
integration take place?  
Part I answered ‘where’ the integration will take place and described the setting, i.e. 
health system in its wider context of public health. Part II answered the ‘what’ question by 
first describing the broader context of personalized medicine and personalized health care 
and then introducing Gentest, which is an example of a practice model to be integrated 
into the health systems in Europe. Part III presented a systematic approach to assess 
‘how’ this practice model can be integrated in primary care services in European health 
systems. It exhibited an inventory of issues that may be involved in the integration process 
of the practice model we took as our example. 
This last chapter will take a step back and try to reflect on the interaction between the 
contexts of the health systems and personalized health care practices (section 1). I will 
discuss what adaptations are needed within the health system to successfully integrate 
personalized medicine and health care, as well as how personalized practices need to 
change in order to fit in the health systems.  An additional section will reflect on our use of 
a concrete, real life case in this dissertation and how it may contribute to research in this 
field (section 2). 
1. Interaction of health systems and personalized health care 
practices for effective prevention of chronic complex dis-
eases  
This section will first take a look at the past 40 years of public health to see very briefly 
how approaches to disease prevention and health promotion evolved. Following this sce-
ne setting, a case for ‘co-evolution’ of innovations on both health systems and personal-
ized health care practices side will be created. Then, I will look at health system and per-
sonalized health care innovations from each other’s perspective respectively.  
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1.1. Setting the scene: from Health for All to ‘tailored’ and ‘person-
alized’ approaches 
When the vision of ‘Health for All’ (HFA) was born in the World Health Assembly in 1977 as 
“the attainment by all the people of the world by the year 2000 of a level of health that 
will permit them to lead a socially and economically productive life” [3], it breathed new 
life into public health discourse. As introduced briefly in Chapter 2, HFA was a revolution-
ary paradigm shift to bring World Health Organization (WHO) and member states from a 
‘combating disease’ approach to one that considered health and health policy in the 
broadest sense.  
The three words of ‘Health for All’ title reflect the essence of this paradigm shift. With the 
word ‘health’, HFA moved the focus from ‘processes’ towards ‘outcomes’: governments 
were to be held accountable for the ‘health’ of their citizens, not just for the ‘health ser-
vices’ they provided [4]. Moreover, health wasn’t seen as merely ‘the absence of disease’ 
anymore. It was a state of well-being physically, mentally and socially. 
With the phrase ‘for all’, HFA addressed the value of ‘equity’, emphasizing that everyone 
had the right to attain their full health potential [5] (see also Chapter 2). Additionally, HFA 
clarified that it is not only the task of ministries of health or the health sector to attain this 
goal. ‘All' sectors, including the ones other than health, had a responsibility and role to 
achieve HFA. 
How can countries around the world achieve HFA? The primary intent of the International 
Conference on Primary Health Care, in Alma-Ata, in 1978, was to put forward the strate-
gies to realize HFA across the globe. The declaration proposed ‘Primary Health Care’ as the 
model to reach HFA around the world
1
.  
In an effort to develop the required strategies to realize the HFA vision in the European 
region, in 1984, WHO Europe developed and adopted the 38 targets for ‘Health for All by 
the year 2000’ [6]. This policy document made a great contribution to the spread and 
recognition of a broad understanding of health promotion [4]. Soon after, Ottawa Charter 
for Health Promotion was adopted in 1986 at an international conference held in Ottawa, 
Canada, under the leadership of WHO. It framed health as a ‘resource for everyday life’ 
and defined health promotion as the process of enabling people to increase control over, 
and to improve, their health. It emphasized “Health promotion is not just the responsibil-
ity of the health sector, but goes beyond healthy life-styles to well-being”. Ottawa Charter 
proposed 5 key action areas that involve all levels that have an impact on the individual’s 
health, from macro to micro: 1) building healthy public policy, 2) creating supportive envi-
                                                                
1
 ‘Primary health care’ and ‘primary care services’ are different concepts, as summarized in Chapter 
2.  
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ronments, 3) strengthening community actions, 4) developing personal skills, and 5) reori-
enting health services.  
In late 80s, as a response to interventions that focus on only the ‘individual’ and informing 
them to change their lifestyle, without considering the context they live in, an ‘ecological’ 
approach started to evolve in the field of health promotion. Sole focus on individual life-
style changes was criticized to be a ‘victim-blaming ideology’ because it neglected the 
importance of social influences on health and disease [7]. People’s lifestyle is not deter-
mined only by the decisions of the individuals. It is shaped by the social, economical and 
physical opportunities and constraints of the environment they live in. Ecological models 
proposed to take this into account and assume that “appropriate changes in the social 
environment will produce changes in individuals, and that the support of individuals in the 
population is essential for implementing environmental changes.”[7]  
Thus, Ottawa Charter and the ecological approach concurrently brought into attention the 
environment (or the context) in which individuals live in as an important determinant that 
underlies behavior and lifestyle. They proposed to target this environment, among others, 
to allow for healthy behavior and positive health outcomes.  
It was very important at that point in time to understand that the context of the individual 
is a conglomeration of interacting determinants that shapes individual behavior and life-
style choices. The elements that constitute the environment are shared to a certain ex-
tent. However, in each individual context they may interact in slightly different ways, 
shaping the health environment of each individual in a unique way. In particular for inter-
ventions that aim to change the individual’s behavior, this requires different communica-
tion and behavior change strategies to reach different individuals. Realization of this fact 
triggered moving away from the ‘one-size fits all’ approaches and initiated ‘targeted’ and 
‘tailored’ approaches in health education and promotion in 1990s and 2000s [8]. Here, 
targeting means that a single intervention is developed for a specific, clearly defined tar-
get population (for example, 40-65 year old black women in the whole country or blue-
collar man in a certain workplace), whereas tailoring aims to reach each person with in-
formation or change strategies based on the unique way in which that individual’s charac-
teristics and environment are interlinked.  
Interestingly, late 1990s and early 2000s is also the time when the ‘personalized’ ap-
proaches to medicine and health care started to be discussed in the literature and scien-
tific fora. In the earlier phase, the term ‘personalized’ and ‘individualized’ was used mostly 
for genome-based and information/ communication technologies (ICT) driven applica-
tions, but later these terms broadened to cover various other ones, including practices 
that have no technological component (see Chapter 4). Concurrent development of ‘per-
sonalization’ and ‘tailoring’ concepts in different fields points that there has possibly been 
a general societal trend that drove these. 
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Chapter 6 introduced a personalized health care practice that aimed to prevent common 
chronic diseases in primary care settings. This practice model, Gentest, utilizes individuals’ 
personal health information, detailed lifestyle analysis, body composition, genotype, and 
other biomarkers in order to prevent the onset or progression of major chronic diseases in 
a targeted way. Such comprehensive personalized health care practices have the potential 
to integrate different ‘personalized’ and ‘tailored’ tools into a single practice model that 
can be used to manage the ‘health’ of the individuals in a holistic way and lead to effective 
lifestyle changes. Nevertheless, this potential can be achieved only if the health system is 
ready to host them. 
1.2. The need to innovate 
In spite of the reorientation from disease to health, from cure to prevention, and from 
uniform to tailor-made approaches in the past 4 decades, even 15 years after the target 
year of 2000, we still haven’t completed the paradigm shift towards HFA. A large part of 
our health budgets is still spent on diagnosing and curing ‘diseases’, rather than on pro-
motion of ‘health’ and prevention of 'diseases’. Additionally, the translation of health 
promoting efforts into policies and actions in countries is progressing slowly. Following the 
footsteps of Ottawa charter, serious efforts have been spent to involve sectors other than 
health into health policy, in particular with the ‘governance for health’ concept and health 
in all policies [9-11]. However, in many countries around the globe, health is still mainly 
seen as a function/outcome of health services.  
Thus, the ‘old’ HFA vision is not only still valid, but also still provides a coherent overarch-
ing framework for the overall goal of public health, as we’ve set it in Chapter 2. It would 
thus provide an excellent ‘base’ for innovative technologies and could rejuvenate old ideas 
concerning a holistic and context-based approach to health. 
If we look at the health systems more closely, to attain HFA, we need to shift towards 
proactive and health oriented services focused on prevention as well as chronic cure and 
care, covering the whole spectrum of health care (not only medicine). There are the 
countless efforts to develop intervention models or tools to prevent disease and/or pro-
mote health, however, they often focus on specific diseases or specific intervention areas 
(such as smoking cessation, healthy nutrition and physical activity). An integrated ap-
proach to prevention
2
, as well as diffusion of the existing individual interventions in the 
health system, although presented often on paper and in policies, are still largely lacking in 
reality. To attain the desired paradigm shift at the system level, we need think outside the 
box; we need to innovate. 
                                                                
2
 i.e. an approach covering each individual from birth till death, involving the entire health spectrum 
of that individual, and taking the unique constellation of biological as well as lifestyle and environ-
mental determinants of that individual into consideration 
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In the health sector, the term ‘innovation’ is mostly perceived as equivalent to ‘new tech-
nologies’, such as development of pharmaceutical and other therapies, as well as medical 
devices such as diagnostics [12]. We also see this tendency in the field of personalized 
medicine, as raised earlier in Chapter 4. However, technical and technological innovation 
at the level of health interventions, such as ‘personalized’ practices like phar-
macogenomics or tumor genomics, is not enough. They alone cannot have a profound 
impact on the burden of chronic diseases. It is not enough to simply release them, as the 
system, where they will be used, also needs to be innovated to be able to effectively 
adopt them.  
In Chapter 4, this issue was taken more specifically, for the case of the interaction among 
‘personalized’ innovations and the health practices. It was emphasized that innovations on 
the science and technology side are not enough. To realize the vision of personalization, 
they need to be adapted and further developed on the health practice side. At the end of 
the day, those practices will actually construct how personalized approaches will take 
place in medicine and health care, not only specific techniques or technologies. 
 
Figure 1: Co-evolution of personalized health care and health system innovations  
Health systems need to innovate to  better host personalized medic ine and health  care inn o-
vat ions and personal ized innovat ions need to innovate again to adapt to the health system. 
This creates  a cycle  of co -evolut ion of innovat ion,  which helps to elevate each other to  a 
higher level  to better meet the needs of the populat ion.  
If we enlarge our focus from health practices towards capturing the health system in its 
entirety, we see that what was set forth in Chapter 4 is also true for the interaction among 
the innovations in personalized health care and innovations in the health system. To inno-
vate in the health system, we should look at the entirety of the health system as a ‘com-
plex-adaptive’ system [13, 14]. There is a need to re-think how health systems, as well as 
health services as a part of it, are organized and to investigate what kind of innovations 
are needed at the systems level to enable and host the upcoming innovative interven-
tions, such as personalized medicine and health care, in the best possible way. If we are 
really aiming to achieve the paradigm shift that is required to tackle the burden of chronic 
diseases, we need to look at both areas, instead of focusing on only one of them. We need 
Personalized 
health care 
innovations 
Health 
system 
innovations 
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to initiate a process of co-evolution (or termed as ‘co-production’ in current science, tech-
nology and society studies [15]), in which ‘personalized’ practices adapt in order to fit to 
the health system, and in which health system changes to make the innovative practices 
of personalized medicine and health care fit. (See Figure 1) 
The following two headings will look at this interaction from two perspectives. First one is 
looking at health systems and required innovations from the perspective of personalized 
medicine and health care. The other one is looking at ‘personalized’ practices and efforts 
in this field from the perspective of health systems and policies. This will be done in light 
of the HFA vision, since it was proposed as the overarching framework for public health in 
Chapter 2. As it was throughout this dissertation, Gentest, the practice model chosen as 
the example, will be the ‘vehicle’ to make this discussion effectively.  
1.3. Personalized health care in public health and health systems; 
an overview of relevant concepts 
The practice model introduced in Chapter 6 (Gentest) is a comprehensive and integrative 
model of personalized health care for prevention of common chronic diseases. It includes 
a wide range of tools, which, in combination, help the individual achieve a healthy lifestyle 
and manage his/her health according to individual health priorities.  
Following its pilot in Turkey and upon being identified as a ‘best practice model’ by Public 
Health Genomics European Network (PHGEN) in 2008, it was seen that the main imple-
mentation area for such a preventive health care product would be primary care services 
in Europe, where it can be provided via general practitioners/ family physicians. 
This sub-section will propose to revisit some of the public health concepts, including 
health systems, in light of the developments in the personalized medicine and health care 
field, in particular our practice model. I will first shortly go through a few conventional 
approaches in public health and prevention and question if they are ready for the upcom-
ing practices of personalized health care. The practice model will be used as a starting 
point for contemplation. As the concepts are revisited, I will make proposals for alterna-
tives to some of them (looking forward). Then, I will go back to basics to emphasize the 
transformation needed within primary care services for effective prevention of chronic 
diseases, and show how our practice model could be instrumental for that. Lastly, the 
answer to question that was already covered in Part III (Chapter 7) will be summarized, 
but this time in a more explicit way: what kind of health systems would facilitate the inte-
gration of the practice model in the best possible way? 
1.3.1. Looking forward: innovation for prevention of chronic diseases 
Chapter 1 introduced the ‘disease development curve’ and pleaded to focus on earlier 
phases of diseases development (Phase I in Figure 2-a. in this chapter) in order to prevent 
chronic diseases effectively. The introduction of ‘personalized’ practices at the early phas-
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es will have a profound effect on how we approach ‘prevention’ in the context of chronic 
diseases, as well as public health concepts. 
 
Figure 2: ‘Disease development curve’ – (a) Development of chronic diseases in a time perspective 
and (b) preventive approaches for different phases of disease development  
Source:  The ‘disease development curve’  was  developed by Serdar Savas at GENAR Ins t itute  
for Publ ic  Health and Genomics Research,  Ankara,  Turkey,  in 2008,  inspired by the disease 
progress ion curve of Snyderman [16]  to a certain extent.  The concept of proposing health 
management,  r isk management and disease management as prevent ive appro aches in di f-
ferent phases  of d isease development was developed by Serdar  Savas for Diabetes 2020: 
Vision and Targets  project [17] .  
In Chapter 7 (Part III) we identified 24 areas that should to be investigated to assess how 
our practice model can be integrated into a health system. One of them briefly introduced 
in which areas the practice model could challenge the conventional mindsets in health 
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sector (‘9. General environment and culture of the health system for innovation’ in Sup-
plementary Material of Chapter 7). The approach to prevention was one of them. This 
section will take this further and attempt to revisit some rather conventional approaches 
and classifications and/or fuel already existing debates. 
Personal vs. population based strategies for prevention 
The classical prevention approach, which dates back to Rose, 1985, suggests that there are 
two strategies to prevention: population based and individual. The first seeks to control 
the determinants of disease in the population as a whole. Population based mass inter-
ventions make small benefits for individuals, but their cumulative effect on the burden of 
disease on the population level is substantial. Within the second strategy, individual inter-
ventions for prevention of diseases are reserved for high-risk susceptible individuals. This 
strategy seeks to identify and offer high-risk individuals some protection [18, 19]. One of 
the main reasons for proposing a population based approach to prevention by Rose has 
been that approaching each and every individually for prevention with the tools and re-
sources available in that period would not have been possible. 
While several scholars still support Rose’s ‘population based vs. high-risk individual’ pre-
vention strategies, there are some calls to revisit the dichotomy for a number of reasons. 
Firstly, identification of high-risk individuals has improved in accuracy and some believe 
that this obviates the need for population-wide prevention strategies [20, 21]. Additional-
ly, the population based approach was criticized for its potential to exacerbate disparities. 
To prevent that, Frolich and Potvin proposed a vulnerable population approach to com-
plement the population based ones [22]. More recently, Burton et al. proposed that an-
other strategy would be segmenting the population by risk in to a number of strata, to 
each of which differential interventions may be applied. While determining the strata, 
genetic factors might be used. This is called ‘stratified prevention’ and they argue that 
such an approach will lead to consequential advantages in efficiency, effectiveness and 
harm minimization [23]. 
Before presenting my point about revisiting the ‘population based vs. high-risk’ dichoto-
my, it is worth to discuss what is meant by ‘population based’ interventions. Roughly, 
preventive interventions may be seen as representing two extremes of a spectrum, re-
ferred to with different terms by different authors, theories or perspectives. These are for 
instance “superficial” and “radical” [19, 24], “agentic” and “structural”, founded on the 
agency-structure sociological theory [25-27], and “downstream” and “upstream”, from the 
perspective of socioeconomic determinants of health [28, 29]. Although they are driven by 
different theories, there is substantial overlap, which indicates a similar division. On one 
hand, there are interventions that aim to change the behavior of the individual by inform-
ing him/her, relying on the capacity of individuals to make independent, purposive choices 
(superficial, agentic or downstream). On the other hand, there are interventions towards 
the structure underlying individual behavior and lifestyle. This structure then involves 
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social, economic, political, and material contexts within which behavior occurs (radical, 
structural or upstream).  
Ecological models in health promotion provide a wider perspective and claim that there 
are actually more levels between the individual and the whole population [7]. Rather than 
targeting solely the structure or solely the individual behavior, ecological models stress 
that there are intermediate levels in between that interact. The factors range from the 
biological and physiological processes taking place within the body to individual character-
istics such as age, race, sex, behaviors, family, social and community networks, living and 
working conditions, broad social, economic, cultural, health and environmental conditions 
and policies. All these levels are linked, interact, and come together in the individual in 
variety of ways (Figure 3). Which elements play a dominant role and how they interact, 
however, differs from one individual to the other, requiring not only a needs and risk as-
sessment at individual basis, but also intervention at personalized level. Holistic ecological 
models for health promotion, in other words, offer the potential for a tailor-made inter-
vention at the level of the individual. 
Figure 3 introduces a proposal for illustration of how individuals’ biopsychosocial and 
ecological factors interact to explain health and health related behavior. It is based on the 
“Biopsychosocial ecological system” model of Sameroff [30]. The visualization of the eco-
logical context is additionally enriched using the model of the Institute of Medicine (2003) 
[31], which provided an elaborated approach to multiple layers of determinants of health. 
Such holistic approaches towards understanding individuals’ health may start a debate 
around them and facilitate different ways of thinking to develop holistic personalized 
health care practices. 
Ecological models stress the importance of structural interventions at population base 
because they target the deep roots of the chronic diseases, such as the social, economic, 
political and material contexts and, therefore, can produce effective results. For example, 
prohibiting sales of tobacco products to people under 18, creating smoke-free environ-
ments, raising the price of tobacco products through tax and other policies, restrict-
ing/banning tobacco advertisement, countering advertising with prevention and cessation 
messages, and plain-packaging are among the structural interventions have been proven 
to be powerful methods to reduce smoking rates [32, 33]. However, such interventions 
are hard to achieve, since tackling those deep roots of chronic diseases require a strong 
commitment on the side of the politicians and decision makers. This is one of the main 
reasons why structural interventions in other much needed areas, such as decreasing 
sugar and unhealthy fat consumption and increasing physical activity, are developing at a 
very slow pace. Implementation of effective policies to tackle them requires a strong will 
on the decision makers’ side since the interventions will involve agricultural policies at 
large and the food industry [34-37]. 
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Figure 3: A proposal for conceptualization of an integrated bio-psycho-socio-ecological approach 
to health 
Notes of the  f igure:  
1.  This  is  a proposal for conceptualization of  an integrated b io-psycho-socio-ecologica l 
approach to health.  I t  aims to expla in health and health re lated behavior.  For  this model ,  
Sameroff’s  “Biopsychosocial  ecological  system” model  (2010) [30]  and the multi layered 
approach to population health  by Insti tute of Medic ine (2003) [31]  were integrated into a  
single i l lustrat ion.  
2.  (a) Socia l  conditions include,  but are not l imited to:  economic inequali ty,  urbanization,  
mobil ity,  cu ltura l values,  att itudes and pol ic ies re lated to d iscriminat ion and  intolerance 
on the bas is  of race,  gender,  and other di fferences.  
(b)  Other conditions  at  the national level  might include major so ciopoli t ica l sh i fts,  such as 
recess ion,  war,  and governmental col lapse.  
(c)  Pol ic ies at the global,  reg ional,  nat ional,  state/provincia l  and local  levels  
(d) L iv ing and working condit ions may include: Psychosocial  factors,  e mployment status 
and occupat ional factors,  s ocioeconomic status ( income, educat ion,  occupat ion),  t he nat-
ura l and buil t  environments ( transportation,  water and sanitat ion,  housing,  and other d i-
mensions of  urban planning),  and health  serv ices (populat ion based and individual) .  
In the light of the complexity and slow pace of structural changes, individualized preven-
tion, however is still needed. It is for this reason that holistic, ecological approaches pro-
pose to include these levels as well. This calls for strategies that couple structural inter-
ventions at the population level with personal level interventions that motivate and 
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empower people to adopt healthy lifestyles, in particular with ‘tailored’ and/or ‘personal-
ized’ interventions (see 1.1. Setting the scene: from Health for All to ‘tailored’ and ‘per-
sonalized’ approaches).  
In the case of smoking, for example, those who have already started smoking would be 
more motivated by personal reasons (such as seeing the increase in cardiovascular risk 
visually, as well as the potential decrease that will happen when they stop smoking, or 
monetary savings they will gain). They would thus be more empowered by personalized 
recommendations based on an analysis of their underlying causes of smoking, instead of 
generic and usual advice of “you should not smoke because it is bad for your health”.  
Because of their comprehensive nature, personalized health care practices can become 
important tools in ecological approaches to health promotion. They provide an excellent 
opportunity to integrate biological characteristics (at genetic and other physiological lev-
els), and other personal characteristics (age, gender, ethnicity, lifestyle, socioeconomic 
status, living and working conditions, environmental conditions, culture, etc.) into ‘tai-
lored’ and/or ‘personalized’ tools that can be used in practice. Thus, ecological models 
provide the approach and tools we need in order to identify what the individual’s context 
is like. Once the context is known, then ‘personalized’ or ‘tailored’ interventions can be 
developed.  
If we look at our example, Gentest, we see that a main part of its mission is (see Chapter 
6) to change the behavior of the individuals according to their health priorities. And, to do 
that, it incorporates various elements of the individual context. In this sense, it shares a 
similar approach with the ‘tailored’ health promotion interventions that are designed to 
address individual contexts. On the other hand, the second part of its mission is managing 
the health of the individual according to their health priorities. For both components of 
the mission, various assessments are made on the personal health history, family health 
history, lifestyle factors including nutrition, exercise and smoking cessation, as well as on 
the genetic structure of the individual. In this sense, Gentest is in line with ‘personalized 
health care’, as it has the holistic approach to health that ecological models in health pro-
motion call for. (For a more detailed discussion on what ‘personalized health care’ is, see 
Chapter 4 and 5) 
However, personalized health care does not only provide tools that can become central to 
ecological approaches for particular health risks (cardiovascular diseases, diabetes, can-
cers, osteoporosis, chronic obstructive lung diseases, etc.). Unlike many health promotion 
interventions, personalized health care practices, such as Gentest, can be used to monitor 
the health of the entire population. Moreover, it is not a programmatic approach that 
focuses on particular health risk or disease, or on particular high-risk populations. Instead, 
it can monitor our health from birth till the end of life and claims to include most of the 
major health threats. With the effective use of ICT and decreasing costs of genetic tech-
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nologies, the intervention can be delivered to large population clusters, not only high-risk 
groups. This has three implications. First of all, the individualized lifestyle recommenda-
tions can slow down the progression of the disease development curve, and thus may help 
to delay or prevent the development of chronic complex diseases to a certain extent in the 
population. Secondly, as Burton et al. raised earlier, such a model allows stratification of 
the individuals into several risk groups and delivering appropriate preventive interventions 
for each stratum, not only for high-risk strata [23]. Lastly, different strata can be ap-
proached with individual level interventions, as well as population-based interventions, 
depending on the intervention. Thus, personalized health care models may lead to ques-
tioning the classical ‘population based vs. individual (high risk) prevention’ strategy and 
help us approach prevention in different ways. 
Targeting the whole (relevant) population with individual interventions is not a totally new 
concept. Preventive Child Health Services in the Netherlands have already been doing this. 
Although the scope of the dissertation was drawn as ‘major adult onset chronic diseases’, 
it is worth to take a brief look at this example in the wider context of this general discus-
sion. Preventive Child Health Services offered by well-baby clinics (Consultatiebureaus) for 
the ages of 0-4 and regional public health centers (Gemeentelijke Gezondheidsdiensten, 
GGD) for 4-18 include both individual and collective services [38]. In the individual level, 
children are invited for standardized health examinations at specific intervals: 15 times 
between 0 and 4 years of age and 3 times in the ages of 4-18. They are screened for a 
number of physical, social and psychological problems, the growth is monitored, and par-
ents are provided advice based on specific needs, which are all interventions in line with 
the ‘health oriented’ paradigm. Nevertheless, several of the Preventive Child Health ser-
vices are still ‘disease oriented’. The approach to psychosocial problems of children is an 
example to this. If the symptoms of the child lead to a diagnosis, further investigation and 
therapy is offered. However, if the symptoms don’t cluster into certain diagnostic criteria 
at that moment, the child and the family might not get the help they need. This ‘disease 
oriented’ paradigm can create a hurdle for early interventions to neurodevelopmental 
problems.   
The underlying routine screening structure with standardized measures provides a valua-
ble opportunity for the Dutch Preventive Child Health Services to monitor the child in a 
prospective way and predict the child’s physical and psychosocial development, as well as 
any potential problems in those areas. In addition, effective integration of different as-
sessment components can enable looking at the child in a holistic way. Thus, Dutch Pre-
ventive Child Health Services hold a huge potential to transform into a more predictive, 
preventive, participatory and ‘personalized health care’ model [39]. Personalized health 
care practices such as Gentest might inspire such transformations in the whole spectrum 
of health care, including child health services. 
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The idea of targeting the whole population for primary prevention with individual level 
interventions seems to be also gaining its place in the literature [40, 41]. As they argue for 
the case of stroke prevention, by using ICT, it is easier to reach masses while individualiz-
ing the intervention. 
Considering the promising role personalized health care models such as Gentest can play 
in reviving non-vertical comprehensive HFA strategies and considering the co-productive 
nature of innovation and health system as discussed above, one can conclude that, if we 
want to introduce practice models such as Gentest, we will need a health system that is 
ready to host comprehensive, prevention based approaches to health, risk and disease. 
So, when considering the introduction of personalized health care into the health system 
of a particular country in Europe we need to also assess its readiness for such an ap-
proach.  
Primary, secondary and tertiary prevention 
Classically, primary prevention is the effort to prevent a healthy person from falling ill. 
Secondary prevention entails the efforts to early detect a disease, so that the progression 
can be arrested and if possible the disease can be eradicated. Primary prevention is prac-
ticed prior to the biological origin of the disease, where secondary is practiced after the 
disease can be recognized, but before it has caused symptoms for the individual [42]. 
Tertiary prevention is aimed at arresting the progress of established disease. The target 
group for primary prevention includes those that are healthy, with respect to a target 
disease. Secondary prevention targets people who are already ill without being aware of 
it. Tertiary prevention is directed towards people who are already known to have a dis-
ease. Therefore, actually it is a form of care.[43] 
Approaching prevention at primary and secondary levels started with the Commission on 
Chronic Illness in 1957 and later, the tertiary prevention is added to them. In 1983, Gor-
don published a critique and an alternative classification. In his critique, he reminded that 
the classification of primary, secondary and tertiary prevention arose in an era when con-
cepts of health and disease were principally mechanistic [42]. In this way, this classifica-
tion seems to be in line with the reductionist approach dominant in that era, which as-
sumed ‘single cause -> single disease -> single treatment’, which was briefly introduced in 
Chapter 1. Primary, secondary and tertiary classification is mostly useful in responding to 
acute diseases because one can specifically tell the time of their onset. However, in chron-
ic complex diseases, the disease progression is gradual; one cannot tell the exact time of 
the onset of, for example, diabetes of a person. This creates a problem in differentiating 
‘primary’ and ‘secondary’ prevention. Moreover, for example, the end-organ damage 
already starts even before the onset of the diabetes; higher than normal blood glucose 
(not diabetic yet) initiates the end-organ damage. So, there is a continuum in develop-
ment of chronic diseases that is dispersed in decades, which cannot be captured by the 
classical reductionist approach.  
 
Chapter 8 
260 
With practical considerations that govern proper application of preventive interventions 
by health authorities, Gordon proposed an alternative ‘operational classification of dis-
ease prevention’. Here, ‘Universal prevention’ is a measure that is for the general popula-
tion regardless of the risk profile, ‘selective prevention’ is for sub-groups who have in-
creased risk, and indicated prevention is for individuals who have found to be at 
sufficiently high risk to require preventive intervention [42]. As Gordon’s classification is 
also about whom to approach individually and whom to approach collectively, based on 
the arguments conveyed earlier, it is not applicable to the case of a personalized health 
care model that aims to provide individual level prevention to the population at large. We 
need an approach that indicates the point and nature of intervention in the continuum of 
disease development, as depicted in Figure 2-a.  
If we look at our case of Gentest from the classical primary, secondary, tertiary prevention 
approach, we see that it has the potential to cover the whole prevention spectrum. The 
purpose of this practice model is prevention of the major complex diseases and their 
complications, within the whole continuum (from the point where there is no disease to 
the point where there is fully established disease). Based on the case it is applied to, it can 
serve as a primary, secondary or tertiary prevention tool.  
When implemented on a healthy individual, the practice model serves as a primary pre-
vention tool since it aims to prevent development of the disease. If there are no risk fac-
tors, the individual receives nutrition and exercise recommendations based on his/her 
health priorities with the practice model. 
If the disease hasn’t fully developed yet, but there is a progression to the disease and 
individual has properties that put him/her into a ‘risk group’; for example for diabetes 
such as the weight, waist circumference, age, some laboratory tests such as plasma glu-
cose and LDL-cholesterol; the practice model serves as a secondary prevention tool. It can 
also be considered as a ‘risk screening’ tool. 
If the disease has developed, then the practice model will serve to prevention of the com-
plications of the disease, such as prevention of cardiovascular and kidney diseases for 
diabetics. 
The extent of the benefits gained by the practice model is expected to diminish from pri-
mary towards tertiary prevention. Thus, it would likely be most beneficial for people with-
out disease, and help prevention of and/or delaying development of diseases. It would 
probably be less effective for individuals with risk factors, compared to people without 
any disease, but it is still very beneficial to manage their risks. The recommendations may 
help stopping the progression of or delaying the onset of the disease, such as diabetes or 
heart attack. For people with developed disease, the benefits would be less, compared to 
people without the disease but it is still a valuable tool to support the management of the 
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disease. With this practice model, for example, the primary care physician can see the risk 
of chronic kidney disease of a diabetic. For a cancer patient, the practice model will advise 
on diet during and after treatment. For a person with ischemic heart disease, the omega-3 
fatty acid need will be calculated. So, at whichever point the progression of the disease is 
caught by the practice model, it is beneficial, but, if the person would have got it done in 
earlier phases, it would have probably been more beneficial. 
It should also be noted that since the practice model Gentest has multiple diseases in its 
scope, it can be a primary prevention tool for disease A, while it is a secondary or tertiary 
prevention tool for disease B. For instance, for a patient with cardiovascular disease, it will 
serve as a tertiary prevention tool for cardiovascular disease whereas the nutritional ad-
vice will help for the primary prevention of cancer. Overall, it aims to prevent the onset 
and/or progression of the risk factors and diseases, in the whole continuum. 
Thus, this practice model serves to ‘personal health management’ of individuals with no 
health problem, ‘risk management’ of individuals with risk factors, and ‘disease manage-
ment’ of individuals with a manifested disease. As further tools that approach individuals 
in a comprehensive way for prevention of complex diseases emerge, the ‘primary, sec-
ondary and tertiary prevention’ terminology can be challenged and perhaps gradually 
replaced by the ‘personal health management’, ‘risk management’ and ‘disease manage-
ment’ terminology, which suits better to the case of prevention of chronic complex dis-
eases. The timing of these preventive approaches in relation to the ‘disease development 
curve’ is visualized in Figure 2-b. 
Until now, I proposed to revisit two concepts that can be regarded as ‘classical’ in preven-
tion. First one is that population based and high-risk individual prevention strategies are 
not the only options for prevention because with the introduction of tools such as Gen-
test, individual level interventions can be provided to large population groups. Secondly, I 
proposed that considering the continuum of development of chronic diseases, ‘personal 
health management’, ‘personal risk management’ and ‘personal disease management’ can 
be an alternative to primary, secondary and tertiary prevention classification. Although 
they are not traditional, they are still compatible with HFA, since these are different ways 
of ensuring to maintain and promote health, instead of providing solely disease oriented 
approaches.  
After reviewing of both concepts, it is seen that an ecological approach to health is re-
quired to address all relevant determinants of health with ‘tailored’ and/or ‘personalized’ 
practices. Health systems need to innovate to accommodate to this ecological approach. 
Instead of focusing on “one problem at one visit” in a reactive manner, the services should 
approach the individuals proactively and provide ‘tailored’ health promotion and preven-
tion interventions under integrated health management, risk management and disease 
management programs. Such personalized health care practices should cover the health 
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of the individual in a holistic way, rather than focusing on specific lifestyle or disease area, 
or starting at a certain level of progression towards the disease (such as practices that 
target only people with risk factors or only people with certain diseases). The use of tech-
nologies such as ICT will very soon allow us to provide such services to the whole popula-
tion. But, to enable that, health systems must move away from the dichotomy of ‘popula-
tion based vs. high risk individual’ interventions and embrace proactive personalized 
health care approaches that can target the whole population to manage each individual’s 
health, risk factors and diseases. 
The concept of ‘public health’ and place of ‘personal’ and ‘population based’ health 
services within ‘public health’ 
Chapter 2 (Part I) stated that ‘public health’ is a contested term and has different connota-
tions, mainly depending on the use of the word ‘public’. Some use it to refer to ‘public 
health services’, meaning either as ‘publicly provided health services’ as opposed to pri-
vately provided ones (such as public health insurance vs. private health insurance), or 
‘services provided to public, i.e. population, as opposed to the ones that are provided at 
the personal level. In either way, using the term public health to cover a set of services 
would make its scope narrow and demean it. Instead, we proposed, public health term 
must be defined and used in its broadest sense, i.e. “the attainment by all peoples of the 
highest possible level of health”, which is the objective of HFA, as well as the WHO as 
described in its Constitution. Thus, everything that relates to a society’s health should be 
categorized as a part of public health. This allowed us to frame every effort for health 
under the broad scope of ‘public health’, including health system, as well as the personal 
and population based services under it. The overall conceptual framework was called 
‘Health Globe’. 
Personalized health care practices, such as Gentest, will enable us to manage the health of 
all, or at least a large part of, the individual citizens of a particular society, thus reaching 
beyond the population versus individual controversy. Moreover, Health Globe considers 
all health interventions a part of ‘public health’. It uses this term in the broadest sense: 
everything that relates to a society’s health should be a part of public health, in the sense 
that they aim “the attainment by all peoples of the highest possible level of health”. Thus, 
developments in personalized health care would fit the Health Globe framework without 
any problems. However, if public health is used to cover only a set of services, positioning 
of an individual level intervention that targets large population groups, such as Gentest, 
would be disappointing because it will not make the fullest use of such practices and will 
miss a good opportunity to progress on the road to the long delayed HFA. 
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1.3.2. Back to basics: primary care services for prevention of chronic dis-
eases  
The earlier pages emphasized the importance of changing mindsets and adapting health 
systems to support potential solutions to reduce burden of chronic diseases. Nevertheless, 
in order to approach individuals within their ecological contexts in a comprehensive way 
and manage their health, risks and diseases effectively, there is one area where we need 
to go back to decades old recommendations: strengthening primary care services, while 
emphasizing the need for innovation there. 
Primary care is the most suitable line of health services to prevent chronic complex dis-
eases with a comprehensive, proactive and personalized approach [44]. Within the Health 
Globe framework (Chapter 2), health services were described in 9 levels of services. Per-
sonal health promotion, personal disease prevention, primary diagnostic and curative and 
primary care rehabilitative services were defined to be the services provided by ‘primary 
care services’ (Figure 4). Here, practice model Gentest can serve as a useful tool for per-
sonal health promotion and disease prevention services. 
Primary care services in their current form are not strong enough to provide services for 
prevention of chronic diseases effectively. Their strengthening has been among the rec-
ommendations of various major health policy documents since 1980s. It is known that 
countries with stronger primary care services have less rates of all cause mortality and all 
cause premature mortality, in particular mortality cause by chronic diseases [45]. The 
importance of primary care services was also emphasized in Chapter 3, in the context of 
the U.S. health system, which has a weak foundation for primary care, as compared to 
other high-income countries [46].  
To strengthen primary care services, we need to innovate and develop new models of 
delivery. This need is emphasized by various recent reports around the globe [44, 47-49]. 
They address the need for more proactive, preventive and personalized services provided 
by multidisciplinary teams, as are the needs of the overall health system. They also ask to 
approach individuals considering their social and ecological contexts. Among those re-
ports, a comprehensive view to primary care services was introduced by WHO in World 
Health Report 2008 under ‘people centered primary care’ [47]. The properties of this ap-
proach in comparison with conventional medical care and programs that are oriented 
towards controlling diseases are presented in Table 1. 
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Figure 4: Health Services Facade (Facade 1) of the health system pyramid within the Health Globe 
framework 
Primary care services are highlighted with a red circ le to emphasize where Gentest wi l l  be 
integrated.  
 
Table 1: Aspects of care that distinguish conventional health care from people-centered primary 
care 
 
Source:  Wor ld Health Report  2008: “Now more than ever”  [47] .  
Our practice model Gentest can potentially be a tool that supports and empowers ‘peo-
ple-centered primary care’ in many of the aspects listed in Table 1. These will be intro-
duced briefly below. 
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Focus on health needs: The mission of our practice model is to change the behavior of the 
individual and allow the primary care physician (general practitioner/ family physician, 
abbreviated as GP) to manage the health of the individual according to his/her priorities. 
This allows the primary care team and the individual to tailor the lifestyle and medical 
follow-up plans according to the individual’s health needs. 
Enduring personal relationships: At a first glance, it might look counterintuitive that the 
practice model may improve ‘relationships’, since the Gentest report will be produced by 
software and will be communicated, partly, via computers. However, if used effectively by 
the primary care providers, it actually may provide a communication ground on the per-
sonal conditions and various lifestyle habits of the individuals.  
Comprehensive, continuous and person-centered, as opposed to program-defined ‘dis-
ease control’ interventions: Programs that focus on prevention of chronic diseases have 
been mostly following a model orientated towards a single specific health issue. Each 
major disease or risk condition has been seen as the starting point for the development 
and implementation of a specific prevention program, separate from other diseases or 
conditions and therefore known as a vertical program
3
. These vertical programs are thus 
not integrated and this is reflected in the multiplicity of chronic disease prevention initia-
tives that do not necessarily relate to one another. However, integrated approaches are 
needed to maximize the benefits of investing in prevention and lead to more effective 
results. [50] 
Our practice model may serve as a powerful approach to integrate the prevention efforts 
in primary care services, with a focus on the diseases and risk conditions that cause the 
highest burden in the society. Instead of running separate programs such as cardiometa-
bolic risk assessment and management, healthy nutrition (for example increasing fruit and 
vegetable consumption), smoking cessation, and physical activity and exercise, a single 
tool can be used to help manage main lifestyle factors and disease risks. If integrated as 
envisaged in the ideal case, i.e. by becoming an integral part of the health records of the 
individual and with the follow-up program, it can become a tool for the GP to manage the 
health of people that are registered to his/her practice in a continuum.  
People are partners in managing their own health: The participation of the individuals in 
the follow-up program with online tools is likely to empower and engage individuals to 
take control of their health.  
                                                                
3
 Vertical programs reflect the ‘combating disease paradigm’, which was the focus of public health 
interventions in the last century, in particular the period before the HFA approach was introduced 
(see sub-section 1.1 in this chapter and Chapter 2). 
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As seen above, the practice model can be a useful tool for the primary care services to 
provide the ‘people-centered’ care, as envisaged in the World Health Report 2008. On the 
other hand, accommodating to host personalized health care practices such as our model, 
might help primary care services evolve towards a ‘people-centered care’, signifying the 
‘co-evolution’ of the system and the practice (Figure 1). 
It is of note that in the recent years, publications have started emerging in the literature 
for reporting implementation of cardiovascular risk assessment and management pro-
grams in primary care services as personalized preventive interventions [51-54]. This also 
shows that there is need for timely and valid introduction of Gentest into primary care 
services. 
At this point, it is important to note a perception of primary care to be often seen synon-
ymous with simple and low-tech services provided by not so skilled professionals, particu-
larly in case of low-resourced settings/ low income countries. This is a dangerous oversim-
plification, as the World Health Report 2008 warns [47]. As the primary care services are 
strengthened, their resources, i.e. infrastructure, human resources and knowledge, also 
need to be improved and developed. In terms of the costs, what matters should not simp-
ly be the cost of the intervention, but the health gains achieved with the costs, i.e. cost-
effectiveness. ICT can provide important tools that help to improve efficiency and effec-
tiveness in primary care. As the cost of genomic technologies is rapidly decreasing, their 
usage may become cost effective in population wide strategies.  
1.3.3. Properties of health systems that would better facilitate the integra-
tion of a preventive personalized health care model 
Chapter 7 proposed a systematic approach to assess how the practice model Gentest can 
be integrated into a health system. For this purpose, 24 areas of assessment, as well as 
numerous issues and criteria under them, were identified. Additionally, examples from the 
Netherlands and the UK, as well as other relevant European settings, were provided to 
illustrate these areas. This work also included several directions important to answering 
the question ‘What kind of health systems would better facilitate the integration of this 
practice model?’. The answer to the question that was already covered in Chapter 7 will 
be summarized here in a more explicit way. 
 Progress in the paradigm shift 
As highlighted in Chapter 1, as well as the first pages of this chapter, health systems need 
a paradigm shift from reactive, disease oriented, acute diagnostic and curative services 
focusing on medical services towards proactive, preventive, health oriented, focused on 
chronic cure and care covering the whole spectrum of health care. This also calls for an 
ecological approach to health, which aims to understand and tailor the services according 
to the context of the individuals. Our practice model provides an example to this new 
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paradigm. It approaches individuals in a comprehensive manner and aims to cover a wide 
range of determinants of health. It aims to prevent the development and progression of 
chronic diseases in a proactive way.  
For successful integration, the health system that will host the practice model should al-
ready have started its transformation towards the new paradigm, or at least have strong 
willingness to do so.  
 A strong primary care system and its scope in terms of (primary) prevention  
A strong primary care system with a good focus on prevention is a prerequisite for its 
effective integration. If the GP is not a ‘gate keeper’ in the health system, its effectiveness 
is very likely to be diminished. If the GPs don’t have the mandate to manage the health of 
the individuals, don’t have prevention among its tasks, and focus only diagnosis and 
treatment (reactive approach), their willingness to implement it in their practice would 
probably be low. Countries with weak primary care services wouldn’t be a suitable place 
for implementation of the practice model, unless it is considered to be embedded within a 
program on restructuring and strengthening of primary care services. 
Thus, a strong primary care is a prerequisite, but its not enough. Primary care should also 
have a mandate towards preventing chronic diseases, and not focus only on medical inter-
ventions, i.e. but also be ready to embrace to providing lifestyle interventions. 
 Financing system towards awarding outcomes 
The financing system should be more towards awarding health outcomes, rather than 
processes or outputs, so that the GPs can be incentivized with the possible health gains 
due to the practice model. 
 The positive environment towards change 
Integration of the practice model will require changing of conventional mindsets in the 
health system. As raised in earlier sections of this chapter, classically, interventions for 
primary prevention of chronic diseases have been assumed to target the population level. 
As covered earlier, the practice model challenges this approach by providing individual 
level services for primary prevention, while still targeting the whole population. Thus, to 
understand the model and make an informed decision on its integration, the stakeholders 
and health authorities will first need to ‘think out of the box’.  
Moreover, reorganization and redesign of preventive services in primary care will highly 
likely be required for successful implementation of the model, signifying the importance 
of ‘co-evolution’ conveyed in Figure 1. It also requires change management and, to some 
extent, social engineering focusing on health sector. Thus, the attitude and openness of 
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the health sector as a whole towards innovations is an important factor in the integration 
of the practice model. 
In some cases, there might be willingness to attain the paradigm shift and integrate the 
practice model to the health system, but the system might not be in the desired status. In 
these cases, the practice model can also be used as one of the vehicles to carry out the 
desired transformation. For example, if the country doesn’t have a strong primary care 
system, but there is a willingness to transform towards that, our practice model can be 
embedded within a program on restructuring and strengthening of primary care services. 
Such cases would create concrete examples of the co-evolution of the health system with 
a personalized health care practice (Figure 1). 
Overall, the example of our practice model indicates that developments in the field of 
personalized medicine and health care will have a profound effect on how services are 
delivered, and could eventually lead to service redesign and reorganization. Such applica-
tions may actually be used as a practical opportunity to realize the paradigm shift required 
in the health services, i.e. towards services that are proactive, health oriented, focused on 
chronic cure and care covering the whole spectrum of health care. This means, the health 
system and the personalized health care innovations need to evolve together, leveraging 
one another (Figure 1) towards the goal of ‘attainment by all peoples of the highest possi-
ble level of health’, i.e. HFA. 
1.4. Innovations for personalized health care in light of health sys-
tems 
In sub-section 1.2, the co-evolvement concept was introduced: health systems must inno-
vate to better host ‘personalized’ practices and ‘personalized’ practices must innovate to 
better fit into the health system context (Figure 1). In line with it, the previous section 
looked at the potential areas of innovation for the health system. Now, it is turn of per-
sonalized medicine and health care to feed into co-evolvement introduced in Figure 1. The 
first heading of this sub-section will briefly discuss how ‘personalized’ practices should 
innovate to serve to the goal of HFA. Then, the room for innovation for a specific personal-
ized health care model (Gentest) will be presented.  
Chapter 4 provided examples of personalized practices from USA, France and Taiwan to 
show how health system context matters when it comes to their integration into health 
services. Chapter 7 took it further and provided a systematic approach to identification 
and assessment of integration issues. The last heading in this sub-section will provide 
additional argumentations to emphasize why the field of personalized medicine and 
health care needs to be aware of the importance of the health system context to reach 
successful integration of the tools they are developing, into health systems. 
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1.4.1. The need for innovation for ‘personalized’ practices 
Just like health systems, personalized practices also need to innovate towards proactive, 
preventive, health oriented, focused on chronic cure and care covering the whole spec-
trum of health care, to serve to the goal of HFA. But, how can they do that?  
To understand which direction ‘personalized’ practices should innovate towards, we need 
to understand what ‘personalized’ practices are. Chapter 4 presented a study that identi-
fied 88 ‘personalized practices’ in the scientific literature with a systematic search and 
inclusion strategy, and analyzed their content. The results showed that ‘personalized’ 
practices by no means are a homogeneous group that can be described in a standard way. 
They contain different practices (commodities in health care market or implementation 
models on how health services are provided), with various purposes (prevention, early 
detection, diagnosis, treatment, prediction of prognosis, etc.) and serving different groups 
(individuals/patients, health professionals, health care organizations, etc.). To ‘personal-
ize’ medicine and/or health care, some of them focus mainly on technologic aspects, such 
as genomic technologies or ICT, while some of them only use behavioral aspects. In par-
ticular, many of the ones that used genomic technologies to ‘personalize’ the services 
focused on a test (which may include single or multiple markers) that leads to a specific 
decision in medical processes such as using a drug or not, without taking into account 
other determinants of health. This reflects a ‘single test -> single intervention’ understand-
ing. Chapter 1, pointed that an earlier reductionist approach in medicine and health care 
assumed ‘single cause -> single diseases -> single cure’ [55], and emphasized that health 
systems must transform towards a  more proactive one that takes a holistic and integra-
tive approach towards health and disease. The ‘single test -> single intervention’ couples, 
in a way, also exhibit a similar understanding in the sense that they try to reduce the com-
plexity of health and disease into a single test and single intervention. Is that the ‘person-
alization’ we’d like to achieve? Is every ‘test’ that uses the genome based information of a 
person means ‘personalizing’ medicine and health care?  
As was conveyed in Chapter 4, excessive technological focus, in particular for genome-
based technologies, might actually be hampering the progress towards ‘personalization’ 
vision for two reasons. First of all, it creates attribution of currently unfulfilled expecta-
tions of genomic medicine to the broader application of ‘personalization’ vision. Secondly, 
as also raised in Chapter 5, genomics is one of the components, but it is not the only factor 
that makes individuals unique or medicine/ health care personalized.  
However, focusing on only ‘non-biological’, or behavioral factors to ‘personalize’ health 
and health care would also not be a truly holistic approach, since, as suggested in Figure 3, 
all levels including biology, psychology and social and ecological context interact. 
Within the ‘personalization’ vision, it is very important to realize that ‘personalization’ can 
only be achieved when we understand and use the individual contexts in a holistic way, 
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rather than focusing on a single factor, be it high-tech or low-tech, biological or non-
biological. Each person is unique within their own context that is constituted by multiple 
(levels of) determinants of health, as presented in Figure 3. To truly personalize health and 
health care, we need to develop comprehensive approaches that take this unique context 
into consideration. This means, personalized health care practices should ideally consider 
all available/possible determinants of health that can be used for a specific purpose, as 
shown in Figure 3. By careful analysis of each case, it can be possible to identify which 
interventions might be most effective for the individual context. Moreover, instead of 
thinking merely in singular interventions, multiple ones should be provided, as much as 
possible, in an integrative manner towards the desired effect. All these call for being com-
prehensive in terms of the integrated bio-psycho-socio-ecological approach to health, 
while personalizing and integrating the health care. 
If we look at the 88 practices identified for the study in Chapter 4, it is seen that only a 
limited number of them involved multiple determinants of health, and among them, only 
a handful had some sort of holistic approach towards health, which considered the unique 
context of individuals that are constituted by multiple (levels of) determinants, at least to 
a certain extent, and claimed to provide multiple interventions for them [56-62]. This 
shows that, just like health systems, personalized medicine and health care innovations 
also need to work hard to evolve towards a holistic, comprehensive and integrative ap-
proach to personalize health care. 
1.4.2. Innovation to adapt to target countries and health systems 
‘Personalized’ practices need to continue to innovate in order to adapt to the needs and 
conditions of the health system. Thus, as was introduced in Chapter 4, innovation does not 
follow a simplified linear process or a ‘pipeline’, which ends when the ‘product’ is out in 
the market. ‘Personalized’ practices and the health systems continue to co-evolve (Figure 
1). 
Gentest was developed and is currently provided in Turkey as a service to individuals who 
are willing to get it and are eager and able to pay for it. The way it is implemented in Tur-
key has been briefly described in Chapter 6. But, how can that be a part of primary care 
services? How would it be implemented there? To help us imagine that, a brief vignette is 
presented in Box 1 on a fictitious individual and a primary care setting. 
Box 1: Vignette for the practice model implemented in a primary care setting 
Mr. Yilmaz, who is a 50-year-old man, receives a letter from his GP to participate a new 
health check, with some leaflets. He reads that this check will evaluate him 360 degrees 
with his personal health information, lifestyle factors (nutrition, exercise and smoking), 
body composition, genetic structure and other biomarkers (cholesterol, glucose, etc.). He 
is asked to devote a good two hours’ time for the first appointment, as it involves filling in 
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a detailed online questionnaire with team of his GP. He should also drop by another time 
after an overnight fasting to give blood and urine sample. He makes an appointment to do 
both on Monday morning. For more information, there is a brochure he is encouraged to 
read until the appointment. 
On Monday morning when he goes to the GP, he is taken to a room where he watches a 
video of about 10 minutes that explains all the procedure, what the results will tell and 
how they will look like. This is in line with the information in the brochures. Then, the 
nurse practitioner comes in to ask him if he has any questions. After answering his, it is 
the nurse’s turn to ask him questions to validate that he understands the procedure. Then, 
he reads and signs a consent form. 
The nurse draws blood (for conventional biomarkers and genetic testing) and then makes 
several measurements, including weight, height, waist circumference, fat ratio (bioimped-
ance measurement), pulse and blood pressure. Afterwards, he sits in front of a big screen 
computer to fill in a detailed questionnaire including these areas: 
• Personal data 
• Medical history 
• Family history 
• Living and working conditions 
• Physical activity and exercise 
• Smoking and drinking habits 
• Supplement consumption 
• Nutritional habits 
• Food consumption  
 
While filling in the food consumption data, he answers the questions using the photo-
graphs on the portion sizes of different food items. He is also offered a choice to make a 
record of all he eats for three days using an app for his smartphone. At the end of the 
appointment, he is curious what will come as a report. 
The information retrieved today will be an integral part of Mr. Yilmaz’s patient profile and 
thus, his GP will use the inputs, as well as the report he will get, to manage his health and 
any upcoming disease. 
The information collected, including the measurements and questionnaires, goes to a 
central server. The blood sample is analyzed in a local laboratory for conventional bi-
omarkers, whereas an additional tube goes to a central lab for genotyping. Results of 
these tests also go to the central server. 
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Figure 5: Images from the food portion size atlas 
All the data is processed to produce a ‘health check’ report in the central server. Here, his 
current status in terms of body composition, nutrition, exercise, smoking (including causes 
of smoking), health information (including blood pressure, pulse, and laboratory test re-
sults), and genetic markers are summarized. Then, risk assessments for most common 
chronic complex diseases are presented. These include myocardial infarction, stroke, type 
2 diabetes, osteoporosis and most prevalent cancers (lung, breast, prostate, colon and 
stomach). This includes the current status of his risk profile, as well as potential decreases 
if he adopts the optimum lifestyle and medical follow-up plan. The report of an individual 
includes the results of the analysis and an optimum lifestyle plan developed for this indi-
vidual. It includes a plan for reaching and/or maintaining optimum body composition, 
menu plans and exchange lists, a supplement plan, and an exercise plan. Personalized 
smoking cessation recommendations are given based on the individual causes of smoking. 
Recommendations are given for medical follow-up with personalized screening plans. Each 
report can be checked and modified by the GP, if she deems necessary. 
In the 4 weeks period when his report is prepared by the central server, Mr. Yilmaz goes to 
a seminar organized by his GP practice. They are offered once every week to all people 
who are participating the ‘health check’. The seminar covers various topics needed to 
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understand the results of the report, such as how genetic structure interacts with lifestyle 
factors, what ‘risk’ means for different diseases, how they are calculated, why healthy 
lifestyle is important for healthy and long life, etc.  
When his report is ready, Mr. Yilmaz is invited to visit his GP for an hour. At the appoint-
ment, he first shortly visits his GP, who presents his printed report to him. She provides an 
overview of the results to Mr. Yilmaz and any issues that have medical significance. With 
his report, he then moves to another room to meet with the nurse practitioner to talk 
about optimum lifestyle and medical follow-up plans in more details. The nurse makes 
some modifications in the lifestyle plan according to his wishes and possibilities. 
Since he doesn’t have serious risk factors (such as obesity or other risk factors that require 
a more intensive lifestyle program), his follow-up visit with the nurse practitioner is 
planned for 6 months later. Meanwhile, he can record his food consumption and exercise 
online to see if he is reaching his goals. He can use a smartphone app for these too. Never-
theless, he can call or take an appointment from the nurse when he has questions, or 
contact her online, which might be more practical.  
This vignette presents very briefly how one can imagine Gentest taking place in a primary 
care setting. While reading it, one would start asking several questions on how things 
should be arranged, such as the data collection and storage, ethical issues, the role of 
different personnel working in a GP premise, how they will be trained, the additional 
workload that will come with such an application, the required infrastructure, how the GP 
will be paid for this, if the GP (and the individuals) would like to implement it, etc. The 
answer to them, and several more, would depend on where it will be used/ practiced. 
That’s why, a systematic approach was proposed in Chapter 7 to identify and assess these 
issues and others.  
In the example of our practice model, the health system context will probably need to 
innovate to be able to host it and yield most effective results. On the other hand, the prac-
tice model also needs to innovate to adapt to the specific setting. Simply translating the 
questionnaire and reports will definitely not be enough. For example, the tools used to 
measure lifestyle need to be adapted for each target country. For each country or group 
of countries, new nutritional questionnaires and food portion size atlases must be devel-
oped, or adapted from already existing ones. As it needs to be optimized at primary care 
settings, the current questionnaire will probably needed shortening, as well as the report. 
For standard information that the individual needs to use to understand their reports, 
educational videos can be prepared to save the time of the staff at the primary care set-
ting. Seminars can also be carried out in certain days of the month to convey such stand-
ard information. Further tailoring of reports for different health literacy levels might be 
considered. Most importantly, the knowhow behind the practice model needs to be trans-
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lated into a fully operational software to enable its ‘mass production’ in large population 
groups.  
As any other intervention, our practice model also needs to be revised and accommodat-
ed to use the latest developments in the scientific and technological fields involved. The 
advantage of the practice model is that its components can be updated while maintaining 
the integrative approach behind it. The main innovation lies in the comprehensive ap-
proach that takes the health and behavior of the individual as a whole. So, instead of hav-
ing separate programs for healthy diet, exercise, smoking cessation, etc. in terms of life-
style, and cardiovascular risk management, diabetes risk management, cancer risk 
management in terms of diseases; this practice model can be implemented as a single 
program to manage the health of individuals in primary care services. 
The update would involve contemporary approaches in all relevant fields, including ge-
nomics, lifestyle assessment methods, lifestyle interventions, in particular the ones devel-
oped with ‘tailored’ approach in health promotion and education, disease risk assessment, 
screening and follow-up guidelines, and many others. 
It is of note that effectiveness and cost-effectiveness of the practice model hasn’t been 
demonstrated yet. Chapter 6 stated that designing and conducting a study that would 
collect data on the effectiveness of the model was envisaged after its pilot. However, due 
to external conditions and constraints of the funding environment in Turkey, it was not 
possible to carry it out. For the case of integration of Gentest in Europe, after the adaption 
and update, as summarized above, the next step needs to be a pilot and, then, evaluation 
study in a country where there is willingness to integrate this practice model. Medical 
Research Council of UK provides valuable guides for evaluation of complex interventions, 
such as our practice model [63-65]. Since this practice model is not only a complex inter-
vention but also one that require service re-design and re-organization while it is integrat-
ed, the pilot and evaluation sites will need to go through important changes in their organ-
ization and service delivery. As we’ve briefly listed above, the practice model also needs to 
evolve, to accommodate to the specific case of the health system, leading to their co-
evolution (Figure 1). Thus, the results of the evaluation would depend on not only the 
intrinsic qualities of the practice model, but also how well the context is adopted for its 
integration. Therefore, the pilot and evaluation process would probably not only evaluate 
the practice model, but also the whole co-evolved program with newly designed services 
and organization to a large extent.  
A strategy to facilitate decision-making could be to pilot the program in which the practice 
model is implemented in a limited geographical area, and then, to gradually expand to-
wards a larger area as the collected data indicates favorable results. The short-term evalu-
ation could be made on surrogate markers and as decisions are made for gradual expan-
sion, long-term outcome data would become available. Since it will not be possible for 
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decision makers to have conclusive decisions while on surrogate markers, an option for 
financing would be ‘access with evidence development’, or in other words, conditional 
coverage [66]. This is a reimbursement policy option that go beyond the traditional ‘yes’, 
‘no’, or ‘yes with restrictions’ options. ‘Access with evidence development’ models serve 
to promoting research and development [67], while reducing the risk for the health sys-
tem payers.  
In the further future, data generated with this population wide application in primary care 
services can create a feedback loop to research with large amounts of data (‘big data’), 
providing valuable insights to health and diseases. The mining of this data can help to 
better define health and disease, discover who is more likely to respond to which lifestyle 
interventions and develop more accurate risk assessment tools. 
1.4.3. ‘Personalized’ practices in health system contexts 
Chapter 7 reported that the documents, reports and discussions on integration of ‘per-
sonalized’ practices into health services mostly focus on diagnostics and pharmaceuticals 
and provide a bullet list of ‘barriers’ or ‘challenges’ that need to be overcome to deliver 
personalized medicine and health care to the society. An important point here is to realize 
that the problems of the health systems are actually reflected in those reports and discus-
sions in a profound way. What would happen if we remove the words ‘personalized med i-
cine’ from the titles of the lists of ‘barriers’ or ‘challenges’? It is highly likely that those 
‘barriers’ will hold valid for any innovative practice introduced in those health systems, 
because those ‘barriers’ are probably the weaknesses of the system in its wider context, 
not specific to the ‘personalized’ practices. However, the field of personalized medicine 
and health care, which mostly consist of people from science and technology domains, 
spend considerable effort to find solutions to them while preparing those documents, as 
well as at various meetings, conferences, etc. At this point, it might be wise to turn to the 
field of health systems and policies to understand the underlying reasons and develop 
solutions to those problems, as was done in this dissertation. 
Chapter 4 gave the example of USA, France and Taiwan as very different cases of imple-
menting ‘personalized’ practices in countries. Chapter 3 summarized the problems of the 
U.S. health system in comparison to other high-income countries, independent from the 
purpose of integrating ‘personalized’ practices: low effectiveness, low efficiency and seri-
ous problems with inequity [46, 68-70]. As can be seen in Chapter 4, these problems have 
a profound effect on how ‘personalized’ practices are implemented in the USA.  
Leroy Hood, an important opinion leader who has been pushing the field of personalized 
medicine and health care forward for more than a decade proposed that P4 medicine (a 
form of personalized medicine/ health care) would eventually lead to a universal democra-
tization of health care by increasing the effectiveness of preventive and curative interven-
tions, and reducing the costs, thus lessening the social and financial burden of diseases 
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[71, 72]. Indeed, as conveyed earlier in Figure 1, personalized health care can be used as a 
tool to innovate health systems. However, while envisaging that, there are two important 
issues that need to be taken into account. 
First of all, in line with the ‘co-evolution’ concept presented earlier (Figure 1), personalized 
practices can help to transform health care and, thus, the health system, but alone, they 
cannot change the inherent weaknesses of a health system. Those weaknesses must be 
recognized and targeted with structural reforms, such as the ones recommended for the 
USA in Chapter 3. The other way of looking at the issue is probably also true. A strong 
health system, i.e. an effective, efficient and equitable one, will probably integrate innova-
tions more easily and effectively. For example, in the example of France in Chapter 4, we 
see that France, whose health system satisfies these conditions to a large extent, has 
achieved implementation of a country-wide program for cancer genomics. 
Secondly, if ‘personalized’ practices are to be used for transformation of a health system, 
a systematic approach towards health system must be taken. The one developed and 
presented in Chapter 7 is an example to that because it can also be used to map where 
our practice model can be used to facilitate the paradigm shift in the health system, as 
well as to pinpoint the underlying problems which probably cannot be overcome while 
integrating the practice model. 
All in all, the field of health systems and policies has much to offer to the field of personal-
ized medicine and health care to have a comprehensive approach to integration of ‘per-
sonalized’ practices. As raised in Chapters 4 and 7, effective communication, collaboration 
and interaction among different fields are crucially required to reach a more personalized, 
predictive, preventive and participatory health care. 
2. Methodological considerations  
Present research took place in a changing environment of the personalized medicine and 
health care field and was fed by the new emerging dimensions and visions. In addition, 
there have been no specific examples on analysis of integration of preventive ‘persona l-
ized’ practices in health systems. Therefore, rather than having a fixed PhD roadmap, this 
research evolved gradually and each stage of the research brought new questions and 
dimensions to address in the next stage(s) in order to meet the dissertation aim effective-
ly. Some chapters evolved together, such as Chapter 7 and this chapter of General Discus-
sion. Therefore, many of the concluding remarks were already highlighted in Chapter 7 
against the recent literature. In this section, I will reflect on my PhD journey retrospective-
ly.  
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This journey started with the practice model Gentest, which I used as my vehicle. It helped 
to keep the research focused on a real life example, rather than floating on hypothetical 
cases or generic uses of genome based knowledge and technologies.  
In this sense, the research approach used in this PhD is broadly in line with constructive 
research approach that is mainly seen in business administration and accounting, as well 
as engineering fields. Constructive research aims “…producing innovative constructions, 
intended to solve problems faced in the real world and, by that means, to make a contri-
bution to the theory of the discipline in which it is applied.” [73] It can be regarded as a 
specific approach under ‘case study method’ in social sciences. The critical point here is to 
focus on a real world problem and by doing that developing theoretically grounded solu-
tions for practical purposes.  
 
Figure 6: The central elements of the constructive research approach  
Source:  ‘What is  a constructive research approa ch? ’  by Lukka [73] .  
The PhD research didn’t follow the specific process of constructive research, which had 
been described in particular for business administration and accounting field in a step-by-
step manner [73]. Nevertheless, looking at my research retrospectively, I see that the 
approach used in this dissertation is generally in line with several central elements of con-
structive research (Figure 6). The starting point of this research was a real life problem 
(integrating Gentest to health systems) that is relevant to be solved in practice (the case is 
introduced in its larger context in Chapters 4-6) and produced an innovative construction 
to solve the initial world problem (as proposed in Chapter 7), which is linked to prior theo-
retical knowledge (Chapters 2 and 3) and has the potential to contribute to the theory in 
this field (Chapter 7). 
 
Chapter 8 
278 
Use of a real life case example has been a very useful approach in this PhD research. First 
of all, it would not be possible to address ‘integration’ issues of all potential health care 
practices that are linked to personalized medicine and health care with a single approach. 
As seen in Chapter 4, the practices presented under personalized medicine and health 
care are very heterogeneous. There is no unified definition for them, nor a classification 
can be made using conventional frameworks. It is not possible to reach a solution that 
applies to all these diverse practices in a uniform way. Therefore, this research had to take 
a concrete case example.   
Secondly, starting the PhD research with a real life example and its problem, i.e. integra-
tion into health systems, enabled the research to be more concrete, down to earth and 
practice oriented, rather than being theoretical. 
Thirdly, while trying to solve the integration ‘problem’ for our practice model, we’ve de-
veloped a systematic approach that might be useful for other ‘personalized’ practices, as 
well as the innovations in health care in the broader sense. Using health systems frame-
work to approach integration issues in a systematic way is an innovative solution and has 
also the potential to contribute to the theory in this field.  
3. Main conclusions 
This dissertation took a journey involving health systems and policies, prevention of 
chronic diseases, and personalized medicine and health care. Main conclusions also span 
in these diverse fields. 
- The ‘Health for All’ (HFA) vision, i.e. “the attainment by all peoples of the highest 
possible level of health”, still hold valid and provide a coherent overarching frame-
work to the overall goal of public health. Public health is what we do to reach this 
goal. Since a health system is the main actor that serves to this goal, but not the only 
one, it is a part of ‘public health’. 
- To reach HFA vision, health systems must shift from being reactive, disease oriented, 
focusing on acute diagnostic and curative services with medical processes towards 
proactive and health oriented services focusing on prevention as well as chronic cure 
and care, covering the whole spectrum of health care (not only medicine). 
- Personalized health care offers important opportunities to combat the increasing 
burden of chronic complex diseases while serving to the required paradigm shift. 
- Innovations for personalized medicine and health care, and health systems and poli-
cies need to co-evolve, adapting themselves to the needs of each other while lever-
aging one another. 
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- For successful integration of personalized health care practices, issues related to in-
tegration needs to be approached systematically, not in a piecemeal way. Health sys-
tem frameworks can provide the required analytical frameworks to identify and as-
sess issues related to integration of those practices. 
- ‘Personalized’ practices are not a homogeneous group. They contain different prac-
tices (commodities in health care market or implementation models on how health 
services are provided), with various purposes (prevention, early detection, diagnosis, 
treatment, prediction of prognosis, etc.) and serving different groups (individu-
als/patients, health professionals, health care organizations, etc.). Therefore, it is 
necessary to focus on a specific case when aiming to identify integration issues.   
- For successful integration of personalized health care practices such as Gentest, we 
need to overcome some traditional boundaries in terms of our approach to preven-
tion. 
- As in the whole health system, primary care services need to innovate to attain the 
HFA vision, towards the required paradigm shift, and to better host personalized 
preventive practices.  
- ‘Personalization’ means providing a comprehensive approach to the individual within 
his/her unique context. 
- Personalized practices such as Gentest also need to innovate to adapt to the health 
system where it will be integrated. 
- An effective dialog among the fields of personalized medicine and health care and 
health systems and policies may facilitate better and faster integration of ‘personal-
ized’ practices into health systems. 
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This dissertation aimed to explore how a personalized health care model, such as Gentest, 
can be integrated into primary care services in European health systems for prevention of 
chronic diseases.   Thus, the main question of the dissertation is ‘how to integrate?’, not ‘if 
to integrate?’. It is indeed a crucial point to know if this practice model is worth integrat-
ing. However, evaluation of the content of Gentest wasn’t covered in the scope of the 
dissertation, since it requires other research questions and a project that runs with dedi-
cated funds. Moreover, it is not feasible to answer both questions at a single dissertation. 
The starting point of this dissertation was that Gentest had been piloted in Turkey and 
identified as a best practice model by Public Health Genomics European Network. 
However, readers of this dissertation will probably have several questions raised in their 
minds about what Gentest is and how it has been implemented in Turkey. Main properties 
and practice principles were already covered in Chapter 1 - Introduction and Chapter 6, 
the paper dedicated to Gentest. This appendix complements them with additional infor-
mation in order to help the readers of this dissertation get a better picture on what Gen-
test is and what it is not. Particular attention was paid to cover the answers to the most 
frequently asked questions at scientific and technological platforms where Gentest was 
presented. (Main occasions where Gentest was presented were mentioned in Chapter 6 
and a list of additional presentations is provided under 'List of publications and presenta-
tions' section).  
This appendix contains two sections. First one is a summary of the timeline for develop-
ment and implementation of Gentest. Then, a SWOT analysis for Gentest, which was orig-
inally carried out for another project, is presented. 
1. A summary of research, development and implementation 
history of Gentest 
GENAR Institute for Public Health and Genomics Research was founded by Serdar Savas, 
MD and Gentest was conceived and developed under his leadership. The story of devel-
opment of Gentest dates back to 1998-1999 when Dr. Savas was serving World Health 
Organization Europe as the Director for Programme Management / Deputy Regional Di-
rector in Copenhagen. During those years, he realized that developments in genetics could 
lead to solutions for the burden of chronic complex diseases. Then, he started monitoring 
scientific developments in genetics and exploring how these can be used for prevention of 
chronic diseases (idea development phase, 1998-199). 
In 2000, Dr. Savas returned to Turkey and established BSS – United Health Systems consul-
tancy, where he started planning for a center working on prevention of chronic diseases 
using genetic technologies, as well as inputs from other disciplines (planning phase). After 
the preparations, in 2004, it was established in Hacettepe University Science part as 
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‘GENAR’, which was a privately funded research facility (small and medium size enter-
prise/ SME). Its first unit was ‘GENAR Laboratory for biotechnology and Molecular Genet-
ics’. At the time of its establishment, GENAR Laboratory was the highest throughput geno-
typing laboratory in Turkey. Later, GENAR Center for Nutrigenetics and Lifestyle Research 
and GENAR Center for Personalized Medicine and Pharmacogenetics joined to the Labora-
tory, and all became “GENAR Institute for Public Health and Genomics Research”. In those 
years, GENAR was the third center working in Europe on the newly developing concept of 
public health genomics. The author of this dissertation, Tomris Cesuroglu, MD, served as 
the Research and Development Coordinator of GENAR Institute. 
GENAR carried out various projects funded by national and international research and 
development funds, such as Framework Programme 6 of the European Commission and 
the Scientific and Technological Research Council of Turkey (TUBITAK). A major output of 
the research and development efforts of GENAR has been the practice model Gentest. It is 
a personalized health care practice that aimed to prevent common chronic diseases in 
primary care settings. It approaches health in a comprehensive manner and utilizes indi-
viduals’ personal health information, detailed lifestyle analysis, body composition, geno-
type, and other biomarkers in order to prevent the onset or progression of major chronic 
diseases in a targeted way. [1, 2]  (Research and development phase 2004-2008) 
In 2008, Gentest was identified as a ‘Best Practice Model’ for public health genomics in 
Europe by the Public Health Genomics European Network (PHGEN I), based on the charac-
teristics of the practice model being comprehensive (containing various factors such as 
personal, medical, lifestyle and genetic information), multidisciplinary, prevention orien-
tated and implemented through health professionals [3]. It was piloted by authorized 
practitioners (physicians/or dieticians) as a service to 500 individuals in 2008-2009. At that 
period, the model was mainly practiced in the Gentest Implementation Center, which was 
run by GENAR. Genotyping was carried out at GENAR’s high-throughput genotyping labor-
atories. After the pilot, designing and conducting a study that would collect data on the 
effectiveness of the model was envisaged, as conveyed in Chapter 6. However, due to 
external conditions and constraints of the funding environment in Turkey, it was not pos-
sible to carry it out. (Pilot implementation phase 2008-2009) 
After completion of the research and development phase of Gentest, GENAR has closed 
down its facilities at Hacettepe Science Park, as well as its Gentest implementation center 
in 2009. Since then, Gentest has been continued as a service provided through a number 
of authorized practitioners (physicians) in major cities in Turkey. Individuals who would 
like to get the Gentest pay for the service out-of-their pockets. The genotyping services for 
Gentest are purchased from a third party laboratory. (implementation phase since 2009) 
Based on the current trends and developments in the world (such as demographic and 
epidemiologic transition and the need of health systems to reduce morbidity, mortality 
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and costs related to complex diseases), feedback of scientific and industrial communities 
on the model, and past experiences with Gentest, it was identified that the main imple-
mentation area for such a preventive health care product would be wide spread popula-
tion based approaches where Gentest is provided via primary care services in Europe.  
Towards this vision, Tomris Cesuroglu received a Marie Curie Fellowship from the Europe-
an Commission under Framework Programme 7. During her fellowship, she worked at the 
Institute for Public Health Genomics at Maastricht University to carry out the project “P4-
MEDICINE@EU” Evaluation of a Best Practice Model (Gentest) for Personalized Health Care 
within Public Health Genomics” (2011-2014). Within the P4-MEDICINE@EU project, among 
other tasks, she did an extensive literature review and carried out semi-structured inter-
views with various opinion leaders and experts around the world to explore opinions and 
topics regarding the implementation of personalized health care. This dissertation was 
carried out independent from the Marie Curie project and the interview data wasn’t used 
for the articles of this dissertation. Nevertheless the overall fellowship process, including 
the literature review, the interviews and the conferences attended, helped her to gain 
valuable insights to the various topics in the field of personalized health care. 
2. SWOT analysis of Gentest 
Among the various tasks of the above mentioned Marie Curie project (P4-MEDICINE@EU), 
a SWOT analysis was carried out. This aimed to assess the strengths, weaknesses, oppor-
tunities and threats of/for the Gentest model from the perspective of its integration into 
Europe. In this this section, a modified version of the results of the SWOT analysis is pre-
sented. Many of these issues have already been reflected to different sections of the Gen-
eral Discussion of this dissertation (Chapter 8). Nevertheless, below analysis offers a con-
cise overview of all strengths, weaknesses, opportunities and threats of/for Gentest in a 
single section. 
The data source of the SWOT analysis was the publication on Gentest [2], sample ques-
tionnaire and report of Gentest, the proposal of the P4-MEDICINE@EU project, and inter-
nal and external documents of GENAR (such as business plans). In addition, the results of 
other tasks carried out under the P4-MEDICINE@EU project were considered.  
2.1. Strengths 
 It is a health service model. 
Gentest is an integrative health service model, not a test. Being a health service model, it 
contains not only the ‘tests’ and ‘assessments’ (i.e. analysis) but also recommendations 
that include comprehensive lifestyle and follow-up plans designed for the needs of the 
individual (i.e. synthesis). Additionally, this service model contains tools to empower the 
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health professionals to implement the model as well as manage the health of the individ-
uals based on their health priorities.  
 It is to be implemented inside health services, via trained health profes-
sionals. 
The pilot in Turkey, as well as the envisaged implementation model in Europe (primary 
care setting), involves application of the model via trained health professionals (mainly 
physicians, as well as the dietitians). In the current practice in Turkey, the training for the 
health professionals is carried out in collaboration with Turkish Society of Public Health 
Genomics and Personalized Medicine (TOGEN). Only health professionals who complete 
the training successfully are authorized to become ‘authorized practitioners of Gentest 
application’. 
When compared with some direct-to-consumer applications, application via health pro-
fessionals is an important strength. 
 It is a comprehensive model that utilizes a large spectrum of inputs. 
Gentest is based on the determinants of health model and aims to include relevant factors 
in all determinant areas as much as possible, including biological factors, lifestyle and 
environmental factors, socioeconomical factors and health systems. It makes a 360 de-
grees assessment of an individual using personal information (age, gender), detailed 
health information (personal health history including diseases and medications and family 
health history), living and working conditions, lifestyle information, including physical 
activity and exercise, smoking and drinking habits, supplement consumption, nutritional 
habits, food consumption (24 h recall and food frequency) using Gentest Food Portion Size 
Atlas (all these collected through a questionnaire (44 pages)); anthropometric (height, 
body weight, waist circumference), bioimpedance (body composition), pulse and blood 
pressure measurements; biomarkers (common markers such as LDL-, HDL- and total cho-
lesterol, fasting plasma glucose, triglycerides, etc.); and genotype information (currently 
65 polymorphisms). 
 It is a model that assesses these inputs in an integrative way. 
Gentest has an integrative approach which incorporates the above mentioned inputs for 
assessment of current status and development of personal medical follow-up and lifestyle 
plans. The assessments include, nutritional assessment (quantification of intake of all 
nutrients based on the information in the questionnaire and comparison with the recom-
mended minimum and maximum intake levels), body composition assessment, assess-
ment of physical activity and exercise (assessment of the current status and comparison 
with the recommended level), assessment of causes of smoking, assessment of current 
health information, genotype assessment, assessment of biomarkers, and assessment of 
the risks of major complex diseases: heart attack, stroke, type 2 diabetes, osteoporosis, 
and most common cancers (lung, breast, prostate, colon and stomach). 
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 It has a holistic approach to health, by addressing major chronic complex 
diseases in a single service model. 
Gentest covers major chronic complex diseases where lifestyle interventions play a very 
important role in development: cardiovascular diseases, diabetes, obesity, cancers and 
osteoporosis. Nevertheless, the lifestyle plan is expected to provide benefit in the whole 
spectrum of the health of the individual and has the potential to increase the quality of 
life.  
There are programs on risk assessment and disease management of specific health areas 
in the world, such as cardiometabolic risk management programs or diabetes disease 
management programs. However, Gentest model has an inclusive approach to health to 
cover the broadest spectrum for managment of the health of the individual. 
 It is a dynamic model which is open to addition of new types of inputs and 
assessments, as well as modification of prior ones based on new scientific 
developments. 
Gentest is open to addition of new inputs, assessments, and recommendations, which can 
be derived from the scientific developments. It is not a static model. Developments can be 
incorporated to the model. 
 It is a multidisciplinary approach. 
Gentest aims to bring the knowledge from different disciplines in a way that complements 
each other. Multidisciplinary work is usually a very challenging task since the language, 
knowledge, skills and priorities of different disciplines vary, making it a complex task to 
deliver a multidisciplinary work. Gentest model has accomplished to combine the exper-
tise from different disciplines, including medicine (as a whole and with its different spe-
cialties), nutrition & dietetics, exercise physiology, epidemiology, (bio)informatics, life 
sciences (including genomics), behavioral sciences, public health, and others. 
 It addresses a very important challenge in prevention of complex diseas-
es: behavior change. 
Currently, the best known prevention for complex diseases is adopting a healthy lifestyle. 
However, this is not achieved in many places of the world. Effective intervention models 
including lifestyle changes for prevention of these diseases is urgently needed. Gentest 
aims to address this need. Risks are identified individually, therefore Gentest creates per-
sonal vulnerability and risk perception and motivate individuals to implement the advices 
of the report. 
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 It addresses a very important challenge in prevention of complex diseas-
es: a holistic tool for the health professionals for management of the 
health of the individual according to health priorities. 
Gentest empowers the health professionals (in particular primary care practices) by 
providing a holistic program on how to follow-up the individual based on their needs and 
health priorities. Thus, the primary care practice can have a program for each individual in 
his/her catchment area. 
 Design and content of reports 
The unique design of reports makes the report visually nice looking. Reports convey the 
message to the consumer in a simplistic way and also show how the results would be 
changed based on the behavior of the individuals to motivate the individual towards be-
havior change. 
 Promoting personal autonomy in health 
Gentest empowers the individuals with knowledge and tools to manage their health by 
making required lifestyle changes, and help them take the lead in management of their 
health.  
On the other hand, the report might be perceived to restrict the lifestyle choices an indi-
vidual can make (see 2.4. Threats, “Concerns on restriction of personal autonomy”). 
 Use of data collected for Gentest for research purposes.  
The data collected for the implementation of the practice model can be used for research 
purposes as a feedback for further research and development. This data can be used to 
improve the algorithms of Gentest, making predictions and recommendations more accu-
rate.  
On the other hand, this use is also linked to a threat, which is ensuring compliance with 
the data protection legislations (see 2.4. Threats, “Data protection” in this appendix and 
the supplementary material of Chapter 7) 
2.2. Weaknesses  
 Not scalable from the perspectives of production capacity and economic 
feasibility 
Gentest reports are generated based on sets of algorithms and tools, however, these are 
not translated to a software. Reports are prepared by qualified human resources who can 
use these algorithms and tools. Preparation of each report requires time and effort of 
qualified labor. This limits the number of reports that can be generated per day and also 
increases the cost of the model. 
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For the model to be implemented in a large scale in primary care services a software must 
be developed. This will reduce the costs as well as turnaround time. Additionally, as the 
volume increases, the cost of genotyping will decrease, making the model economically 
more feasible. (See also 2.3. Opportunities, “Development and use of software for collec-
tion of information, processing and reporting.” and “Cost of genetic analysis is decreasing 
exponentially.”) 
 Challenges in assessment of nutritional status 
Currently, assessment of nutritional status is carried out based on the reported consump-
tion by each individual. This requires recall of food consumption by the individual (24 
hours food consumption and food frequency questionnaire), which are dependent on the 
recall ability of the individual. Discoveries on biological markers of assessment of nutri-
tional status would provide much more robust results. (See also 2.3. Opportunities, ”Use 
of biomarkers for assessment of nutritional status”) Also, development of smart phone 
apps using the food portion size atlas or use of existing apps for collection of 24-hour food 
consumption data is an important opportunity.  
 Data collection consumes time. 
Gentest is a comprehensive model, which includes personal information, health infor-
mation, living and working conditions, lifestyle information (including very detailed food 
consumption information) using a questionnaire (see 2.1. Strengths, “It is a comprehen-
sive model that utilizes a large spectrum of inputs.”). Collection of data and information 
consumes considerable amount of time (around 1 hour) of the health professional or 
his/her trained assistant, as well as the individual.  
Putting the questionnaire into a software in a way that can be filled by the individual more 
rapidly would decrease related time and costs. (See also 2.3. Opportunities, “Development 
and use of software for collection of information, processing and reporting.”) Also, priori-
tization can be done on the extent of the analysis and thus the type and amount of the 
data to be collected. 
 Effectiveness and cost-effectiveness not demonstrated yet 
The effectiveness and cost-effectiveness of the model hasn’t been demonstrated yet.  
The effectiveness and cost effectiveness are closely related to the context where the im-
plementation will take place (see also Chapter 8 - General Discussion). Therefore, studies 
on effectiveness and cost-effectiveness of the model must take place in the setting where 
the model will eventually be implemented.  
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The following are update and further development areas that are currently not 
present in the model. Their addition will improve the model significantly. 
 Genetic markers 
As scientific publications provide new insights to genetic basis of diseases and response to 
lifestyle factors, the genetic markers (currently polymorphisms) used in Gentest need to 
be updated as well. An update on the list of polymorphisms is currently underway, which 
is envisaged to be completed by the end of 2015. Newly developing opportunities on oth-
er biological markers such as epigenetics, expression profiling and metabolomics should 
also be explored in the following periods. 
 Assessment of functional physical fitness is not present. 
Currently, the model assesses the physical activity and exercise status of the individuals 
based on the type, duration and intensity of the exercises they report, in six physical fit-
ness areas. Actual fitness status is not assessed and this should be added to provide a 
more comprehensive picture on the individual. For measurement of physical fitness, 
measurement of VO2max for cardiorespiratory fitness (by measuring oxygen consumption 
during exercise in a controlled clinical environment); measurement of hand grip as an 
indication of muscle strength; and tests for measurement of flexibility can be used. 
 Basal metabolic rate measurement is not present. 
The basal metabolic rate that is used for calculation of recommended calorie intake and 
macronutrients is currently estimated with calculations, not measured. Measurement of 
basal metabolic rate in controlled environment (or resting metabolic rate) would enable 
the results be more personalized. 
 Assessments of psychological and functional status are not present. 
The psychological aspects of health are not currently included in the model. Mental health 
should be included in the model with appropriate questionnaires. In particular, assess-
ment of stress levels should be made and algorithms for stress reduction recommenda-
tions should be developed.  
For an overall assessment of functional physical and mental health, a questionnaire such 
as the Short Form 36 Health Survey can be incorporated (it includes following scales: phys-
ical functioning, physical role, bodily pain, general health, vitality, social functioning, emo-
tional role, mental health). 
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Before implementing to new countries adaption is needed in following areas: 
 Methodology for assessment of food consumption needs to be adapted for 
each country. 
The current food consumption questionnaire and the food portion size atlas are devel-
oped for Turkey. These need to be adapted for each country (or groups of countries) that 
are targeted for implementation.  
In addition, currently an international food composition database is used. For each new 
country (or groups of countries) their own food composition database (if present) must be 
used for calculation of nutrient intakes. (see also Chapter 8 - General Discussion). 
 Risk assessment algorithms need to be adapted for each country. 
Currently, international risk assessment algorithms are used. However, accuracy of risk 
assessment algorithms varies from country to country. Therefore, if existing, risk assess-
ment algorithms of the target country must be adopted in the model. (see also Chapter 8 - 
General Discussion). 
 Medical, nutritional and other algorithms need to be adapted for each 
country, if national consensus guidelines exist in those areas. 
Currently, international and Turkish guidelines are used in the model. If the target country 
has national guidelines, the algorithms on medical assessment and recommendations, 
nutritional assessment and recommendations, and others need to be adapted to be in line 
with them. (see also Chapter 8 - General Discussion). 
 The reports must be adapted to the health literacy level of the target pop-
ulation. 
Current report targets people with medium health literacy. The reports must be adapted 
to different health literacy levels of the target population. This should be done both in 
country level and for different socioeconomic levels in a country (as an indicator of health 
literacy). Different report templates may need to be produced for targeting different soci-
oeconomic levels. (see also Chapter 8 - General Discussion). 
2.3. Opportunities  
 Scientific developments in the whole spectrum of genome-based 
knowledge and technologies. 
At the time of the development of Gentest model, the most prominent markers on devel-
opment of complex diseases were polymorphisms. Due to scientific developments, new 
parameters may be derived from the whole spectrum of omics, i.e. epigenetics, gene ex-
pression, proteomics and metabolomics. Their incorporation to Gentest model provides 
an opportunity. 
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 Development and use of software for collection of information, processing 
and reporting. 
When a software is developed for the model, it will be possible to collect information, 
process and generate the Gentest report using the software. This will not only increase 
the production capacity, but also lower the costs. 
A major challenge for development of a software for this model is its dynamic content (see 
2.1. Strengths, ”It is a dynamic model which is open to addition of new types of inputs and 
assessments, as well as modification of prior ones based on new scientific develop-
ments.”). The developed software should also allow the model to be dynamically updated. 
As software development approaches and methods improve in time, this need will be 
better met. 
 Provision of the model to the whole world via internet. 
By using a web portal, the components (such as food consumption methods including the 
food portion size atlases) or the whole of the model can be provided as a service to the 
whole world. 
 Cost of genetic analysis is decreasing exponentially. 
The cost of genetic analysis has been decreasing rapidly. This provides an important op-
portunity for Gentest to decrease the costs while increasing the number of genetic mark-
ers. 
 Use of whole genome/exome sequencing in health care. 
The cost of sequencing a whole genome has been decreasing exponentially, in particular 
after the development of second generation DNA sequencing technologies in 2008 [4]. 
The use of whole genome or exome sequencing (WGS/WES) in newborn screening is also 
debated. Wide use of WGS/WES has the opportunity to include an enormous amount of 
genetic information in the model. 
UK prime minister announced in December 2012 their plans to carry out whole genome 
sequencing in 100.000 patients with cancers and rare diseases within UK’s National Health 
Services. This indicates that decision makers can be willing to use genetic information in 
the mainstream of the health services, and provides an additional opportunity for the 
future. [5] 
 Use of biomarkers for assessment of nutritional status 
The scientific developments in the fields of proteomics and metabolomics are expected to 
allow assessment of nutritional status, as well as other lifestyle factors, using biomarkers. 
This will help to standardize these assessments and help create more robust results for 
nutritional assessments. 
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 The pressure for innovation in health 
Health systems are under pressure to find solutions to the problems of the aging popula-
tion and ever increasing burden of chronic complex diseases which require long term care. 
Innovation is addressed as one of the key solutions to approach these problems effective-
ly.[6] “…But now and for the foreseeable future we must meet these demands from within 
our current real terms funding, while at the same time improving quality. This means that 
simply doing more of what we have always done is no longer an option. We need to do 
things differently. We need to radically transform the way we deliver services. Innovation 
is the way – the only way – we can meet these challenges. Innovation must become core 
business for the NHS”[7]. (see also Chapter 8 –  General Discussion) 
Gentest is an innovation addressing the major challenges in prevention of complex diseas-
es, i.e. behavior change and management of health together with the health professional. 
It is an opportunity for Gentest to be implemented in an environment where decision 
makers have understood the need for innovation effectively.  (see  2.4. Threats, “Re-
sistance to change the current paradigm in health care services” in this chapter and Chap-
ter 8 –  General Discussion) 
 The pressure for changing the current paradigm in health services  
Due to the same reasons laid down in the previous item (The pressure for innovation in 
health) there is a need for paradigm shift in health care services. Currently, the services 
are reactive, disease oriented, focused on acute and medical services. However, to tackle 
with the challenge of complex diseases, the services should be proactive, health oriented, 
focused on chronic cure and care covering the whole spectrum of health care, not only 
medicine.  
Gentest model targets health care services within this shifted paradigm. If the need for the 
shift is well understood, it will provide a very positive environment for the implementation 
of Gentest. If the need for the paradigm shift is not in the agenda of the health system of 
the country, or overall Europe, it is very difficult to implement Gentest (see 2.4. Threats, 
“Resistance to change the current paradigm in health care services” in this chapter and 
Chapter 8 –  General Discussion). 
 Use in other countries 
Gentest model can be adapted and implemented in various other countries, as it is the 
subject to this dissertation is to investigate how it can be integrated into countries in Eu-
rope. (For some specific aspects on adaptation to new countries, see 2.2. Weaknesses 
“Before implementing to new countries adaption is needed in following areas:”) 
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 The trends of incorporating risk assessment and management programs 
into primary care services 
In the recent years, increasing number of risk assessment and management programs for 
primary care services and/or primary prevention are being developed and reported in the 
literature [8-13]. This validates that it is a timely and valid case to introduce Gentest into 
primary care services. 
2.4. Threats  
 Potential misuse by health insurances and employers 
There is a potential that Gentest report can be misused by health insurances and current 
and potential employers. Legislative precautions must be in place to provide security to 
the individuals. 
 Potential misuse within the family 
There is a potential that Gentest can be misused in the family context. Genotype data can 
be used to assess or verify the biological parental relationships. The risk profile and rec-
ommended lifestyle changes can create pressure on family members, or the family mem-
bers can create pressure on the individuals. 
It is not possible to address these points by legislations. Other methods must be found to 
minimize threats that may come from them. 
 Data protection 
The Data Protection Directive (Directive 95/46/EC on the protection of individuals with 
regard to the processing of personal data and on the free movement of such data) pro-
vides the general framework on data protection issues in EU countries. However, legal and 
administrative requirements for data protection vary in practice among EU countries. This 
creates a challenge since Gentest must comply with the regulatory and administrative 
framework of each country individually. 
A proposal for General Data Protection Regulation was released in 2012 to unify data 
protection within EU. The adoption is aimed for in 2014 and it is planned that the regula-
tion takes effect in 2016. However, discussions on the content of the proposed regulations 
still continue. Use of personal data for unspecified future research purposes is a major 
topic debated under data protection issues. (See also 2.1. Strengths, “Use of data collect-
ed for Gentest for research purposes.” In this appendix and the supplementary material in 
Chapter 7) 
 Security of the data stored 
When Gentest is implemented on wide populations, an enormous size of data will be gen-
erated for all enrolled individuals. This data needs to be securely stored, which creates a 
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challenge, in particular from the perspective of protection of unauthorized access to the 
data. 
 Effects on health disparities 
There is a possibility that uptake of the messages of Gentest report might be better in 
higher socio-economical status (SES) groups and worse for lower SES groups. This may 
increase the health disparities among different groups. This must be addressed by adap-
tion of the reports to different health literacy levels within the target populations (see also 
2.2. Weaknesses, “The reports must be adapted to the health literacy level of the target 
population.”) 
 Limited knowledge and skills of health professionals on genomics 
The knowledge and skills of the health workforce (physicians including general practition-
ers, nurses, dietitians, etc.) on genomics is limited. Health professionals may have difficul-
ty in comprehending the role of genomics in this model. Therefore, appropriate training 
programs for health professionals must be developed. 
 Possible concerns of the primary care workforce 
Even if data collection is streamlined using a software, it will still consume time (of prac-
tice nurse and/or physician assistant). Additionally, the report must be explained to the 
individual by a health professional (physician, practice nurse and dietitian). These are 
likely to be major concerns of the workforce for implementation of the model, in particu-
lar considering the current organization of the family physician settings and their work 
load. (See also the supplementary material in Chapter 7) 
One solution can be prioritization of different components of the model based on the 
potential benefit they provide and the time they consume. In this approach, only the 
components that have high added benefit when compared to the time they consume 
would be included and components with less added value (compared to the time they 
consume) would be left out. 
 Resistance to change the current paradigm in health care services  
Currently, the health care services are reactive, disease oriented, focused on acute and 
medical services. However, to tackle with the challenge of complex diseases, the services 
should be proactive, health oriented, focused on chronic cure and care covering the whole 
spectrum of health care, not only medicine. (see also 2.3. Opportunities, “The pressure for 
changing the current paradigm in health services” in this appendix and the supplementary 
material of Chapter 7) 
Gentest model targets health care services within this shifted paradigm. Successful 
implementation of the model requires shifting the mindsets of the players within a health 
system and, which is a serious challenge. It will be very difficult to implement Gentest in 
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an environment where players have a resistance for changing their paradigm on health 
care services. 
 Concerns on restriction of personal autonomy 
The model is envisaged to promote the personal autonomy of individuals to manage their 
health (see 2.1. Strengths, “Promoting personal autonomy in health”). However, there is 
also a possibility that the report might be perceived to restrict the lifestyle choices an 
individual can make, i.e. “being told what to do”. On the other hand, the individual is em-
powered by the information she/he gains from the report, and it is up to his/her free will 
to implement it or not. 
 Competition with other applications 
Under 2.3. Opportunities, it was reported that increasing number of risk assessment and 
management programs for primary care services are being developed and reported in the 
literature [8-13]. This may create a competition for Gentest. Nevertheless, it should be 
noted that the reported programs are vertical one which focus on a single disease/ health 
area (cardiovascular/ cardiometabolic risk/health), whereas Gentest integrates lifestyle 
interventions for major chronic diseases that create the biggest burden of disease on the 
society. 
2.5. Overview 
Overall, Gentest provide a very different profile than commonly known consumer ge-
nomics products which use genetic information to make ‘personalized’ recommendations, 
such as 23andMe. First of all, unlike 23andMe, Gentest is not a ‘test’; it is a service model. 
Moreover, it is provided via health professionals, not directly to consumer. Finally, it is not 
a service focused on genetics. It is a comprehensive approach to health and genetics is 
one of the lines of the inputs. These properties indicate that Gentest is not comparable to 
consumer genomics products such as 23andMe.  
Overall, addressing major chronic complex diseases in a single test combining genetic 
information, anthropometric and lifestyle factors etc., and potentially empowering indi-
viduals to manage their health are among the main strengths of Gentest. Lack of effec-
tiveness/ cost-effectiveness data seems to be its main weakness. Some ideas on how the 
practice model can be evaluated were presented in Chapter 8 (General Discussion). The 
areas which need to be updated and/ or adapted to target countries can be regarded as 
both weaknesses and opportunities for further improvement. One of the main opportuni-
ties is development of a software to collect information and generate 'Gentest' reports. 
Also, data generated with its potential population wide application in primary care can 
create a feedback loop to research providing valuable insights to health and diseases. A 
main threat is the limited knowledge and skills of the health workforce on genomics and 
its contribution to more targeted health interventions. 
An overview of the SWOT analysis is presented in Figure 1.  
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This universe is not outside of you.  
Look inside yourself; everything that you want, you are already that. 
Mevlana Rumi 
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Summary 
Chronic complex diseases create a huge burden and economic toll on health systems and 
societies. Driven by scientific and technological developments, personalized medicine and 
personalized health care have a potential to provide solutions for effective prevention of 
chronic diseases. However, integration of ‘personalized’ practices into health services has 
been a challenging process.  
This dissertation used a preventive personalized health care model called ‘Gentest’ as a 
practical example to address the integration issues effectively. Studying how it can be 
integrated into health systems helped us to identify directions required to assess and 
address integration issues effectively, as well as drawing lessons for other ‘personalized’ 
practices. Thus, the aim of this dissertation has been to see how a personalized health 
care model, such as Gentest, can be integrated into primary care services in the European 
health systems, for prevention of chronic diseases. To answer that, three sub-questions 
were asked: 1. Where will the practice model be integrated?; 2. What will be integrated?; 
and 3. How can the integration take place?  
The dissertation took a journey through the fields of personalized medicine and health 
care, and health systems and policies, using Gentest as its vehicle. Part I answered 
‘where’ the integration will take place and described the setting, i.e. health system in its 
wider context of public health. Part II answered the ‘what’ question by first describing the 
broader context of personalized medicine and health care and then introducing Gentest 
as an example of a practice model to be integrated into the European health systems. Part 
III presented a systematic approach to assess ‘how’ this practice model can be integrated 
into primary care services around Europe. It provided an inventory of areas and issues 
that can be involved in the integration process of the practice model. More specifically, 
the dissertation journey provided the following chapters as its output. 
Chapter 1 showed an urgent need to develop solutions to reduce the burden of chronic 
complex diseases that reached an epidemic level globally. To achieve that, health systems 
need a paradigm shift towards a more proactive, health oriented and preventive services 
that are better focused on chronic cure and care covering the whole spectrum of health 
care (not only medicine). Personalized health care practices can provide important oppor-
tunities to facilitate this shift and contribute to prevention of chronic complex diseases. 
The example we used is Gentest, a practice model which provides a comprehensive ap-
proach to major chronic diseases and related risk factors to prevent development and 
progression of diseases in a targeted way. Upon its pilot in Turkey and having been identi-
fied as a ‘best practice model’ in Europe, it was identified that the main implementation 
area for such a preventive intervention should be primary care services in Europe, where 
it can be provided via general practitioners/family physicians. However, there has been no 
successful example of integration of such a preventive personalized health care model 
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provided to large populations. Therefore, we needed to explore how to integrate Gentest 
into primary care services in Europe. This would be done by answering the where, what 
and how questions, as laid above. 
Part I aimed to describe the setting where the practice model will be integrated into. It 
was seen that the whole debate on where to integrate needed to build on the concepts of 
‘public health’ and ‘health systems’. However, there is confusion around these concepts, 
and how they are interrelated. As a solution, in Chapter 2, we took the endeavor to inte-
grate concepts of public health, including health system and its components, into a single 
coherent framework called ‘Health Globe’. This served to the purpose of achieving a co-
herent terminology for policy makers and those who guide them internationally. Health 
Globe uses the World Health Organization’s ‘Health for All’ vision, introduced in 1977, as 
its overarching framework. The broad approach to health brought by ‘Health for All’ was 
defined as public health. Thus, all activities that directly or indirectly affect individuals’ 
health, should fall within the scope of ‘public health’. This includes medical and non-
medical interventions, governmental decisions and practices, and activities of the public 
sector, the private sector and NGOs. Health system is a part of the Health Globe. It con-
sists of activities under the mandate of the ministry of health. As a result of this exercise, a 
framework for the objectives and functions of a health system was introduced. This in-
cluded a description of different layers of health services. The specific setting where our 
practice model will be integrated into is primary care services. Therefore, within the de-
scription of health services, the scope and position of the primary care services was clearly 
depicted.  
The USA has a leading position regarding development of the concepts and practices of 
personalized medicine and health care, as most of the existing examples and publications 
are originating from there. Chapter 3 investigated the U.S. health system to understand 
the context of these ‘personalized’ practices and learn lessons from their situation when 
discussing how to and how not to integrate personalized practices in Europe. This chapter 
showed that what USA has is hardly a ‘system’ designed in a coherent way. Moreover, in 
terms of policy, USA has prioritized ‘freedom’ and ‘free market’ over ‘equity’ as policy 
values. These have led to serious shortcomings in terms of the main outcomes of a health 
system, i.e. effectiveness, efficiency and equity. After conveying the problems and under-
lying reasons, this chapter proposed how to develop American health policy and health 
system to increase its effectiveness and efficiency, while reducing inequity. The recom-
mended solutions were heavily drawn on the experiences of European countries.  
Part II of the dissertation aimed to explore what will be integrated by describing the broad 
context of personalized medicine and health care, as well as our specific case example 
Gentest. Chapter 4 showed that the future vision of personalization of medicine and 
health care cannot be uniformly defined using standard definitions. Moreover, the terms 
used now have been defined in a top-down manner by influential people or committees 
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and may not adequately reflect the real-life field. Chapter 4 provided a different angle 
with a ‘practice-based perspective’ (or a ‘bottom-up perspective’) to the debate by analyz-
ing the content of ‘personalized’ practices published in the literature. These practices 
were identified with a systematic search in the scientific literature. The content analysis 
indicated that the definition of the personalized approaches is problematic and the ‘per-
sonalized’ practices are not a homogeneous group. In terms of the application form and 
context, a ‘personalized’ practice can be a commodity in health care market, a way how 
health services are provided, or a keyword for emerging applications. A ‘personalized’ 
practice can serve various groups for different purposes: It can help individuals/patients 
to empower them to gain control of their health, health professionals to provide better 
services, health care organizations to increase effectiveness and efficiency of health care 
delivery in the competitive environment, or national health systems to increase perfor-
mance in terms of not only effectiveness and efficiency but also equity. Additionally, using 
three country examples (USA, France and Taiwan), it was identified that for successful 
integration of the practices into health services, not only the attitude of the country to-
wards innovations, but also the health system and policies context is crucially important.  
Chapter 4 showed the various facets of the personalized approaches but it was Chapter 5 
where a working definition of personalized health care was made. The article clarified 
what commonly used terms in the field, such as personalized medicine, personalized 
health care and individualized medicine, mean to their authors. Initially, ‘personalized 
medicine’ was considered as equal to ‘genomic medicine’. However, our genome is not 
the only factor that makes us unique. Individuals must be considered in their entire con-
text, including exposure to pathogens or toxins, socioeconomic factors, physical activity, 
nutrition and other lifestyle factors, which are constantly interacting with each other, as 
well as with the genomes. Thus the article called for an integrative approach covering 
various determinants of health for both the scientific discoveries and the personalized 
approaches in practice. In its conclusion, it urged to prepare health systems and policy 
makers in a timely manner for the paradigm shift towards the personalized approaches. 
Having set the scene of personalized medicine and health care in Chapters 4 and 5, Chap-
ter 6 provided a concrete example of personalized health care used in this dissertation: 
Gentest. It is a comprehensive and integrative model of personalized health care for pre-
vention of common chronic diseases. It utilizes individuals’ personal health information, 
detailed lifestyle analysis, body composition, genotype, and other biomarkers in order to 
prevent the onset or progression of major chronic diseases in a targeted way. The mission 
of this practice model is changing the behavior and managing the health of individuals 
according to their health priorities. It was developed by GENAR Institute for Public Health 
and Genomics Research in Ankara, Turkey. The article conveyed how the (pilot) imple-
mentation was provided to over 500 individuals via authorized practitioners, i.e. health 
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professionals (mainly physicians) who completed a training programme for this purpose. 
The positive and negative criticisms towards this practice model were also briefly covered. 
After Part I, which described the setting, i.e. health systems, and Part II, which described 
the personalized preventive practice model in its wider context of personalized health 
care, Part III explored how the practice model can be integrated into the into the setting, 
i.e. health system. 
If we want to integrate models such as Gentest into primary care services in Europe, what 
are the issues that we should investigate? How can we approach this in a systematic and 
analytical way? What areas of the health system of the country should be investigated? 
Chapter 7 aimed to answer these questions. To identify all relevant integration issues, a 
systematic approach was developed using the health systems framework, which was in-
troduced in Chapter 2. Thus, the functions of the health system provided the overarching 
framework to this systematic approach. As was shown in Chapter 4, ‘personalized’ prac-
tices are diverse and cannot be covered with a generic approach. Therefore, Gentest was 
used in this exercise for identification of the issues to be covered. As a result, 24 areas 
were compiled to be assessed under the functions of health systems. The application of 
the systematic approach was enriched with examples provided from the Netherlands and 
the UK, as well as other European settings. A prioritization among these 24 areas were 
made to identify which ones are crucial and with high priority when a practice model is 
integrated into a health system. In general, Chapter 7 conveyed a systematic approach to 
identify and assess issues related to integration of the practice model into primary care 
services in European health systems. Since this method can be applied to other practices 
and countries, it provides a solution to the broader problem of the integration of person-
alized medicine and health care practices into health systems.  
Chapter 8 took a step back and reflected on the interaction between the contexts of 
health systems and personalized health care practices. While setting the scene, it was 
conveyed that the Health for All vision, born in 1977, eventually led to development of 
ecological approaches to health, which emphasize the importance of understanding the 
bio-psycho-socio-ecological context of individuals. As each individual has slightly differing 
contexts, understanding the individual context and designing interventions that are tai-
lored/ personalized to it provide an important opportunity to approach health in a com-
prehensive way. Moreover, with integrative personalized health care models that address 
health, risks and diseases of individuals holistically, such as Gentest, we may progress 
towards attaining the goal of ‘Health for All’. However, in order to host such practices 
effectively, as well as to attain the ‘Health for All’ goal, health systems need to innovate to 
shift towards proactive and health oriented services focused on prevention as well as 
chronic cure and care, covering the whole spectrum of health care (not only medicine). 
This also calls for revisiting conventional concepts in public health, such as the dichotomy 
of ‘population based vs. high risk individual’. We need to move towards a preventive par-
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adigm which understands that personalized approaches may help to target the population 
with individual level interventions. Moreover, considering the continuum of development 
of chronic diseases, ‘personal health management’, ‘personal risk management’ and ‘per-
sonal disease management’ can be considered as a new classification of preventive inter-
ventions. Another important area of innovation is strengthening the primary care services 
so that they can provide such preventive and personalized approaches to the population 
in a proactive way. The practice models for personalized health care, such as Gentest, may 
also be used as a practical opportunity to realize the paradigm shift within the health 
systems. 
Those innovations on the side of health systems must be coupled by efforts to innovate 
the personalized health care practices. First of all, innovation is needed to bring a com-
prehensive approach to so-called ‘personalized’ practices. Can we regard practices that 
use a single test, whose result leads to a single intervention for diagnosis or therapy of a 
disease, as a ‘personalized’? ‘Personalization’ can only be achieved when we understand 
and use the individual contexts in a holistic way, rather than focusing on a single factor, be 
it high-tech or low-tech, biological or non-biological. Moreover, to adapt to the target 
countries and health systems, personalized health care practices, such as Gentest, need to 
continue to innovate. Eventually, the field of personalized medicine and health care needs 
to realize that the discoveries they are making and technologies and tools they are devel-
oping cannot have a profound effect on the society unless a comprehensive approach to 
their integration into health systems is developed. 
In terms of methodological considerations, Chapter 8, reflected on the usefulness of using 
a concrete, real life case in this dissertation and how it may contribute to research in this 
field.  
Chapter 8 ended with listing the main conclusions derived from this dissertation. Very 
briefly, it was shown that personalized health care offers valuable opportunities to com-
bat the increasing burden of chronic complex diseases while serving to the required para-
digm shift. To achieve this shift and to attain the goal of ‘Health for All’, innovations for 
personalized medicine and health care, and health systems and policies need to co-evolve, 
adapting themselves to the needs of each other while leveraging one another. For suc-
cessful integration of personalized health care practices, issues related to integration need 
to be approached systematically, not in a piecemeal way. Health system frameworks can 
provide the required analytical frameworks to identify and assess issues related to inte-
gration of those practices. An effective dialog among the fields of personalized medicine 
and health care and health systems and policies may facilitate this integration process to 
be better and faster. 
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Samenvatting 
Complexe, chronische ziekten veroorzaken een behoorlijke belasting voor en economi-
sche druk op onze gezondheidssector en de maatschappij. Vanwege de wetenschappelijke 
en technologische ontwikkelingen heeft ‘personalized medicine/ personalized health care’ 
een hoog potentieel om deze complexe, chronische ziekten te bestrijden. ‘Personalized 
medicine/ personalized health care’, wat vertaald kan worden als ‘gepersonaliseerde ge-
neeskunde/ gepersonaliseerde gezondheidszorg’, kan gezien worden als behandeling / 
zorg die afgestemd is op de specifieke karakteristieken van de patiënt. Gepersonaliseerde 
geneeskunde/ gepersonaliseerde zorg is veelbelovend en biedt nieuwe uitdagingen voor 
de praktijk. 
Aan de hand van het gezondheidsmodel Gentest wordt in dit proefschrift beschreven hoe 
integratie van gepersonaliseerde zorg geëffectueerd kan worden respectievelijk wat wij 
kunnen leren van de praktijk van gepersonaliseerde zorg. Het doel van dit proefschrift is 
om te kijken hoe een gepersonaliseerd model, zoals Gentest, kan worden geïntegreerd in 
Europese gezondheidssystemen. Om deze vraag te beantwoorden wordt er gekeken naar 
drie sub-vragen: 1. Waar zal het model worden geïntegreerd?; 2. Wat zal er worden geïn-
tegreerd?; 3. Hoe kan de integratie tot stand komen?  
In Deel I van het proefschrift wordt besproken ´waar´ integratie van gepersonaliseerde 
zorg plaats zal vinden en de samenhang binnen de bredere context van publieke gezond-
heid. In Deel II wordt uitgelegd ´wat´ gepersonaliseerde zorg precies inhoudt en met Gen-
test als voorbeeld. Ten slotte wordt in Deel III uiteengezet ´hoe´ dit model in de eerstelijns 
zorg binnen Europa kan worden geïntegreerd. Verder is het proefschrift verdeeld in 
hoofdstukken waarin de verschillende onderwerpen meer in detail worden besproken. 
Hoofdstuk 1 toont de noodzaak tot oplossingen voor de belasting die chronische ziekten 
leggen op onze maatschappij. Om chronische ziekten in een eerder stadium aan te kunnen 
pakken, is er een paradigmaverschuiving in de gezondheidszorg vereist. Tegenwoordig 
wordt er nog veel nadruk gelegd op curatie (het genezen van mensen die al ziek zijn) bin-
nen de gezondheidszorg, maar, in het continuüm tussen vroeg preventief en hoog gespe-
cialiseerde curatieve zorg, zou meer accent moeten liggen op vroeg preventief. In dit op-
zicht kan gepersonaliseerde zorg een grote rol spelen. Gentest is hierbij als voorbeeld 
gebruikt. Gentest is een praktijk model dat focust op de belangrijkste complexe, chroni-
sche ziektebeelden. Hierbij kunnen er aan de hand van risicotaxaties uitspraken worden 
gedaan over de kans op een bepaalde ziekte en kan er worden geprobeerd te voorkomen 
dat deze mensen ziek worden door ze persoonlijke geneeskunde aan te bieden. Geduren-
de de proefperiode van Gentest in Turkije is het uitgeroepen als het ‘beste praktijk model’ 
in Europa. Omdat er nog echter geen soortgelijke modellen zijn geïntegreerd in Europa, 
was het belangrijk om uit te zoeken hoe een integratie van een model als Gentest kan 
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plaatsvinden en welke facetten hierbij een rol speelt. Om dit uit te zoeken zijn de ‘waar’, 
‘wat’ en ‘hoe’ vragen gebruikt.  
In deel I wordt de omgeving besproken waarin Gentest geïntegreerd kan worden binnen 
de bredere context van ‘public health’ (publieke gezondheid) en ‘health systems’ (zorg-
stelsels). In hoofdstuk 2 wordt een samenhangend kader gepresenteerd, ‘Health Globe’ 
(Wereldbol van de Gezondheid), om meer eenheid van taal te bevorderen voor beleids-
makers in de gezondheidszorg. Hierdoor wordt een coherente terminologie voor beleids-
makers op internationaal niveau toegankelijker gemaakt. De ‘Health Globe’ maakt gebruik 
van de visie ‘Gezondheid voor iedereen’ en werd geïntroduceerd in 1977 door de Wereld-
gezondheidsorganisatie (WHO). Binnen deze brede benadering van gezondheid speelt 
naast de individuele gezondheidszorg een belangrijke rol, maar ook collectief gerichte 
publieke sector inclusief de overheid. 
In hoofdstuk 3 wordt het gezondheidssysteem in de Verenigde Staten besproken aange-
zien het Amerikaanse systeem een voorloper is wat betreft gepersonaliseerde genees-
kunde/ gepersonaliseerde gezondheidszorg. Van het Amerikaanse systeem kunnen we 
leren wat de stimulerende en belemmerende factoren zijn met betrekking tot een succes-
volle integratie van gepersonaliseerde zorg in Europa te komen. In het Amerikaanse sys-
teem staan ‘keuzevrijheid’ resp. “marktwerking” in de zorg beleidsmatig meer op de voor-
grond dan “het principe van rechtvaardigheid en billijkheid”. Dit kan leiden tot 
tekortkomingen in de gezondheidszorg waar het gaat om doelmatigheid, doeltreffendheid 
en rechtvaardigheid. Op basis van een nadere analyse van de mogelijke onderliggende 
oorzaken van deze tekortkomingen in, worden voorstellen geformuleerd om efficiëntie en 
effectiviteit te bevorderen en de onbillijkheid te reduceren in relatie tot de integratie van 
een gepersonaliseerd zorgmodel in Europa.  
Zoals eerder vermeld, beschrijft deel II van het proefschrift de inhoudelijke aspecten van 
gepersonaliseerde geneeskunde/ gepersonaliseerde gezondheidszorg en wordt ook een 
specifiek praktijk model, Gentest, nader beschreven. Hoofdstuk 4 presenteert een toe-
komstvisie over gepersonaliseerde geneeskunde/ gepersonaliseerde gezondheidszorg, 
vanuit een praktijkgestuurd “bottom-up” perspectief, als tegenhanger van “top-down” 
processen. Op basis van literatuuronderzoek wordt dit ‘praktijkgestuurd perspectief’ na-
der beschouwd en wordt er gekeken naar de uitvoeringspraktijken van gepersonaliseerde 
geneeskunde/ gepersonaliseerde gezondheidszorg. Gepersonaliseerde geneeskunde/ 
gepersonaliseerde zorg kan immers voor verschillende doeleinden worden ingezet: om 
mensen zelf meer controle te geven over hun gezondheid, om de gezondheidszorg beter 
en efficiënter te maken en om iedereen gelijke toegang tot de gezondheidszorg aan te 
kunnen bieden. Bovendien toont dit hoofdstuk aan de hand van drie voorbeelden (Ameri-
ka, Frankrijk en Taiwan) aan dat niet alleen de visie van de overheid (op gepersonaliseerde 
geneeskunde/ gepersonaliseerde gezondheidszorg) een rol speelt bij de integratie, maar 
ook de verschillen in gezondheidssystemen en wetgeving in de verschillende landen. 
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Waar in hoofdstuk 4 de verschillende facetten worden besproken voor de mogelijkheden 
tot persoonlijke geneeskunde, wordt in hoofdstuk 5 gepersonaliseerde zorg nader gedefi-
nieerd in relatie tot begrippen als gepersonaliseerde geneeskunde, individuele genees-
kunde. Aanvankelijk werd gepersonaliseerde geneeskunde synoniem gebruikt voor ‘ge-
nomic medicine’ (geneeskunde die zich enkel richt op de genetische (genoom) 
eigenschappen van een patiënt). Het is echter niet alleen ons genoom (DNA) dat ons uniek 
maakt en een rol speelt bij onze gezondheid. Factoren zoals fysieke beweging, voeding, 
leefstijl en blootstelling aan omgevingsfactoren (zoals rook of andere schadelijke stoffen) 
hebben immers eveneens een grote invloed op onze gezondheid. Een integrale benade-
ring van de diversiteit aan gezondheidsdeterminanten wordt geplaatst in het perspectief 
van een paradigmaverschuiving naar een gepersonaliseerde zorg. 
In hoofdstuk 6 wordt een concreet voorbeeld gegeven van toepassing van gepersonali-
seerde zorg in de praktijk: Gentest. Gentest is een uitgebreid model dat rekening houdt 
met verschillende factoren en zo een risicotaxatie geeft met betrekking tot de kans om de 
meest voorkomende chronische, complexe ziekten te ontwikkelen. Om deze risicotaxatie 
te geven, maakt Gentest gebruik van persoonlijke gezondheidsinformatie, gedetailleerde 
leefstijl analyse, lichaamssamenstelling, genotype (DNA) en biomarkers die voorspellend 
zijn. Het model is oorspronkelijk ontwikkeld door het GENAR instituut in Ankara, Turkije. 
In Turkije is dit model al toegepast bij 500 personen. De positieve en negatieve punten die 
hierbij geleerd zijn, worden ook kort besproken in dit hoofdstuk.  
In deel III wordt uitgezocht hoe een dergelijk model nu geïntegreerd kan worden in het 
Europees gezondheidssysteem.  
Als we Gentest willen integreren in de eerstelijns gezondheidszorg in Europa, waar moe-
ten we dan rekening mee houden? Hoe bepalen we de factoren waar we rekening mee 
moeten houden? Welke onderdelen van de gezondheidszorg en van het specifieke land 
moeten we onderzoeken? Hoofdstuk 7 richt zich op het beantwoorden van deze vragen. 
Om alle factoren te bepalen die een rol spelen bij de integratie, werd het ‘Health Globe’-
kader uit Hoofdstuk 2 gebruikt. Zo werden 24 deelgebieden onderscheiden en vervolgens 
geordend om te identificeren welk van die deelgebieden cruciaal zijn voor een succesvolle 
integratie van een model als Gentest, met voorbeelden uit diverse Europese landen. Meer 
algemeen omvat Hoofdstuk 7 analyse van de belangrijkste factoren die hierbij een rol 
spelen  
Hoofdstuk 8 beschouwt de interactie tussen de verschillende onderdelen van de gezond-
heidszorg en toepassingen van gepersonaliseerde  zorg. Zoals eerder besproken is het de 
visie ‘Health for All’ van de Wereldgezondheidsorganisatie (WHO) die in 1977 het belang 
benadrukte van een bio-psycho-sociaal-ecologisch denkkader, ook op individueel niveau. 
Vanwege de interindividuele verschillen is het belangrijk om gepersonaliseerde genees-
kunde / gepersonaliseerde zorg aan te kunnen bieden. Gentest is een model dat hieraan 
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bijdraagt en wellicht kan zorgen voor ‘Gezondheid voor iedereen’. Zulke modellen zullen 
echter alleen efficiënt blijven als de gedachtegang van de gezondheidszorg en beleidma-
kers proactief blijft en zich niet alleen op behandelen richt, maar ook op (vormen van) 
preventie van ziekte.  
Naast de verandering in gedachtegang, wordt er in Hoofdstuk 8 ook een praktisch voor-
beeld besproken hoe Gentest er in de praktijk uit kan zien.  
Ten slotte worden in hoofdstuk 8 de belangrijkste conclusies van dit proefschrift weerge-
geven. Kort samengevat, dit proefschrift toont dat gepersonaliseerde geneeskunde / ge-
personaliseerde gezondheidszorg een belangrijke rol kan spelen om chronische, complexe 
ziekten aan te pakken. Hiervoor is er wel een paradigma shift nodig en moet er meer na-
druk komen te liggen op preventie. Om deze gedachtegang te bewerkstelligen en toch het 
‘Gezondheid voor iedereen’-principe te behouden, is het wenselijk dat innovatieve ont-
wikkelingen op het gebied van gepersonaliseerde zorg, gezondheidszorg en gezondheids-
beleid samengaan en op elkaar worden afgestemd. Voor een succesvolle integratie van 
een gepersonaliseerd zorg model zoals Gentest, moet de onderlinge relatie tussen de 
verschillende domeinen in acht worden genomen en als één geheel worden beschouwd. 
Hierin kan een kader zoals de ‘Health Globe’ ondersteuning bieden. Effectieve communi-
catie tussen de gebieden van de gepersonaliseerde geneeskunde, de gezondheidszorg en 
de beleidsmakers, kan het integratieproces wellicht verbeteren en versnellen. 
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Özet 
Kronik kompleks hastalıklar sağlık sistemleri üzerinde muazzam bir toplumsal ve finansal 
yük oluşturmaktadır. Bilimsel ve teknolojik gelişmeler sonucunda ortaya çıkan kişiye özel 
tıp ve kişiye özel sağlık hizmetleri kronik hastalıkların önlenmesi konusunda önemli 
fırsatlar sunmaktadır. Ancak ‘kişiye özel’ uygulamaların sağlık hizmetlerinin bir parçası 
haline getirilmesi, yani sağlık sistemlerine entegrasyonu önünde ciddi engeller 
bulunmaktadır.  
Bu tezde kişiye özel sağlık uygulamalarının sağlık hizmetlerine entegrasyonu konusu ele 
alınmıştır. Konuyu etkili bir şekilde inceleyebilmek için kişiye özel koruyucu bir sağlık 
uygulaması olan ‘Gentest’ tezin vaka örneği olarak kullanılmıştır. Gentest gibi uygulamaya 
geçmiş, gerçek hayattan bir örneğin kullanılması, tez kapsamında incelenen konunun farklı 
boyutlarını ortaya koyabilir ve diğer kişiye özel uygulamalar için de dersler çıkarmayı 
sağlayabilir. Dolayısıyla bu tezin amacı, Gentest gibi kronik hastalıklardan korumaya 
yönelik bir kişiye özel sağlık uygulamasının Avrupa sağlık sistemlerinde birinci basamak 
hizmetlere nasıl entegre edilebileceğini incelemektir. Cevaba ulaşabilmek için tez 
kapsamında üç alt soru sorulmuştur: 1. Nereye entegre edilecektir? 2. Ne entegre 
edilecektir? 3. Entegrasyon nasıl gerçekleşebilir? 
Tez, Gentest’i bir araç olarak kullanarak kişiye özel tıp, kişiye özel sağlık, ve sağlık 
sistemleri ve politikaları alanlarında bir seyahate çıkmıştır. I. Kısım entegrasyonun 
‘nerede’ gerçekleşeceği sorusunu cevaplamış ve konumu tanımlamıştır: sağlık sistemleri. 
Bu bölümde sağlık sistemleri daha geniş bağlamı olan halk sağlığı kapsamında ele 
alınmıştır. II. Kısım ‘ne’ sorusunu cevaplamış ve öncelikle kişiye özel tıp ve sağlık alanını 
tanımlamıştır. Ardından, Avrupa’da sağlık sistemlerine entegre edilmesi düşünülen bir 
kişiye özel sağlık uygulama modeli olan Gentest’i tanıtmıştır. III. Kısım Gentest’in 
Avrupa’da birinci basmak sağlık hizmetlerine ‘nasıl’ entegre edilebileceği konusunda 
sistematik bir yaklaşım sunmuştur. Bu şekilde, söz konusu uygulama modelinin 
entegrasyonu sürecinde ele alınması gereken alanların ve konuların kapsamlı bir 
çerçevesini belirlemiştir. Bu üç kısımda yer alan bölümlerin özeti aşağıda sunulmuştur.  
Bölüm 1’de kronik kompleks hastalıkların dünya çapında nasıl bir ‘salgına’ dönüştüğünü 
aktararak başlamıştır. Bu hastalıkların yükünün azaltılması için acilen çözümler 
geliştirilmesi gereklidir. Bunun için sağlık sistemlerinde bir paradigma değişimine gidilmesi 
gereklidir: daha proaktif, hastalıklardan ziyade yerine sağlığa ve sağlığı korumaya 
odaklanan, aynı zamanda kronik tedavi ve bakım hizmetleri veren ve sadece tıbbi 
hizmetleri değil, sağlık hizmetlerinin bütününü ele alan bir sisteme ihtiyaç vardır. Kişiye 
özel sağlık hizmetleri sağlık sistemlerinin bu yöndeki dönüşümünü desteklerken kronik 
hastalıklardan korunma açısından önemli fırsatlar sunmaktadır. Bu  tezde kullanılan vaka 
örneği hastalık yükünün büyük kısmından sorumlu kronik hastalıklardan ve risk 
faktörlerinden korunma konusunda kapsamlı bir yaklaşım sunan ve kişiye özel bir sağlık 
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uygulama modeli olan Gentest’tir. Bu model kronik hastalıkların oluşması, gelişmesi ve 
ilerlemesinin kişiye özel bir şekilde önlemeyi hedeflemektedir. Türkiye’deki pilot 
uygulamanın ardından Gentest Avrupa’da ‘en iyi uygulama modeli’ olarak belirlenmiştir. 
Bu noktada, Gentest gibi bir koruyucu sağlık uygulamasının esas uygulama alanının 
Avrupa’daki aile hekimliği/ birinci basamak sağlık hizmetleri, olduğu görülmüştür. Ancak, 
kişiye özel koruyucu sağlık modellerinin geniş toplum kesimlerine uygulanması konusunda 
başarılı örnekler henüz bulunmamaktadır. Bu nedenle, Gentest’in Avrupa’da birinci 
basamak sağlık hizmetlerine nasıl entegre edilebileceğinin incelenmesi gereklidir. Bunun 
için de yukarda sunulan ‘nerde’, ‘ne’ ve ‘nasıl’ sorularının cevapları aranmalıdır.  
I. Kısım uygulama modelinin entegre edileceği konumu tanımlamayı amaçlamıştır. 
Öncelikle, bu tartışmanın bütünü ile ‘halk sağlığı’ (public health) ve ‘sağlık sistemleri’ 
kavramları üzerine inşa edilmesi gerektiği görülmüştür. Ancak bu kavramlar ve bunların 
birbiri ile ilişkileri konusunda netlik bulunmamaktadır. Bu nedenle, Bölüm 2 ‘halk sağlığı’ le 
ilişkili kavramları ve birbiri ile ilişkilerini tutarlı bir şekilde açıklayan bir kavramsal çerçeve 
sunmuştur. ‘Health Globe’, yani ‘Sağlık Küresi’ adı verilen bu çerçevede sağlık sistemi ve 
bileşenleri de içerilmiştir. Bu girişimin amacı, üst düzey sağlık yöneticileri (politika 
üreticiler) ve onlara uluslararası platformlarda rehberlik edenler için tutarlı bir terminoloji 
sunmaktır. Dünya Sağlık Örgütü’nün 1977’de başlattığı ‘Herkes için Sağlık’ (Health for All) 
vizyonu ‘Sağlık Küresi’nin kapsayıcı kavramsal çerçevesini oluşturmaktadır. ‘Herkes için 
Sağlık’ şiarı tarafından sağlığa getirilen geniş yaklaşım ‘halk sağlığı’ olarak tanımlanmıştır. 
Böylece, bireylerin sağlığını doğrudan ya da dolaylı bir şekilde etkileyen her türlü faaliyet 
‘halk sağlığı’nın kapsamına dahil olmaktadır. Bu, tıbbi ve tıbbi olmayan tüm hizmetler, 
devletlerin/hükümetlerin kararları ve uygulamaları ve kamu, özel ve sivil toplum 
sektörlerinin faaliyetlerini kapsamaktadır. Sağlık sistemi, ‘Sağlık Küresi’nin bir parçasıdır ve 
sağlık bakanlığının sorumluluk alanına giren tüm faaliyetleri kapsar. Bu bölümde sağlık 
sisteminin amaçları ve işlevleri konusunda bir çerçeve de sunulmuştur. Gentest’in entegre 
edileceği bağlam birinci basamak sağlık hizmetleri olduğu için sağlık hizmetleri 
tanımlanırken birinci basamağın yeri ve kapsamı net bir şekilde gösterilmiştir.  
Amerika Birleşik Devletleri (ABD) kişiye özel tıp ve kişiye özel sağlık kavramları ve 
uygulamaları konusunda dünyanın önde gelen ülkelerinden biridir. Bu konudaki örneklerin 
ve yayınların büyük kısmı ABD kökenlidir. Bölüm 3’te, ‘kişiye özel’ uygulamaların ortaya 
çıktığı bağlamı anlamak ve Avrupa’da entegrasyonun nasıl yapılması ve yapılmaması 
gerektiği konusunda dersler çıkartmak için ABD sağlık sistemi incelenmiştir. Bu bölümde 
ABD’nin tutarlı bir şekilde tasarlanmış bir sağlık ‘sistemi’ne sahip olmadığını görülmüştür. 
Politika (policy) değerleri açısından ABD ‘özgürlük’ ile ‘serbest piyasa’yı ‘hakkaniyet’ 
değerinin üzerinde tutmuştur. Bu durum sağlık sisteminin temel sonuçları olan etkililik, 
verimlilik ve hakkaniyet açısından ciddi sorunlara neden olmuştur. Bu bölümde temel 
sorunlar ve altında yatan nedenler ortaya konduktan sonra Amerika’da sağlıkta etkililik ve 
verimliliği artırmak ve eşitsizlikleri azaltmak için nasıl bir sağlık politikası ve sağlık sistemi 
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geliştirilmesi gerektiği konusunda bir çerçeve sunulmuştur. Verilen öneriler ağırlıklı olarak 
Avrupa ülkelerinin tecrübelerine dayanmıştır.  
II. Kısım hem kişiye özel tıp ve kişiye özel sağlık hizmetleri bağlamını hem de vaka 
örneğimiz olan Gentest’i tanımlayarak neyin entegre edileceğini ortaya koymayı 
amaçlamıştır. İlk olarak, Bölüm 4’te tıpta ve sağlıkta görülen ‘kişiye özelleşme’ vizyonunun 
farklı kişi ve kurumlar tarafından farklı şekillerde tanımlandığını aktarmıştır. Bu konuda 
standart tek bir tanım bulunmamaktadır. Ayrıca, tanımlamalar alanında sözü geçen kişiler 
ve komiteler tarafından yapılmıştır. Dolayısıyla, gerçek hayatta, yani sağlık hizmetleri 
sahasında ne olup bittiğini yeterince yansıtmıyor olabilir. Bu tartışmaya farklı bir açıdan 
yaklaşmak için Bölüm 4’te ‘uygulamaya dayalı bakış acısı’ (ya da ‘tabandan yaklaşım’) 
kullanılmıştır. Bilimsel literatürün sistematik bir şekilde taranması sonucunda 
belirlenmiştir yayımlanmış ‘kişiye özel’ uygulamalar belirlenmiş, daha sonra da bunların 
içeriği analiz edilmiştir. Sonuç olarak ‘kişiye özel’ uygulamaların çok çeşitli olduğu ve ‘kişiye 
özel’ kavramının tanımında ciddi farklılıklar bulunduğu görülmüştür. Uygulama şekli ve 
bağlamı açısından bakıldığında, ‘kişiye özel’ bir uygulama sağlık pazarında bir meta ya da 
sağlık hizmetlerinde bir sunum şekli olabileceği gibi yeni geliştirilen teknolojik 
uygulamalarla ilgili bir anahtar kelime olarak de kullanılabilmektedir. ‘Kişiye özel’ 
uygulamalar çok çeşitli gruplara farklı amaçlar için hizmet edebilir. Bu geniş yelpazede 
bireyleri hedefleyen uygulamalar (sağlıklarını bireysel olarak kontrol etmeye başlamaları 
için), sağlık kurumlarının uygulamaları (artan rekabet ortamında sağlık hizmetlerinde 
etkililik ve verimliliklerini artırabilmeleri için) veya ulusal sağlık sistemlerinin programları 
(etkililik ve verimliliğin yanı sıra hakkaniyeti de içerecek şekilde performanslarını 
artırabilmeleri için) yer almaktadır. Ayrıca, üç ülke örneği incelendiğinde (ABD, Fransa ve 
Tayvan), uygulamaların sağlık hizmetlerine başarılı bir şekilde entegre edilebilmesi için 
sağlıkla ilgili yeniliklere (innovasyon) karşı ülkedeki tutumun yanı sıra sağlık sistemi ve 
politikaları bağlamının da kritik önem taşıdığı görülmüştür.  
Bölüm 4’te mevcutta yer alan kişiye özel uygulamaların çeşitli boyutları ortaya konduktan 
sonra Bölüm 5’te bu tez kapsamında ‘kişiye özel sağlık hizmetleri’nin ne olduğu 
tanımlanmıştır. Bu alanda sıkça kullanılan ‘kişiye özel tıp’, ‘kişiye özel sağlık’, ‘bireysel tıp’ 
gibi kavramların bu makalenin (bölümün) yazarları için ne ifade ettiği ortaya konmuştur. 
Kavramların gelişmeye başladığı ilk dönemlerde ‘kişiye özel tıp’ ve ‘genomik tıp’ kavramları 
eş kabul edilmiştir. Ancak genom bireyleri özel ve biricik yapan tek faktör değildir. Genom, 
patojenler ve toksinlere maruziyet, sosyoekonomik faktörler ve fiziksel aktivite, beslenme 
ve diğer yaşam tarzı faktörleri sürekli olarak birbiri ile etkileşmektedir. Bireyler bunları 
kapsayacak şekilde tüm bağlamları içinde ele alınmalıdır. Bu nedenle hem bilimsel 
çalışmalar, hem de kişiye özel sağlık hizmetleri bağlamında sağlığın çeşitli belirleyicilerini 
kapsayan, bütünleştirici bir yaklaşım uygulanması gereklidir. Bu bölümün sonucunda sağlık 
sistemleri ve politikalarının kişiye özel yaklaşımlara yönelik dönüşüm için hazırlanması 
gerektiği de vurgulanmıştır.  
 
Summary  - Samenvatting - Özet 
319 
Bölüm 4 ve 5’te kişiye özel tıp ve kişiye özel sağlık uygulamaları zemini ortaya konduktan 
sonra Bölüm 6’da bu tez kapsamında kullanılan kişiye özel tıp uygulaması tanıtılmıştır: 
Gentest. Gentest sık görülen kronik hastalıkların önlenmesini hedefleyen kapsamlı ve 
bütüncül bir kişiye özel sağlık hizmeti modelidir. Bireylerin kişisel sağlık bilgilerini, ayrıntılı 
yaşam tarzı analizlerini, vücut bileşimlerini, genotiplerini ve diğer biyomarkerlarını 
kapsayan bu uygulama sık görülen kronik hastalıkların ortaya çıkması veya ilerlemesini 
kişiye özel bir şekilde engellemeyi hedeflemektedir. Gentest’in misyonu bireylerde 
davranış değişikliğini sağlamak ve bireylerin sağlığını onların sağlık önceliklerine göre 
yönetmektir. GENAR Toplum Sağlığı ve Genombilim Araştırmaları Enstitüsü tarafından 
Ankara’da geliştirilmiştir. Bu bölümde Gentest’in yetkili uygulayıcılar  tarafından  500’ün 
üzerinde bireye hangi modelle uygulandığı aktarılmıştır. Yetkili uygulayıcı olmak için sağlık 
profesyonelleri (ağırlıklı olarak hekimler) özel bir eğitim programı tamamlamışlardır. Bu 
bölümde ayrıca Gentest’e yönelik olumlu ve olumsuz eleştirilere de kısaca yer verilmiştir. 
I. Kısım konumu, yani sağlık sistemlerini, II. Kısım ise kişiye özel koruyucu uygulamayı 
(Gentest) ‘kişiye özel sağlık’ bağlamında tanımlamıştır. Bunlara dayanarak III. Kısım, bu 
uygulama modelinin (Gentest) konuma, yani sağlık sistemlerine nasıl entegre 
edilebileceğini incelemiştir. 
Eğer Gentest gibi bir uygulama modelini Avrupa’da birinci basamak sağlık hizmetlerine 
entegre etmek istiyorsak hangi konuları incelememiz gerekir? Bunları sistematik ve 
analitik bir şekilde nasıl belirleyebiliriz? Bir ülkenin sağlık sisteminde hangi alanların 
incelenmesi gerekir? Bölüm 7 bu soruları cevaplamayı amaçlamıştır. Entegrasyonla ilgili 
tüm konuların belirlenebilmesi için 2. Bölüm’de sunulmuş olan ‘sağlık sistemleri 
çerçevesi’ne dayanarak bu bölümde sistematik bir yaklaşım geliştirilmiştir. Bu kapsamda, 
sağlık sisteminin işlevleri bu sistematik yaklaşımın kavramsal çerçevesini oluşturmuştur. 
Bölüm 4’te aktarıldığı üzere ‘kişiye özel’ uygulamalar çok çeşitli olup tek genel bir hizmet 
sınıfı altında toplanması mümkün değildir. O nedenle bu bölümde Gentest’in Avrupa’da 
birinci basamak sağlık hizmetlerine entegrasyonu örneği kullanılmıştır. Sonuç olarak sağlık 
sisteminin işlevleri altında 24 alan belirlenmiştir. Bu sistematik yaklaşım başta Hollanda ve 
İngiltere olmak üzere çeşitli Avrupa ülkelerinden örneklerle zenginleştirilmiştir. Daha 
sonra, bu 24 alandan hangilerinin entegrasyon için ‘kritik’ ve hangilerinin ‘yüksek 
öncelikte’ olduğu belirlenmiştir. Özetle Bölüm 7, bir uygulama modelinin Avrupa sağlık 
sistemlerinde birinci basamak hizmetlere entegrasyonu ile ilgili konuların belirlenmesi ve 
değerlendirilmesi için sistematik bir yaklaşım ortaya koymuştur. Bu yöntem farklı 
uygulama modelleri ve ülkelere uygulanabileceğinden kişiye özel tıp ve kişiye özel sağlık 
uygulamalarının sağlık sistemlerine entegrasyonu sorununa kapsamlı bir çözüm önerisi 
getirmektedir.  
Bölüm 8 konuya daha yukardan bakarak sağlık sistemleri ve kişiye özel sağlık uygulamaları 
bağlamları arasındaki etkileşimle ilgili bazı görüşler ortaya koymuştur. 1977’de ortaya 
konan ‘Herkes için Sağlık’ vizyonu bireylerin biyo-psiko-sosyo-ekolojik bağlamını 
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anlamanın önemini vurgulayan ‘ekolojik’ yaklaşımın gelişmesini sağlamıştır. Her bireyin 
bağlamı diğerlerinden az ya da çok farklıdır. Bireysel bağlamı anlayıp buna göre 
müdahaleler geliştirmek sağlığa kapsamlı bir şekilde yaklaşma konusunda önemli fırsatlar 
sunmaktadır. Gentest gibi bireylerin sağlığını, risklerini ve hastalıklarını kapsamlı bir 
şekilde ele alan bütüncül ve kişiye özel sağlık uygulamaları ile ‘Herkes için Sağlık’ hedefine 
yönelik önemli mesafeler kat edilebilir. Ancak bu tür uygulamaları bünyesine başarılı bir 
şekilde dahil edebilmesi ve ‘Herkes için Sağlık’ hedefine ulaşabilmesi için sağlık 
sistemlerinin daha proaktif, hastalıklardan ziyade yerine sağlığa ve sağlığı korumaya 
odaklanan, aynı zamanda kronik tedavi ve bakım hizmetleri veren ve sadece tıbbi 
hizmetleri değil, sağlık hizmetlerinin bütününü ele alan bir sisteme evrilmesine, bunun için 
de yenilikler yapılmasına ihtiyaç vardır. Bunun için ‘topluma dayalı koruyucu hizmetler mi, 
yüksek riskli bireylere yönelik koruyucu hizmetler mi?’ gibi bazı geleneksel kavramların da 
yeniden gözden geçirilmesi gereklidir. Ayrıca, kronik hastalıkların gelişimindeki süreklilik 
göz önüne alındığında koruyucu müdahaleler için yeni bir sınıflama olarak ‘kişisel sağlık 
yönetimi’, ‘kişisel risk yönetimi’ ve ‘kişisel hastalık yönetimi’ kavramları gündeme girebilir. 
Bu tür koruyucu kişiye özel sağlık uygulamalarının topluma proaktif bir şekilde 
sunulabilmesi için birinci basamak hizmetlerinde yeniliklere ve güçlendirmeye ihtiyaç 
vardır. Gentest gibi kişiye özel sağlık uygulamaları sağlık sistemlerindeki paradigma 
değişimini gerçekleştirmek için pratik bir fırsat olarak da kullanılabilir.  
Sağlık sistemlerindeki yenilikler tek başına yeterli değildir; kişiye özel sağlık hizmetlerinde 
de sürekli yenilenmesi gerekir. Öncelikle, ‘kişiye özel’ uygulamaların kapsamlı bir nitelik 
kazanması için yeniliğe ihtiyaç vardır. Bir laboratuvar analizi gibi tek bir testi kullanan, tek 
bir hastalığın tanısı veya tedavisi ile ilgili bir uygulama ‘kişiye özel’ olabilir mi? İster yüksek 
ister düşük teknolojik olsun, ister biyolojik, ister biyolojik olmayan bir faktör olsun, tek bir 
faktörü ele alan bir uygulama ne kadar ‘kişiye özel’ olabilir? Bir uygulamanın ‘kişiye özel’ 
olması için bireysel bağlamın bütüncül bir şekilde anlaşılması ve kullanılması gereklidir. 
Ayrıca, Gentest gibi kişiye özel sağlık uygulamalarının hedeflenen ülkelere ve sağlık 
sistemlerine uygun hale gelmesi için sürekli olarak yenilenmesi gerekir. Kişiye özel tıp ve 
kişiye özel sağlık alanında çalışanların şunun farkına varmaları gerekir: gerçekleştirdikleri 
bilimsel keşifler ile geliştirdikleri teknolojiler ve araçların toplumda belirgin bir etki 
yapabilmesi için bu uygulamaların sağlık sistemlerine entegre olması konusunda kapsamlı 
bir yaklaşım gerekir.  
Tezin metoduyla ilgili olarak Bölüm 8’de yapılan tartışmada gerçek hayatta kullanılan 
somut bir uygulamanın bu tezde ele alınmasının avantajları ve bu alandaki araştırmalara 
nasıl bir katkıda bulunabileceği aktarılmıştır.   
Bölüm 8 bu tezin temel sonuçları ile bitirilmiştir. Özetle, kişiye özel sağlık uygulamaları 
hızla artan kronik kompleks hastalık yükü ile mücadele için önemli fırsatlar sunmaktadır. 
Aynı zamanda, sağlık sistemlerinde ihtiyaç duyulan paradigma değişimine de hizmet 
etmektedir. Bu değişimi gerçekleştirmek ve ‘Herkes için Sağlık’ amacına ulaşabilmek için 
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kişiye özel tıp ve kişiye özel sağlık alanındaki yenilikler ile sağlık sistemleri ve politikaları 
alanındaki yenilikler birlikte evrilmeli, bu iki alan etkileşim içinde olmalıdır. Bu şekilde 
yeniliklerin birbirlerinin ihtiyaçlarına göre şekillenmesi mümkün olabilir. Kişiye özel sağlık 
uygulamalarının başarılı bir şekilde hizmete geçmesi için entegrasyon ile ilgili konular 
parça parça değil, sistematik bir şekilde ele alınmalıdır. Sağlık sistemi kavramsal çerçevesi, 
entegrasyon ile ilgili konuların belirlenmesi ve değerlendirilmesi için gereken analitik 
çerçeveyi sunmaktadır. Kişiye özel tıp ve kişiye özel sağlık alanı ile sağlık sistemleri ve 
politikaları alanı arasında etkili bir diyalog kurulması entegrasyon sürecinin daha etkili ve 
hızlı olmasına yardımcı olacaktır.   
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The dissertation started with the following paragraph: 
“Every day, we read about new scientific discoveries and technological advancements in 
the newspapers. The news are very promising for medicine and health, in particular in 
reference to ‘genetics’ in the past 15-20 years: “Diabetes gene is found!”, “Heart attack 
gene is found!”, “Cancer gene is found”, “We’ll be able to prevent diabetes in 10 years!”… 
However, we don’t see these ‘genes’ in health services. Somehow, they don’t complete 
their journey from the laboratory to the society” 
This journey is actually a winding road, as it involves in science, technology, health and 
society domains and various hurdles in each. The innovations are usually envisaged to be 
transferred from one domain to the other in this order. However, as presented in Chapter 
4, innovation does not follow a simplified linear process or a ‘pipeline’, which ends when 
the ‘product’ is out in the market. Innovations co-evolve with the involvement of different 
domains.  
The health domain, which includes the health system, plays a crucial role in effective inte-
gration of innovations. Therefore, this PhD research focused on this domain, and tried to 
answer the question how a personalized health care model can be integrated into health 
systems in Europe. While answering it, a real life practice model, i.e. Gentest, was used as 
the case. Thus, the topic of this dissertation was involved with developing guidance for 
valorization of scientific and technological developments in the field of personalized 
medicine and personalized health care.  
Use of a case to investigate integration issues provided a novel approach that hasn’t been 
applied in this field before. As the starting point was a real life example that was seeking 
for integration into new health systems, the research was highly practice oriented rather 
than being solely a theoretical one. Thus, the ‘valorization’ has already been an inherent 
priority of this research. 
The implications of the dissertation are two folds. On one hand, the dissertation may facil-
itate the fields of personalized medicine and health care and health systems to learn to 
talk to each other and work together. On the other hand, the dissertation provides a use-
ful tool, i.e. the systematic approach presented in Chapter 7, to guide integration of per-
sonalized practices into different health systems.   
Implications for the fields of personalized medicine and health 
care and health systems 
As the topic of the dissertation was involved with valorization of personalized practices, 
several implications have been presented in Chapters 7 and 8. Here, these will not be 
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repeated, but concrete messages for the fields of personalized medicine and health care 
and health systems will be put forward. 
Health systems are facing a huge problem with the rapidly increasing burden of chronic 
complex diseases. They need to shift towards proactive and health oriented services fo-
cused on prevention as well as chronic cure and care, covering the whole spectrum of 
health care (not only medicine). Rather than running separate programs for each lifestyle/ 
disease area, holistic approaches to disease prevention and health promotion should be 
developed. Personalized health care practices can be the answer of health services to 
these needs. At this point, the practice model used in this dissertation, Gentest, can in-
spire integrative and holistic programmes not only for prevention of late onset chronic 
diseases, but also in other fields such as child and youth health care, with a life course 
perspective. 
To achieve integrative and holistic approaches to health, innovations in the fields of per-
sonalized medicine and health care, and health systems need to co-evolve. To do that, 
people working in these fields should first start talking to each other, learning one anoth-
er’s language, and developing ways to collaborate. This doesn’t simply mean making con-
ferences or meetings that bring people from these fields together, and provide ‘network-
ing’ opportunities. Moreover, many of the so-called ‘collaborative’ projects that bring 
different fields together do not always help them collaborate. Most of such projects assign 
specific tasks or work packages to groups that are from the same discipline or field. Thus, 
each discipline does its own work; they don’t necessarily work together in a cross-
disciplinary way.  
To facilitate co-evolution, a coherent and concrete agenda should be provided to people 
in the fields of personalized medicine and health care, and health systems. They should 
first start working on smaller and simpler projects, where they can start learning each 
other’s languages and priorities. Then, they can move towards bigger and more complex 
projects.  
These fields should also be made aware of the differences in their perspectives and jar-
gons. As provided in Chapter 4 with a bottom-up approach, personalization may mean 
different things for the practices. Therefore, special effort should be paid towards harmo-
nization of the language. As provided in Chapter 8, personalization cannot simply mean 
use of molecular technologies, or any technology. The harmonization of the language 
should include clarification of the purpose and means of personalization.   
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Implications for personalized practices which will be integrated 
into different health systems 
The PhD research has implications for personalized practices in general, as well as the 
specific practice model that was used in this dissertation: Gentest.  
In general, the science and technology (including academia and industry) domains seem to 
have a quest for using the knowledge and tools they are developing to personalize medi-
cine and health care. These domains take leadership roles as thought leaders or entrepre-
neurs. To successfully integrate the knowledge and tools they generate, they first need to 
understand that ‘personalization’ is not only about genetics, or technology. It involves 
‘practices’, as well as health systems that surround them. At this point, the dissertation 
provides a valuable perspective to them to understand what is relevant in health systems.  
For personalized practices which seek for integration into health systems, the dissertation 
provides a systematic approach (Chapter 7) which can be applied to different cases. It can 
be used not only for ‘personalized medicine and health care’, but also in general for inno-
vations in health. The author of the dissertation is currently presenting this approach to 
various organizations involved in scientific and technological innovations in health. When 
it is picked up by others and applied on different cases, it may evolve into a practical tool 
for investigation of integration issues for innovations in health. 
The dissertation also has several implications for the case of Gentest, as provided in Chap-
ters 7 and 8. For successful valorization of Gentest, it is important to find a country where 
the health system supports the crucial areas, as well as most of the priority areas, de-
scribed in Chapter 7. Then, right partnerships should be developed within the academia, 
(local) health authorities, industry, and civil society, possibly leading to a public private 
partnership initiative. This partnership should agree on a roadmap which includes adapta-
tion and further development of the model within the target country, software develop-
ment, piloting, and evaluation phases.  
Overall, this dissertation has large potential for valorization. It can be used to facilitate co-
evolution of health systems and personalized health care practices. The research also has 
profound implications on integration of personalized practices into health systems. The 
practice model used in the dissertation, i.e. Gentest, can inspire holistic and integrative 
programmes not only for prevention of chronic diseases, but also for other health fields 
such as child and youth health care with a life course perspective. 
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İlim ilim bilmektir  
İlim kendin bilmektir  
Sen kendini bilmezsen  
Ya nice okumaktır 
Knowledge should mean a full grasp of the path to knowledge 
Knowledge means to know yourself, heart and soul.  
If you have failed to understand yourself,  
Then all of your reading has missed its call.  
Okumaktan mana ne  
Kişi Hakk'ı bilmektir 
Çün okudun bilmezsin  
Ha bir kuru emektir 
 
What is the purpose of reading those books?  
So that Man can know the God/ the Truth 
If you have read, but failed to understand, 
Then your efforts are just a barren soil. 
Okudum bildim deme  
Çok taat kıldım deme 
Eri Hak bilmez isen  
Abes yere yelmektir 
 
Don't boast of reading, mastering science  
Or of all your prayers and obeisance. 
If you don't identify Man as God,  
All your learning is of no use at all. 
Dört kitabın manası 
Bellidir bir elifte 
Sen elif dersin hoca 
Manası ne demektir 
 
The true meaning of the four holy books  
Is found in the alphabet's first letter. 
You talk about that first letter, teacher;  
What is the meaning of that - could you tell? 
Yunus Emre der hoca 
Gerekse var bin hacca 
Hepsinden iyice 
Bir gönüle girmektir 
 
Yunus Emre says to you, teacher,  
Make the holy pilgrimage if need be  
A hundred times - but if you ask me, 
To win a heart is the best of all. 
Yunus Emre
1
  
 
                                                                
1
 Yunus Emre was a Turkish poet and Sufi mystic who lived in the 13-14th centuries in 
Anatolia.  
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